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Abstract

Ligand-targeted drug delivery is currently one of the most challenging areas in
pharmaceutical research involving the judicious choice of the drug, linker and
targeting ligand. A promising new strategy involves conjugating a cytotoxin with a
tumour-targeting protein through an acid-labile linker that is stable at physiological
pH. Internalisation at the target tumour site via receptor-mediated processes exposes
the conjugate to endosomal and lysosomal pH (4.5-6.0), resulting in selective release
of the original cytotoxin inside the tumour cell. This thesis describes the synthesis of
a new targeted anti-cancer agent and in particular, the development of the drug and
linker component.
Drug development: Isatin (11) and its derivatives are present in numerous
natural products including the Australian marine mollusc, Dicathais orbita. These
derivatives possess a broad spectrum of biological properties including anti-cancer
activity. New tricyclic and polycyclic derivatives of isatin (11) were prepared since
previous research within our group indicated isatin derivatives exhibit highly potent
cytotoxic effects against a variety of human cancer cell lines. To expand the
cytotoxic structure-relationship activity of isatin derivatives, the N1-C7 region of
isatin (11) was investigated through the addition of a 5- or 6-membered ring (i.e.
pyrrolo[3,2,1-hi]indole-1,2-dione

and

pyrrolo[3,2,1-ij]quinoline-1,2-dione

derivatives respectively) to yield 23 analogues, 18 of which were novel. In vitro
assays revealed the inclusion of the extra ring reduced cytotoxicity compared to the
parent molecules. However, a novel brominated tetracyclic acridine-based isatin,
4-bromo-6H-pyrrolo[3,2,1-de]acridine-1,2-dione (144), displayed an IC50 value of
3.01 µM against U937 lymphoma cells
~ xix ~

and was the most cytotoxic

tricyclic/polycyclic isatin derivative synthesised within this project. In general, the
tetracyclic and pentacyclic isatins displayed greater activity than the analogous
tricyclic derivatives.
Linker development: The design, synthesis and utility of a series of novel
acid-labile, imine-based linkers, which were attached to a potent )-alkylisatinderived

cytotoxin,

5,7-dibromo-)-(p-methoxybenzyl)isatin

(24)

was

also

investigated. In order to model the conjugation of these acid-labile linkers to the
lysine residues of tumour-targeting proteins, the aryl imines (153-157) were coupled
via their free carboxylic acids to a protected lysine amino acid residue to produce a
novel series of imine-lysine conjugates (158-162). Both the aryl imines (153-157)
and the imine-lysine conjugates (158-162) were stable for an extended period at
pH 7.4 but readily cleaved in aqueous acidic solutions at physiological temperature,
with half-lives ranging from 17.0 to 85.2 min. Observed rates of hydrolysis for the
embedded imine-acid moiety were in the order para-phenylpropionic acid >
phenylacetic acid (para > meta) > benzoic acid (meta > para).
The 3-iminoisatins (153-157) and the isatin-lysine conjugates (158-162) were
also assessed for biological activity. 3-Iminoisatins 153-157 displayed cytotoxicity
in the low to sub-micromolar region against U937 cells, while isatin-lysine
conjugates 158-162 all exhibited cytotoxicity in the nanomolar region after being
exposed to U937 cells for 24 h. The meta-substituted isatin-lysine 161 was the most
cytotoxic molecule synthesised within this entire project, with an IC50 value of
165 nM against U937 cells.
Ligand-targeted drug development: Finally, the 3-iminoisatin 155 was
conjugated to the tumour-targeting proteins PAI-2 (an endogenous inhibitor of the
urokinase plasminogen activation system) and transferrin (Tf) via amide bond
~ xx ~

formation with free lysine residues. UV-Vis spectrophotometry was used to visualise
evidence of the isatin-protein conjugates 165 and 166. Upon treating the transferrin
receptor over-expressing breast cancer cell line MDA-MB-231 with the isatin-Tf
conjugate (166) for 48 h, a significant cytotoxic response (compared to Tf) was
observed. At the highest concentration tested (1.56 µM), the conjugate 166 was
47±13% more cytotoxic than the Tf control. This work suggests that imine-linked
isatin-protein conjugates possess the potential to be used as new therapeutic agents in
the future.
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CHAPTER 1
Introduction
1.1 General Introduction
Cancer will affect one in two men and one in three women before the age of
85.1 Today, cancer is the second leading cause of death in the developed world,
killing over 39,000 people in Australia in 2005 and accounting for 29% of the total
mortalities.1 People of all ages may be affected by cancer, although incidence
generally increases with age. Due to Australia’s increasingly aging population, it is
estimated that the number of deaths caused by cancer will increase by 800 people per
year.1 Financially, cancer costs the Australian health system $3.8 billion per year, a
total of 7.2% of the entire health system expenditure.2 However, mortality rates have
decreased and survival rates have improved over recent years. As of 2004, 58% of
males and 64% of females in Australia with cancer survive within five years of
initial diagnosis compared to just 41% and 53% respectively in 1986.1 Although this
data is promising, there is still a pressing need to improve current cancer therapeutics
to further increase survival rates, to reduce the risk of metastatic, or secondary
cancers and to mitigate harmful side effects associated with the treatments.

1.2 Molecular Biology of Cancer
Cancer is characterised by a range of abnormal cell behaviour but a key
hallmark is the uncontrolled division of cells. Metastasis occurs when a cancerous
cell has escaped its primary origin site and invades other sites of the body such as the
bones, the brain and the lungs.3 Metastatic cancer cells are able to degrade
~1~
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membranes and natural barriers in the body to aid their escape. The treatment of
these cancers is difficult compared to those that are localised, primarily due to the
cells being undetectable at the time of screening.
Although it is a common disease, at the cellular level, the development of
cancer is a very rare event.4 Malignant progression requires multiple genetic
modifications and for this reason, the majority of cells do not give rise to cancer.
One of the initial steps in the development of malignant tumours is the formation of
a benign tumour. Cells in this type of tumour are no longer responsive to the usual
growth control signals, and at the same time, lack the ability to invade normal tissue
or metastasise.4 To metastasise, a cell from the benign tumour must detach itself
from its initial origin, migrate and invade surrounding tissue, and subsequently
degrade the components of the extracellular matrix (ECM) including the basal
lamina (Figure 1.1). By disintegrating the membrane, the cancer cells gain access to
the blood and lymphatic vessels allowing colonisation at distant sites around the
body.5,6 This migration is the major cause of cancer related death.
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Figure 1.1 The step-by-step schematic representation of how a benign tumour
develops into a metastatic malignant tumour. Adapted from Alberts et al.7
The human body is composed of 1015 cells and a subset of these, particularly
skin, bone marrow and red blood cells, regularly divide and differentiate to
repopulate organs and tissues which require cell turnover.8 There are approximately
1012 cell divisions per day and molecular mechanisms such as cell cycle checkpoints
and apoptotic pathways are in place to govern cell proliferation and cell death.
Alterations in these pathways often lead to cancer.

1.2.1 The Cell Cycle and Cancer
Each cell passes through a series of distinct stages that form the cell cycle. This
cycle is divided into four phases: the G1, S and G2 phases which constitute
interphase, and mitosis, the M phase (Figure 1.2). Mitosis is the process by which
duplicated chromosomes are separated into two nuclei, while interphase is the period
between cell divisions.9
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Figure 1.2 Phases of the cell cycle.10

Most cells except e.g. stem cells, spend the majority of their time in the
interphase, which allows them to grow and undergo metabolic activities. The S phase
is the time in which the cell synthesises DNA. The G1 and G2 phases are rest
periods. At this time, cellular DNA passes through numerous cell cycle checkpoints,
is inspected for damage, and if necessary, repaired before proceeding to the next
phase. When a cell does not respond to cell cycle checkpoints, it proceeds through
the cell cycle with damaged DNA giving rise to daughter cells with pre-cancerous
characteristics and altered morphology. Through developing further alterations,
known as mutations, the cell may develop into a malignant tumour.

1.2.2 Cell Death and Cancer
Cancer is not only characterised by uncontrolled proliferation but also cell
immortality. Each day our bodies produce approximately 60 billion cells and each
second, almost one million cells will die.11 This cycle of cell birth and cell death is
regulated by mechanisms that control the rates of input and output. Therefore,
programmed cell death (referring to strict genetic control) is crucial for the survival
~4~
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of almost all multicellular organisms. Physiological or programmed cell death
usually occurs through the process of apoptosis, although cell death may also occur
through necrosis.
Apoptosis is a series of morphological and biochemical changes that take place
in cells that have been “instructed” to die in response to certain stimuli, DNA
damage or reaching the end of their lifespan. Changes associated with apoptosis
include chromatin condensation, nuclear fragmentation, cell shrinkage and blebbing
from the plasma membrane.11,12 Apoptotic cells are removed in vivo by
phagocytosis, whereby the dying cells are “eaten alive” by phagocytes and their
“corpses” are recycled back into the body.11
Unlike apoptosis, necrosis is considered to be a passive response to a huge
cellular insult12 and is free from strict genetic control. A lack of cellular energy
production, an imbalance of intracellular calcium flux and the activation of
non-apoptotic proteases may induce necrosis. The process of phagocytosis in
necrotic cells is much more challenging because the disorderly death does not send
“eat me” signals to phagocytes to engulf the cell. This lack of signaling makes it
difficult for the immune system to locate and recycle the dead cells.
The cellular features of necrotic cells also differ from apoptotic cells. Necrotic
cells feature damaged membrane lipids, random DNA degradation and swelling of
cellular organelles.12 These organelles then burst releasing harmful contents that
potentially damage neighbouring cells. As a result, an inflammatory response occurs.
In order to treat cancer chemotherapeutically, pharmaceutical agents have two main
strategies to halt cell proliferation or to induce cell death in cancer cells.
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1.3 Current Cancer Therapeutics (Non-Selective)
Cancer was considered a terminal disease until the 19th Century when
anaesthesia made surgery more feasible. Radiation therapy became the next
treatment, but even surgery and radiation combined were insufficient to control
metastatic cancer. In 1942 the era of chemotherapy began with the first
chemotherapeutic agent, mechlorethamine (1), a nitrogen mustard DNA-alkylating
drug used for the treatment of non-Hodgkin’s lymphoma13 (Figure 1.3A). Use of this
drug has now discontinued due to its potential application as a chemical warfare
agent.14 Although the cancer treated with 1 was in remission for only a few weeks, it
proved that systemically administered drugs could induce tumour regression.
A plethora of chemotherapeutics have been developed and clinically employed
in subsequent years. Most of these drugs interfere with DNA replication such as the
purine- and pyrimidine-based anti-folates 6-mercaptopurine (2) and 5-fluorouracil
(5-FU) (3) respectively; DNA-intercalating drugs such as the anthracyclines
[e.g. doxorubicin (4) and daunorubicin (5)]; and metal-based DNA-alkylating drugs
such as cisplatin (6) and oxaliplatin (Figure 1.3A). Additionally, there are
chemotherapeutics that inhibit cell proliferation through interference with
microtubule assembly such as vinblastine (7), a tubulin destabiliser and paclitaxel
(8), a tubulin stabiliser15 (Figure 1.3B). Microtubules are the basic components of
cell structure and play a role in various cellular functions including intracellular
transport, maintenance of cell shape, motility and chromosome segregation during
mitosis.16 While all of these agents demonstrated anti-proliferative properties, many
chemotherapeutic drugs experience resistance after repeated use.17,18
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Figure 1.3 Chemotherapeutics used clinically both in the past and at present. A)
Chemotherapeutic drugs that inhibit DNA replication; B) Chemotherapeutic drugs
that interfere with microtubule assembly.

Chemotherapy largely relies on the premise that cancer cells proliferate at
much higher rates than normal cells and are therefore more likely to be killed by a
cytotoxic agent.3,19 The major drawback of cytotoxins is they have little, if any,
specificity. This leads to serious damage of non-tumour tissue20 and systemic
toxicity, resulting in severe side effects such as hair loss, liver or kidney damage.19
Therefore, there was a need to design and develop more targeted drugs with limited
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additional systemic effects. It was not until the late 1980s that the era of “targeted
therapy” began.13 Targets for cancer chemotherapy include signaling molecules,
modulators of apoptosis and molecules involved in the promotion of angiogenesis.

1.4 Site-Specific Cancer Therapy
Site-specific drug delivery is currently one of the most challenging problems in
pharmaceutical research since the drug has to be transported through the systemic
circulation, pass complex tissue barriers and be selectively delivered to tumours.21
Effective site-specific drug delivery increases the availability of the drug at the target
site while reducing its availability at other sites, especially those which display
toxicity.22 As of 2009, there were 22 Food and Drug Administration (FDA) approved
site-specific cancer therapies (nine monoclonal antibodies (mAbs), 12 small
molecule drugs and one fusion protein).23 Site-specific cancer therapies represent a
growing focus area for pharmaceutical companies with more than a 200% increase in
sales in the United States in 2009 compared to 2005.23
Targeting drugs to specific sites is especially important for compounds which
are highly toxic, have a narrow therapeutic index and/or limited solubility as these
issues can limit the clinical use of potentially highly effective drugs. Site-specific
drug delivery can be achieved by: application of the drug directly to the target organ
such as dermal or ocular formulations; site-specific bioactivation where the drug is
distributed throughout the body but undergoes bioactivation only at the target site24
such as kinase inhibitors or; conjugation of a drug to a targeting moiety where a
carrier molecule delivers the drug to the tumour site.
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1.4.1 Kinase Inhibitors
Cellular division at some point relies on protein kinases. These enzymes
transfer a phosphate group from adenosine-5’-triphosphate (ATP) to a tyrosine,
serine or threonine residue in a protein. Hence, these kinases can be further divided
into tyrosine kinases or serine/threonine kinases.25 Dysfunctional protein kinase
activity has been linked to angiogenesis and various forms of cancer,26 and thus,
kinase inhibitors are appealing therapeutics for the treatment of cancer.27 The first
small molecule kinase inhibitor to be approved by the FDA was imatinib mesylate
(Glivec®, Novartis; Gleevec in USA) (9) (Figure 1.4) in May 2001 for the treatment
of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumours
(GIST).28,29 Glivec® was an orphan drug for CML and received the fastest ever FDA
approval for an anti-cancer drug.28 The drug is capable of inhibiting the tyrosine
kinase enzyme Bcr-Abl in CML30 rather than non-specifically inhibiting and killing
all rapidly dividing cells.
In January 2006 the FDA approved sunitinib malate (Sutent®, Pfizer) (10)
(Figure 1.4) for the treatment of renal cell carcinoma and GIST,31 particularly for
imatinib-resistant or advanced stage GIST.32 This drug was the first multi-targeted
receptor tyrosine kinase inhibitor, targeting vascular endothelial growth factor
receptor-2 (VEGFR-2), platelet-derived growth receptor-β (PDGFR-β), stem cell
factor receptor, fetal liver tyrosine kinase receptor-3,25 colony-stimulating factor type
1 and glial cell-line derived neurotrophic factor receptor.33 Due to its ability to target
multiple kinases, 10 may be applicable in the treatment of other cancers.34 Recently,
Phase III trials have demonstrated that the drug also possesses promising cytotoxic
activity towards pancreatic neuroendocrine35 and non-small cell lung cancers.36
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Figure 1.4 Clinically used kinase inhibitors imatinib mesylate (9) and sunitinib (10).

1.4.2 Site-Specific Cancer Therapy using Conjugates
Further examples of site-specific drug delivery involve targeting receptors or
proteins that are over-expressed on tumour cells. Oncology treatments could be
significantly improved if a tumour recognising moiety and a cytotoxic agent were
attached either directly or via a suitable linker to form a tumour-targeting conjugate.
To improve the therapeutic potential of cytotoxic drugs, there has been a significant
amount of research in recent years regarding the conjugation of cytotoxins to
macromolecules or carrier molecules such as antibodies, proteins and synthetic
polymers.37 In their simplest form, these conjugates consist of the cytotoxin and the
macromolecule bound either directly or via a spacer, or linker, which may be cleaved
at the target site through enzymatic cleavage (e.g. cathepsin B38 or esterases) or
under acidic conditions to release the active cytotoxin (see Section 1.6) (Figure 1.5).
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Figure 1.5 Schematic representation of a simple drug conjugate.

Tumour-targeting conjugates are essentially prodrugs, which should not be
toxic to the host, be stable in circulation and readily cleaved to release the cytotoxic
agent once the conjugate has entered the cancer cell.20,39 The process of entering the
intracellular environment of the targeted cell can be accomplished through
receptor-mediated endocytosis (RME).40 First, ligands are able to bind to specific
receptors on the cell surface. These receptors are then gathered into clathrin coated
pits and enter the cells efficiently in conjunction with the ligand. Upon
internalisation, the vesicles in the receptor-ligand complex are uncoated by an
ATP-dependent enzyme.41 The internalised molecules are then guided to the early
(or “sorting”) endosomes and the receptors and ligands dissociate from one another
in the acidic environment of the endosomes (pH 5.5-6.8).42,43 In many cases,
receptors are recycled to the cell surface, while the released ligand is delivered to
endosomes or lysosomes (pH 4.5-5.0)37 for degradation.40,44
The key elements of a successful drug conjugate involve the judicious choice
of the drug, the linker and the targeting ligand. The work described here is aimed at
the design and development of a new site-specific cancer therapy using:
~ 11 ~
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•

an isatin-based anti-cancer agent as the drug;

•

acid-labile imine chemistry as the linker;

•

and, two tumour-targeting proteins (transferrin and PAI-2) as the
targeting ligands.

1.5 Choice of Drug: Isatins as Anti-Cancer Agents
Isatin (1H-indole-2,3-dione) (11) (Figure 1.6) was first discovered by
Erdman45 and Laurent46 in 1840 as a product arising from the oxidation of indigo
(12) (Figure 1.6) by nitric and chromic acids. The compound was considered
synthetic for almost 140 years until its presence was discovered in fruits of the
cannon ball tree, Couroupita guianensis Aubl.,47 (Figure 1.7A). Isatin (11) is also a
component of the secretion from the parotid gland of the Bufo melanostrictus (Asian
black spined toad) and Bufo gargarizans (Asiatic toad) toads from the Bufo genus48
(Figure 1.7C, D). Derivatives of isatin (11) have also been found in fungi,49
Dicathais orbita, an Australian marine mollusc50 (Figure 1.7E), and in plants from
the Isatis genus, in particular Isatis tinctoria (woad flowers, sometimes incorrectly
referred to as Isatis indigotica) (Figure 1.7B) which contain isatisine A (13),51 an
alkaloid for which the total synthesis has only recently been reported.52

Figure 1.6 Structures of isatin (11), indigo (12) and isatisine A (13).
~ 12 ~
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Figure 1.7 Flora and fauna containing isatin (11) and its derivatives. A) The plant
Couroupita guianensis Aubl;53 B) The plant Isatis tinctoria;54 C) The toad Bufo
melanostrictus;55 D) The toad Bufo gargarizans;56 E) The marine mollusc Dicathais
orbita.50

In humans, isatin (11) is an endogenous molecule. The synthetic and metabolic
pathways of 11 are unconfirmed although it is hypothesised that it may be
synthesised from tryptophan-rich foods such as meat, dairy and whole grains. The
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tryptophan is converted to indole by bacteria from the gastrointestinal tract and then
transported to the liver where it is oxidised.57,58 Isatin (11) also plays a role in many
physiological pathways.

1.5.1 Biological and Pharmacological Effects of Isatin and its Derivatives
Isatin (11) was found to be a major component of tribulin, an endogenous
selective inhibitor of monoamine oxidase type B.59 Isatin (11) is also a metabolic
derivative of adrenaline and a potent antagonist of atrial natriuretic peptide,60 the
peptide responsible for natriuresis (sodium excretion), diuresis (water excretion) and
vasodilatation. Additionally, 11 is anxiogenic (causes anxiety) due to its actions on
central benzodiazepine receptors,57 which correlates to studies finding increased
levels of isatin (11) in rat urine during times of stress such as exposure to acute
cold.61
Increased levels of 11 lead to decreased food intake due to the compound
increasing serotonin levels, and by directly affecting the medial hypothalamus in the
brain.62 Therefore, it may be regarded as a satiating agent and interestingly, elevated
levels of 11 have been found in the cerebrospinal fluid of humans with the eating
disorder bulimia nervosa.63
The synthetic versatility of 11 has led to the preparation of a variety of
derivatives. Originally, analogues were synthesised with substituent changes at C2 of
the molecule through oxygen alkylation or alterations at C3 using nucleophilic
attack, however, in recent years there has been a surge in the synthesis of
)-substituted isatins.64-68 This has led to isatin derivatives with a broad spectrum of
biological

properties

including

anti-inflammatory,69
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anti-convulsant,70

anti-histaminic,71

anti-fungal,72

anti-viral,73

anti-ulcer74

anti-amyloid75 and anti-cancer71,76 activities.

1.5.2 Isatin as a Cytotoxin
Isatin (11) has been tested against a variety of human cancer cell lines
including HL60 (promyelocytic), PC12 (pheochromocytoma) and N1E-115
(neuroblastoma) and was found to be an inhibitor of cell proliferation in all the cell
lines investigated.69 During apoptosis, 11 caused DNA fragmentation as well as
chromatin condensation and reduced cell proliferation by 80% at a concentration of
100 µM compared to controls. This effect was concentration dependent as only 20%
cell death was observed at 10 µM.69 Further research using human neuroblastoma
SH-SY5Y cells confirmed that the effect of 11 on cell proliferation was dose and
time dependent.60 After 48 h of exposure to 11, cells containing lower concentrations
of 11 began to undergo apoptosis, while cells with increased levels of 11 produced a
late apoptotic/necrotic response (Figure 1.8). Cells containing 400 µM of 11
demonstrated the greatest cell death, with an apoptotic response of 82%.60
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Figure 1.8 Morphological modifications in cell structure of SH-SY5Y
neuroblastoma cells. Cells were treated for 48 h with 50 µM (B and E) and 100 µM
(C and F) of isatin (11). As a positive control 100 nM (A and D) staurosporine was
used. Slides A-C were analysed using light microscopy while slides D-F were
analysed with propidium iodide. Arrows show cells with apoptotic morphology.60

1.5.3 Isatin Derivatives as Cytotoxins
The cytotoxic nature of isatin derivatives was established over 30 years ago77,78
and a comprehensive review of recently synthesised cytotoxic isatin analogues was
published by our research group in 2009.79 Research into the cytotoxic nature of
isatins commenced at the University of Wollongong in 2002 when it was discovered
that chloroform extracts of the egg masses of the Australian muricid mollusc,
Dicathais orbita, exhibited cytotoxic activity.80 Among the components of the
extract were tyrindoleninone (14), tyriverdin (15), and 6-bromoisatin (16) (Figure
1.9). While tyrindoleninone (14) was shown to be the most active component in a
cell-based assay using human monocyte-like, histiocytic lymphoma cells (U937)
(IC50 = 4 µM against U937 cells, 195 µM against human mononuclear cells)81
(IC50 = concentration required to inhibit 50% of the population), it was unstable, as
was the weakly cytotoxic component, tyriverdin (15).82
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Figure 1.9 Components from the egg masses of the Australian mollusc Dicathais
orbita (14-16); and highly cytotoxic brominated isatin derivatives (17-18).

Attention thus turned to the significantly more stable brominated isatin 16,
which was subsequently shown to possess modest cytotoxic activity towards U937
cells (IC50 = 84 µM).81 In an effort to then acquire a variety of brominated isatin
motifs, 5,7-dibromoisatin (17) (Figure 1.9) was synthesised and shown to display
increased cytotoxicity against U937 cells (IC50 = 10.5 µM).81 In an independent
study, the introduction of a 5-bromo substituent to isatin (11) also increased the
anti-cancer activity of the parent molecule.83 In contrast, nitro and methoxy
substituents at the C5 position of isatin (11) led to a decrease in cytotoxic activity
against

U937

(IC50 = 6.76 µM)81

cells.81
with

Furthermore,
the

addition

cytotoxic
of

another

activity
bromine

was

enhanced

atom,

as

in

5,6,7-tribromoisatin (18) (Figure 1.9). Unfortunately, the compound was a side
product from the bromination of 6-bromoisatin (16) and proved difficult to produce
in large quantities.
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)-Alkylated indoles are well known to exhibit anti-cancer activity84,85 and the
cytotoxic activity of the first )-alkylisatin was described soon after. The )-benzyl
compound 19 (Figure 1.10) induced apoptosis in a panel of human cancer cell lines,
but not normal cells, at micromolar concentrations.86 Further screening by the
National Cancer Institute found that the dichlorinated compound 19 exerted a
cytostatic effect (inhibiting cell growth by 50-100%) on 40 out of the 48 cell lines
tested, at a concentration of 10 µM. At 10 times this concentration however, the
compound exhibited 100% cytotoxicity on virtually all cell lines, suggesting that this
effect may be due to non-specific toxicity.86
Since the brominated isatins 16-18 displayed increased potency compared to
the parent isatin (11) (IC50 = 565 µM),81 and it had been demonstrated that
)-alkylation significantly enhanced the cytotoxicity of 11, Vine et al. synthesised a
series of brominated )-substituted isatins (e.g. 20-25) (Figure 1.10) and evaluated
their cytotoxicity against a panel of cancer cell lines in vitro.64 Structure-activity
relationship (SAR) studies indicated that the introduction of an )-benzyl group with
electron withdrawing groups substituted at the meta or para position of the
substituent phenyl ring showed increased cytotoxicity compared to ortho derivatives.

Figure 1.10 Early examples of cytotoxic )-alkylisatins.
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Nine of the 24 compounds synthesised by Vine et al. displayed
sub-micromolar IC50 values and generally demonstrated greater selectivity toward
leukemia and lymphoma cell lines over other cell lines tested (e.g. prostate, breast,
colon, melanoma). The )-(p-methyl)benzyl compound 25 was the most active of the
series, displaying an IC50 value of 490 nM against U937 and human leukemic T cell
(Jurkat) cell lines after 24 h.64 This effect was enhanced further by at least a factor of
two when the incubation time was increased from 24 h to 72 h, making this class of
compounds >10 times more active than the conventional chemotherapeutic agents
5-FU (3), vinblastine (7) and paclitaxel (8) against U937 cells.79
Following on from this work, and in order to establish a more comprehensive
SAR for the dibrominated )-alkylisatins, a family of )-phenethyl and )-phenacyl
isatin derivatives were synthesised (26-30 and 31-35)65,87 (Figure 1.11). All five
)-phenethyl derivatives (26-30) exhibited low to sub-micromolar cytotoxic activity
against a panel of human leukemic, lymphoma and carcinoma cell lines, where
introduction of a hydrophobic bromo substituent in the meta (27) or para (28)
position yielded the most active compounds.65 Interestingly, the corresponding
)-phenacyl (31-35) derivatives were at least 3-5 times less active against the U937
cells and as a result were not tested against other cell lines.
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Figure 1.11 Cytotoxic )-phenethyl (26-30) and )-phenacyl (31-35)
5,7-dibromoisatin derivatives.

Further examples of )-substituted isatins that display cytotoxic activity
include the dibrominated )-1- and )-2-naphthylmethyl derivatives 36 and 37
(Figure 1.12). The )-naphthylmethyl isatins displayed nanomolar cytotoxicity
against U937 and Jurkat cell lines, with IC50 values for the )-1-naphthylmethyl
derivative 36 of 190 and 910 nM, respectively, along with low micromolar
cytotoxicity towards a panel of human carcinoma cell lines, including those derived
from breast (MDA-MB-231 and MCF-7), colon (HCT-116) and prostate (PC-3)
tissue.65 Interestingly, compound 36 represents the most cytotoxic )-alkylisatin
reported to date, when compared with other )-alkylisatins tested over 24 h. This
suggests that increasing the hydrophobicity of the )-substituent through site-specific
placement of an additional aromatic ring is important for enhancing cytotoxic
activity.
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Figure 1.12 Cytotoxic 5,7-dibromo-)-naphthylmethylisatin derivatives 36 and 37.

In addition to their potent cell killing ability, )-alkylisatins have also been
found to induce G2/M cell cycle arrest (see Section 1.2.1) and dramatically alter
lymphocyte morphology64,65 (Figure 1.13B) in a similar manner to the tubulin
destabiliser vinblastine (7) (Figure 1.13C).

Figure 1.13 Elongated cell morphology after treatment with isatin derivatives. A)
DMSO vehicle control; B) )-2-Naphthylmethyl compound 37 at 0.39 µg/mL; C)
Vinblastine (7) at 0.39 µg/mL. Magnification 1000 ×.65
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Considering cells treated with tubulin-interfering chemotherapeutics such as
vinblastine (7) and paclitaxel (8) display similar cell morphology to those treated
with )-alkylisatins, an array of )-alkylbenzylisatins including the highly potent
)-phenethyl (26, 28) and )-naphthylmethyl (36, 37) derivatives were screened for
their ability to interfere with microtubule dynamics. A cell-free in vitro tubulin
polymerisation assay was performed (Figure 1.14). Vinblastine (7) and paclitaxel (8)
were used as a known microtubule destabiliser and stabiliser respectively. Consistent
with literature reports,16,88 at 10 µM paclitaxel (8) stabilised microtubules while
vinblastine (7) was a potent microtubule destabiliser (Figure 1.14). The test
compounds, in particular the )-2-naphthylmethyl derivative 37, appeared to be
potent microtubule destabilisers at 10 µM (Figure 1.14), as observed by the shift of
the curve to the right of the control, indicating a decrease in the rate of tubulin
polymerisation. This trend is consistent with reports that structurally similar
indole84,89 and indolinone88,90 compounds inhibit tubulin polymerisation.

Figure 1.14 Effects of )-alkylisatins 26, 28, 36 and 37 on the tubulin polymerisation
assay.65
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The mode of action of cytotoxic isatin derivatives is strongly dependent on the
nature of substitution within the molecule (Figure 1.15). While )-alkylation results
in cytotoxic compounds with nanomolar activity inducing morphological change by
interfering with tubulin polymerisation, isatin analogues derivatised at the C2
position exhibit CDK1, CDK291 and GSK392 kinase inhibition. Similarly, isatin
derivatives functionalised at the C3 position display kinase inhibitory activity,
including inhibition of VEGFR-2, PDGFR-β, fibroblast growth factor receptor and
epidermal growth factor receptor.89 Derivatisation around the aryl ring generally
leads to isatin analogues which induce cancer cell death via apoptosis in the mid to
low micromolar range and necrosis in the high micromolar range.79

Figure 1.15 Structure-activity summary of cytotoxic isatin derivatives.79

Further sites to explore around the isatin nucleus include the region between
N1 and C7, and this forms the basis of the chemistry component within this thesis.
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To expand the cytotoxic SAR of the )-alkylated isatins, new derivatives were
considered which would partially restrain conformational mobility in the important
)-arylalkyl substituent group. To this end, target structures were envisaged which
incorporated a new ring between N1 and C7 of the isatin nucleus. In the new target
compounds, the original hydrophobic C7-substituent was to be subsumed by a
methylene or methine in the new ring (Figure 1.16).

O

R
7

O

N1
Ar

R = H, halogen

Figure 1.16 General structure of the proposed new target isatin compounds
incorporating an additional ring between N1 and C7 of the isatin nucleus.

Restrained conformational flexibility is frequently used within medicinal
chemistry in an attempt to increase biological activity. Recent examples of molecules
which have benefited from the introduction of rigidity into the structure include the
clinically used breast cancer treatment tamoxifen,94 the macrolide natural product
family of epothilones95 and combretastatin A-4,96-98 which is currently undergoing
clinical trials as a cytotoxin and tubulin polymerisation inhibitor. These parent
molecules all increased in cytotoxicity when an additional ring system was
introduced as shown in Figure 1.17.
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Figure 1.17 Structures of tamoxifen, epothilone D and combretastatin A-4 and their
more cytotoxic partly rigidified analogues. A) Tamoxifen and its benzoxepin
derivative against MCF-7 breast cancer cells;94 B) Epithilone D and its cyclopentene
derivative against CCRF-REM leukemia cells;95 C) Combretastatin A-4 and its
furazan derivative against SH-SY5Y neuroblastoma cells.96

The results from the synthesis of the novel isatin molecules incorporating
structural modifications in this area will be discussed in Chapters 2 and 3.
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Investigations into the cytotoxic activity and the SAR of the novel isatin derivatives
will be discussed in Chapter 6.

1.6 Choice of Linker: Acid-Labile Linkers
Selecting an appropriate linker for the conjugation of a cytotoxin to the carrier
molecule is critical for successful drug delivery and release of the drug.43 Most
receptor targeted drugs are delivered via RME, therefore conjugate linkers are
required to be acid-labile to ensure hydrolysis in the reduced pH of endosomes and
lysosomes (pH 4.5-6.0), while remaining stable at physiological pH (7.4).
The first reported acid-labile linker was the cis-aconityl linker between
daunorubicin (5) and Affi-Gel 701 (aminoethyl polyacrylamide beads) and
poly(D-lysine).99 Here, Shen and Ryser reported that the hydrolysis half-life of the
cis-aconityl linker on the Affi-Gel 701 conjugate was less than 3 h at pH 4.0 and
greater than 96 h at pH 6.0 and above. Over the years the cis-aconityl linker has been
utilised to conjugate daunorubicin (5) to monoclonal antibodies (mAbs),100 and
doxorubicin (4) to polymers101,102 (Figure 1.18A).
However, the most comprehensively studied acid-labile linker is the hydrazone
linker.103 A hydrazone linker has been used to successfully conjugate anthracyclines
such as doxorubicin (4) and daunorubicin (5) to mAbs via the exocyclic C13-keto
position104 (Figure 1.18B). The doxorubicin conjugate shown in Figure 1.18B was
found to exhibit stability at physiological temperature and pH, with less than 10%
release of 4 after 5 h. At pH 4.5, however, the conjugate released greater than 50% of
4 after a few hours.103 The acid-labile hydrazone linkage has also been applied to
other commercially available therapeutics such as 5-fluorouridine, chlorambucil,
daunorubicin (5) and vinblastine (7).103
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Clinically, the hydrazone linker was used to create Mylotarg® (Wyeth/Pfizer),
a conjugate containing the mAb gemtuzumab and the cytotoxic antibiotic
ozogamicin (see Section 1.7.1). Mylotarg® was 7000-fold more potent than the
analogous amide linker conjugate against the CD33 positive HL-60 cell line in vitro,
and 100-fold more cytotoxic than ozogamicin alone.43
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Figure 1.18 Examples of drug conjugates containing acid-labile linkers (highlighted
in blue). Doxorubicin (4) conjugated to A) a polymer through a cis-aconityl linker;
B) a monoclonal antibody through a hydrazone linker.
Examples of other acid-labile linkers include acetals,105,106 oximes107 and
imines.38,108 Imines are not widely used in drug delivery due to their perceived
instability,109 however, in recent years stabilised imines have shown great potential
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for further development.110 Chapter 4 of this thesis will focus on imines as
acid-labile linkers for site-specific cancer therapy using conjugates (Figure 1.19).

Figure 1.19 General schematic of the proposed drug conjugate utilising an imine
linker.

1.7 Choice of Targeting Ligand: Macromolecular Drug Delivery
Many drugs used in the clinic have serious drawbacks that could be greatly
reduced through improved site-specificity and biodegradation protection, leading to
decreased side effects. One strategy to overcome these problems is to use
macromolecular drug delivery, where a macromolecule such as a protein or an
antibody is attached to a drug through a bio-reversible linkage to provide selective
drug delivery.111 The physiological absorption and distribution of a drug is
dependent on the physicochemical properties of the macromolecule, not the drug
itself. The advantages of using macromolecules in drug delivery are an improvement
in the therapeutic index of a drug by reducing the interactions with non-target tissues
and also decreasing premature drug metabolism and excretion.112 Other drug
delivery systems incorporate the use of polymers,113 nanoparticles114,115 and
liposomes,116 which have been widely reviewed.
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1.7.1 Antibodies
Antibody-drug conjugates, in particular mAbs which alter cell signaling,3 are
the most commonly used proteins in targeted therapies. They can be cytotoxic to
cancer cells in their own right, or conjugated to drugs, bacterial or plant toxins, or
radionuclides to improve their efficacy.117-119 By binding to antigens on the surface
of cancer cells, the conjugate can be internalised through RME and then the
therapeutic agent can be cleaved from the mAb.
More than 20 unconjugated mAbs have been approved for clinical use120 such
as

trastuzumab

(Herceptin®,

Genentech/Roche)

and

lapatinib

(Tykerb®,

GlaxoSmithKline) for the treatment of HER2-positive breast cancer.121 In contrast,
only one mAb-drug conjugate has been granted approval by the FDA to date.
Gemtuzumab-ozogamicin (Mylotarg®, Figure 1.20) was approved in 2000 for the
treatment of acute myelogenous leukemia.19,118 This conjugate comprised a
humanised anti-CD33 hP67.6 mAb attached to the cytotoxic antibiotic ozogamicin
()-acetyl-γ-calicheamicin) via a hydrazone bond.3 However, in June 2010, Pfizer
voluntarily withdrew Mylotarg® due to post-approval studies revealing the conjugate
did not demonstrate increased survival rates.122
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Figure 1.20 Structure of Mylotarg®. The antibiotic, ozogamicin, is conjugated to the
monoclonal antibody, gemtuzumab.

Currently, there are six mAb-cytotoxin drug conjugates in Phase II or III
clinical trials122 (Figure 1.21), with the trastuzumab-emtansine conjugate121 (entry 2,
Figure 1.21) in the latest stage of clinical development. In July 2010, a biological
license application for this conjugate was filed by Genentech to the FDA. Other
preclinical research in progress involves conjugating mAbs with taxanes such as
paclitaxel (8) and synthetic analogues of natural products.24

Figure 1.21 Monoclonal antibody-cytotoxin drug conjugates in Phase II or III
clinical trials as of July 2010.122
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The only other immunoconjugates approved by the FDA were the
radioimmunoconjugates Zevalin® (ibritumomab tiuxetan) in 2002 and Bexxar®
(tositumomab) in 2003, both for the treatment of B-cell lymphomas. These
conjugates contain an anti-CD20 mAb attached to cytotoxic radioactive yttrium-90
and iodine-131, respectively.3,118
However, mAbs are expensive, time-consuming to produce and suffer from
issues of immunogenicity. Other problems arise with the use of mAb-drug
conjugates, including poor penetration into tumours19 due to their relatively large
molecular size. This can be resolved by utilising truncated mAb fragments which
have been shown to penetrate tumours more readily than the full-length mAb,
although this also has drawbacks as the fragment is cleared from the circulation more
rapidly.19

1.7.2 Transferrin
Non-mAb ligands such as transferrin (Tf) are an alternative option for targeted
macromolecular drug delivery. Transferrins are monomeric glycoproteins weighing
approximately 80 kDa and consisting of a single polypeptide chain with 670-700
amino acids.123 Transferrins transport iron to sites of absorption, storage and
utilisation, and control levels of free iron in body fluids by binding, sequestering and
transporting Fe(III) ions.124 The advantages of using Tf as a carrier molecule are that
it is a commercially available protein and in the case of anti-cancer drug therapy,
there is considerable uptake of Tf in tumour tissue due to elevated levels of Tf
receptors (TfR) on the cell surface of tumour cells (150,000 – 1,000,000 per cell).125
A variety of chemotherapeutics have been conjugated to Tf via cleavable
linkers, allowing the release of the cytotoxin within the acidic intracellular tumour
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cell environment after RME. The most widely reported examples involve
conjugating Tf to doxorubicin (4) in an attempt to decrease the cardiotoxicity
associated with the free drug and to combat resistance to this drug.126 Doxorubicin
(4) has been linked to Tf through amide/hydrazone125 and imine127 linkers, which all
exhibited an increase in efficacy in H-mesothelioma cells when compared to the free
drug.
Tf has also been conjugated to the cytotoxin, chlorambucil (Leukeran®,
GlaxoSmithKline) through a hydrazone bond (38) (Figure 1.22), which displayed
IC50 values 3 to18-fold lower than those for chlorambucil alone against the MCF-7
(breast) and MOLT4 (leukemia) cell lines.123
Recently, the anti-malarial compound artemisinin, derived from Artemisia
annua (sweet wormwood), proved to also possess cytotoxic activity128 and was
subsequently conjugated to Tf via a hydrazone bond129 (39) (Figure 1.22). The Tf
conjugate contained ~16 molecules of artemisinin and displayed increased
cytotoxicity against DU 145 prostate tumour cells compared to free artemisinin.

Figure 1.22 Examples of drugs which have been conjugated to Tf.
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1.7.3 The Urokinase Plasminogen System
Another alternative and novel strategy which shows promise for the
site-specific

delivery

of

cytotoxins

involves

a

different

non-antibody

macromolecular system, the urokinase plasminogen activation (uPA) system.
Tumour progression is strongly associated with pericellular proteolytic activity of the
serine proteinase, plasmin.130 This is due to unregulated expression of the uPA
system, comprising the 53 kDa serine protease uPA, its cell-membrane anchored
receptor uPAR and its two endogenous inhibitors PAI-1 and PAI-2.131 PAI-1 and
PAI-2 both belong to the serpin (serine proteinases inhibitor) family. PAI-1 is
thought to be the primary inhibitor of uPA but both PAI-1 and PAI-2 have been
shown to inhibit metastasis,131,132 although it has also been reported that elevated
tumour levels of PAI-1 lead to tumour progression.133
The uPA system catalytically converts inactive plasminogen in circulation to
the active proteinase, plasmin by cleaving the arginine-valine bond.134 Plasmin at the
cell surface catalyses the degradation of proteins in basement membranes and the
ECM and therefore assists tumour cell passage to distant areas of the body132 (Figure
1.23). A direct correlation exists between the amount of uPA expressed on the
surface of cancer cells and the potential for metastasis to occur.135-137 The majority of
cells under normal physiological conditions do not express uPA activity,135 whereas
over-expression of the uPA system is observed in numerous malignancies including
breast, prostate, endometrial, gastrointestinal, pancreatic and colorectal cancers.138
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Figure 1.23 The urokinase plasminogen activation (uPA) system.139 By binding
PAI-1 and PAI-2 to uPA, plasminogen conversion to plasmin is inhibited causing
malignant progression to be discontinued.

The uPA system is an appealing target for anti-cancer therapy.138 Cell invasion
and metastasis could be stopped by inhibiting the catalytic activity of uPA, thus
preventing uPA from binding to its receptor,131,140 by inhibiting plasmin138 or by
exploiting the receptor to deliver cytotoxic agents into tumour cells.135,141,142 This
latter strategy is achievable since PAI-1 and PAI-2 trigger a series of events which
internalise the cytotoxic conjugate/inhibitor/uPA/uPAR complex. The complex
encounters members of the low density lipoprotein receptor family of endocytosis
receptors before it is internalised by RME through clathrin coated pits.143 The entire
complex is then able to be degraded in the acidic environment of the late endosomes
and lysosomes, effluxing the free drug into the cytosol to cause cell death, while the
uPAR is recycled back to the cell surface143 (Figure 1.24).
While PAI-1 has been exploited to deliver cytotoxic agents to cells,135 the
targeting ability of PAI-2 is yet to be fully explored. However, PAI-2 has numerous
advantages over PAI-1 in terms of targeted cancer therapy. Firstly, it is a very stable
protein in vitro and in vivo and does not revert to an inactive form compared to
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PAI-1.144 As with PAI-1, PAI-2 is a protein of human origin and it does not elicit an
immune response. Additionally, abnormally elevated levels of plasma PAI-2 in late
pregnancy are not associated with toxicity, indicating that as a targeting agent, PAI-2
is unlikely to cause adverse effects.144 Other benefits related to its function include
being limited to uPA inhibition without secondary effects e.g. cell signaling elicited
by PAI-1.133

Figure 1.24 PAI-2 conjugated to a toxin targeting the uPA system. The conjugate is
internalised by receptor-mediated endocytosis and then cleaved in the acidic
environments of the late endosomes or lysosomes releasing the active drug (Tox)
into the cytosol and causing cell death.

At the commencement of this research project, the only successful targeting of
a toxin conjugated to PAI-2 had involved the use of the α-emitting radiolabelled
isotope (213Bi).142,145,146 The conjugate selectively caused apoptosis in a prostate
cancer cell line (PC3) and did not target or destroy normal tissue which does not
express uPA.142 In vivo studies on the radioimmunoconjugate also demonstrated
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promising activity against breast carcinomas.145,146 Investigations into conjugating
other toxins, in particular synthetic cytotoxins, were required since problems arise
due to the radioactivity, cost, availability and short half-lives of α-emitting
isotopes.144
In early 2010, our research group reported the first example of a synthetic
cytotoxin-PAI-2 conjugate.147 The cytotoxic metabolite of 5-FU (3), 2’-deoxy-5fluorouridine, was conjugated to PAI-2 through an ester-labile succinate linker.
In vitro investigations revealed the PAI-2 conjugate preferentially killed tumour cell
lines with elevated levels of uPA expression.147 This result confirms that the uPA
system demonstrates potential in regard to selectively delivering anti-cancer agents
to tumour cells.
The conjugation of a cytotoxic isatin to tumour-targeting proteins via an imine
linker (Figure 1.25) will be discussed in Chapter 5.

Figure 1.25 General schematic of the proposed drug conjugate utilising PAI-2 or Tf
as the tumour-targeting ligand.
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1.8 Aims of Project
Effective targeted delivery of chemotherapeutic agents remains an unsolved
problem. It may be possible to selectively deliver the cytotoxic isatin derivatives into
tumour cells by conjugating them to a tumour-targeting protein such as Tf or PAI-2.
Linking the isatin derivative to a protein with an acid labile group would facilitate
hydrolysis of the drug after internalisation and exposure to the acidic environment of
the endosomes and/or lysosomes (Figure 1.26). This targeted isatin-imine linker
conjugate would limit undesirable systemic toxicity by providing specific delivery of
the chemotherapeutic agent to the tumour.

Therefore, the specific aims of this research project were:
•

Drug: To further explore the cytotoxic SAR of isatin derivatives by
synthesising novel isatin scaffolds through the introduction of additional ring
systems and measuring their cytotoxicity (Chapters 2, 3 and 6);

•

Linker: To design and evaluate an appropriate acid-labile, imine linker
system to attach cytotoxic isatins to a tumour-targeting protein (Chapter 4)
and,

•

Targeting Ligand: To conjugate the optimal cytotoxic isatin derivative to the
tumour-targeting proteins Tf and PAI-2 via the most suitable imine linker and
evaluate the conjugate efficacy in vitro (Chapters 5 and 6).

~ 37 ~

Chapter 1 - Introduction
____________________________________________________________________

Figure 1.26 Proposed mechanism of pH-triggered, intracellular release of active
cytotoxic drug inside the tumour cell.
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CHAPTER 2
Synthesis of Pyrrolo[3,2,1-hi]indole Derivatives
2.1 Initial Synthetic Targets
Isatin (11) has been derivatised at the C2, C3, C5, C6 and C7 positions,
however, there are a few examples of isatins incorporating new ring systems
between N1 and C7. As restrained conformational flexibility is frequently used in
medicinal chemistry to increase biological activity (see Section 1.5.3), it was
envisaged that a new ring system attached to N1-C7 in the isatin could either be 5- or
6-membered, yielding pyrrolo[3,2,1-hi]indole-1,2-dione (6,5,5-fused tricyclic isatins,
this chapter) and pyrrolo[3,2,1-ij]quinoline-1,2-dione derivatives (6,5,6-fused
tricyclic isatins, Chapter 3) respectively (Figure 2.1). To facilitate comparison
between previously reported )-alkylisatins and the new tricyclic isatins, )-alkyl
substituents were also to be incorporated into the structure. Modifications to the
aromatic ring on isatin would include substituting a halogen (preferably bromine) in
the C7 position to retain its cytotoxic activity (Figure 2.2).81,83

Figure 2.1 General structures of the pyrrolo[3,2,1-hi]indole-1,2-diones and
pyrrolo[3,2,1-ij]quinoline-1,2-diones.
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As shown in Figure 2.2, the pyrrolo[3,2,1-hi]indole-1,2-diones could be
synthesised via two distinct routes. The construction of ring C is possible from the
cyclisation of isatin (11) or one of its derivatives via free radical cyclisations or
metal-catalysed cross-coupling reactions (route B) or alternatively, ring B may be
prepared from the cyclisation of indoline (40) or one of its derivatives via a
Sandmeyer or Stolle isatin synthesis (route A).

Figure 2.2 Summary of the proposed synthetic strategies in the formation of
pyrrolo[3,2,1-hi]indole-1,2-diones.

Herein, the attempted synthesis of novel pyrrolo[3,2,1-hi]indole-1,2-diones
will be discussed. The biological activity of these pyrrolo[3,2,1-hi]indole-1,2-diones
including their cytotoxicity, will be discussed in Chapter 6.

2.2 Pyrrolo[3,2,1-hi]indole-1,2-dione Derivatives
The pyrrolo[3,2,1-hi]indole ring system was first reported in 1928148 but the
scaffold was proven to be incorrect in 1939.149 The parent compound,
pyrrolo[3,2,1-hi]indole (41) was not synthesised until 1969,150 although the
1,2,4,5-tetramethylpyrrolo[3,2,1-hi]indole (42) and 1,2,4,5-tetrahydropyrrolo[3,2,1~ 40 ~
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hi]indole (43) derivatives (Figure 2.3) had been reported earlier in 1961.151 The first
report of 1,2-dihydropyrrolo[3,2,1-hi]indole (44) (Figure 2.3) was described in
1958152 and nowadays, the pyrrolo[3,2,1-hi]indole core is present in over 2000
compounds153 including anti-convulsants154 and a cyclin-dependant kinase (CDK)
inhibitor155 (45) (Figure 2.3).
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Figure 2.3 A) Structures of the first reported pyrrolo[3,2,1-hi]indoles; B) Structure
of a pyrrolo[3,2,1-hi]indole-containing kinase inhibitor.

While the pyrrolo[3,2,1-hi]indole scaffold is well known in the scientific
literature, there are only three examples of pyrrolo[3,2,1-hi]indole-1,2-diones
(6,5,5-fused tricyclic isatins) at the time of writing (46-48).156-158 This may be
attributed to the fact that 6,5,5-fused indole ring systems are highly strained (see
Section 2.2.4). However, this strain can be reduced slightly by cyclising an indoline
instead157 and then dehydrogenating it to form a pyrrolo[3,2,1-hi]indole (Figure 2.4).
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Figure 2.4 The three reported pyrrolo[3,2,1-hi]indole-1,2-diones (46-48). A) 8%
yield over 2 steps;156 B) 48% yield over one step;157 C) 84% yield over one step.158
ote: All these compounds were accessed by the formation of the dione ring B in
the final step.

2.2.1 Free Radical Cyclisations
Reactions involving free radicals are important to the pharmaceutical industry
and have been heavily researched in recent years as they provide many avenues for
the synthesis of heterocycles.159 Free radicals occur when weak chemical bonds are
broken (homolysis) and the atoms receive one bonding electron each. Homolysis is
promoted by an initiator in the first stage of the mechanism. Examples of initiators
include diatomic halogen molecules, peroxides, and azo compounds such as
1,1’-azobis(cyclohexanecarbonitrile),160

and

azobis(isobutyronitrile)

(AIBN).

Peroxides are highly reactive and are able to abstract an atom from many organic
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molecules,161 whereas AIBN is more suitable for weaker bonds such as the Sn-H
bond.
Intramolecular free radical reactions are often employed to synthesise
5-membered rings. It was envisaged that the desired tricyclic isatins could be
prepared via a free radical cyclisation of )-allyl-7-bromoisatin (49) as shown in
Scheme 2.1.

H
Initiation

AIBN

SnBu3 +

H SnBu3
CN

CN

O
Propagation

O
O

Bu3Sn

O
N

N
Br

H SnBu3
49

O
O

+

SnBu3

N
50

Scheme 2.1 Proposed mechanism for the radical cyclisation of )-allyl-7-bromoisatin
(49) to yield the 5-membered tricyclic isatin 50.

During initiation, AIBN is able to abstract the hydrogen from tributyltin
hydride (Bu3SnH), leaving Bu3Sn• as a free radical (Scheme 2.1). This free radical
subsequently undergoes propagation, whereby it can abstract the bromine atom from
weak C-Br bonds and facilitate intramolecular ring closure, leading to the formation
of a new radical centre which is able to abstract another hydrogen from Bu3SnH,
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thus regenerating the Bu3Sn• free radical. Intramolecular radical reactions such as in
Scheme 2.1 are favoured over intermolecular reactions since the double bond acts as
a “radical trap” and is in close proximity to the radical.161 This results in cyclisations
occuring rapidly, even with unactivated double bonds.

2.2.1.1 Attempted ring closure via free radical cyclisation

Scheme 2.2 Proposed steps in the synthesis of tricyclic isatin 50.

The key precursor to the isatin 50, and to other isatins in this aspect of the
project was 7-bromoisatin (55). Although this compound is available commercially,
it is costly and only available in small quantities and hence, an efficient multi-gram
in-house synthesis was required. 7-Bromoisatin (55) is readily produced from
2-bromoaniline (51) using the Sandmeyer method, the oldest and most frequently
used procedure to synthesise isatins.162-164 The reaction can be applied to a wide
array of substrates, including anilines with electron withdrawing substituents,165
heterocyclic amines166 and )-alkylanilines.167 The Sandmeyer method involves
reaction of the appropriate aniline with chloral hydrate and hydroxylamine
hydrochloride (or other hydroxylamine salt) in the presence of sodium sulfate to
yield the isonitrosoacetanilide intermediate (Scheme 2.3). Exposure of the
intermediate to conc. H2SO4 for a short period of time and high temperatures yields
the heterocyclic isatin (Scheme 2.3). The synthesis of 7-bromoisatin (55) was
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straightforward using this method and its structure was confirmed by 1H nuclear
magnetic resonance (NMR) spectroscopy, which revealed three aromatic protons at
7.02, 7.51 and 7.78 ppm, together with a NH signal at 11.31 ppm, which
corresponded to literature values.168 Mass spectrometry (MS) supported the
molecular weight of 55 with molecular ion peaks at m/z 225 and 227 ([M]+ and
[M + 2]+), corresponding to the 79Br and 81Br isotopes within the molecule.

Reagents and conditions: (a) chloral hydrate, Na2SO4, hydroxylamine.HCl, H2O, HCl, 85 ºC, 3 h,
53 = 86%, 54 = 83%; (b) conc. H2SO4, 80 ºC, 15 min, 55 = 47%, 56 = 58%.

Scheme 2.3 Synthesis of 7-haloisatins via the Sandmeyer method.

The 7-bromoisatin (55) (and 7-iodoisatin (56) which will be discussed later in
Section 2.2.2.1.1) was subjected to )-alkylation to yield the allyl isatin derivative 49,
for subsequent free radical cyclisations to the desired tricyclic isatins. Previously,
)-alkylated isatins have been successfully produced using an alkyl halide under
basic conditions such as sodium hydride, potassium carbonate or cesium
carbonate.64,65,74 In this case, 55 was treated with sodium hydride to yield the
intensely purple coloured anion intermediate 57 (Scheme 2.4) by removal of the
acidic proton on the nitrogen. The intermediate 57 is an ambident anion whereby it is
possible for )- and O-alkylation to occur,169 although )-alkylation is preferred. After
the formation of the anion 57, allyl bromide was added and the reaction mixture was
heated overnight (Scheme 2.4). A catalytic amount of potassium iodide was added to
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facilitate alkylation through in situ formation of allyl iodide, which leads to a more
reactive intermediate due to the superior iodine leaving group in the nucleophilic
substitution. )-Alkylation of the product is likely to occur via an SN2 reaction
mechanism whereby the nucleophilic nitrogen anion attacks the carbon attached to
the halide, while the halide ion is displaced (Scheme 2.4).

Reagents and conditions: (a) NaH, DMF, RT, 20 min; (b) KI, 60 ºC, 18 h, 81% (over 2 steps).

Scheme 2.4 Synthesis of )-allyl-7-bromoisatin (49) via )-alkylation of
7-bromoisatin (55) with allyl bromide.

The allylated isatin 49 was successfully synthesised in high yield and readily
characterised using conventional spectroscopic techniques. The 1H NMR spectrum
indicated the presence of alkenyl protons at 5.23, 5.26 and 5.99 ppm, which confirm
the presence of this functional group. There was the absence of a NH signal in
1

H NMR spectrum, however, this would also occur in the case of O-alkylation.

Through

13

C NMR spectroscopy, signals observed at 158.7 and 182.6 ppm were

consistent with the amide carbonyl group at C2 and the ketone at C3 respectively. As
such, there was no indication of the O-alkylated product from the gHMBC or
13

C NMR spectra. If O-alkylation had occured, an alkoxyimine group would have

been present. Compound 49 was then carried through for the ring closing free radical
cyclisations.
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Although smaller rings should form faster than larger rings in intramolecular
free radical cyclisations,161 Rashatasakhon et al. have described the preferential
6-endo-trig cyclisation (60) of )-allyl-7-bromo-3a-methylhexahydroindolinone (58)
compared to the corresponding 5-exo-trig product (59) (Scheme 2.5).170 According
to Baldwin’s rules (see Section 3.2.2), the formation of the 5-exo-trig (59) and
6-endo-trig (60) products are both favourable,171 however, 5-exo-trig and 6-exo-trig
are the most typical cyclisation routes for intramolecular radical cyclisations.172 With
the bromide 58, the 6-endo-trig radical intermediate was thermodynamically more
stable than its 5-exo-trig counterpart and hence, it was formed as the major isomer
(Scheme 2.5). The yield of the 5-exo-trig product (59) was able to be increased by
using a more concentrated solution of Bu3SnH (0.1 M cf. 0.01 M).170

Reagents and conditions: (a) AIBN, Bu3SnH, benzene, reflux, 12 h, 59 = 20% (optimal conditions),
60 = 89%.

Scheme 2.5 Reported free radical cyclisation of )-allyl-7-bromo-3amethylhexahydroindolinone (58), yielding the 5-exo-trig (59) and 6-endo-trig (60)
products as minor and major products respectively.170

With )-allyl-7-bromoisatin (49), radical cyclisation could lead to the formation
of both the 5-exo-trig (50) and 6-endo-trig (61) products (Scheme 2.6). The reaction
was attempted several times with varying conditions. Fresh Bu3SnH was employed
and added dropwise over a long period of time and the equivalents were varied
(1.5-4 equiv.), as were the equivalents of the initiator AIBN (0.1-1 equiv.), time
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(3-14 h) and solvents (toluene and benzene). In each case, analysis by MS revealed
either a complex mixture of products or only a trace of product at m/z 187. This peak
may be attributed to the cyclised products 50 or 61, or )-allylisatin, which may be
formed as a result of the bromine abstraction during the propagation step of the free
radical cyclisation (Scheme 2.1). The lack of product/s may be explained by the fact
the tricyclic isatins 50 and 61 contain a higher degree of ring strain than the
indolinones in Scheme 2.5. Hence, another synthetic strategy had to be employed to
produce the desired tricyclic isatins.

Reagents and conditions: (a) AIBN, Bu3SnH, benzene, reflux, 14 h.

Scheme 2.6 Schematic representation of the attempted radical cyclisations to yield
5- and 6-membered tricyclic isatins.

2.2.2 Metal-Catalysed Cross-Coupling Reactions
Metal-catalysed cross-coupling reactions have transformed the synthesis of
carbon-carbon bonds over the last 30 years and the number of publications regarding
these couplings has grown exponentially over this time.173 Transition metal catalysts
allow synthetic entry into compounds which have proven difficult to prepare
previously, through the catalyst’s high selectivity and efficiency.174 Pd catalysts are
the most frequently used metal catalysts in synthesis today and form the basis of the
Sonogashira, Suzuki, Negishi and Heck cross-coupling reactions175,176 (named after
Akira Suzuki, Ei-ichi Negishi and Richard F. Heck who were jointly awarded the
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2010 Nobel Prize in Chemistry for the discovery and development of these
reactions). Metal-catalysed reactions are appealing in the synthesis of heterocycles
due to their ability to yield complicated structures under mild conditions using
readily available starting materials.177
The indole scaffold is an abundant feature in many heterocycles and thus is one
of the major areas of focus for synthetic organic chemists. For over 100 years, a
variety of methods for the synthesis of indoles have been developed. The most well
known method for the construction of indoles is the Fischer indole synthesis which
involves heating an aldehyde/ketone and an arylhydrazine in the presence of an acid
or acid catalyst.178 Other alternatives for indole synthesis include reductive
cyclisations,179 heteroannulations involving internal alkynes such as the Larock
heteroannulation180 and the cyclisation of 2-alkynylanilines.181
Within this project, it was decided that the tricyclic isatin scaffold may be
successfully synthesised by adapting the cyclisation method for 2-alkynylanilines. If
isatins can be considered as masked anilines containing a secondary instead of a
primary amine, then cyclisation upon this amine may be viable, leading to the
construction of a third ring. i.e. a tricyclic isatin (Scheme 2.7).

Scheme 2.7 Cyclisation of 2-alkynylanilines to corresponding tricyclic isatins.
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2-Alkynylanilines are readily prepared by the Sonogashira reaction and the
subsequent cyclisation to an indole can be realised through several avenues. The
2-alkynylanilines may be reacted with a Cu(I) acetylide via the Castro indole
synthesis,182,183 or be exposed to a base such as sodium ethoxide,184 NaOH185 or
tetrabutylammonium halide salts186,187 to yield the corresponding 2-substituted
indole. Pd-catalysed cyclisations of 2-alkynylanilines are now routinely reported in
the literature and are frequently used in the preparation of indoles.179 Other less
commonly used metal catalysts such as Rh,188 Zn,189 Pt,190 Ir,191 Hg192 and In193 have
been reported in recent years as being capable of cyclising 2-alkynylanilines.

2.2.2.1 Sonogashira Reactions
The Sonogashira reaction is the cross-coupling of a vinyl or aryl halide (I, Br
or OTf) and a terminal alkyne.194 It evolved from the Stephens-Castro reaction which
involves the cross-coupling of a vinyl or aryl halide with a Cu(I) acetylide.182,183
Typically, a Pd(0) catalyst such as Pd/C195,196 or Pd(PPh3)4197 is used in the
Sonogashira reaction, however, Pd(II) catalysts such as PdCl2(PPh3)2198 or
Pd(OAc)2199,200 can be used since the catalyst may be reduced to Pd(0) through the
consumption of the terminal alkyne within the reaction. A Cu(I) halide salt is also
required within the Sonogashira reaction, together with an amine such as
triethylamine (Et3N) or diethylamine which serves as a base and may be used as a
solvent or co-solvent. A phosphine is also usually included as a ligand for Pd. There
are reports of the Sonogashira reaction being performed under copper-, phosphineand amine-free conditions,199,200 under aerobic conditions201 and in a microwave
reactor.202,203
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The mechanism for the Sonogashira reaction initially involves the Pd catalyst
reacting with a vinyl or aryl halide through an oxidative addition. The complex then
reacts with the Cu acetylide produced from the Cu cycle, followed by the conversion
from a trans to a cis configuration, before the final Sonogashira product is released
through reductive elimination and regeneration of Pd(0) (Figure 2.5).
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Figure 2.5 General Sonogashira reaction mechanism.194

2.2.2.1.1 Applying Sonogashira Reactions
In preparation for a Sonogashira reaction, 7-iodoisatin (56) was synthesised
in a moderate yield using the Sandmeyer method as described previously for
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7-bromoisatin (55) (see Section 2.2.1.1, Scheme 2.3). The structure of the dark
red/brown product 56 was confirmed through

1

H NMR spectroscopy, which

indicated an aromatic proton displaying a triplet signal at 6.89 ppm and was ascribed
to H5. This proton was directly coupled to doublet signals at 7.49 and 7.94 ppm,
representative of the H4 and H6 protons. A NH signal, integrating for one proton
was observed at 11.00 ppm. The spectral data coincided with that previously
reported in the literature.204 The 7-iodoisatin (56) was then subjected to an one-pot
Sonogashira/indole cyclisation method based on the conditions of Layek et al.205
This paper reported that a 5-membered ring could be introduced onto 8-iodo-4-oxo1,4-dihydroquinoline-3-carboxylic acid ethyl ester (62) to form 2-substituted
6-oxopyrrolo[3,2,1-ij]quinolines (63) (Scheme 2.8). (More information on
pyrrolo[3,2,1-ij]quinolines will be discussed in Chapter 3).

~ 52 ~

Chapter 2 – Pyrroloindole Derivatives
____________________________________________________________________
O
O

CO2Et

O

a
N
H

I

OEt

R

+

N

62

R = alkyl, aryl
R

CuI, BH+
BH+, IO

O

CO2Et

CO2Et

+

-

BH , I

N

N
R
63

CuI, B

Cu

R

Reagents and conditions: (a) 10% Pd/C, PPh3, CuI, Et3N, EtOH, 80 ºC, 2-8 h 45-95%.205

Scheme 2.8 Reported one-pot synthesis of 2-substituted 6-oxopyrrolo
[3,2,1-ij]quinolines (63).205

The 7-iodoisatin (56) was reacted with the terminal alkyne, phenylacetylene
(64) (Table 2.1). Theoretically, the reaction of these two substrates could lead to the
Sonogashira product 65 or the tricyclic isatin 66 in an one-pot synthesis (Table 2.1).
The first attempt to produce the alkynylisatin 65 or the tricyclic isatin 66 was based
on the method of Layek et al.205 (Table 2.1, entry 1). From the 1H NMR spectrum, it
was concluded that the alkynylisatin 65 had formed due to the presence of an NH
signal at 8.44 ppm. The reaction conditions were varied slightly in the next few
attempts to hopefully increase the product yield, although Pd/C remained employed
as the catalyst. The molar equivalents of the catalyst were altered along with varying
time periods (Table 2.1, entries 2-3). Higher concentrations of the catalyst and longer
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time periods led to a detrimental effect on the yield of 65 (Table 2.1, entry 3 cf. entry
2). The incorporation of Pd(PPh3)4 as a catalyst increased the yield of 65 compared
to Pd/C when the reaction was performed in EtOH (Table 2.1, entry 4). The yield of
65 could be further increased by using Pd(PPh3)4 in presence of CH3CN (Table 2.1,
entry 6). Using PdCl2(PPh3)2 in CH3CN led to a slight decrease in the yield of 65
(Table 2.1 entry 5 cf. entry 6). The use of Et3N as the solvent also did not increase
the yield of 65 (Table 2.1, entry 7). The optimal yield of 65 (69%) was produced
utilising Pd(PPh3)4 together with ),)-dimethylformamide (DMF) as the solvent
(Table 2.1, entry 8). In retrospect it can be concluded that the descending order of Pd
catalyst efficiency in the synthesis of the 7-alkynylisatin 65 is Pd(PPh3)4 >
PdCl2(PPh3)2 > Pd/C, while the descending order of solvent efficiency is DMF >
CH3CN > Et3N > EtOH.
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Table 2.1 Reaction conditions attempted in the synthesis of the alkynylisatin 65.

a

No evidence of the tricyclic product 66 was obtained in any reaction.

As mentioned earlier, the structure of 65 was confirmed through 1H NMR
spectroscopy, which revealed a broad singlet peak at 8.44 ppm, indicating the
presence of NH. The 13C NMR spectrum showed two signals at 81.4 and 96.9 ppm,
which were ascribed to the two C≡C signals in 65 and additionally, the high
resolution electron ionisation mass spectrum (HREI-MS) revealed a molecular ion at
m/z 247.0634, consistent with the molecular formula (C16H9NO2 [M+]). Hence, it was
confirmed that 7-iodoisatin (56) had not cyclised to form 66 but alternatively, the
novel alkynylisatin 65 had been prepared.
With 65 in hand, metal-catalysed cyclisations were attempted to effect
cyclisation to the tricyclic isatin 66 (Scheme 2.9). Following the work of Castro
et al.,182,183 Ezquerra et al. confirmed Cu(I)-mediated intramolecular cyclisations of
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2-alkynylanilines were possible in the absence of a Pd catalyst.198 The group
described how 2 equiv. of CuI in DMF at 100 ºC for 3 h promoted the
heteroannulation of the 2-alkynylaniline. However, within the current work, the
alkynylisatin 65 was unable to be cyclised under these conditions as observed by
1

H NMR spectroscopy, which revealed the presence of an NH signal at 8.44 ppm.

According to Ezquerra et al., longer reaction times are ineffective at improving the
yield and instead lead to the formation of side products.198 Other metal catalysts such
as AgNO3, Au(PPh3)Cl and a PdCl2(PPh3)2/CuI system were also investigated since
they

have

been

reported

as

excellent

catalysts

in

the

cyclisation

of

alkynylpyrrolidinones and alkynylpiperidinones.206 These reactions also did not yield
the desired isatin 66 and this was confirmed by the presence of the NH signal at
8.44 ppm in the 1H NMR spectrum, indicating the intermediate alkynylisatin 65 had
not reacted. Additionally, MS analysis revealed only the starting material was
present.

~ 56 ~

Chapter 2 – Pyrroloindole Derivatives
____________________________________________________________________
O

O

a
O
N
H

Ph

O

N

65

Ph

66

b

O

O

c

O
O

O
N
H

Ph

N

67

68

O

Ph

Reagents and conditions: (a) metal catalyst, > 70 ºC, 3.5-5.5 h; (b) (CH2OH)2, PTSA, PhMe, reflux,
72 h, 43%; (c) metal catalyst, > 70 ºC, 11.5-24 h.

Scheme 2.9 Attempted metal-catalysed cyclisations of the alkynylisatins 65 and 67.

After several attempts to cyclise alkynylisatin 65, it was decided that the C3
carbonyl on the compound should be protected to avoid any competing reactions and
to reduce detrimental ring strain effects on cyclisation. The C3 carbonyl group in
isatins is quite reactive and has the opportunity to interfere and stop reactions from
proceeding.81,207,208 For example, in Pd-catalysed reactions containing PPh3, the C3
carbonyl on the isatin may undergo Wittig reactions and/or form a dimerised
product.209 To obviate this, the C3 carbonyl on 65 can be protected as an ethylene
ketal (67) prior to cyclisation. Once the cyclised isatin 68 is obtained, the ethylene
ketal should hydrolyse under acidic conditions210 to yield the tricyclic isatin 66.
Synthesis of ketals is usually accomplished through reacting an alcohol and a
ketone in the presence of an acid catalyst under dehydrating conditions. In the
synthesis of the protected alkynylisatin 67, Dean-Stark conditions were used to
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remove water formed from the reaction of ethylene glycol and 65 (Scheme 2.9). The
reaction led to the protected alkynylisatin 67 in 43% yield. Its structure was
confirmed through 1H NMR spectroscopy, whereby two triplet signals at 4.31 and
4.53 ppm, integrating for two protons each, were ascribed to the four protons on the
ketal protecting group. Furthermore, the

13

C NMR spectrum illustrated only one

carbonyl signal, at 174.5 ppm, which was attributed to the C2’ carbonyl. The
HREI-MS also revealed a molecular ion at m/z 291.0893, consistent with the
molecular formula (C18H13NO3 [M+]).
Once the protected alkynylisatin 67 was formed, it was exposed to Cu(I)
cyclisation conditions198 with subsequent heating at 100 ºC for 24 h, but this only
gave unreacted 67 as determined by 1H NMR spectroscopy. Another attempt to
cyclise 67 was made using PdCl2 in CH3CN at 70-75 ºC for 11.5 h. This Pd catalyst
is known to cyclise 2-alkynylanilines into 2-substituted indoles211 and was successful
in cyclising 8-arylethynyl-1,2,3,4-tetrahydroquinolines (69) into the corresponding
2-aryl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolines212 (70) (Scheme 2.10). However,
in our case, the cyclisation of the protected alkynylisatin 67 proved to be
unsuccessful as determined by 1H NMR spectroscopy, which revealed unreacted
starting material.
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Scheme 2.10 Reported synthesis of 2-aryl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]
quinolines (70).212

2.2.2.1.2 A Model Sonogashira Reaction
Since there had been great difficulty in synthesising the 6,5,5-fused tricyclic
isatins, it was decided that a model reaction should be performed to prove if
Pd-catalysed cyclisation is possible. It was postulated that the difficulty in cyclising
the 7-alkynylisatin 65 arises from the fact it contains a secondary amide with an
acidic proton and a 6,5-bicyclic scaffold which would introduce further ring strain
into the molecule if it were cyclised. In Schemes 2.8 and 2.10, the structures 62 and
69 respectively, were successfully cyclised by Pd but both these compounds
contained a 6,6-bicyclic system, which contains a decreased amount of ring strain
compared to a 6,5-bicyclic system.205,212 To test the hypothesis that indoles may be
cyclised under Pd-catalysed conditions, the Sonogashira product 71 was prepared
from 2-iodoaniline (52) (Scheme 2.11). The 2-alkynylaniline 71 was synthesised in
good yield (72%) using the same method as in the synthesis of the 7-alkynylisatin
65. The 1H NMR spectral data for this compound was consistent with those reported
in the literature,213 and the MS revealed a molecular ion at m/z 193, confirming the
molecular weight. The 2-alkynylaniline 71 was then exposed to PdCl2 to yield
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2-phenylindole (72) in 74% yield (Scheme 2.11). The structure of this compound
was confirmed through 1H NMR spectroscopy, which revealed a signal at 8.37 ppm
integrating for one proton. This was ascribed to the NH, a secondary amine, as
opposed to the primary amine present in the 2-alkynylaniline 71. The remainder of
the 1H NMR spectral data was also in agreement with those published previously in
the literature.214

c

a, b

N
H

NH2
NH2

I
52

71

72

Reagents and conditions: (a) Pd(PPh3)4, CuI, Et3N, DMF, RT, 1 h; (b) phenylacetylene (64), 80 ºC,
4 h, 72% (over 2 steps); (c) PdCl2, CH3CN, 75 ºC, 8 h, 74%.

Scheme 2.11 Synthesis of 2-phenylindole (72).

The cyclisation conditions described above were used successfully by Ezquerra
et al. in the synthesis of 2-aryl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolines,212
however, when applied in the current work, the reaction conditions were
unsuccessful in cyclising the protected 7-alkynylisatin 67 (Table 2.1). This suggests
that Pd-catalysed cyclisations are a viable method in the synthesis of indoles and the
compound may contain a secondary amine, as is the case for 2-aryl-5,6-dihydro-4Hpyrrolo[3,2,1-ij]quinolines. The lack of success in cyclising isatins in this project,
may be attributed to the ring strain caused by a 6,5,5-fused ring system (see Section
2.2.4). It is possible that the orbitals on the alkynyl bond in the 8-arylethynyl-1,2,3,4tetrahydroquinolines (69) are within reach of the nitrogen when exposed to
cyclisation conditions, but this is not the case with the alkynyl orbitals present in the
7-alkynylisatin 65. The lack of success in forming the desired tricyclic isatins led to
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further studies of some other possible metal-catalysed reactions as outlined in the
following section.

2.2.2.2 Miscellaneous Metal-Catalysed Reactions
In an attempt to synthesise the dehydrogenated isatin 74, it was envisaged that
a )-vinylisatin derivative such as 7-bromo-)-vinylisatin (73) could undergo an
intramolecular Heck reaction (see Section 3.2.2) to form the isatin 74 (Scheme 2.12).

Scheme 2.12 Proposed synthesis of the tricyclic isatin 74 via an intramolecular Heck
reaction of 7-bromo-)-vinylisatin (73).

Previously, it had been shown that a 7-bromo-)-vinylated indole derivative
could cyclise into the corresponding pyrrolo[3,2,1-hi]indole.215 In the current project,
a model vinylation reaction on isatin (11) to yield )-vinylisatin (75) was attempted
since 75 is not widely reported in literature. )-Vinylisatin (75) cannot be formed by
a conventional SN2 nucleophilic substitution reaction using a vinyl halide due to the
attachment of the halide to an sp2 carbon. However, 75 can be prepared using vinyl
acetate and NaPdCl4 as a catalyst under refluxing conditions216 (Scheme 2.13).
)-Vinylisatin (75) was synthesised in 42% yield and the structure was confirmed
through 1H NMR spectroscopy, which indicated the vinyl protons were present at
5.17, 5.87 and 6.67 ppm. The vinylation of 55 proved to be unsuccessful and only
starting material was present as determined by MS.
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Reagents and conditions: (a) vinyl acetate, Na2PdCl4, reflux, 12 h, 75 = 42%, 73 = 0%; (b)
1,2-dibromoethane, Et3N, CH3CN, 70 ºC, 6 h, 73 = 0%.

Scheme 2.13 Synthesis of )-vinylisatin derivatives.

The synthesis of 7-bromo-)-vinylisatin (73) was then attempted based on the
method by Iddon et al. which utilised a pyrazole derivative with 1,2-dibromoethane
to yield the corresponding )-vinylpyrazole.217 Analysis by 1H NMR spectroscopy
revealed a complex mixture of products had formed and no 7-bromo-)-vinylisatin
(73) was present. Difficulties in synthesising 73 may arise due to steric hindrance
between the bromine atom and the vinyl group.

2.2.3 Other Cyclisation Reactions
The synthesis of 6,5,5-fused tricyclic isatins was also attempted according to
the method of Albrecht et al. which involved an iodonium ion intermediate.218
Firstly, )-allylisatin (76) was synthesised from isatin (11) and allyl bromide in 69%
yield (Scheme 2.14). The structure of this compound was confirmed through
1

H NMR spectroscopy, which revealed the three allyl protons at 4.37, 5.29 and

5.85 ppm, matching reported data.219 Following the method of Albrecht et al., 76
was then reacted with I2, although the procedure proved to be unsuccessful. Analysis
by MS and TLC revealed only starting material was present.
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Reagents and conditions: (a) NaH, DMF, RT, 20 min; (b) KI, allyl bromide, 65 ºC, 18 h, 69% (over 2
steps); (c) I2, K2CO3, CH3CN, RT, 20 h.

Scheme 2.14 Attempted synthesis of 77 from an iodocyclisation of )-allylisatin
(76).
Another strategy to form the 6,5,5-fused tricyclic isatins utilised
)-formylindoline (78) as the starting material (Scheme 2.15).220 The complex
mechanism involves a carbene intermediate, followed by dimerisation before the
corresponding isatin is formed. )-Formylindoline (78) was successfully prepared
using the method of Berry et al.221 starting from indoline (40) (Scheme 2.15). The
)-formylindoline (78) was synthesised as a mixture of rotamers (83:17) in a similar
ratio to that previously reported,222 although in low yield, which suggests this
synthetic method is not ideal for this particular substrate. Its purity and structure
were confirmed by 1H NMR spectroscopy, which coincided with reported data.223
Once

78

had

been

prepared,

it

was

reacted

with

oxalyl

chloride,

),)-diisopropylethylamine (DIPEA) and Br2 (Scheme 2.15) in an attempt to
synthesise 46. This reaction had been reported to result in a 79% yield220 although in
this case, MS revealed a complex mixture of uncharacterisable products, none of
which were identified as the tricyclic isatin 46. The assortment of products observed
in the MS may be due to the involvement of the carbene intermediate which is
unstable and could yield many products.
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Reagents and conditions: (a) imidazole, TMSCl, DMF, RT, 12 h, 10%; (b) (COCl)2, DIPEA, Br2,
35 ºC, 1 h.

Scheme 2.15 Attempted synthesis of tricyclic isatin 46 from )-formylindoline (78).

2.2.4 The Stolle Isatin Synthesis

Scheme 2.16 Overall proposed mechanism in the synthesis of tricyclic isatin 46.

The Stolle isatin synthesis is also a widely used route to produce isatin and its
derivatives.163 It involves reacting the appropriate aniline (e.g. 79) with oxalyl
chloride to form a chlorooxalylanilide intermediate such as 80, which cyclises to
yield the corresponding isatin (11) upon treatment with a strong Lewis acid such as
AlCl3 or boron trifluoride diethyl etherate163 (Scheme 2.17).

Reagents and conditions: (a) (COCl)2, reflux, 3 h; (b) AlCl3, reflux, 3 h.

Scheme 2.17 General scheme for the preparation of isatins via the Stolle procedure.

~ 64 ~

Chapter 2 – Pyrroloindole Derivatives
____________________________________________________________________
The Stolle method has been employed in the synthesis of a variety of isatins
including )-aryl and polycyclic isatins.224 In 1979, Welstead Jr. et al. reported the
first synthesis of the tricyclic isatin 46 from indoline (40) in 8% overall yield using
the Stolle procedure.156 The yield was reportedly increased to 22% in 1996 by
Norman et al. by increasing the molar equivalents of oxalyl chloride from 0.5 to 2.0
and using dichloromethane (DCM), rather than ether as the reaction solvent.225
However, on closer inspection Norman et al.’s yield of 22% was only for the second
synthetic step, from the intermediate 81 to the final product 46. If the yield was
calculated from indoline (40), it would have been 15%. On the contrary, Welstead Jr.
et al. reported the yield of the intermediate 81 to be 58% and did not calculate a yield
for the second step to the product 46. When the yield of the second synthetic step in
Welstead Jr. et al.’s synthesis was calculated manually from the manuscript, it was
found to be 31% and the overall yield for 46 from 40 should be 17%.
Both procedures by Welstead Jr. et al. and Norman et al. were adapted and
repeated within the current work (Scheme 2.18). In the first instance, indoline (40)
was heated at reflux with oxalyl choride in anh. THF for 3.5 h before the solvent was
removed by rotary evaporation to yield a sticky red residue. The residue was then
dissolved in refluxing anh. DCM and AlCl3 was added portionwise over 10 min
before the reaction mixture was heated at reflux for another 1 h (Table 2.2, entry 1).
Analysis by MS revealed a complex mixture of products, with none of them being
the desired isatin 46.
The above method was modified by increasing the molar equivalents of AlCl3
(Table 2.2, entry 2 and 4) and changing to solvents with higher boiling points
(CHCl3 and 1,2-dichloroethane) (Table 2.2, entry 2 and 4) but again, analysis by MS
revealed none of the desired tricyclic isatin 46. A small amount of K2CO3 was also
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added to oxalyl chloride to remove excess HCl and try to facilitate the cyclisation of
indoline (40) (Table 2.2, entry 3). In this case, there was no evidence of the
intermediate 81 being formed as determined by MS so the experiment did not
proceed.
Many of the previous attempts had not been successful, however, the synthetic
method based on the work by Norman et al. finally provided the desired tricyclic
isatin 46, albeit in only 6% overall yield (Table 2.2, entry 5). The intermediate 81
was able to be produced without difficulty by using DCM as the reaction solvent and
lower temperatures than previous attempts. It was then treated with 5 equiv. of AlCl3
neatly for 20 min at 110 ºC until HCl gas ceased evolving, followed by the addition
of ice-H2O and further stirring for 2 h at RT. The structure of 46 was confirmed
through 1H NMR spectroscopy, whereby two methylene signals were present at 3.38
and 4.09 ppm and ascribed to H5 and H4 respectively. The 1H NMR spectral data
was in accordance with those reported by Norman et al.225

Reagents and conditions: (a) (COCl)2, DCM, RT, 3 h, 40%; (b) AlCl3, 110 ºC, 20 min, 6%; (c) Br2,
95% EtOH, 70-75 ºC, 33%.

Scheme 2.18 General synthetic route for the production of tricyclic isatins 46 and 82
via the Stolle procedure.
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Table 2.2 Reaction conditions attempted in the preparation of the tricyclic isatin 46.

Since it had been previously reported that bromination at the C5 position on
the isatin scaffold resulted in more potent cytotoxicity than the parent molecule,81,83
the tricyclic isatin 46 was exposed to Br2 to yield the novel brominated tricyclic
isatin 82 through an electrophilic aromatic substitution. The C5 position (which is
numbered C7 in the tricyclic isatin 46) is partial to electrophilic halogenation due to
the meta-directing C3 carbonyl and the para-directing N1 atom. The tricyclic isatin
46 was dissolved in hot glacial AcOH before Br2 was added, although this reaction
yielded a complex mixture of products due to the limited solubility of 46 in the
solvent. The bromination of 46 was successful (Scheme 2.18) when it was added to
95% EtOH, which is a known strategy in the synthesis of brominated isatins.81
The structure of the novel compound was confirmed through 1H NMR
spectroscopy, which revealed two aromatic protons at 7.49 and 7.66 ppm, ascribed to
H8 and H6 respectively. Analysis by high resolution electrospray ionisation
spectrometry (HRESI-MS) resulted in a protonated molecular ion of m/z 251.9655,
consistent with the protonated molecular formula of C10H7NO279Br [M+H]+.
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Although the tricyclic isatin 46 had been synthesised in low yield, it was
thought that indole (83) may be subjected to the same chemical conditions to
produce the dehydrogenated tricyclic isatin 74 using the Stolle procedure. The indole
intermediate 84 was able to be isolated as a red/brown powder in 19% yield (Scheme
2.19) but on treatment with AlCl3 under neat conditions, no isatin 74 was able to be
obtained as the MS revealed the product was once again a complex mixture of
uncharacterisable products.

Reagents and conditions: (a) (COCl)2, DCM, RT, 3 h, 19%; (b) AlCl3, 110 ºC, 20 min.

Scheme 2.19 Attempted preparation of 74 via the Stolle isatin synthesis.

The problem of cyclising the above indole (83) and indoline (40) compounds
using the Stolle procedure may be due to the lack of activating substituents on the
benzene ring which could activate the C7 position towards electrophilic aromatic
substitution. The Stolle isatin synthesis has resulted in 4,5-dihydro-6,8dimethoxypyrrolo[3,2,1-hi]indole-1,2-dione (47) (Figure 2.4B) being produced in a
moderate yield (48%)157 from 4,6-dimethoxyindoline due to the indole C7 position
being activated by the two methoxy substituents on the indoline. The acid chloride
intermediate was therefore formed at C7, rather than the traditional N1 position, and
cyclisation was completed in the presence of AlCl3. 4,6-Dimethoxy-2,3-diphenyl1H-indole, the precursor to 48, (Figure 2.4C) is so activated by the two phenyl and
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two methoxy substituents that AlCl3 is not required to facilitate cyclisation. The
cyclisation is completed in 84% yield in the presence of only oxalyl chloride.158
Unfortunately, 48 was susceptible to ring opening upon treatment a reducing agent
such as NaBH4 or LiAlH4 which confirms the issue of ring strain within 6,5,5-fused
ring systems.
This body of work highlights the difficulties in synthesising pyrrolo[3,2,1hi]indole-1,2-diones and may explain why only three of these compounds exist in the
literature (Figure 2.4).156-158 Conformational analysis at the AM1 level was also
performed on the tricyclic isatins 46 and 74 using the molecular modeling program
Materials Studio 4.4.226 The results indicated that both compounds have a large heat
of formation (∆Hf) of 10.9 kcal/mol and 43.2 kcal/mol respectively (Figure 2.6). In
contrast, isatins containing a 6,5,6-fused tricyclic systems such as 85-87 exhibited
much lower ∆Hf values (Figure 2.6), suggesting that they may be easier to synthesise.
These results confirm the ring strain within the 6,5,5-fused tricyclic isatins and
further verifies why compounds of this structure are very difficult to synthesise. Free
radical cyclisation and metal-catalysed cross coupling reactions were unsuccessful in
synthesising these tricyclic isatins. The only successful syntheses of pyrrolo[3,2,1hi]indole-1,2-diones arose from adapting literature methods using the Stolle isatin
synthesis156,225 to synthesise the known pyrrolo[3,2,1-hi]indole-1,2-dione (46),
followed

by

electrophilic

substitution

to

yield

the

novel

brominated

pyrrolo[3,2,1-hi]indole-1,2-dione 82. The results of the evaluation of the cytotoxic
and potential DNA intercalatory activity of these two tricyclic isatin derivatives are
presented in Chapter 6. Furthermore, four cyclisation precursors described in this
chapter (49, 65, 75 and 76), were also tested for their cytotoxicity, which will be
described in Chapter 6.
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Figure 2.6 Heat of formation values (∆Hf) for 6,5,5- and 6,5,6-fused tricyclic isatins
as calculated by Material Studios 4.4.226

Due to the difficulties encountered in trying to synthesise novel derivatives
from this rare class of compounds, it was decided to change focus to the homologous
6,5,6-fused series, of which there is both greater literature precedence and promising
results from the conformational analysis as shown in Figure 2.6. The next chapter
will therefore focus on the synthesis of the 6,5,6-fused tricyclic isatins,
(pyrrolo[3,2,1-ij]quinoline-1,2-diones), and various other novel polycyclic isatin
derivatives as a potential new class of (potent) cytotoxic agents.
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CHAPTER 3
Synthesis of Pyrrolo[3,2,1-ij]quinoline Derivatives and Other
Polycyclic Isatin Derivatives
3.1 Initial Synthetic Targets
As mentioned in Chapter 2, incorporation of an extra ring between N1 and C7
of the isatin nucleus was of interest in order to partially restrain conformational
flexibility in the )-substituent group. This chapter will focus on the addition of a
6-membered ring to isatin (11) i.e. 6,5,6-fused tricyclic isatins, known formally as
pyrrolo[3,2,1-ij]quinoline-1,2-diones (Figure 3.1). To facilitate the comparison
between previously reported )-alkylisatins, the pyrrolo[3,2,1-ij]quinoline-1,2-diones
were designed to incorporate similar )-alkyl substituents. Two different routes were
considered for the synthesis of the pyrrolo[3,2,1-ij]quinoline-1,2-diones (Figure 3.1),
in a similar fashion to the pyrrolo[3,2,1-hi]indole-1,2-diones discussed in Chapter 2.
The 6-membered ring C in the pyrrolo[3,2,1-ij]quinoline-1,2-diones was to be
approached from isatin (11) via a metal-catalysed cross-coupling reaction (route B)
or alternatively, ring B was proposed to be accessed through the cyclisation of a
reduced quinoline (88) via a Stolle or Sandmeyer isatin synthesis starting from a
quinoline (route A) (Figure 3.1).
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Figure 3.1 Proposed synthetic
pyrrolo[3,2,1-ij]quinoline-1,2-diones.

strategies

for

the

formation

of

In this chapter, the synthesis of pyrrolo[3,2,1-ij]quinoline-1,2-diones and
extensions to other benz-fused polycyclic isatins (pyrrolophenanthridinediones and
pyrroloacridinediones) will be discussed. The biological activity (including
cytotoxicity) of the prepared compounds will be discussed in Chapter 6.

3.2 Synthesis of Pyrrolo[3,2,1-ij]quinoline-1,2-dione Derivatives
The indole-based pyrrolo[3,2,1-ij]quinoline nucleus is well known in the
scientific literature205,212,227-231 and the ring system occurs in many natural products
including alkaloids from the Amaryllidaceae (perennial herb and flowering bulb)
species228,232 (see Section 3.3.1). Compounds containing a pyrrolo[3,2,1-ij]quinoline
scaffold have been reported to exhibit a broad spectrum of biological activities
including

analgesic,

anti-pyretic,

anti-inflammatory,228

anti-hyperlipidemic,

anti-hypertensive,230 anti-convulsant154 (89), platelet activating factor production
inhibition,233 anti-epileptic, anti-obesity234 (90) and anti-cancer235 (91) activities
(Figure 3.2A). However, only approximately 50 of the analogous isatin-based
pyrrolo[3,2,1-ij]quinoline-1,2-diones have been reported in the literature to date. The
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most recognised examples of pyrrolo[3,2,1-ij]quinoline-1,2-diones (92 and 93)
exhibit fungicidal activity (Figure 3.2B).13,14

Figure 3.2 A) Structures of pyrrolo[3,2,1-ij]quinolines with anti-convulsant,
anti-obesity and anti-cancer activities; B) Structures of fungicidal pyrrolo[3,2,1-ij]
quinoline-1,2-diones.

3.2.1 Synthesis of Pyrrolo[3,2,1-ij]quinoline-1,2-dione Derivatives via Route A
3.2.1.1 Attempted Sandmeyer Isatin Synthesis
The Sandmeyer isatin synthesis, which relies on the formation of an isonitroso
amide intermediate, is the most frequently used procedure to synthesise isatins (see
Section 2.2.1.1). Applying this method allowed the formation of 7-bromoisatin (55)
and 7-iodoisatin (56) in Chapter 2. Using this rationale, it was thought that the
pyrrolo[3,2,1-ij]quinoline-1,2-dione

(85)

could

also

be

prepared

from

1,2,3,4-tetrahydroquinoline (THQ) (88) via the Sandmeyer method. THQ (88) may
be considered a masked aniline containing a secondary amine, and therefore still has
one hydrogen available to participate in the cyclisation.
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In our work, the THQ (88) was exposed to chloral hydrate, Na2SO4 and
hydroxylamine

hydrochloride

with

heating

in

an

attempt

to

yield

the

isonitrosoacetanilide intermediate 94 (Scheme 3.1). However, no intermediate 94
was observed and only starting material 88 was recovered so this approach was not
continued. If the reaction had been successful, 94 would have been exposed to conc.
H2SO4 and high temperatures to yield the cyclised isatin 85. The difficulty in
synthesising the intermediate 94 reveals, perhaps, that steric issues are a factor in the
initial secondary amine attack on chloral with a ring-fused aniline. In contrast,
)-alkylanilines, which contain a secondary amine but not within a ring-fused system,
have been successfully cyclised to the corresponding )-alkylisatins through the
Sandmeyer method.167

Reagents and conditions: (a) chloral hydrate, Na2SO4, hydroxylamine.HCl, H2O, HCl, 80 ºC, 1.5 h;
(b) conc. H2SO4, 80 ºC, 15 min.

Scheme 3.1 Attempted synthesis of the tricyclic isatin 85 via the Sandmeyer method.

~ 74 ~

Chapter 3 – Pyrroloquinoline Derivatives
____________________________________________________________________
3.2.1.2 Stolle Isatin Synthesis

Scheme 3.2 Stages in the synthesis of tricyclic isatins using the Stolle isatin
synthesis.

Due to the success of synthesising pyrrolo[3,2,1-hi]indole-1,2-diones using the
Stolle isatin synthesis (Chapter 2), this methodology was applied to quinoline
derivatives to form pyrrolo[3,2,1-ij]quinoline-1,2-diones. A modification of the
Stolle isatin synthesis was initially attempted based on a Friedel-Crafts acylation of
THQ (88). It has been reported that )-methylisatins (96) may be prepared through
Friedel-Crafts acylation of p-substituted ),)-dimethylanilines (95) in the presence of
oxalyl chloride and a base (Scheme 3.3).236 This rationale seemed applicable to other
secondary aromatic amines and in our case, we chose the secondary aromatic amine,
THQ

(88).

Oxalyl

chloride

was

added

dropwise

to

the

base,

diazabicyclo[2,2,2]octane (DABCO) (which Cheng et al. determined to result in the
best yields16), to form a pale yellow salt. A solution of THQ (88) was then added and
the reaction mixture was heated at reflux for 20 h in CHCl3. Unfortunately, MS
analysis on the crude yellow semi-solid product revealed only the starting material
88 was present. The synthesis of the )-methylisatin 96 in Scheme 3.3 may be
enhanced through the p-electron donating methoxy group on the aniline 95, which
would lead to an activated system, as opposed to unsubstituted THQ (88) which is
possibly not sufficiently activated for Friedel-Crafts acylation.
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Reagents and conditions: (a) (COCl)2, DABCO, CHCl3, reflux, 22 h; (b), 5% NaOH, 83% (over 2
steps).236

Scheme 3.3 Reported cyclisation of an aromatic secondary amine to the
corresponding isatin via Friedel-Crafts acylation.236

The synthesis of pyrrolo[3,2,1-ij]quinoline-1,2-dione (85) was then attempted
by closely following the method described for tricyclic isatin 46 in Chapter 2, to
yield the desired tricyclic isatin 85 in 31% yield (Scheme 3.4). The tricyclic isatin 85
was able to be formed in solution, rather than neat conditions, as was the case for the
tricyclic isatin 46 in Chapter 2.
Although 85 is a known compound, no account of its synthesis has been
reported since 1989237 (prepared using the Stolle isatin synthesis) and comprehensive
characterisation data was unavailable. Through NMR spectroscopy, the structure of
85 was confirmed. The 1H NMR spectrum revealed the absence of an NH proton
signal suggesting that cyclisation had occurred. Additionally, the 13C NMR spectrum
exhibited two carbonyl signals at 156.9 and 183.9 ppm, indicative of C2 and C1
respectively and analysis by HREI-MS displayed in a molecular ion peak at
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m/z 187.0638, consistent with the molecular formula of the desired product
(C11H9NO2 [M+]).

Reagents and conditions: (a) (COCl)2, THF, reflux, 3.5 h; (b) AlCl3, DCM, reflux, 3 h, 31% (over 2
steps); (c) Br2, 95% EtOH, 70-75 ºC, 78%.

Scheme 3.4 Synthesis of tricyclic isatin 85 and its brominated analogue 92.

The tricyclic isatin 85 was readily brominated through electrophilic
substitution to afford 92 in high yield (Scheme 3.4). The isatin 92 was previously
synthesised238 although no yield or thorough characterisation data were reported. The
structure of 92 was confirmed through MS which revealed the molecular ion as
isotopic peaks at m/z 265 and 267 ([M]+ and [M + 2]+), indicating a bromine atom
was present, together with the correct molecular weight. Analysis by 1H NMR
spectroscopy also revealed two aromatic singlet signals at 7.47 and 7.49 ppm,
ascribed to H9 and H7 respectively.
To further investigate the cytotoxic SAR of the 6,5,6-fused tricyclic isatins,
structures incorporating )-alkylaryl substituents were desired. The selective addition
of an aryl substituent to the cyclised isatin 85 was expected to be difficult, hence the
required )-alkylaryl moiety would need to be incorporated into the structure prior to
cyclisation. It was envisaged that by starting from quinoline (97), substituents could
be added into the C2 position, which upon cyclisation with oxalyl chloride and
AlCl3, would yield the desired )-alkyl tricyclic isatins. Quinolines substituted at the
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2-position are able to be synthesised by reacting quinoline (97) with an
organolithium239 or Grignard reagent.240 Initially, it was thought that this type of
reaction would result in the formation of the 4-substituted quinoline241 or as a
mixture of the 2- and 4-substituted quinolines,242 although later it was demonstrated
that these nucleophilic substitution reactions only yielded the 2-substituted
quinoline.239
Using this rationale, quinoline (97) was reacted with the Grignard reagent,
phenylmagnesium bromide (PhMgBr), to form 2-phenyl-1,2-dihydroquinoline (98)
(Scheme 3.5). The product has chirality introduced at the C2 position, however, in
this project all chiral compounds were used as racemic mixtures as several attempts
at separating of the diastereoisomers formed using resolving salts was unsuccessful.
1,2-Dihydroquinolines are known to be air-sensitive and readily oxidise back to the
original quinoline,243 as well as being susceptible to disproportionation reactions
which lead to a mixture of the parent quinoline and the corresponding THQ.244 For
this reason, the dihydroquinoline 98 was used in further reactions immediately after
its preparation, although analysis by NMR spectroscopy and MS revealed the
mixture contained the dihydroquinoline 98, together with other quinoline-based
products. Purification of the mixture was not attempted due to the instability of
1,2-dihydroquinolines. Upon treatment with oxalyl chloride and AlCl3, 98 was
cyclised to form the novel tricyclic isatin 99 in trace amounts, which may be
explained by the use of impure 2-phenyl-1,2,-dihydroquinoline (98). The structure of
99 was verified through

13

C NMR spectroscopy which displayed two carbonyl

signals at 157.4 and 182.4 ppm, ascribed to C2 and C1 respectively. Additionally,
HRESI-MS revealed a molecular ion of m/z 262.0882, consistent with the protonated
molecular formula of C17H12NO2 [M+H] +.
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Reagents and conditions: (a) 1 M PhMgBr, THF, reflux, 18 h, 90% (crude yield); (b) (COCl)2, THF,
reflux, 3.5 h; (c) AlCl3, CHCl3, reflux, 18 h, 99 = 1% (over 2 steps); 101 = 5% (over 2 steps); (d) Na,
EtOH, reflux, 2 h, 70%; (e) Br2, 95% EtOH, 70-75 ºC, 50%.

Scheme 3.5 Synthesis of )-alkyl tricyclic isatins 99, 101 and 102 from quinoline
(97).

To prepare the saturated analogue of tricyclic isatin 99, the dihydroquinoline
98 needed to be reduced to 2-phenyl-1,2,3,4-tetrahydroquinoline (100). This
reduction was accomplished using a 0.25 M solution of 98 in refluxing EtOH with
Na metal (Scheme 3.5).240 The THQ 100 was obtained as a yellow/orange oil in good
yield and analysis by MS and 1H NMR spectroscopy confirmed its structure. The
1

H NMR spectral data coincided with those reported in the literature.244 In a similar

fashion to the tricyclic isatin 99, the THQ derivative 100 afforded the tricyclic isatin
101 upon treatment with oxalyl chloride and AlCl3 (Scheme 3.5). The yield of this
compound, although poor, was slightly higher than the analogous unsaturated
tricyclic isatin 99. Even though the tricyclic isatin 101 has been synthesised
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previously,237 only a melting point had been reported as characterisation data. The
structure of 101 was readily ascertained through NMR spectroscopy. In the 1H NMR
spectrum, four multiplets between 2.16-2.66 ppm, integrating for one proton each,
were ascribed to the tetrahydro protons H5 and H6. The C5 and C6 signals were
observed in the

13

C NMR spectrum at 27.6 and 19.7 ppm, which is typical of

methylene signals.245 Additional confirmation of 101 was provided through
HREI-MS which revealed a molecular ion at m/z at 263.0949, consistent with the
molecular formula (C17H13NO2 [M+]) .
The tricyclic isatin 101 was then exposed to Br2 in 95% EtOH at 70-75 ºC to
yield the brominated tricyclic isatin 102 in moderate yield (Scheme 3.5). The
structure of 102 was confirmed through 1H NMR spectroscopy, which exhibited two
singlets at 7.50 and 7.59 ppm, attributed to H7 and H9 respectively, and no evidence
of H8. Additionally, the structure of 102 was verified through MS which revealed
molecular ion peaks at m/z 341 and 343, ([M]+ and [M + 2]+), characteristic of the
79

Br and 81Br isotopes within the molecule.
The brominated analogue of 99 was also desired for inclusion in the SAR

study. Bromination through an electrophilic substitution reaction was not viable
since the alkene, rather than the aromatic ring in 99 would be preferentially attacked
by the bromine. To overcome this obstacle, the bromo substituent needed to be
introduced into the molecule at the beginning of the synthesis. This was achieved by
starting the reaction sequence from 6-bromoquinoline (103). 6-Bromoquinoline
(103) may be synthesised from the bromination of THQ (88) and subsequent
reduction to form the quinoline.246 However, the synthesis is unfavourable since
bromination of THQ (88) yields 6-bromo- and 6,8-dibromo-tetrahydroquinoline as a
mixture. Furthermore, the ensuing reduction reaction utilises 2,3-dichloro-5,6~ 80 ~

Chapter 3 – Pyrroloquinoline Derivatives
____________________________________________________________________
dicyano-1,4-benzoquinone (DDQ), which is capable of liberating HCN gas if the
reaction is not performed under scrupulously anhydrous conditions. As an
alternative, commercially available 6-bromoquinoline (103) was reacted with the
Grignard reagent PhMgBr overnight in refluxing THF to yield 6-bromo-2-phenyl1,2-dihydroquinoline (104) (Scheme 3.6), together with some other quinoline-based
products. As with the previous 1,2-dihydroquinoline 98, the 6-bromo derivative 104
was not purified due to the instability of the compound.
Upon exposure to oxalyl chloride and AlCl3 under the aforementioned
cyclisation conditions, the brominated dihydroquinoline 104 cyclised to form the
brominated tricyclic isatin 105 (Scheme 3.6). The yield of 105 was low, similar to
the yields of the tricyclic isatins 99, 101 and 102, however, it was obtained in a pure
form and in sufficient quantity for biological activity evaluation. HRESI-MS
revealed a molecular ion at m/z 339.9965, consistent with the protonated molecular
formula of C17H11NO279Br [M+H]+. Analysis of the 1H NMR spectrum revealed the
absence of an NH proton signal and the 13C NMR spectrum exhibited two carbonyl
signals at 181.1 and 157.7 ppm, arising from C1 and C2 respectively, which
additionally verified the structure of 105.

Reagents and conditions: (a) 1 M PhMgBr, THF, reflux, 18 h, 66%; (b) (COCl)2, THF, reflux, 3.5 h;
(c) AlCl3, CHCl3, reflux, 18 h, 2% (over 2 steps).

Scheme 3.6 Synthesis of the brominated )-alkyl tricyclic isatin 105.
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3.2.2 Synthesis of Pyrrolo[3,2,1-ij]quinoline-1,2-dione Derivatives via Route B
Metal-catalysed cross-coupling reactions are an important class of reactions
within organic chemistry and are a valuable tool for the preparation of compounds
which have proved difficult to synthesise using alternative methods. In Chapter 2,
Sonogashira reactions were discussed in the synthesis of 6,5,5-fused tricyclic isatins.
Herein, the synthesis of 6,5,6-fused tricyclic isatins will utilise the Heck reaction,
which is the Pd-mediated cross-coupling of an aryl or alkenyl halide (or triflate) with
an alkene to form a substituted alkene.247 It is an extremely resourceful procedure in
the formation of carbon-carbon bonds and is widely used in heterocyclic synthesis.248
Typically, the Heck reaction is performed under moderate temperatures (> 80 ºC)
with an organopalladium catalyst such as Pd/C, Pd(PPh3)4, PdCl2 or Pd(OAc)2, an
olefin, a base such as Et3N, K2CO3 or NaOAc, and a ligand such as PPh3.173,249,250
Furthermore, the addition of tetrabutylammonium salts greatly enhances the
reactivity and selectivity of inter- and intramolecular Heck reactions.251
Tetrabutylammonium

chloride

(TBACl)

is

far

more

reactive

than

tetrabutylammonium bromide (TBAB) and tetrabutylammonium hydrogen sulfate,
and the reaction rate is known to increase in proportion to the amount of TBACl
used.252 The Heck reaction is also known to proceed at or near RT under ligand-free
conditions252 with enhanced activity and yield and is commonly referred to as
“Jeffrey’s ligand-free conditions.”181
The mechanism of the Heck reaction has some similarities to the Sonogashira
mechanism (see Figure 2.6). The first step involves the addition of an alkenyl or aryl
halide to the Pd(0) catalyst to form a Pd(II) complex (Figure 3.3). Due to the
increase in electrophilicity, the olefin is readily inserted as a syn-addition into the Pd
complex. The complex is rotated to the trans isomer to relieve torsional strain before
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the beta-hydride elimination step to release the product. The new Pd(II) complex is
destroyed through base-induced reductive elimination to regenerate the Pd(0)
catalyst.173

B-HX
reductive
elimination

Pd(0)
PdL2

B

oxidative
addition

(14e)

Pd(II) L2Pd

R1 X

H
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X
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R2
H

(16e)
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Figure 3.3 Mechanism of the Heck reaction.249

Many intramolecular Heck reactions have previously been applied to indoles to
form tricyclic indoles. These include the cyclisations of 3-alkenyl-4-bromoindoles to
form 3,4-annulated indoles253,254 and )-alkenyl-2-iodoindoles to form 1,2-annulated
indoles.255 More relevant to this project was the high yielding cyclisation of the
)-allyl-7-bromoindole 106 to form the 1,7-annulated indole 107 as reported by
Black et al.256 (Scheme 3.7). The formation of a 1,7-annulated isatin with an
eight-membered ring through an intramolecular Heck reaction has also been
reported, 39 but not with smaller ring sizes.
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Reagents and conditions: (a) Pd(OAc)2, P(o-tol)3, Et3N, CH3CN, 100 ºC, 15 h, 96%.256

Scheme 3.7 Reported synthesis of a 1,7-annulated indole 107 via an intramolecular
Heck reaction.256

Using the rationale from Scheme 3.7, it was envisaged that the synthetic
strategy could be applied to the synthesis of the desired 6,5,6-fused tricyclic isatins
by starting from )-allyl-7-bromoisatin (49). This compound was discussed
previously in Chapter 2 where it was used in the attempted synthesis of 6,5,5-fused
tricyclic isatins via radical cyclisations. Exposing 49 to an intramolecular Heck
reaction could lead to the formation of four isomeric products (86, 87, 108, 109)
(Figure 3.4). According to Baldwin’s rules, the formation of the 5-exo-trig (108,
109) and 6-endo-trig (86, 87) products are both favourable.171 Exo ring closure is
highly selective for 5-, 6- and 7-membered rings as they are more sterically
favourable and have transition states with lower energies than the endo products.257
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Figure 3.4 Possible products from the intramolecular Heck reaction of the isatin 49.

Firstly, the )-allyl-7-bromoisatin (49) was subjected to Heck conditions
similar to those reported by Black et al.256 and Keller215 (Table 3.1, entry 1).
Although 49 may cyclise to yield 5- and 6-membered ring products, the cyclisation
of 49 led only to the formation of the 6-endo-trig products 86 and 87 (Scheme 3.8).
It is thought that this may be due to the bromo and allyl substituents being in a peri
position which results in the reactive allylic carbons being further away from the
organopalladium halide site and therefore, bond formation occurs involving the
terminal allyllic carbon.256 From 1H NMR spectroscopic monitoring of the product, a
mixture of the 6-membered ring isomers in a 5:4 ratio was present. The isomers 86
and 87 could be isolated by preparative TLC.
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Table 3.1 Reaction conditionsa attempted for the intramolecular Heck reaction of 49.

a

Entry 1 was performed in CH3CN, entries 2-8 in DMF.

Using 2D NMR (gHMBC), the isomers 86 and 87 could be distinguished. In
each case, the C2 carbonyl correlated with the H4 proton within the molecule,
however, the C2 carbonyl (153.2 ppm) within the 6H isomer 87 correlated with the
H4 proton (6.95 ppm) (Figure 3.5), which integrated for one proton. Hence, the
alkenyl bond was in the C4-C5 position, with H6 (3.60 ppm) integrating for two
protons. Therefore, it could be deduced that the other compound was the 4H isomer
86, and in this case the C2 carbonyl (157.6 ppm) correlated with H4 (4.62 ppm),
which integrated for two protons.
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Figure 3.5 An excerpt from the gHMBC 2D NMR spectrum of the tricyclic isatin 87
showing the correlation between C2 and H4 within the molecule.

In a bid to increase the yield of the products 86 and 87, tetrabutylammonium
iodide (TBAI) was added to improve the reactivity and selectivity of the reaction251
(Table 3.1, entry 2). Unfortunately, this attempt was unsuccessful as judged by MS
analysis

which

revealed

many

unidentified

products.

Changing

the

tetrabutylammonium salt to TBACl, which is known for its superior reactivity,252
also yielded none of the desired product (Table 3.1, entry 3). MS analysis of the
crude products from both of the above reactions revealed a complex mixture of
components, with no molecular ion peak at m/z 185, the molecular weight of the
tricyclic isatins 86, 87, 108, 109. In Table 3.1, entries 4 and 5, PPh3 and
tris(p-trifluoromethylphenyl)phosphine (TTFMPP) were chosen as the phosphine
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ligands respectively, but these were also to no avail – none of the desired products
were observed by MS.
Jeffrey’s “ligandless” conditions were also attempted in the cyclisation of 49
(Table 3.1, entries 6-8). The base was also changed from NaOAc to K2CO3 due to its
higher reactivity. The advantages of using ligandless conditions in a Heck reaction
are the lower reaction temperatures and shorter reaction times necessary, and,
encouragingly, higher yields of 86 and 87 were produced (Table 3.1, entries 6 and 7).
Upon reacting 49 with Pd(OAc)2, TBACl and K2CO3 at 90 ºC for 40 min, a yield of
17% was obtained (Table 3.1, entry 6). According to TLC and

1

H NMR

spectroscopic analysis, a mixture of isomers in a 2:1 ratio was present. The isomers
were able to be separated once again through preparatory TLC. By increasing the
reaction time to 2 h (Table 3.1, entry 7), the yields of 86 and 87 were increased to
52%. Analysis of the products by 1H NMR spectroscopy revealed they were formed
in a 3:1 ratio. The reaction time was also extended to 4 h (Table 3.1, entry 8) but
then the yields of 86 and 87 decreased to only 5%. Subsequent analysis by 1H NMR
spectroscopy illustrated that the mixture contained 86 and 87 in a 2.6:1 ratio. It can
be concluded that using ligandless conditions during an intramolecular Heck reaction
increases the yield of products. In general, longer reaction times lead to decreased
yields (Table 3.1, entry 7 > entry 6 > entry 8) with no significant difference in
isomer selectivity. It was found that the optimal conditions for the Heck cyclisation
were 2 h at 85 ºC (Table 3.1, entry 7).
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Reagents and conditions: (a) TBACl, K2CO3, Pd(OAc)2, DMF, 85 ºC, 2 h. Compounds 86 and 87
synthesised in 52% yield in a mixture of isomers (3:1). Compounds 111 and 112 synthesised in 49%
yield in a mixture of isomers (3:2).

Scheme 3.8 Synthesis of tricyclic isatins 86, 87, 111, 112 via an intramolecular Heck
reaction.

To obtain the 8-bromo analogues of 86 and 87 for cytotoxicity testing, an
electrophilic bromination using Br2 was not applied since the bromine would attack
the alkene in 86 and 87 yielding the corresponding dibrominated products. As in the
case of 8-bromo-4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (105), the bromo
substituent needed to be inserted prior to undergoing the Heck cyclisation, even
though product yields may be compromised by alternative Pd insertion at the C5-Br
position. The required starting material )-allyl-5,7-dibromoisatin (110) was
synthesised using the same conditions as for the allylisatins 49 and 76 (Chapter 2).
The )-allyl-5,7-dibromoisatin (110) was synthesised in 87% yield and its 1H NMR
spectral data coincided with those reported in the literature.64 Subsequent exposure
of the )-allylisatin 110 to the optimal intramolecular Heck conditions (as determined
in Table 3.1), gave the brominated tricyclic isatins 111 and 112 in a moderate yield
(Scheme 3.8). Analysis by 1H NMR spectroscopy revealed the 4H and 6H isomers
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(111 and 112) had formed in a 3:2 ratio, with the 4H isomer 111 again being the
predominant isomer formed.
The NMR spectral data for the brominated tricyclic isatins 111 and 112 was
similar to those observed for the analogous unsubstituted tricyclic isatins 86 and 87.
The key difference was the absence of the signal for the H8 proton and the downfield
shift (~ 0.14 ppm) of the H7 and H9 proton signals in the 1H NMR spectrum of 111
and 112 when compared to 86 and 87. Confirmation of the molecular formula was
observed through HRESI-MS, which exhibited a molecular ion at m/z 263.9659 for
the 4H isomer 111, consistent with the protonated molecular formula of
C11H7NO279Br [M+H]+, and m/z 267.9611 for the 6H isomer 112, consistent with the
protonated molecular formula of C11H9NO281Br [M+H]+.
The Heck reaction was also applied to other )-allylated isatins to yield the
tricyclic isatins 114, 116, 118 (Scheme 3.9). 7-Bromoisatin (55) was reacted with
crotyl bromide to yield 7-bromo-)-crotylisatin (113) in good yield (Scheme 3.9).
The structure of this novel compound was verified through 1H NMR spectroscopy,
which revealed the absence of the NH proton signal. The correct molecular weight of
the product was corroborated through HRESI-MS which exhibited a molecular ion
of m/z 279.9969, consistent with the protonated molecular formula of
C12H11NO279Br [M+H]+. The crotyl isatin 113 underwent an intramolecular Heck
reaction using identical conditions to those used in Scheme 3.8 to yield the tricyclic
isatin 114 in poor yield (Scheme 3.9). The 6-methyl-6H-pyrrolo isomer 114 was
formed exclusively as determined by 1D and 2D NMR spectroscopy. Due to the low
yield of 114, the brominated analogue of this compound was not attempted.
7-Bromoisatin (55) was also reacted with cinnamyl bromide providing
7-bromo-)-cinnamylisatin (115) in excellent yield (Scheme 3.9). Once more, the
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structure of this novel compound was confirmed through NMR spectroscopy and
HRESI-MS. Upon undergoing an intramolecular Heck reaction, 115 was able to
form 6-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (116) in poor yield (Scheme
3.9), albeit in higher yield than 114. Interestingly, the tricyclic 116 was formed
exclusively as the 4H-pyrrolo isomer with no evidence of the 6H-pyrrolo
regioisomer in the 1H and 13C NMR spectra, in contrast to the 6-methyl-6H-pyrrolo
tricyclic isatin 114 (Scheme 3.9). The 2D NMR spectral data showed that C6 is a
quaternary carbon; hence, it must have cyclised onto the isatin, confirming the
formation of 116. Additionally, the LREI-MS data confirmed the loss of a bromine
atom from the starting material 115 and the correct m/z peak for the tricyclic isatin
116 parent ion.
The

synthesis

of

the

brominated

analogue

of

6-phenyl-4H-

pyrrolo[3,2,1-ij]quinoline-1,2-dione (118) was also attempted. By beginning with
5,7-dibromoisatin (17) and reacting it with cinnamyl bromide, the )-cinnamyl5,7-dibromoisatin (117) was prepared in essentially quantitative yield (Scheme 3.9).
1

H NMR spectral data of the purified compound agreed with those previously

reported in the literature.64 However, difficulties were encountered when
synthesising the Heck cyclisation product 118 (Scheme 3.9). By applying the same
reaction conditions as in previous Heck cyclisations (i.e. 85 ºC, 2 h), there was no
evidence of the desired product being formed. Extending the reaction time to 4 h also
yielded no product. Analysis using MS revealed the isolated crude product was a
complex mixture of compounds including the starting material 117. Presumably
alternative reactivity at the C5-Br position in 117 was one of the contributing factors
to the product mixture complexity.
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Reagents and conditions: (a) NaH, DMF, RT, 20 min; (b) crotyl or cinnamyl bromide, KI, 60 ºC,
18 h, 113 = 59% (over 2 steps); 115 = 97% (over 2 steps); 117 = 48% (over 2 steps); (c) TBACl,
K2CO3, Pd(OAc)2, DMF, 85 ºC, 114 = 2.5 h, 8%; 116= 2 h, 17%; 118 = 2-4 h.

Scheme 3.9 )-Alkylation of isatins 55 and 17 and subsequent intramolecular Heck
reactions to yield the tricyclic isatins 114 and 116.

With a range of pyrrolo[3,2,1-ij]quinoline-1,2-diones synthesised for future
cytotoxicity testing, it was decided that attention should be turned to larger
benz-fused polycyclic isatins, which would also provide useful information for our
SAR.

3.3 Synthesis of Polycyclic Isatins
In order to further explore the isatin scaffold for the development of novel
cytotoxins and to incorporate the )-benzylic substituent moiety into a fused aromatic
ring, attention was turned to extending the quinoline nucleus to benzoquinolines
containing a benzo ring fused onto the benzene or heterocyclic ring of quinoline.258
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Reactions with the 3,4-annulated benzoquinoline, phenanthridine (119), will be
discussed in this section. Cyclisation chemistry associated with the 2,3-annulated
benzoquinoline, acridine (120), and will be outlined in Section 3.3.2. The synthetic
strategies involved in the preparation of isatins based on pyrrolophenanthridines and
pyrroloacridines

include

the

Stolle

isatin

synthesis

and

metal-catalysed

cross-coupling reactions (Figure 3.6). There are also possibilities to form isatins
containing a benzophenanthridine nucleus (as depicted by rings E, F and G in Figure
3.6) through the above reactions.

Figure 3.6 Proposed structures and synthetic strategies in the formation of
A) pyrrolophenanthridines and B) pyrroloacridines.
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3.3.1 Phenanthridine-based Derivatives
The phenanthridine-based isatin derivatives portrayed in Figure 3.6A contain a
pyrrolo[3,2,1-de]phenanthridine nucleus. The related indole structural core is
prevalent in alkaloid metabolites from almost all of the genera in the Amaryllidaceae
(perennial herb and flowering bulb) family208 and include alkaloids such as
oxassoanine (123), hippadine (124) and pratorinine (125) (Figure 3.7).232,259

Figure 3.7 Examples of alkaloids from the Amaryllidaceae family containing a
pyrrolo[3,2,1-de]phenanthridine nucleus.

3.3.1.1 The Stolle Isatin Synthesis
One compact route to synthesise phenanthridine-based isatins is to apply the
Stolle isatin method to phenanthridine (119) (Scheme 3.10). In order for this to
succeed, the imine bond in phenanthridine (119) needs to be reduced to allow for
subsequent cyclisation with oxalyl chloride and AlCl3. The reduction of 119 was first
attempted using tin powder in refluxing HCl,260 however, analysis by MS revealed
only starting material was present. Replacing tin with NaCNBH3, a reagent known to
reduce hydrazones and imines,261 yielded 5,6-dihydrophenanthridine (121) in good
yield (Scheme 3.10). The structure of 121 was confirmed through LREI-MS which
exhibited a molecular ion at m/z 181, some 2 atomic mass units higher than that of
the starting material, indicating that the imine bond of 119 had been reduced. The
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1

H NMR spectral data also contained a singlet signal at 4.39 ppm, integrating for two

protons, which can be attributed to H6.

Reagents and conditions: (a) AcOH, EtOH, reflux, 30 min; (b) NaCNBH3, reflux, 1.5 h, 77% (over 2
steps); (c) (COCl)2, DMAP, DIPEA, THF, reflux, 3.5 h; (d) AlCl3, CHCl3, reflux, 1.5 h, 15% (over 2
steps); (e) Br2, AcOH, 70-75 ºC, 69%.

Scheme 3.10 Synthesis of the pyrrolophenanthridines 126 and 127 via the Stolle
isatin procedure.

When the previously discussed Stolle reaction conditions were applied to
5,6-dihydrophenanthridine (121), the reaction did not proceed and only starting
material was recovered from the reaction mixture as determined by MS analysis. In
this case, the addition of Et3N and a catalytic amount of 4-(dimethylamino)pyridine
(DMAP) was employed to facilitate the formation of the oxamide intermediate prior
to the Friedel-Crafts acylation to yield phenanthridine-based isatin 126 (Scheme
3.10). Previously, it had been shown that the addition of Et3N and DMAP to
5,6-dihydrophenanthridine (121) was necessary to achieve good yields of amide
derivatives.262 The yield of the phenanthridine-based isatin 126 was not high,
although enough pure material was obtained for future reactions. Confirmation of the
structure of 126 through

13

C NMR spectroscopy, which revealed signals for the C4

and C5 carbonyl signals at 183.2 and 157.9 ppm respectively, characteristic of the

~ 95 ~

Chapter 3 – Pyrroloquinoline Derivatives
____________________________________________________________________
isatin core. Analysis by HREI-MS indicated a molecular ion at m/z at 235.0625,
consistent with the molecular formula of C15H9NO2 [M+].
Initially, there were difficulties in brominating the phenanthridine-based isatin
126. The compound was insoluble at 75 ºC in 95% or absolute EtOH. Eventually,
bromination proceeded at 75 ºC in glacial AcOH to yield 127 in good yield (Scheme
3.10). The NMR spectral data for this compound appeared similar to 126, except for
the absence of the H2 proton in the 1H NMR spectrum. The presence of a bromine
atom in the molecule was confirmed by LREI-MS which showed characteristic
molecular isotopic peaks at m/z 313 and 315 ([M]+ and [M + 2]+).

3.3.1.2 Biaryl Coupling
Another avenue to synthesising phenanthridine-based isatin derivatives is to
utilise metal-catalysed cross-coupling reactions. As mentioned in Sections 2.2.2 and
3.2.2, Pd catalysts are very versatile and are able to catalyse an array of important
organic chemistry reactions. Pd catalysts are also useful in biaryl coupling reactions
where an aryl-aryl bond formation is desired. More specifically, arenes are able to
react with aryl halides or triflates to form an aryl-aryl bond. These types of reactions
commonly occur as intramolecular cyclisations263,264 to form polyarenes such as
fullerenes265 and phenanthridine-based alkaloids,266 including those shown in Figure
3.7.
The pyrrolo[3,2,1-de]phenanthridine scaffold contains a biaryl linkage which
may be formed via the Pd-catalysed intramolecular cyclisation of a )-alkylindolebased compound (Scheme 3.11).228
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Scheme 3.11 Example of a Pd-catalysed intramolecular biaryl coupling of
)-alkylindole-based compound.228

The biaryl coupling may proceed via a halide on the benzyl moiety as in Figure
3.11 or via a halide on the indole nucleus. Applying this rationale, it was thought that
additional novel phenanthridine-based isatins could be prepared through the
Pd-catalysed biaryl intramolecular coupling of )-alkylisatins such as 7-iodo)-(1-naphthylmethyl)isatin (128) and 7-iodo-)-(2-naphthylmethyl)isatin (129). This
strategy has also been utilised previously by Garden et al. who synthesised
pyrrolophenanthridine derivatives from 7-halo-)-alkylisatins.208
Commencing from 7-iodoisatin (56), 7-iodo-)-(1-naphthylmethyl)isatin (128)
was able to be prepared in good yield (Scheme 3.12). Compound identity was
confirmed through 1H NMR spectroscopy which revealed ten aromatic protons in the
6.90-7.99 ppm region. The

13

C NMR spectrum gave evidence that )-alkylation had

occurred through presence of the )-alkyl CH2 signal at 42.1 ppm. The next step in
the synthesis would typically be the biaryl coupling, but due to the reactivity of the
C3 carbonyl in 128, protection of this functional group was required prior to
exposure to Pd.208,232 The isatin 128 was protected as a cyclic ketal using typical
Dean-Stark conditions as described in Section 2.2.2.1.1 and the cyclic ketal
derivative 130 was obtained as a light brown powder in high yield (Scheme 3.12).
Conversion to the ketal group was verified through
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confirmed the presence of the two ketal carbon signals through a large signal at
66.3 ppm, and the absence of a signal from the carbon of the ketone carbonyl group
usually observed at ~ 180 ppm.

Reagents and conditions: (a) NaH, DMF, RT, 20 min; (b) 1-(chloromethyl)naphthalene, KI, 60 ºC,
18 h, 58% (over 2 steps); (c) (CH2OH)2, PTSA, PhMe, reflux, 48 h, 75%; (d) Pd(OAc)2, TBAB,
NaOAc, DMF, 90 ºC, 5 h, 86%; (e) 6 M HCl/THF (1:1), reflux, 5 h, 67%; (f) NBS, CH3CN, RT, 18 h.

Scheme 3.12 Synthesis of pyrrolophenanthridines 131 and 132 through Pd-catalysed
biaryl coupling reactions.

Reaction of the isatin 130 with Pd(OAc)2 enables an intramolecular biaryl
coupling to take place with the possibility of two regioisomers being formed. If the
biaryl coupling occurs between the halide and C2 of the naphthyl moiety in isatin
130, the pyrrolophenanthridine 131 is prepared, whereas coupling via C8 on the
naphthyl moiety will result in the formation of a pentacyclic isatin featuring a
7-membered ring (134) (Figure 3.8). It was deduced from examination of the
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1

H NMR spectrum, that the pyrrolophenanthridine 131 was synthesised with

complete regioselectivity and in high yield (Scheme 3.12). The aromatic proton
signals for H9’ (7.56 ppm) and H10’ (7.50 ppm) were observed as triplets which
were coupled to one another (Figure 3.9). While the isatin containing the
7-membered ring 134 may contain triplet signals for H9’ and H12’, these protons are
not coupled to one another and hence, the pyrrolophenanthridine 131 is the only
possible regioisomer to contain two triplet signals in the 1H NMR spectrum which
are coupled to one another.

Figure 3.8 Possible regioisomers 131 and 134 from the Pd-catalysed intramolecular
biaryl coupling of the isatin 130.
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Figure 3.9 An excerpt from the gCOSY 2D NMR spectrum of the
spiro-pyrrolophenanthridine 131 showing the correlation between H9’ and H10’
within the molecule.

Under acidic conditions the ketal moiety on the pyrrolophenanthridine 131 was
hydrolysed to yield the isatin 132 as a dark red powder in good yield (Scheme 3.12).
The red colour of the compound suggested that the ketal had been destroyed and that
the C4 carbonyl, an important element in the chromophore of the isatin core, had
been restored. The structure of the compound was verified through

13

C NMR

spectroscopy, which notably revealed the absence of the ketal carbon signal and the
presence of the C4 carbonyl at 182.9 ppm. Bromination of the isatin 132 was
unsuccessful due to solubility problems. The isatin derivative 132 was poorly soluble
in glacial AcOH, EtOH or CH3CN at 70-75 ºC following the bromination procedures
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described in earlier synthetic schemes. By replacing Br2 with )-bromosuccinimide
(NBS) as the source of bromine, the bromination was still ineffective and analysis by
MS revealed only the starting material 132 was present.
Pyrrolophenanthridines using 7-iodo-)-(2-naphthylmethyl)isatin (129) as the
starting material were also prepared. 7-Iodo-)-(2-naphthylmethyl)isatin (129) was
synthesised from 7-iodoisatin (56) in 2 steps (Scheme 3.13). The structure of the
naphthyl compound was confirmed through 1H NMR spectroscopy, which showed
the absence of an NH proton signal and the presence of a singlet at 5.64 ppm,
integrating for two protons and ascribed to the benzylic protons.
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Reagents and conditions: (a) NaH, DMF, RT, 20 min; (b) 2-(bromomethyl)naphthalene, KI, 60 ºC,
18 h, 36% (over 2 steps); (c) (CH2OH)2, PTSA, PhMe, reflux, 64 h, 92%; (d) Pd(OAc)2, TBAB,
NaOAc, DMF, 90 ºC, 5 h, 67%; (e) 6 M HCl/THF (1:1), reflux, 5 h, 90%; (f) NBS, CH3CN, RT, 18 h,
39%.

Scheme 3.13 Synthesis of pyrrolophenanthridines 136-138 through Pd-catalysed
biaryl coupling reactions.

Again the )-naphthylmethylisatin 129 was subjected to Dean-Stark conditions
in the presence of ethylene glycol to protect the ketone as a cyclic ketal prior to
biaryl coupling. This reaction resulted in excellent yield of 135 (Scheme 3.13) and
the

13

C NMR spectrum lacked a C3 carbonyl signal and displayed a relatively

intense signal at 66.3 ppm, arising from the two ketal carbons.
As with the related compound 130, the intramolecular biaryl coupling of 135
could lead to two regioisomers. If the biaryl coupling proceeds via C1 on the
naphthyl ring of 135, pyrrolophenanthridine 136 will form, whereas formation of a
new bond to C3 on the naphthyl ring of 135 will lead to pyrrolophenanthridine 139
(Figure 3.10). Through

1

H NMR spectroscopy it was ascertained that the
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pyrrolophenanthridine 136 was formed exclusively and in good yield (Scheme 3.13).
If the pyrrolophenanthridine 139 had been formed, the 1H NMR spectrum should
have contained two singlets attributed to H8’ and H13’. However, aromatic singlet
signals were not observed and it could be deduced that the pyrrolophenanthridine
136 had been prepared. The structure of the pyrrolophenanthridine 136 was further
verified through 1H NMR spectroscopy which revealed a pair of coupled doublets
(H8’ and H9’ at 7.21 and 7.74 ppm respectively) and two triplet signals coupled to
each other (H11’ and H12’ at 7.50 and 7.56 ppm respectively). The regioselectivity
of this reaction is in accordance with results for similar reactions reported by Torres
et al.232

Figure 3.10 Possible regioisomers 136 and 139 from the Pd-catalysed intramolecular
biaryl coupling of the isatin 135.

Cleavage of the ketal functionality on 136 under acidic conditions liberated the
pyrrolophenanthridine 137 in very high yield (Scheme 3.13). The

13

C NMR

spectrum of 137 exhibited a signal at 183.4 ppm, ascribed to the C4 carbonyl and the
signal at 66.3 ppm attributed to the ketal carbons had disappeared. The compound
137 was a red powder, which also suggested restoration of the carbonyl. The
pyrrolophenanthridine 137 had higher solubility in organic solvents relative to the
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pyrrolophenanthridine 132 and consequently was able to be brominated using NBS
in CH3CN producing the bromo derivative 138 in moderate yield (Scheme 3.13).
Analysis by 1H NMR spectroscopy revealed the absence of the H2 proton signal and
hence, verified the structure of 138. The LREI-MS also had isotopic molecular ion
peaks at m/z 363 and 365 ([M]+ and [M + 2]+), indicative of the brominated
pyrrolophenanthridine 138.

3.3.2 Acridine-based Derivatives
Derivatives of acridine (120) exhibit an array of pharmacological properties,
and during the early 20th century, anti-bacterials and anti-malarials based on acridine
(120) were used clinically.267,268 In recent decades attention has turned to the
cytotoxic properties of acridine (120) and its derivatives.269-271 The 9-anilinoacridine
derivative amsacrine (140) was one of the first cytotoxic acridines discovered268 and
due to the planarity of the molecule, its mode of action is primarily as a DNA
intercalating agent. Amsacrine (140) and other acridine-based derivatives (141 and
142, Figure 3.11) also express topoisomerase II inhibitory activity, an enzyme which
is important for the control of DNA structure,270,272 and these compounds also show
DNA quadruplex binding selectivity.273
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Figure 3.11 Examples of acridine derivatives with cytotoxic activity (140),
topoisomerase II inhibitory activity and DNA quadruplex binding selectivity (141
and 142).

To further investigate the cytotoxicity of acridines, it was decided that a
pyrroloacridine based on the isatin scaffold would be synthesised. This novel series
of acridine derivatives would also serve as an extension into the investigation of
benzoquinoline-based isatins and their cytotoxicity could be compared to the
phenanthridine-based isatins prepared in Section 3.3.1.
Initially, the imine functionality on acridine (120) was reduced to
9,10-dihydroacridine

(122)

to

allow

for

subsequent

cyclisation.

The

9,10-dihydroacridine (122) was synthesised in moderate yield (Scheme 3.14) and
1

H NMR spectroscopy revealed the presence of the NH proton as a broad singlet at

5.95 ppm, confirming reduction of the 120 to the dihydro compound 122. The
remainder of the signals in the 1H NMR spectrum coincided with those previously
reported in the literature.274
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Reagents and conditions: (a) AcOH, EtOH, reflux, 30 min; (b) NaCNBH3, reflux, 1.5 h, 47% (over 2
steps); (c) (COCl)2, THF, reflux, 3.5 h; (d) AlCl3, CHCl3, reflux, 18 h, 15% (over 2 steps); (e) Br2,
AcOH, 70-75 ºC, 41%.

Scheme 3.14 Synthesis of pyrroloacridines 143 and 144 via the Stolle isatin
procedure.

The Stolle isatin synthesis method was utilised to cyclise 122 to the
pyrroloacridine 143 (Scheme 3.14). There is only one account of this compound in
the literature and it was synthesised using the Stolle method.275 The synthetic
procedure contained a limited amount of characterisation data hence, spectroscopic
techniques were employed to confirm the structure. As expected for the structure of
143, the signal arising from the amino proton was absent from the 1H NMR spectrum
and the 13C NMR spectrum exhibited signals for C1 and C2 at 155.5 and 182.3 ppm
respectively. HREI-MS analysis also revealed a molecular ion peak at m/z 235.0633,
consistent with the molecular formula (C15H9NO2 [M+]). The pyrroloacridine 143
was subsequently brominated with Br2 in glacial AcOH generating the brominated
pyrroloacridine 144 (Scheme 3.14). Examination of the 1H NMR spectrum revealed
the absence of the H4 proton, indicating that substitution had occured. The LREI-MS

~ 106 ~

Chapter 3 – Pyrroloquinoline Derivatives
____________________________________________________________________
also showed isotopic molecular ion peaks at m/z 313 and 315 ([M]+ and [M + 2]+),
characteristic of the presence of one bromine.
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This chapter reported the successful synthesis of 17 novel pyrrolo[3,2,1ij]quinoline-1,2-diones

including

one

novel

acridine-

and

seven

novel

phenanthridine-based polycyclic isatins through metal-catalysed cross-coupling
reactions

and

the Stolle isatin

synthesis.

The facile synthesis

of the

pyrrolo[3,2,1-ij]quinoline-1,2-diones confirms that this series of compounds have a
decreased amount of ring strain compared to the pyrrolo[3,2,1-hi]indole-1,2-diones
discussed in Chapter 2. As theoretically predicted using Material Studios software
(Section 2.2.4), synthesis of the pyrrolo[3,2,1-ij]quinoline-1,2-diones was more
facile and this was a reflection of their lower calculated ∆Hf values compared to
those of pyrrolo[3,2,1-hi]indole-1,2-diones.
Evaluation of the cytotoxic activity of the newly generated 6,5,6-fused tricyclic
and polycyclic isatins and two cyclisation precursors (115 and 136) are presented in
Chapter 6, along with a preliminary assessment of their possible modes of cytotoxic
action by DNA intercalation.
In the succeeding chapter, discussion will focus on the design, synthesis and
evaluation of isatin derivatives with acid-labile linkers. These drug-linker
compounds were designed to be suitable for attachment to a targeting protein with
the ultimate aim of selective delivery and release of the cytotoxic isatin derivative
within tumour cells.
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CHAPTER 4
Synthesis and Efficacy of Acid-Labile Linkers
4.1 Introduction to Acid-Labile Linkers
Ligand-targeted drug or prodrug delivery is currently one of the most
challenging areas in pharmaceutical research and involves the judicious choice of
the drug, linker and targeting ligand.22 The entire conjugate must then be
transported intact through the systemic circulation and pass several complex
barriers en route to the target site before it becomes activated.21 In chemotherapy,
drug conjugates that are non-toxic to the host, stable in the circulatory system and
then readily cleaved at the target site are often used for this purpose.20
Previously, it was believed that the tumour specificity of anti-cancer agents could
be improved by linking the drugs directly to a targeting moiety via non-cleavable
amide bonds. However, in many cases the conjugates lacked potency and were
less cytotoxic than the unconjugated drugs themselves.276,277 Over the past decade
however, the significance of the chemical link between the drug and the carrier
molecule in relation to its pharmacological activity has come to the
forefront.24,278,279 A promising strategy involves conjugating a cytotoxin with a
tumour-targeting protein through an acid-labile linker that is stable at
physiological pH.20 Internalisation at the target tumour site via processes such as
RME280 exposes the conjugate to the acidic environment of the endosomes or
lysosomes (pH 4.5-6.0), resulting in selective release of the original cytotoxin
inside the tumour cell (e.g. Figure 4.1).22,103
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Figure 4.1 Schematic representation of a cytotoxin bound to the exposed lysine
residues of a tumour-targeting protein via an acid-labile linkage such as an imine,
hydrazone or oxime. Upon receptor-mediated endocytosis of the conjugate at the
target tumour, the native cytotoxin is selectively released inside the tumour cell.

Over the years, a wide variety of functional groups have been employed in
the development of linkers that are stable at physiological pH (7.4), but cleave at
endosomal/lysosomal pH including acid-sensitive hydrazones, cis-aconityl
groups

(see

Section

1.6),

trityl

groups,103,281

orthoesters282

and

)-ethoxybenzylimidazoles.283 The hydrazone linker has, however, been reported
to cleave at non-target sites284 and at pH 7.4,285 which suggests that this linker
may be unstable in the circulatory system. Other less commonly employed
acid-labile linkers include acetals,105,106 ketals,105 oximes107 and imines.38,108
Imine linkers are not widely used in drug delivery due to their perceived
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instability,109 however, recent studies have shown that aromatic imines with
extended π-π conjugation are stable at physiological pH, while readily
hydrolysing in mildly acidic solutions (e.g. pH 4.5-6.8).110,286-289 The macrocyclic
antibiotic amphotericin B (AMB) has been conjugated to poly(ethylene glycol)s
(PEG) of varying lengths through an imine linker (Figure 4.2). All conjugates
were stable at physiological pH and temperature, with only 5% of AMB being
hydrolysed after 24 h. Conversely, at pH 5.5, AMB was rapidly released and the
conjugates exhibited half-lives between 2-45 min.287 The rate of hydrolysis was
dependent on substitution patterns on the benzene ring and not on the molecular
weight of the PEG linker.

Figure 4.2 Structure of the imine-linked amphotericin B-poly(ethylene glycol)
conjugate.287
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More recently, Müller et al. have described the conjugation of a fluorophore,
7-amino-4-methylcoumarin

(AMC),

to

the

self-immolative

p-aminobenzyloxycarbonyl linker system (Figure 4.3), which is activated under
acidic conditions to release AMC.289 At pH 5.0, the imine bond was rapidly cleaved
(t1/2 = 17-173 min), whereas at pH 7.4 the 12 compounds displayed greater stability
(t1/2 = 8-365 h). For acid-sensitive anti-cancer prodrugs, long-term stability at pH 7.4
(t1/2 > 48 h) is vital289 and in this case, two of the model AMC conjugates exhibited
efficient hydrolysis rates at pH 5.0 together with long-term stability at physiological
pH.

Figure 4.3 Structure of the imine-linked 7-amino-4-methylcoumarin conjugate.289

4.2 Initial Synthetic Targets
As described in the Introduction (Chapter 1), our research group has
previously described the generation of a series of over 35 highly potent
)-substituted isatin-derived cytotoxins, several of which show nanomolar
cytotoxicity against a diverse panel of human cancer cell lines while being
inactive towards human mononuclear cells (Figure 4.4).64,65,81 We were interested
to develop a strategy to conjugate these potent cytotoxins via a pH-sensitive
linker to the exposed lysine residues of tumour-targeting proteins (e.g. Figure
4.1) such as Tf,123,124 PAI-2142,145,146 and the antibody Herceptin,121,290 which is
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selective for the HER2 receptor and is overexpressed in 20-30% of human breast
carcinomas.3

Figure 4.4 Cytotoxic activity of isatin (11) and its derivatives against the human
monocyte-like histiocytic lymphoma U937 cell line.64,65,81

The various isatin-based cytotoxins developed within the group are
derivatised on both the aromatic ring and via )-substitution.64,65,81 Therefore, the
aim of this study was to generate a pH-sensitive linker that did not interfere with
these areas of the molecule. Within our research group we have previously
conjugated a )-alkylisatin derivative to PAI-2 and Tf through a succinate linker
(Figure 4.5).291 The succinate linker is degraded enzymatically by esterases
present within the lysosomes of tumour cells. The limitation of this linker system
is that the succinate bond is susceptible to hydrolysis from non-specific esterases.
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Figure 4.5 Structure of a )-alkylisatin derivative
tumour-targeting ligand via a succinate linker.291

conjugated

to

a

Therefore, to improve our conjugation method, we decided to create a
pH-sensitive linker which would capitalise the available carbonyl group at C3,
which is present in all of the above mentioned isatin-derived cytotoxins. This
could be achieved using an imine linker. As described later in Chapter 6, the most
potent isatin analogues turned out to be the 5,7-dibrominated )-alkylisatins rather
than the newly prepared, tricyclic/polycyclic derivatives. For this reason,
5,7-dibromo-)-(p-methoxybenzyl)isatin (24) (Figure 1.10), which has an IC50
value of 1.83 µM against U937 cells,64 was chosen as the starting cytotoxin, in
addition to its ready synthetic availability and structural simplicity, which
facilitates product characterisation via NMR spectroscopy. While 24 is less active
than

the

most

promising

)-subsituted-5,7-dibromoisatin

cytotoxins

(IC50 = 1.83 µM vs. < 1 µM respectively),64 the bioconjugation strategy presented
here should apply equally well to any of the )-substituted isatin-derived
cytotoxins, all of which contain an available carbonyl at C3. This strategy is also
expected to apply to the bioconjugation of well known anti-cancer agents such as
epipodophyllotoxin (145), camptothecin (146) and colchicine (147) to enhance
their effectiveness even further292,293 (Figure 4.6).
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Figure 4.6 Structures of known carbonyl-containing anti-cancer agents (145-147)
which could be used for bioconjugation strategies via an imine linker.

Reaction of the isatin-derived cytotoxin 24 with a bifunctional linker such
as the anilino carboxylic acids 148-152, would give the aryl imine-linked
cytotoxins 153-157 (Scheme 4.1). These compounds, with a free carboxylic acid
available for coupling to the exposed lysine residues on a tumour-targeting
protein, would be expected to be stabilised by extended resonance delocalisation.
Furthermore, it is expected that acid-catalysed hydrolysis of the imine-linked
cytotoxins would result in selective release of the original cytotoxin (Figure 4.1).
This would be an improvement over several of the existing pH-sensitive
bioconjugation strategies, where hydrolysis of the linker generates a modified
derivative, which is often of lower potency than the original cytotoxin. This was
observed

when

doxorubicin

(4)

was

conjugated

through

a

)-ethoxybenzylimidazole linker. The modified doxirubicin derivative released
under acidic conditions displayed an IC50 value of ~ 12 µM against human
ovarian carcinoma 2008 cells, while doxorubicin (4) exhibited greater than
10-fold lower IC50 value against the same cell line.283
Prior to development of a cytotoxin-protein conjugate, it is important to
conduct preliminary model studies to demonstrate the viability of the proposed
selective imine hydrolysis strategy for ultimately releasing the cytotoxin in vivo.
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Thus, the cytotoxic isatin derivative 24 was coupled to a )- and C-terminii
protected L-lysine amino acid residue via incorporation of the bifunctional,
acid-amine linkers (148-152) (Scheme 4.1), and their hydrolytic efficiency was
evaluated using UV-Vis spectrophotometry. Herein, is the first instance of the
pH-dependent selective release of a potent )-alkylisatin-derived cytotoxin
through the acid-catalysed hydrolysis of an imine linker.

4.3 Synthesis of 3-Iminoisatins
The five novel aryl imine derivatives 153-157 were readily prepared by
the

acid-catalysed

reaction

of

the

potent

cytotoxin,

5,7-dibromo-)-

(p-methoxybenzyl)isatin (24), with a range of commercially available anilino
carboxylic acids (148-152), differing in terms of their aromatic substitution
patterns and by the length of the linker between the aromatic ring and the
carboxylic acid moiety (Scheme 4.1). For this study, para- and meta-benzoic
(148, 151), para- and meta-phenylacetic (149, 152) and para-phenylpropionic
(150) anilino carboxylic acids were selected. The isatin 24 and the appropriate
acids 148-152 were heated at reflux in MeOH or EtOH together with a catalytic
amount of AcOH for 1.5 h to yield the imines 153-157. Reactions in this study
proceeded in moderate to high yield, with the phenylacetic and phenylpropionic
acids (e.g. 154, 155, 157) affording higher yields than 153 and 156 (68-71% cf.
18-56% respectively). Imines 154-157 were produced in higher yields with the
higher boiling EtOH rather than MeOH (56-71% cf. 14-18% respectively), while
153 was the only imine to favour MeOH over EtOH (18% cf. 11% respectively).
Lack of the AcOH catalyst led to a decrease in chemical yield (18% cf. 13% for
156 when using MeOH as the solvent). There was also no evidence, as seen by
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1

H NMR spectroscopy, (DMSO-d6) of self-cleavage of the imines 153-157 to the

free isatin 24.
O
Br
O
N
Br
OMe

24
a
n CO2H

CO2H

H2N

H2N

n

151 n = 0
152 n = 1

148 n = 0
149 n = 1
150 n = 2
n CO2H

N

CO2H

N

Br

n

Br
O
Br

O

N
PMB

Br

153 n = 0
154 n = 1
155 n = 2
Reagents and conditions:
(PMB = para-methoxybenzyl).

a)

N
PMB
156 n = 0
157 n = 1

EtOH,

AcOH

(cat.),

reflux,

1.5

h,

18-71%;

Scheme 4.1 Synthesis of the 3-iminoisatins 153-157.

Imines 153-157 were obtained as mixtures of E and Z isomers about the
imine bond which were unable to be separated by either TLC or HPLC, as has
been reported for other 3-arylimino-2-indolinones.294 The 1H NMR spectra of the
imines 153-157 in DMSO-d6, revealed that most compounds (153-156) were
synthesised as approximately 1:1 mixtures of E/Z isomers, with the exception of
the meta-phenylacetic imine (157) where the E isomer was favoured over the Z
isomer in an approximate 2:1 ratio. The E stereochemistry was assigned to a
particular isomer based on the following: the signal from H4 (on the isatin core)
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of the E isomer in the 1H NMR spectrum was shifted upfield 1.2-1.5 ppm relative
to the H4 signals of the Z isomer and the parent compound 24, presumably due to
shielding by the ring current on the iminophenyl ring (Figure 4.7). The isomeric
ratios of each compound were therefore determined by comparing the size of the
integrals from the H4 signals of the E and Z isomers, as has been described
previously by our research group for a related series of compounds.81 Although
some 2-indolinones containing a substituent at C3 have been described as
predominantly E isomers,76 elsewhere it has been reported that the E and Z
isomers of 3-imino-2-indolinones interconvert rapidly in solution at room
temperature and that the ratio of isomers is solvent dependent.294

Figure 4.7 Differences in chemical shift between the E and Z isomers of
3-iminoisatin 153.
The 1H NMR spectum of the para-propionic imine 155 displayed 40
protons, 20 for each isomer. Characteristic peaks included the eight propionic
protons (E and Z) at 2.55-2.89 ppm and the carboxylic acid proton at 12.13 ppm
for both isomers. Similarly, four propionic carbons (E and Z) were observed at
30.7-36.5 ppm in the

13

C NMR spectrum, together with the carboxylic acid

carbon at 174.5 ppm for both isomers. Analysis by HRESI-MS confimed the
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molecular weight of 155 by finding a mass of m/z 526.9722, consistent with the
molecular formula (C24H19N2O279Br81Br [M-CO2H]-).
The imines 154-157 were formed in good yields (56-71%), whereas 153
was obtained in only 18% yield. This presumably results from the reduced
nucleophilicity of the amino moiety in 153, relative to that in 154-157, due to the
strong electron withdrawing effect of the para-substituted carboxyl group (Figure
4.11).

4.4 Synthesis of Isatin-Lysine Conjugates
The imino acids (153-157) were then coupled to a )- and C-protected
L-lysine

amino

acid

procedures,295,296

residue

utilising

under

standard

carbodiimide

),)'-dicyclohexylcarbodiimide

coupling
(DCC),

1-hydroxybenzotriazole hydrate (HOBt) and ),)-diisopropylethylamine (DIPEA)
to yield the desired novel imine-lysine conjugates 158-162 in good to excellent
yields (Scheme 4.2).
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Scheme 4.2 Synthesis of the isatin-lysine conjugates 158-162.

Once again, the 1H NMR spectra (CDCl3) of the isatin-lysine series
(158-162) revealed that most compounds (158-161) were synthesised as
approximately 1:1 mixtures of E/Z isomers, apart from the meta-phenylacetic
analogue (162) where the Z isomer was favoured over the E isomer in an
approximate 2:1 ratio, the reverse ratio to that observed for the precursor imine
157. This may, however, be due to the change in NMR solvent from DMSO-d6
with 157 to CDCl3 with 162, as has been observed for other imines.294
The 1H NMR spectum of the para-propionic lysine 160 displayed 72
protons, 36 for each isomer. Characteristic peaks included a multiplet at
1.29-1.82 ppm, integrating for 12 protons and ascribed to H3, H4 and H5 for both
the E and Z isomers. Additionally, the amide proton (CH2CONH) of 160 was
observed at 6.32 ppm for both isomers. In the
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lysine carbons (C2-C6, E and Z) contained signals between 22.5-52.1 ppm.
Analysis by HRESI-MS confimed the molecular weight of 160 by finding a mass
of m/z 779.0896 for the molecular formula C34H36N4O679Br81BrNa [M+Na]+.

4.5 Hydrolysis of 3-Iminoisatins and Isatin-Lysine Conjugates
The rate of acid-catalysed hydrolysis in the imino acids 153-157 as a
function of imine absorbance at λ 435 nm over time is shown in Figure 4.8A
(middle panel). Analysis of the hydrolysis kinetics conducted at pH 4.5 (37 °C)
indicated an exponential first order decay process as evidenced by the ln(A/A0)
versus time plots (Figure 4.8A, bottom panel), which showed a linear relationship
at the initial reaction times. No hydrolysis was detected for the derivatives
153-157 when maintained at physiological pH (7.4) in 1 M HEPES buffer at
37 °C over a 240 min period (the first 60 min shown in Figure 4.8A, top panel).
Although compounds 153-157 were monitored kinetically over a 240 min period,
results are only displayed over a 60 min period as all derivatives reached a
plateau in terms of hydrolysis in less than 240 min.
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Figure 4.8 Rates of hydrolysis expressed as a function of absorbance (A/Ao) over
time (pH 7.4 top panel and pH 4.5 middle panel) and the natural log of absorbance
(A/Ao) over time (bottom panel, pH 4.5), measured at λ 435 nm in 1 M sodium
acetate buffer at 37 °C for (A, middle panel): the imino acid derivatives 153-157 (*P
< 0.05 for 153 versus 154-157; 155 versus 154, 156 and 157); and (B, middle panel):
the imino lysine derivatives 158-162 (*P < 0.05 for 158 versus 159-162; 159 versus
160-162; 160 versus 161 and 162).

In addition to the hydrolysis experiments conducted at physiological
temperatures (37 °C), selected hydrolyses for 153, 154 and 156 were also
conducted at ambient temperature. As expected, the rates of hydrolysis at pH 4.5
for the imino acids 153, 154 and 156 were significantly faster at 37 °C than at
room temperature (23 °C) as judged by one-way, repeated measures ANOVA
followed by a Tukey post-test (Figure 4.9). No hydrolysis was detected at
physiological pH at either 23 °C or 37 °C.
~ 122 ~

Chapter 4 – Acid-Labile Linkers
____________________________________________________________________

(B)

A/Ao

(A)
1.0

1.0

0.8

0.8

0.8

*

0.6

0.6

*

0.4

0.4

0.2

0.2

0.2

0.0
0

10

20

30

40

50

60

10

20

30

40

50

60

0

0.0

0.0

-0.3

-0.3

-0.3

-0.5

-0.5

-0.5

-0.8

-0.8

-0.8

-1.0

-1.0

-1.0

-1.3

-1.3

-1.3

-1.5

-1.5
5

10

15

20

25

30

*

0.0
0

0.0

0

23°° C
37°° C

0.6

0.4

0.0

ln(A/Ao)

(C)

1.0

10

20

30

40

50

60
23°° C
37°°C

-1.5
0

5

time (min)

10

15

20

25

30

0

5

time (min)

10

15

20

25

30

time (min)

Figure 4.9 Rates of hydrolysis at pH 4.5 expressed as a function of absorbance
(A/Ao) over time (top panel) and the natural log of absorbance (A/Ao) over time
(bottom panel), measured at λ 435 nm in 1 M sodium acetate buffer at both 23 °C
and 37 °C for the imino acid derivatives: (A) 153 (*P < 0.05); (B) 154 (*P < 0.05);
and (C) 156 (*P < 0.05).

The first order rate constants, k, for the imino acids 153-157, determined by
non-linear regression, ranged from 0.95-3.99 × 10-2 min-1 (Table 4.1), which is
comparable to those reported in an earlier study by Kalavska et al. of
acid-catalysed

hydrolysis

of

some

substituted

derivatives

of

3-phenyliminoxindole at pH 2.0-5.0.297 Although it should be noted that these
derivatives differ from those herein in that they are neither )-alkylated nor
halogenated on the isatin aromatic ring, and bear different imino aryl substituents
at the C3 position.The fastest hydrolysis rate, as indicated by the largest k value,
was observed for the para-phenylpropionic acid derivative 155, with the least
amount of resonance stabilisation in the series and a half-life of 17.4 min.
Conversely, the smallest k value was found for the most conjugated (stabilised)
derivative, the para-benzoic acid derivative 153, which displayed a 4-fold greater
half-life of 72.6 min. As discussed earlier, this compound had the lowest yield of
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imine formation (18%). In contrast, imines which demonstrated efficient
hydrolytic release (154, 156, and 157) were formed in good yields (> 68%).
These three imino acid derivatives did not show any significant differences to one
another in their hydrolysis rates, as judged by one-way ANOVA, and displayed
half-lives ranging from 24.3-29.7 min.

Table 4.1 Rate constants (k) and half-lives (t1/2) for the hydrolysis of the imino acids
153-157 and the imino lysines 158-162 at pH 4.5.a
O
n

N
Br

R
+

O
Br

Imine

H /37°C

O
O

N
PMB

n

O

Br

Br

H 2N

n

R

k (min-1)

t1/2 (min)

0.95 ± 0.0 ×10-2
2.85 ± 0.2 ×10-2
3.99 ± 0.3 × 10-2
2.33 ± 0.2 × 10-2
2.55 ± 0.2 × 10-2

72.6
24.3
17.4
29.7
27.2

0.81 ± 0.0 × 10-2
3.02 ± 0.2 × 10-2
4.07 ± 0.2 × 10-2
2.03 ± 0.1 × 10-2
2.10 ± 0.1 × 10-2

85.2
23.0
17.0
34.1
33.0

Substitution pattern

R = OH
0
para153
1
para154
2
para155
0
meta156
1
meta157
R = (CH2)4CH(NHAc)CO2Me
0
para158
1
para159
2
para160
0
meta161
1
meta162

N
PMB

a

Rates of hydrolysis were measured at 37 °C in 1 M sodium acetate buffer using
UV-Vis spectrophotometry (λ 435 nm).

A similar trend in the hydrolysis rates was obtained for the imino lysine
conjugates 158-162 (Figure 4.8B) with first order rate constants, k, ranging from
0.81-4.07 × 10-2 min-1 (Table 4.1). Again, the fastest hydrolysis rate was
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observed for the para-phenylpropionic acid derivative 160 with a half-life of
17.0 min, and the lowest hydrolysis rate was found for the para-benzoic acid
derivative 158, which had a 5-fold greater half-life of 85.2 min. In this case, the
hydrolysis rates of all but 161 vs. 162 were found to be significantly different
from one another, as judged by one-way ANOVA (Figure 4.8B, middle panel),
with the para-phenylacetic acid derivative 159 significantly faster than both 161
and 162, with half-lives of 34.1 and 33.0 min respectively, compared to 23.0 min
for 159 (Table 4.1). As for the imino acids 153-157, no hydrolysis was detected
for the imino lysine derivatives 158-162 maintained at physiological pH (7.4) in
1 M HEPES buffer at 37 °C over a 240 min period (Figure 4.8B, top panel).
The rates of hydrolysis at pH 4.5 for the imino acids and their analogous
imino lysine derivatives (e.g. 153 vs. 158, 154 vs. 159, etc) were not significantly
different from one another. This can be seen, by comparing the hydrolysis rates
of

each

pair

of

derivatives

(e.g.

153:

k = 0.95 × 10-2 min-1

cf.

158:

k = 0.81 × 10-2 min-1), which showed no significant difference as judged by
one-way, repeated measures ANOVA followed by a Tukey post-test (Figure
4.10). The overlayed graphs in Figure 4.10, clearly show that the distal part of the
compounds, whether a carboxylic acid or extended chain with a protected lysine
residue, did not significantly contribute to the overall hydrolysis rates observed.
Hydrolysis of the various derivatives was found to depend more on the aromatic
substitution pattern and linker length.
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Figure 4.10 Rates of imine hydrolysis at pH 4.5 expressed as a function of
absorbance (A/Ao) over time measured at λ 435 nm, in 1 M sodium acetate buffer at
37 °C for the imino acid and imino lysine derivatives. The graphs show the data
paired in the following combinations: 153 vs. 158; 154 vs. 159; 155 vs. 160; 156 vs.
161; and 157 vs. 162, with *P > 0.05 for all five combinations shown.

Acid-catalysed hydrolysis of imines involves the protonation of the imine to
give an iminum species, which undergoes nucleophilic attack by water. This
gives an unstable hemiaminal intermediate, which upon protonation of the amine
nitrogen, readily collapses to the protonated ketone and free amine, with
subsequent proton loss furnishing the ketone298 (Scheme 4.3).
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Scheme 4.3 General mechanism for the hydrolysis of imines to the corresponding
carbonyl in the presence of acid. Example 153 is shown above where
PABA = para-aminobenzoic acid, R and R’ = isatin nucleus.

The crucial first step in the above mechanism, imine protonation, is largely
dependent on the basicity of the imine. In derivatives 153 and 158, the electron
withdrawing carbonyl group directly attached to the para-position on the phenyl
ring, will reduce the relative basicity of the imine nitrogen through conjugation
(Figure 4.11), leading to lower rates of hydrolysis as observed (Figure 4.8,
middle panel). Conversely, for the homologous 154 and 159 derivatives,
conjugation with the acid or amide carbonyl is disrupted leading to greater
availablity of the nitrogen lone pair of electrons towards protonation.
Furthermore, hyperconjugation in these derivatives could be involved in
increasing electron density on the carbon adjacent to the imine nitrogen and
thereby its relative basicity.299 This hyperconjugative interaction could be more
significant with the para-propionic derivatives 155 and 160, with the counter
delocalising effect of the carbonyl group adjacent to the negative charge on the
Ar-CH carbon being removed. The hyperconjugative effects associated with these
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groups in the meta-position would not be expected to have a marked effect on the
imine basicity.

Figure 4.11 Resonance contributors of the imine 153 showing extended π
delocalisation.
Delocalisation of electron density through the extended conjugation
system of 153/158 also gives rise to an additional resonance contributor
(compared to those in 154-157 and 159-162) that places the electron density on
the oxygen atom of the carboxyl moiety (Figure 4.11). This resonance structure is
energetically more favourable than those of the other isatins where the electron
density is placed on a carbon atom, and may therefore contribute to the marked
increase in stability for 153/158. It is anticipated that this extended delocalisation
in 153 and 158 would reduce the susceptibility of the imine to nucleophilic attack
by water in the second step of the hydrolysis mechanism (Scheme 4.3).
The analogous meta-substituted derivatives 156/161 would not show the
same resonance effects described above, while the phenylacetic acid derivatives
154/159 and 157/162, with an extra carbon between the aromatic ring and
carbonyl of the acid or amide would also display less delocalisation of the imine
bond. The para-phenylpropionic acid derivatives 155 and 160, with a two carbon
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linker between the aromatic ring and carbonyl of the acid/amide, have the least
amount of electron delocalisation possible and consequently display the fastest
rates of hydrolysis from this series. These results are consistent with
complementary studies in the literature on 3-phenyliminoxindole derivatives,
where it was found that electron donating groups at the para-position of the aryl
ring enhanced the rates of acid-catalysed hydrolysis.297 Conversely, the
incorporation of electron withdrawing groups on a series of related aryl imines
were found to have a stabilising effect at physiological pH.289 Thus, the
incorporation of other electron donating or withdrawing groups would allow for
more tunable hydrolysis rates of imine-based compounds.
In conclusion, adjusting the linker length was found to be more important in
determining hydrolysis rates in the para-series compared to the meta-series. For
both the para-substituted carboxylic acid derivatives 153-155 and the lysine
derivatives 158-160, lengthening the linker resulted in a significant increase in
the hydrolysis rate. However, the two meta-substituted derivatives in each series
(156, 157 and 161, 162), showed no significant difference in their hydrolysis
rates. Overall, it appears that electronic effects such as the presence or absence of
a conjugated electron withdrawing group may play a larger role in determining
the hydrolysis rate than extending the linker.
Using )- and C-protected lysine residues as surrogates for the free lysine
residues on tumour-targeting proteins, it was successfully demonstrated that these
model imine-linked isatin-based cytotoxin conjugates undergo hydrolysis at
endosomal/lysosomal pH. These model conjugates were readily prepared and
characterised and are stable at physiological pH. With these results in hand, the
next part of the project involved conjugating the isatin-based cytotoxin to ligands
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such as PAI-2 and Tf.
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CHAPTER 5
Synthesis and Evaluation of Isatin-Protein Conjugates
5.1 Introduction to Cytotoxin-Protein Conjugates
Conventional chemotherapeutics are typically small molecules (< 1000 Da)
capable of diffusing into cells within the human body. Unfortunately, these small
molecules are characteristically non-specific and will diffuse into healthy and tumour
cells indiscriminately, leading to the death of non-tumour tissue and side effects such
as hair loss and organ toxicity.37 To overcome this problem, cytotoxins can be
conjugated to macromolecules such as proteins via a linker group that is cleaved
intracellularly. As described in the Introduction, although much work has focused on
mAbs, they have drawbacks associated with their use and new tumour-targeting
ligands are currently being sought.
As described in Section 1.7.3, the uPA system has appeal as a target for cancer
treatment. The system’s endogenous inhibitor, PAI-2, was recently attached for the
first time to a cytotoxin [2’-deoxy-5-fluorouridine (5-FUdr)] via an esterase-labile
succinate linker147 to form the conjugate 163 (5-FUdrsucc-PAI-2) (Figure 5.1). Up to
7 molecules of 5-FUdrsucc were able to covalently bind to PAI-2 without
compromising the inhibitory activity of the protein. On average, the conjugate 163
contained 3 molecules of 5-FUdrsucc, which was sufficient to display a 4-fold
increase in in vitro cytotoxicity against MDA-MB-231 breast cancer cells when
compared to the free drug.147 The 5-FUdrsucc-PAI-2 conjugate (163) also displayed
specificity towards the uPA over-expressing metastatic cell line MDA-MB-231,
compared to the low uPA expressing, non-metastatic cell line MCF-7.
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Another protein which has been widely exploited for targeting cytotoxins to
cancer cells is the iron-ferrying glycoprotein Tf (see Section 1.7.2). One of the most
recent studies of drug-Tf conjugates was concerned with the attachment of
artemisinin via a hydrazone linker to the )-glycosidic chains of Tf129 to yield the
conjugate 39 (Figure 5.1). Approximately 16 molecules of artemisinin were
conjugated to Tf as determined by MALDI-TOF mass spectrometry. The conjugate
39 was lethal to DU 145 prostate tumour cells in a TfR-dependent manner and its
cytotoxicity did not depend on cell density.129

Figure 5.1 Structure of the first cytotoxin-PAI-2 conjugate (5-FUdrsucc-PAI-2
conjugate) (163); artemisinin-Tf conjugate (39).

This chapter describes the novel cytotoxin-protein conjugates formed from the
targeting ligands PAI-2 and Tf and an imine-linked isatin-based cytotoxin in an
analogous manner to the model studies described in Chapter 4. The designated
3-iminoisatin was conjugated through the available/surface lysine residues of each
protein. The 3-iminoisatin was conjugated to Tf via its lysine residues rather than its
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)-glycosidic chains, since this type of conjugation has also proved to result in
increased cytotoxicity compared to the free drug alone.129 The chemical lability of
the imine-linked conjugates were assessed under varying pH conditions. The in vitro
selectivity and cytotoxicity of the isatin-protein conjugates will be discussed in
Chapter 6.

5.2 Synthesis of Isatin-Protein Conjugates
The 3-iminoisatin 155 displayed the most favourable hydrolytic profile and
shortest half-life (17.4 min) at λ 435 nm in the model studies described in Section
4.5. For this reason, 155 was selected for conjugation to the two proteins under
investigation, PAI-2 and Tf. The ability of the drug conjugate to hydrolyse under
acidic conditions was analysed using UV-Vis spectrophotometry.

5.2.1 Conjugation of the 3-Iminoisatin 155 to the Targeting Ligands PAI-2 and Tf
5.2.1.1 Preparation of the Active Ester
The active ester of 155 was prepared using conditions previously reported for
cytotoxin-protein conjugates.50,300,301 Briefly, the carboxyl group of 155 was
activated by being subjected to DCC/HOBt (similar to the peptide coupling
conditions in Scheme 4.1), forming the active ester 164 (Scheme 5.1). As described
by Vine,50 the active ester is readily formed after 30 min and there is no need for the
reaction to proceed for 3 h, as reported by Krauer et al.301 The active ester 164 was
used without further purification.

~ 133 ~

Chapter 5 – Isatin-Protein Conjugates
____________________________________________________________________

Reagents and conditions: (a) HOBt, DCC, DMF, 0 ºC → RT, 30 min.

Scheme 5.1 Preparation of the active ester 164 from the 3-iminoisatin 155.

5.2.1.2 Conjugation to PAI-2 or Tf
A 20-fold molar excess of the activated ester 164 was added to PAI-2 (or Tf) at
pH 8.5 with continual shaking for 3 h, to yield the isatin-PAI-2 (165) or isatin-Tf
conjugate (166) (Scheme 5.2). The 20-fold molar excess of 155 was selected to
ensure maximum conjugation to the protein.147 Upon completion of the reaction, the
freshly prepared isatin-protein conjugate (165 or 166) was centrifuged at 13,000 rpm
for 5 min to remove any precipitated 155 and other insoluble side products such as
ureas formed from DCC and HOBt during the peptide coupling. The supernatant
(containing

the

isatin-protein

conjugate)

was

purified

by

size-exclusion

chromatography on a PD10 column and the eluted fractions were stored at 4 ºC until
required. The protein yield was > 75% after purification for both conjugates.
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Reagents and conditions: (a) PAI-2 or Tf, PBS pH 8.5, RT, 3 h.

Scheme 5.2 Preparation of the isatin-protein conjugates 165 and 166.

5.3 Attempted Characterisation and Hydrolysis of Isatin-Protein
Conjugates
5.3.1 Isatin-PAI-2 Conjugates
Following the purification of the isatin-PAI-2 conjugate (165) using
size-exclusion chromatography, UV-Vis spectrophotometry was used to visualise the
eluted fractions for evidence of protein conjugation. Column fractions were
monitored at two wavelengths simultaneously, λ 280 nm (corresponding to the
absorbance maximum for the protein, PAI-2) and λ 432 nm (corresponding to the
absorbance maximum for the isatin that appeared furthest from the protein
maximum). The elution profile of the conjugate 165 is shown in Figure 5.2.
Fractions 1-5 and 9-11 showed a similar pattern of absorbance readings between the
protein and isatin at λ 280 and 432 nm, respectively. The isatin-PAI-2 conjugate
(165) eluted in fractions 6-8 as determined by the simultaneous increases in
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absorbancies at λ 280 and 432 nm. The concentration of PAI-2 in the conjugate 165
was measured using the Lowry protein determination assay.

Figure 5.2 Typical size-exclusion chromatography elution profile of the isatin-PAI-2
conjugate (165).

Electrospray ionisation mass spectrometry was employed to further
characterise the isatin-PAI-2 conjugate (165). A freshly prepared sample of the
conjugate and a sample of PAI-2 in PBS pH 7.4, were dialysed overnight into
10 mM NH4OAc buffer to yield a final protein concentration of ~ 10 µM. The results
from the mass spectral analyses are presented in Figure 5.3, whereby the data is
expressed on a m/z scale, and the masses have been converted into Da. The mass
spectrum of PAI-2 (Figure 5.3A) reveals the expected protein peaks at m/z 2971.94
and 3184.69, corresponding to a molecular mass of 44,568 Da. This mass is
consistent with the molecular weight of PAI-2.302 The isatin-PAI-2 conjugate (165)
displayed a very similar mass spectrum to PAI-2 (Figure 5.3B cf. 5.3A), and the
weight of the conjugate 165 was calculated to be 44,677 Da. A difference of 109 Da
was observed between the mass of the conjugate 165 and PAI-2, however, this does
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not correlate with the combined molecular weight of the isatin 24 (425 Da) and the
linker (147 Da, total 572 Da). It was thought that the imine-linker may have cleaved
from the isatin 155 under the MS conditions and attached to PAI-2, although the
mass of the imine-linker is 147 Da, so this also does not correlate to the difference in
mass observed between Figure 5.3B and 5.3A. It was postulated that the imine bond
may be too unstable under the analysis and therefore altering the mass spectrometry
results.103 To overcome this, the conjugate 165 was reacted with NaBH4 in an
attempt to reduce the imine bond within the molecule to an amine, which would be
more stable when subjected to mass spectrometry. However, the mass spectrum from
this experiment did not contain evidence of the conjugate 165 so it cannot be
concluded that the amine bond formed at all. Therefore, the results from mass
spectral analyses were inconclusive and the method could not be used to determine
the number of isatin molecules conjugated to PAI-2.

Figure 5.3 A) Mass spectrum of PAI-2. B) Mass spectrum of the isatin-PAI-2
conjugate (165).
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Other characterisation methods such as SDS-PAGE (sodium dodecyl sulfate
polyacrylamide gel electrophoresis) cannot be used effectively due to the molecular
weight difference between the protein and the conjugate being too small. To
investigate whether the isatin-PAI-2 conjugate (165) was able to be hydrolysed
under acidic conditions, a kinetic study using UV-Vis spectrophotometry was
employed. Similar to the hydrolysis studies of 153-157 and 158-162 in Chapter 4,
the isatin-PAI-2 conjugate (165) was monitored kinetically at λ 435 nm for 240 min
at 37 ºC at pH 4 and pH 7. As shown in Figure 5.4, the conjugate 165 was stable at
pH 7 for at least 240 min. On the contrary, the conjugate 165 appears to display an
inverse hydrolytic profile at pH 4. The sample was stable for approximately 160 min
before there was a gradual, yet consistent increase in absorbance. This result is the
complete opposite of what it expected when hydrolysis occurs. One explanation for
this result may be that there is hydrolysis of the conjugate 165 at pH 4 and that the
precipitation of the isatin 24 (or the protein) is interferring with the light path of the
spectrophotometer.
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Figure 5.4 Results of the kinetic hydrolysis studies for the isatin-PAI-2 conjugate
(165) as determined by UV-Vis spectrometry at λ 435 nm. The study was performed
at pH 4 and pH 7 for 240 min at 37 ºC.

5.3.2 Isatin-Tf Conjugates
The synthesis of the isatin-Tf conjugate (166) was identical to that for the
isatin-PAI-2 conjugate (165) and was also purified using size-exclusion
chromatography.

The

collected

fractions

were

visualised

by

UV-Vis

spectrophotometry for evidence of protein conjugation. The elution profile of the
conjugate 166 is shown in Figure 5.5. Fractions 5-8 revealed the presence of the
conjugate 166 due to the coincident elevated absorbance readings detecting the
protein and isatin at λ 280 and 432 nm, respectively. Hence, it was confirmed that
the isatin 155 was conjugated to Tf. The concentration of Tf in the conjugate 166
was calculated using the Lowry protein determination assay.
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Figure 5.5 Typical size-exclusion chromatography elution profile of the isatin-Tf
conjugate (166).

The isatin-Tf conjugate (166), was dialysed overnight into 10 mM NH4OAc
buffer before being injected into the ESI mass spectrometer for analysis. The mass
spectrum of the conjugate 166 once again was unclear and the difference in
molecular weight between the conjugate 166 and Tf was under 500 Da, indicating
that the 3-iminoisatin 155 may not have been attached in the MS sample. Attempts to
obtain an improved mass spectrum of the isatin-Tf conjugate (166) by changing mass
spectrometer parameters or altering sample matrix conditions such as increasing the
NH4OAc concentration (up to 500 mM) or including various salt solutions were
unsuccessful. Incidentally, there are very few examples of MS data reported for drug
conjugates in the literature.
Once again, the conjugate was reacted with NaBH4 in an attempt to reduce the
imine bond and form the amino analogue. Analysis by mass spectrometry was
inconclusive and the isatin-Tf conjugate (166) could not be identified, therefore it is
uncertain whether the imine bond had been reduced. The absorbance values of the
conjugate 166 were also investigated pre- and post-dialysis (Figure 5.6). It was
hypothesised that the dialysis procedure was possibly degrading the conjugate 166.
As shown in Figure 5.6, the absorbance values at λ 280 and 432 nm decrease
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post-dialysis, however, the conjugate 166 remains intact which can be verified by the
relative proportion of the isatin (λ 432 nm) to the protein (λ 280 nm).

Figure 5.6 Pre- and post-dialysis absorbance values at λ 280 and 432 nm for the
isatin-Tf conjugate (166).

The isatin-Tf conjugate (166) was monitored kinetically at λ 435 nm for
240 min at 37 ºC at pH 4 and pH 7 to assess its ability to hydrolyse under acidic
conditions, while remaining stable under physiological conditions. As shown in
Figure 5.7, the conjugate 166 was stable at pH 7 for approximately 180 min before
the absorbance gradually increased. Similarly, the conjugate 166 appears to be stable
at pH 4 for 120 min before the absorbance values increase, creating an inverse
hydrolytic profile. This outcome is comparable to the results observed with the
isatin-PAI-2 conjugate (165) in Figure 5.4, which suggests a technical issue such as
precipitation of the isatin 24 interferring with the light path of the spectrophotometer.
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Figure 5.7 Results of the kinetic hydrolysis studies for the isatin-Tf conjugate (166)
as determined by UV-Vis spectrometry at λ 435 nm using a quartz plate. The study
was performed at pH 4 and pH 7 for 240 min at 37 ºC.
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The results described within this chapter illustrate the complexities
encountered when working with drug-protein conjugates. It is thought that the
conjugation of an isatin to a protein may be hindered due to the size and
conformation of the protein, which may conceal possible amino acid sites for
conjugation. From Chapter 4, it was reported that the imine bond on the isatin 155
could be hydrolysed when attached to a single amino acid residue (e.g. 160),
although with the studies reported in this chapter, significant diffculties were
encountered in detecting the hydrolysis of the imine bond when 155 was attached to
a protein (i.e. 165 and 166). The resistance of the imine bond to cleave under mildly
acidic conditions from an isatin-Tf conjugate was also observed previously by
Vine.50 In Vine’s work, which involved a meta-phenylacetic acid imine linker on a
cytotoxic )-alkylisatin derivative, the conjugate was observed to be stable at
pH 5.5-7.5 for 20 h at RT and hydrolysis of the imine bond was not detected until pH
3. Additionally, it is postulated that the mass spectral characterisation difficulties
encountered may stem from the imine bond within the conjugates, as satisfactory
mass spectral data were attained previously for isatin-protein conjugates containing a
succinate linker.291
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The ability of the isatin-Tf conjugate (166) to cleave intracellularly under
acidic conditions was further investigated using cell proliferation assays. These
results are discussed in the following chapter.
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CHAPTER 6
Cytotoxicity and Mode of Action Studies

6.1 Overview of Testing Procedures
With 23 new tricyclic/polycyclic isatins and six cyclisation precursors (from
Chapters 2 and 3), 10 novel 3-iminoisatin derivatives (Chapter 4) and two of our
target isatin-protein conjugates (Chapter 5) in hand, our studies turned to the
biological investigation of these compounds. Cytotoxicity testing of the cyclisation
precursors (49, 65, 75, 76, 115 and 136), pyrrolo[3,2,1-hi]indole-1,2-diones (46 and
82), pyrrolo[3,2,1-ij]quinoline-1,2-diones (85-87, 99, 101, 102, 105, 111, 112, 114
and 116), polycyclic isatins (126, 127, 132, 137, 138, 143 and 144), 3-iminoisatins
(153-157) and isatin-lysine conjugates (158-162) were carried out on the U937
lymphoma cell line. This cell line has been utilised previously within our research
group64,65,81 to analyse the in vitro cytotoxicity of isatin derivatives. The human
THP-1 leukemic and MDA-MB-231 breast adenocarcinoma cell lines were also
employed. These three cell lines were selected as they have differing levels of the
receptors involved in endocytosing PAI-2 and Tf, i.e. uPA/uPAR and Tf/TfR
respectively. The receptor expression levels follow the pattern as described by Vine
et al.291 Utilising these cell lines it could be determined if the conjugates were being
internalised, in which case their cytotoxicity would be expected to be greater in those
cell lines expressing higher concentrations of the relevant receptor, i.e. isatin-PAI-2
conjugate (165) would be expected to exhibit the greatest cytotoxicity against the
THP-1 cell line, which expresses the highest level of uPA/uPAR.291 Cytotoxicity
testing was used to identify active compounds based on their IC50 values
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(concentration required to inhibit 50% of the population) and also provided a clearer
understanding of the SAR of these compounds.
Indolinones, in particular 3-substituted indolinones, are known to possess
kinase inhibitory activity.79,303 The well known kinase inhibitor sunitinib (10)
(Figure 1.4), contains an indolinone core. Sunitinib (10) may also be classed as a
3-substituted isatin and for this reason, the 3-iminoisatins (153-157) and their
analogous lysine derivatives (158-162) were selected to be screened as kinase
inhibitors. Compounds were tested against protein kinase A (PKA), a kinase which
has a role in the regulation of apoptosis and over-expression of the enzyme leads to
decreased rates of apoptosis304 (see Section 1.4.1). PKA may be used as an initial
screen for kinase inhibitory activity as it is a validated drug target already employed
in screening for new anti-cancer agents.305 As several kinases share a high degree of
homology, it is expected that compounds showing activity in this screen will also
show activity towards other kinase targets such as the stress-responsive kinases p38
and Jun )-terminal kinases involved in apoptosis, cancer and immune activation.306
A selection of tricyclic/polycyclic isatins were also assessed for their ability to
bind to DNA. Anthracycline chemotherapeutics such as doxorubicin (4) and
daunorubicin (5) contain a planar tetracyclic core and exert their cytotoxic effect by
inserting themselves perpendicularly into DNA without forming covalent bonds.307
Similarly, acridines, which contain a planar tricyclic scaffold are known DNA
intercalators (see Section 3.3.2), as are some polycyclic phenanthridine and indole
derivatives.307 As a result, it was of interest to assess the polycyclic isatins
synthesised in Chapters 2 and 3 for their DNA-binding ability.
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6.1.1 MTS Cell Proliferation Assay
A straightforward and relatively inexpensive method of examining the
cytotoxic activity of pure compounds is to use metabolic assays. The CellTiter 96®
AQueous One Solution Cell Proliferation Assay (MTS assay) was used in this study to
determine the number of viable cells in a cellular population through the use of
colourimetry.308 After incubating the cells in the presence of the test compounds for
24 h, a reagent mix was added to detect cell viability. This reagent contained a
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS) and an electron coupling
reagent, phenazine ethosulfate (PES).308 When combined with PES, MTS yields a
red coloured product that is soluble in the culture medium.
The colourless MTS tetrazolium compound is bioreduced into the coloured
formazan product by dehydrogenase enzymes in metabolically active cells which
produce NADPH or NADH308 (Figure 6.1). Therefore, the intensity of colour in the
assay correlates to the quantity of formazan produced, and is directly proportional to
the number of cells living in culture. After an incubation period of 3 h the
absorbance was measured in a spectrophotometer at 490 nm, the optimal wavelength
for detecting the formazan product. The IC50 values were determined as described in
the experimental section.

~ 147 ~

Chapter 6 – Biological Results
____________________________________________________________________
OCH2CO2H

OCH2CO2H
SO3

N
N N

SO3

N

N

Reduction of NADPH or NADH

N
N NH

S

S

N

N

MTS

Formazan

Figure 6.1 The colourless MTS tetrazolium salt is bioreduced to the red formazan
product by viable cells.

6.1.2 Kinase Inhibition Assays
To evaluate the PKA inhibitory activity of the compounds described in
Section 6.1, the Promega Kinase-Glo® luminescent assay was employed. This
high-throughput assay utilises luminescence to quantify the amount of ATP
remaining after a kinase reaction and may be applied to a variety of kinases.309
As outlined in Figure 6.2, the substrate and ATP react with the kinase to yield a
phosphorylated substrate (Reaction 1, Figure 6.2). Any ATP remaining after this
reaction then reacts with beetle luciferin in the presence of luciferase to produce
one photon of light per turnover (Reaction 2, Figure 6.2). Consequently, the
amount of luminescence produced is inversely proportional to kinase activity.
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Figure 6.2 The Kinase-Glo® assay reactions sourced from Promega.309 Reaction
1 illustrates the kinase enzyme reaction while Reaction 2 shows the beetle
luciferin/luciferase reaction.

The kinase inhibition assays were performed using an incubation time of
30 min at RT for the kinase enzyme reaction (Figure 6.2, Reaction 1), and
30 min at RT for the luciferase reaction (Figure 6.2, Reaction 2). Known, potent
inhibitors of PKA such as staurosporine (167) (IC50 = 23 nM)310 or H89 (168)
(IC50 = 135 nM)311 (Figure 6.3) were used as internal standards within the assay.

Figure 6.3 The known PKA inhibitors, staurosporine (167) and H89 (168).
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6.1.3 DNA Intercalation Studies
The DNA intercalation assays were performed by Dr. Celine Kelso from the
School of Chemistry at the University of Wollongong using electrospray
ionisation mass spectrometry. The compounds to be assessed were mixed with
Rt1 DNA in a ratio of 1:5 (DNA:drug) so any binding of the drug to DNA would
be easily observed. Daunorubicin (5) was used as a control and the binding
ability of the drug samples were compared to 5.

6.2 Cytotoxicity Results and Structure-Activity Relationships
The results of the MTS cell proliferation assays on the cyclisation precursors
(49, 65, 75, 76, 115 and 136), pyrrolo[3,2,1-hi]indole-1,2-diones (46 and 82),
pyrrolo[3,2,1-ij]quinoline-1,2-diones (85-87, 99, 101, 102, 105, 111, 112, 114 and
116), polycyclic isatins (126, 127, 132, 137, 138, 143 and 144), 3-iminoisatins
(153-157), isatin-lysine conjugates (158-162) and isatin-protein conjugates (165 and
166) are outlined in the following sub-sections. The values represent the
concentration (µM) required to inhibit 50% cell viability (IC50) in the cell lines.

6.2.1 Polycyclic Isatins and Precursors
The results of the MTS cell proliferation assays for the cyclisation precursors
(49, 65, 75, 76, 115 and 136) are illustrated in Table 6.1; pyrrolo[3,2,1-hi]indole-1,2diones (46 and 82) and pyrrolo[3,2,1-ij]quinoline-1,2-diones (85-87, 99, 101, 102,
105, 111, 112, 114 and 116) are summarised in Table 6.2; results of the polycyclic
phenanthridines (126, 127, 132, 137 and 138) and acridines (143 and 144) are
outlined in Table 6.3. Results highlighted in red indicate a highly cytotoxic
compound (IC50 < 10 µM).
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Table 6.1 Cytotoxicity results from the MTS assays for the cyclisation precursors
(49, 65, 75, 76, 115 and 136) against U937 cells after 24 h incubation.

a

Values are the mean of triplicates from one experiment.

From Table 6.1, the )-alkylated derivatives 49, 75, 76 and 115 exhibit
varying degrees of cytotoxicity. )-Allylisatin (76) was the least cytotoxic derivative,
with an IC50 value of 125 µM. The brominated analogue, 49, displayed almost a
20-fold increase in cytotoxicity (IC50 = 6.43 µM) and confirms the importance of a
bromo substituent positioned on the isatin core. )-Allyl-7-bromoisatin (49) exhibits
similar cytotoxicity to the dibrominated )-allylisatin 110, which was discovered to
have an IC50 value of 6.67 µM.64 The 7-bromo-)-cinnamylisatin derivative 115 was
also quite cytotoxic, with an IC50 value of 8.17 µM, although not as active as its
dibrominated analogue 117, which has an IC50 value of 2.37 µM.64 )-Vinylisatin
(75) was inactive (IC50 = 107 µM), however, it is anticipated that if the brominated
analogue 73 had been successfully prepared, the compound would have been much
more cytotoxic.
It is interesting to note that the 7-ethynylisatin 65, which is not )-substituted,
displayed an IC50 value of 15.2 µM. While 65 is not considered highly cytotoxic, it
reveals that the phenylethynyl moiety on the compound has the capability to
significantly increase cytotoxicity relative to the parent molecule, isatin (11)
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(IC50 = 565 µM). It is expected that the cytotoxicity of 65 would increase further
with )-alkylation and bromination at C5. This compound is the first 7-ethynylisatin
reported, however, a 7-ethynyloxindole derivative has been shown to exhibit IC50
values of 90 nM and > 3 µM against MDA-MB-468 and MDA-MB-231 breast
cancer cells respectively,312 suggesting that this class of compounds are worthy of
further investigation.
The spiro-phenanthridine 136 exhibited an IC50 value of 29.0 µM, slightly
less cytotoxic than the phenanthridine 137 (IC50 = 23.4 µM) (Table 6.3). This result
is consistent with previous data which revealed that a ketal functionality at the C3
position on isatin is detrimental for cytotoxicity.81,87
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Table 6.2 Cytotoxicity results from the MTS assays for the pyrrolo[3,2,1-hi]indole1,2-diones (46 and 82) and pyrrolo[3,2,1-ij]quinoline-1,2-diones (85-87, 99, 101,
102, 105, 111, 112, 114 and 116) against U937 cells after 24 h incubation.
Compound

Substitution

IC50 (uM)

O
R

46

R=H

> 577

82

R = Br

111 (± 53)

85

R = H, R1 = H

278 (± 23)

92

R = Br, R1 = H

8.36 (± 3.5)

101 R = H, R1 = Ph

99.3 (± 3.9)

102 R = Br, R1 = Ph

15.3 (± 11)

86

R = H, R1 = H, R2 = H

57.1 (± 14)

111 R = Br, R1 = H, R2 = H

19.3 (± 0.7)

99

106 (± 30)

O
N

O
R
O
N
R1
O
R
O
N
R1

R2

O
R
O
N
R1

R = H, R1 = H, R2 = Ph

105 R = Br, R1 = H, R2 = Ph

38.2 (± 3.7)

116 R = H, R1 = Ph, R2 = H

77.8 (± 6.2)

87

R = H, R1 = H

59.3 (± 8.6)

112 R = Br, R1 = H

28.6 (± 2.9)

114 R = H, R1 = CH3

33.2 (± 9.5)

Some interesting conclusions can be drawn from the data presented in Table
6.2 in terms of their SAR. The 6,5,5-fused tricyclic isatin, pyrrolo[3,2,1-hi]indole1,2-dione (46), was found inactive with an IC50 value of > 577 µM (beyond testing
limits) against U937 cells. The brominated analogue 82 displayed an IC50 value of
111 µM, a minimum 5-fold increase in cytotoxicity. However, isatin (11) and
5-bromoisatin have IC50 values of 565 µM and 64.5 µM respectively, against the
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same cell line,81 establishing that the tricyclic analogues 46 and 82 are less active
than the parent isatin molecules. Conversely, the 6,5,6-fused tricyclic isatin,
pyrrolo[3,2,1-ij]quinoline-1,2-dione (85), displayed at least a 2-fold increase in
cytotoxicity compared to 46 and is more active than the parent molecule, isatin (11).
The brominated derivative 92 exhibited a 33-fold increase in activity when compared
to 85. This was the most potent compound in Table 6.1 and the only molecule to be
considered highly cytotoxic (IC50 < 10 µM). This compound was almost 8-fold more
active than 5-bromoisatin, suggesting that the addition of a 6-membered ring to the
isatin scaffold is beneficial for cytotoxicity, while the addition of a 5-membered ring
is detrimental for activity.
Furthermore, the introduction of an alkene into compounds 86 and 87 led to
approximately a 6-fold increase in cytotoxicity when compared to the parent
molecule 85. However, within the corresponding series of brominated analogues, the
saturated compounds were 2-3 times more cytotoxic than the unsaturated derivatives
(i.e. 92 vs. 111; 92 vs. 112 and 102 vs. 105). The inclusion of a substituent at the C6
position in 4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (116) resulted in decreased
cytotoxicity compared to the parent compound (86), while a substituent at C6 in
6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (114) increased activity compared to its
parent compound (87).
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The results of C4 substitution within the 6,5,6-fused

O

tricyclic isatin series is inconclusive. These fused compounds
may be considered as restrained )-alkylisatins and they were

O
N

synthesised to allow comparison to the previously reported,
highly potent )-alkylisatins.64 In the case of 85, the addition of a

169

substituent at C4 increased cytotoxicity from 278 µM to 104 µM (compound 101),
however, a C4 substituent in 92 decreased activity from 8.36 µM to 15.3 µM
(compound 102). )-Benzylisatin (169) was also synthesised within this project for
comparison to its fused analogue (101). Cytotoxicity testing of 169 against U937
cells revealed an IC50 value of 127 µM, which is similar to the IC50 value of 101
(104 µM). This result further confirms the ambiguous effect of )-alkylation (or C4
substitution) on 6,5,6-fused tricyclic isatins with regards to cytotoxicity.
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Table 6.3 Cytotoxicity results from the MTS assays for the polycyclic isatins (126,
127, 132, 137, 138, 143 and 144) against U937 cells after 24 h incubation.
Compound

Substitution

O
R
O
N
R1
R1

IC50 (uM)

126 R = H, R1 = H, R2 = H

46.4 (± 12)

127 R = Br, R1 = H, R2 = H

19.7 (± 2.6)

137 R = H, R1 = -(CH)4-, R2 = H

23.4 (± 9.8)

138 R = Br, R1 = -(CH)4-, R2 = H 18.2 (± 4.7)

R2
R2

132 R = H, R1 = H, R2 = -(CH)4- > 114
O

R

143 R = H

7.21 (± 0.74)

144 R = Br

3.01 (± 1.14)

O
N

A similar pattern was observed for the polycyclic compounds where the
brominated derivatives displayed more cytotoxicity (up to 2.4 times) than their
parent molecules (i.e. 127 vs. 126; 138 vs. 137; 144 vs. 143) (Table 6.3). The
addition of the extra ring system in 137 increased the cytotoxicity 2-fold compared
to 126, while the introduction of an additional ring in derivative 132 decreased
cytotoxic activity at least 2.5-fold compared to 126. The polycyclic acridine 143 was
greater than 6-fold more cytotoxic than the polycyclic phenanthridine 126 and both
acridines (143 and 144) were regarded as highly cytotoxic (IC50 < 10 µM). Both of
these compounds were significantly more cytotoxic than any of the tricyclic
derivatives shown in Table 6.1 with the most active compound (144) having an IC50
value of 3.01 µM against U937 cells. The difference in cytotoxicity between the
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parent polycyclic acridine (143) and the parent pyrrolo[3,2,1-hi]indole-1,2-dione
(46) is at least 80-fold.
Generally, the descending order of cytotoxicity for the compounds described is
polycyclic acridines (3.01 - 7.21µM) > polycyclic phenanthridines (18.2 - > 114 µM)
> pyrrolo[3,2,1-ij]quinoline-1,2-diones (8.36 - 278 µM) > pyrrolo[3,2,1-hi]indole1,2-diones (111 - > 577 µM). Bromination at the C5 position of the isatin nucleus
increases cytotoxicity relative to the non-brominated analogue in all cases from 2 to
33-fold.

6.2.2 3-Iminoisatins and Isatin-Lysine Conjugates
The 3-iminoisatins (153-157) and lysine conjugates (158-162) prepared in this
project were employed as isatin-based linkers and conjugate models respectively.
The compounds were also assessed for cytotoxicity at 24 h using the MTS assay as
described above. The results are shown in Table 6.4. The cytotoxicity values
highlighted in blue indicate compounds with IC50 values in the nanomolar range and
the value highlighted in red is the most cytotoxic derivative.
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Table 6.4 Cytotoxicity results from the MTS assay for 3-iminoisatins (153-157) and
isatin-lysine conjugates (158-162) against U937 cells.
O
n

N

R

Br
O
N
PMB

Br

Imine

n

Substitution

IC50 (uM)

R = OH
153

0

para-

1.95 (± 0.69)

154

1

para-

2.13 (± 0.51)

155

2

para-

0.422 (± 0.09)

156

0

meta-

3.14 (± 0.39)

157

1

meta-

0.463 (± 0.08)

R = (CH2)4CH(NHAc)CO2Me
158

0

para-

0.575 (± 0.37)

159

1

para-

0.642 (± 0.03)

160

2

para-

0.399 (± 0.11)

161

0

meta-

0.165 (± 0.06)

162

1

meta-

0.391 (± 0.13)

The 3-iminoisatins (153-157) are highly cytotoxic (IC50 < 10 µM), with two
derivatives (155 and 157) displaying nanomolar activity towards U937 cells (Table
6.4). The lysine derivatives (158-162) also exhibited potent cytotoxic effects, with all
five analogues possessing nanomolar activity and being more cytotoxic than their
corresponding imino derivatives (a 19-fold increase in the case of 156 vs. 161). The
lysine derivative 161 is the most potent compound (of any class) synthesised within
this project with an IC50 value of 165 nM.
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Within the 3-iminoisatin series, the increase in chain length correlated with
an increase in cytotoxicity (i.e. 153 < 155 and 156 < 157), however, this trend was
not observed within the isatin-lysine series (158-162). In general, meta-substituted
compounds were more cytotoxic than their corresponding para-substituted
analogues. For example, in the 3-iminoisatin series (153-157), nanomolar
cytotoxicity was reached when n = 1 (IC50 = 463 nM) in the meta series (157) but
nanomolar cytotoxicity was not attained until n = 2 (IC50 = 422 nM) in the para
series (155). The same trend was witnessed in the isatin-lysine series (158-162),
where the meta analogues were generally more potent than their corresponding para
derivatives (i.e. 161 vs. 158; 162 vs. 159). The enhanced cytotoxicity of the
isatin-lysine series (158-162) when compared to the 3-iminoisatins (153-157),
suggests that increasing the alkyl chain length of 3-iminoisatins leads to a change in
intracellular target.
Although the compounds in Table 6.3 were used as linkers and model
conjugates with the view to selectively deliver cytotoxins into cells, it appears that
some of the 3-iminoisatin derivatives (154, 155, 157) are considerably more
cytotoxic than the released parent isatin. In the case of 155, which was the most
potent 3-iminoisatin with an IC50 value of 422 nM, the compound is 4 times more
cytotoxic than the released isatin (24), which has an IC50 value of 1.83 µM.64 This
latter result is unexpected but may represent the beginning of an interesting and
novel class of cytotoxic isatin derivatives.

6.2.3 Isatin-Protein Conjugates
The MTS assay was also applied to the isatin-PAI-2 (165) and isatin-Tf (166)
conjugates to determine whether the cytotoxicity was enhanced as a result of
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selective delivery of the isatin into tumour cells. The specificity of the conjugates
towards different tumour cell lines was also assessed based on their cytotoxicity.

6.2.3.1 Isatin-PAI-2 Conjugates
The U937 cells (low level expression of uPA/uPAR) and THP-1 cells (high
level expression of uPA/uPAR) were treated with isatin-PAI-2 conjugate (165) for
48 h. Selection of this exposure time, rather than the usual 24 h, was to allow for the
potential additional time required for RME of the conjugates and release of
cytotoxins within the cell due to the molecular size of the conjugate. Figure 6.4
presents an outline of the results of the cytotoxic assays. In both cell lines PAI-2 and
the conjugate 165 caused cell proliferation, however, the conjugate resulted in less
proliferation than the unconjugated protein in both cases. Based on this result, it
cannot be concluded that the conjugate 165 exhibited any cytotoxicity towards the
two cell lines in this first preliminary study.

Figure 6.4 Cell viability of PAI-2 and the isatin-PAI-2 conjugate (165) at 48 h. Each
data point is the mean of triplicates ± SE. A) Against U937 cells; B) Against THP-1
cells.
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The cytotoxic (or lack of) response of the conjugate 165 was compared
between the two cell lines to determine if 165 displayed any specificity between cell
lines. In theory, the THP-1 cell line, which over-expresses uPA/uPAR, should
exhibit greater cytotoxicity than the U937 cell line, which expresses low levels of
uPA/uPAR. However, as illustrated in Figure 6.5, there is only a small difference in
the cytotoxicity of the isatin-PAI-2 conjugate (165) on either cell line. This result
suggests that either 165 has not been internalised into the tumour cell through RME,
or that 165 was not hydrolysed within the endosomes or lysosomes to release the
free isatin 24. A related isatin cytotoxin has recently been delivered to uPA/uPAR
over-expressing cells using an isatin-PAI-2 conjugate, confirming that it is possible
to deliver cytotoxins using this ligand.291 On the other hand, the latter theory may be
correct as a previous preliminary study on isatin-PAI-2 conjugates connected
through an imine linker revealed that the hydrolysis of the imine and release of the
isatin drug did not occur until pH 3,50 approximately 1.5 pH units lower than that
found within lysosomes.

Figure 6.5 Cell viability of the isatin-PAI-2 conjugate (165) at 48 h against U937
and THP-1 cells, normalised to the PAI-2 control. Each data point is the mean of
triplicates ± SE.
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6.2.3.2 Isatin-Tf Conjugates
The isatin-Tf conjugate (166) was tested for cytotoxicity at 48 h against U937
cells which express low levels of the TfR, and the results are presented in Figure 6.6.
Similar to the results found with the PAI-2 conjugate (165) in Figure 6.4A, the
isatin-Tf conjugate (166) was less proliferative than the protein (in this case Tf) at
the highest concentration tested, however, there was evidence of cell proliferation so
the conjugate 166 cannot be regarded as cytotoxic towards this cell line.

Figure 6.6 Cell viability of Tf and the isatin-Tf conjugate (166) at the highest
concentration at 48 h against U937 cells. Data represented is the mean of triplicates
± SE.

With the aid of an inverted light microscope, photographs were obtained of
U937 cells after treatment with Tf and the isatin-Tf conjugate (166) (Figure 6.7).
Panels A and B in Figure 6.7 illustrate the effects of Tf at 1.56 µM (the highest
concentration tested) and 0.78 µM, respectively. The cells are healthy with circular
intact membranes and no sign of cell death after a 48 h exposure to Tf. Panels C and
D in Figure 6.7 depict the effects of the isatin-Tf conjugate (166) on U937 cells after
48 h of treatment at 1.56 µM and 0.78 µM (equivalent protein concentration),
respectively. These two panels exhibit similar cell morphology to U937 cells treated
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with Tf (Figure 6.7, panels A and B) and display minimal characteristics of
apoptosis.

Figure 6.7 The effects of Tf and the isatin-Tf conjugate (166) on U937 cells at 48 h.
Images were viewed at 400 × magnification using light microscopy. A) Tf at
1.56 µM; B) Tf at 0.78 µM; C) Isatin-Tf conjugate (166) at 1.56 µM; D) Isatin-Tf
conjugate (166) at 0.78 µM.

Upon treating the TfR over-expressing cell line MDA-MB-231 with the
isatin-Tf conjugate (166) for 48 h, a significant cytotoxic response (compared to Tf)
was witnessed as shown in Figure 6.8A. The figure also demonstrates for the first
time that an imine-linked isatin-protein conjugate is capable of inducing a cytotoxic
response and not causing cell proliferation. The data looks promising, although the
IC50 value of the conjugate 166 was unable to be determined due to the solubility
limitations associated with protein concentration. When compared to Tf at the
highest concentration (1.56 µM), the conjugate 166 is 47 ± 13% more cytotoxic, as
shown in Figure 6.8B.
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Figure 6.8 Cell viability of Tf and the isatin-Tf conjugate (166) against
MDA-MB-231 cells at 48 h. Each data point is the mean of triplicates ± SE. A) Dose
response curves of Tf vs. isatin-Tf; B) Viability of Tf vs. isatin-Tf at the highest
concentration (1.56 µM, equivalent protein concentration).

Photographic images were taken of the Tf and isatin-Tf conjugate (166) upon
exposure to MDA-MB-231 cells after 48 h (Figure 6.9). Panels A and B depict Tf at
1.56 µM and 0.78 µM respectively. The effects of treatment with the isatin-Tf
conjugate (166) are shown in Figure 6.9, panels C and D at 1.56 µM and 0.78 µM
respectively. In panel C, apoptosis of MDA-MB-231 cells is clearly demonstrated by
the small and granular appearance of the cells, which can be attributed to chromatin
condensation and membrane blebbing. This panel verifies the results from Figure
6.8A, which revealed that the conjugate 166 was cytotoxic towards MDA-MB-231
cells at the highest concentration (1.56 µM), and the enhanced cyotoxic response can
be explained due to MDA-MB-231 cells over-expressing the TfR. In panel D of
Figure 6.9, the cells do not display characteristics of apoptosis and appear no
different than the Tf treated cells in Figure 6.9B. The lack of cytotoxicity at this
concentration (0.78 µM) confirms the result observed in Figure 6.8A, which
illustrated that the conjugate 166 causes cell proliferation (approximately 150%)
towards MDA-MB-231 cells at a concentration of 0.78 µM.
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Figure 6.9 The effects of Tf and the isatin-Tf conjugate (166) on MDA-MB-231
cells at 48 h. Images were viewed at 400 × magnification using light microscopy. A)
Tf at 1.56 µM; B) Tf at 0.78 µM; C) Isatin-Tf conjugate (166) at 1.56 µM; D)
Isatin-Tf conjugate (166) at 0.78 µM.

The comparison of results shown in Figures 6.6-6.9 reveals that MDA-MB-231
cells display much greater cytotoxic specificity than U937 cells when treated with
the isatin-Tf conjugate (166). This is proportional to the levels of TfR expressed
within the two cell lines. These results suggest that the isatin-Tf conjugate (166) may
be more sensitive to RME than the isatin-PAI-2 conjugate (165), which did not
display any differences in cytotoxicity between under- and over-expressing
uPA/uPAR cell lines (U937 and THP-1 cells respectively). The difference in
specificity between the proteins may also be attributed to the cytotoxic payload and
the ability of Tf to bind on average more cytotoxins than PAI-2 due to the increased
number of lysine residues available for conjugation.291
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6.3 Mode of Action Studies
To investigate the mode of action of the compounds synthesised within this
project, kinase inhibition and DNA intercalation assays were employed. Molecules
with a similar structure to the 3-iminoisatins (153-157) and isatin-lysine conjugates
(158-162) exhibit potent kinase inhibitory activity (see Section 1.4.1) and so these
compounds were evaluated in kinase inhibition assays. Additionally, a selection of
the polycyclic isatins were assessed for their ability to bind to DNA as compounds
containing planar polycyclic ring systems are known to be DNA intercalators (see
Section 3.3.2).

6.3.1 Kinase Inhibition Assays
The 3-iminoisatins (153-157) and the lysine conjugates (158-162) were
assessed for kinase inhibitory activity using the PKA inhibition assay. The results for
compounds 153-157 are presented in Table 6.5.
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Table 6.5 PKA inhibitory results for 3-iminoisatins (153-157).
O
n

N

OH

Br
O
Br

N
PMB

IC50 (uM)

Imine

n

153

0

para-

42.9 (± 13)

154

1

para-

NDa

155

2

para-

20.0 (± 3.4)

156

0

meta-

52.4 (± 9.6)

157

1

meta-

46.7 (± 2.2)

a

Substitution

ND - not determined.

The 3-iminoisatins (153, 155-157) exhibit modest PKA inhibitory activity
(20.0 - 52.4 µM) (Table 6.4). An IC50 value could not be determined for 154 due to
reproducibility errors. Interestingly, the most active PKA inhibitor (155) was the
most cytotoxic 3-iminoisatin in Table 6.3, while the least active PKA inhibitor (156)
was also the least cytotoxic 3-iminoisatin in Table 6.3. This suggests there is a
relationship between the cytotoxicity of the 3-iminoisatins (153-157) and their mode
of action, which appears to be kinase inhibition. Futhermore, kinase assays
performed using purified enzymes exhibit 100 to 1000-fold less activity than
cell-based assays.313 This confirms the trend observed in Table 6.5, where
the 3-iminoisatins (153-157) displayed 10 to 100-fold less activity compared to the
cell-based results in Table 6.4.
The parent isatin, (24), was also assessed for PKA inhibitory activity and
found to possess an IC50 value of 115 µM. This result confirms that a carbonyl at C3
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is detrimental to kinase activity and explains why most indolinone-based kinase
inhibitors (e.g. 10) contain an imine or alkene at the C3 position. It was intriguing to
discover that the isatin-lysine conjugates (158-162), which all contain a C3-imino
functionality, did not display any PKA inhibitory activity (results are not shown).
The absence of PKA inhibitory activity for lysines 158-162 indicates that these
molecules possess a different mode of action to the 3-iminoisatins 153-157, and that
the lysine chain in 158-162 is responsible for this alternate mode of action. Although
compounds 158-162 are not inhibitors of PKA, it is possible that they inhibit other
kinases, however, further investigations into the mode of action of 158-162 are
required.
In an attempt to establish a possible mode of action for the tricyclic isatins, a
model compound (46) was assessed for mitogen-activated protein kinase (MAPK)
inhibitory activity. The assay was performed by Dr. Lenka Munoz from the Faculty
of Pharmacy at the University of Sydney. The isatin 46 did not exhibit any MAPK
inhibitory activity.
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6.3.2 DNA Intercalation Studies
A selection of 12 polycyclic isatins (46, 82, 85-87, 92, 101, 111, 116, 126, 127
and 143) were evaluated in the DNA intercalation assays. The mass spectrum of the
DNA alone (Figure 6.10A) shows two major peaks at m/z 1626.4 and 1951.9.
Subsequently, the DNA was mixed with daunorubicin (5) and its DNA-binding mass
spectrum is shown in Figure 6.10B. Here, neither of the two DNA peaks from Figure
6.10A can be observed, indicating that the m/z signals in Figure 6.10B are the result
of DNA binding with 5. The mass spectrum of DNA + pyrrolo[3,2,1-ij]quinoline1,2-dione (85) is represented in Figure 6.10C. In this spectrum, the peaks m/z 1626.4
and 1951.9 are present which correlate to the m/z signals of DNA alone (Figure
6.10A). Therefore, there is no evidence of 85 acting as a DNA intercalator. The mass
spectra of the remaining 11 polycyclic isatins also gave no indication of binding with
DNA. It was interesting to note that even though polycyclic phenanthridines and
acridines are known to be DNA intercalators,307 the phenanthridines 126 and 127 and
the acridine 143 did not display any ability to bind with DNA.
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Figure 6.10 Mass spectral results from the DNA intercalation assays. A) DNA
alone; B) DNA + daunorubicin (5); C) DNA + compound 85.
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CHAPTER 7
Conclusions and Future Directions

7.1 Conclusions
Significant progress was made towards imine-linked isatin-protein conjugates
to be used for site-specific drug delivery into tumour cells. As discussed in the
Introduction, the key elements of a successful drug conjugate involve the judicious
choice of the drug, linker and targeting ligand. The key findings from this study
regarding these three aspects are described below.

Drug: Synthesis of the pyrrolo[3,2,1-hi]indole-1,2-diones (6,5,5-fused tricyclic
isatins, Chapter 2) proved challenging. Various synthetic methods such as free
radical cyclisations, metal-catalysed cross-coupling reactions and the Sandmeyer
isatin method were attempted, all to no avail. The successful synthesis of the
tricyclic isatin 46 was attained using the Stolle isatin synthesis and its brominated
analogue 82 was prepared through electrophilic substitution. These two compounds
were the only two pyrrolo[3,2,1-hi]indole-1,2-diones able to be synthesised within
this study. Computational chemistry revealed this class of compounds possess high
heats of formation because of ring strain effects, consistent with the difficulties
encountered during their attempted synthesis.
From the in vitro cytotoxicity it was evident that pyrrolo[3,2,1-hi]indole-1,2dione (46) and its brominated analogue 82 were not strongly cytotoxic. In fact, the
additional 5-membered ring decreased cytotoxicity compared to the related parent
molecules. However, cyclisation precursors )-allyl-7-bromoisatin (49) and
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7-(phenylethynyl)isatin (65) displayed activity. Derivatives of 65 in particular
warrant further investigation since the compound displays an IC50 value of 15.2 µM
and it is neither brominated at the C5 position or )-substituted, both which have
been shown in our work to increase cytotoxic activity.
Synthesis of the pyrrolo[3,2,1-ij]quinoline-1,2-diones (6,5,6-fused tricyclic
isatins, Chapter 3) was much more successful than the pyrrolo[3,2,1-hi]indole-1,2diones. This can be attributed to lower calculated heats of formation for this class of
compounds compared to the pyrrolo[3,2,1-hi]indole-1,2-diones, associated with the
significantly reduced ring strain. Twelve target pyrrolo[3,2,1-ij]quinoline-1,2-diones,
nine of which were novel, were synthesised together with seven phenanthridinebased isatins and two acridine-based isatins. The quinolines pyrrolo[3,2,1ij]quinoline-1,2-dione (85), 4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (99),
5,6-dihydro-4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (101) and 8-bromo-4phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (105) were formed utilising the
Stolle

isatin

synthesis,

while

4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione

6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione

(87),

(86),

8-bromo-4H-pyrrolo[3,2,1-

ij]quinoline-1,2-dione (111), 8-bromo-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (112),
6-methyl-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione

(114)

and

6-phenyl-4H-

pyrrolo[3,2,1-ij]quinoline-1,2-dione (116) were attained through an intramolecular
Heck reaction. The phenanthridine, 7H-pyrrolo[3,2,1-de]phenanthridine-4,5-dione
(126) was synthesised using the Stolle isatin method, while phenanthridines
spiro[benzo[i]pyrrolo[3,2,1-de]phenanthridine-4,2’-[1,3]dioxolan]-5(7H)-one
and

(131)

spiro[benzo[k]pyrrolo[3,2,1-de]phenanthridine-4,2’-[1,3]dioxolan]-5(7H)-one

(136) were formed by a metal-catalysed biaryl coupling reaction. The acridine 6H-
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pyrrolo[3,2,1-de]acridine-1,2-dione (143) was also prepared by the Stolle isatin
method.
In vitro cytotoxicity revealed quinoline 85 was inactive, however, its
brominated analogue 92 was 33-fold more cytotoxic, displaying an IC50 value of
8.36 µM. Introduction of an alkene into saturated tricyclics increased cytotoxicity
when compared to the parent molecule (e.g. 86 and 87 vs. 85). However, within the
corresponding series of brominated analogues, the saturated compounds were 2-3
times more cytotoxic than the unsaturated derivatives. The phenanthridine-based
isatins were more active than the pyrrolo[3,2,1-ij]quinoline-1,2-diones, although the
acridine-based isatins displayed the greatest cytotoxicity of any tricyclic or
polycyclic isatin (Figure 7.1). Bromination always yielded more potent analogues (2
to 33-fold). As yet, the cytotoxic mode of action for the tricyclic and polycyclic
isatins is unknown; however, the compounds display no ability to intercalate with
DNA. The brominated acridine 144 was the lead compound within the entire series,
exhibiting an IC50 value of 3.01 µM against U937 cells.
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Figure 7.1 Current cytotoxic structure-activity relationships for tricyclic and
polycyclic isatin derivatives.

Linker: Five novel 3-iminoisatins and their corresponding isatin-lysine
conjugates were synthesised in order to evaluate the hydrolytic efficacy of imine
linkers. All compounds were prepared as a mixture of E and Z isomers, ranging from
ratios of 1:1 to 2:1. At pH 7.4, the imines 153-157 and isatin-lysine conjugates
158-162 were stable for at least 240 min, however at pH 4.5, both series of
compounds were capable of hydrolysing the imine bond to release the free isatin 24.
Within the 3-iminoisatin series (153-157), the half-lives of the compounds at pH 4.5
ranged from 17.4-72.6 min, while the half-lives of the isatin-lysine conjugates
158-162 were 17.0-85.2 min. The fastest imine hydrolysis rates were observed for
the para-propionic acid derivatives 155/160, with the least amount of resonance
stabilisation in the series. In contrast, the slowest hydrolysis rates were noticed with
the para-benzoic acid derivatives 153/158, which display the most resonance
stabilisation.
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When exposed to U937 cells, the 3-iminoisatins 153-157 and the isatin-lysine
conjugates 158-162 were all highly cytotoxic (< 10 µM). Two of the 3-iminoisatins
(155 and 157) displayed nanomolar activity after 24 h, while the five isatin-lysine
conjugates (158-162) all exhibited IC50 values in the nanomolar region. Isatin-lysine
161 was the most cytotoxic compound synthesised in this entire project, displaying
an IC50 value of 165 nM, and is the most potent 5,7-dibromo-)-alkylisatin to date.
The cytotoxic mode of action of 153-157 and 158-162 was investigated
through PKA kinase inhibition assays. The results revealed the isatin-lysines
158-162 possessed no PKA inhibitory activity, while the 3-iminoisatins 153-157
displayed modest rates of PKA inhibition (Figure 7.2).
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Figure 7.2 Cytotoxic and PKA inhibitory structure-activity relationships for
3-iminoisatin derivatives.

Targeting

Ligand: The 3-iminoisatin

155 was

conjugated

to

the

tumour-targeting proteins PAI-2 and Tf using standard bioconjugation techniques.
Analysis of the two isatin-protein conjugates (165 and 166) by UV-Vis
spectrophotometry at λ 280 and 435 nm suggested bioconjugation was successful
due to the simultaneous increases in absorbance at these wavelengths. However,
attempts at characterising 165 and 166 through MS and hydrolysis studies were
inconclusive and revealed that there were problems with detecting 165 and 166 using
these methods. On the other hand, when exposed to the TfR over-expressing
MDA-MB-231 cell line, the isatin-Tf conjugate (166) displayed both cytotoxic and
apoptotic activity at 1.56 µM (the latter evidence by changes to cell morphology),
indicating that receptor-mediated endocytosis had occurred, 166 had been
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hydrolysed within the endosomes/lysosomes and the free drug 24 had been released.
At this concentration, the conjugate 166 was 47±13% more cytotoxic than the Tf
control.

7.2 Future Directions
In a bid to further improve potency of our compounds against U937 cells,
future work on this project could involve the development of further analogues of the
3-iminoisatins (153-162), in particular derivatives related to the isatin-lysine
conjugates (158-162), along with further acridine compounds (143 and 144). In the
former case, the addition of the amino acid residue (lysine) increased the cytotoxic
activity of our compounds 1.1 to 19-fold, therefore, the effect of appending other
amino acids could also be examined. In the latter case, the acridine derivatives were
also found to be extremely potent with IC50 values in the range of 3.01-7.21 µM, and
may well represent an exciting new class of cytotoxic agents for further
development.
The isatin derivatives described in this project could also be tested against a
wider range of human cancer cell lines and normal cells to examine the cell
specificity of the compounds. Also, further studies such as cell-based kinase assays
could be useful to determine the mode of action for these cytotoxins, along with
competitive binding studies with tubulin and known tubulin binding agents such as
colchicine (147) to characterise the potential binding interaction of the isatin
derivatives with tubulin. These studies are currently underway by our collaborators
at the University of Wollongong.
Future studies could also include fine-tuning the acid-labile imine linkers
(e.g. aliphatic imines, aromatic imines with electron donating/withdrawing
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substituents)

and

evaluating

their

hydrolytic

efficiency

using

UV-Vis

spectrophotometry. The new imine linked isatins could be conjugated via the acid
handle to the lysines in the protein Tf (or another tumour-targeting ligand) to
produce a site-specific prodrug that would selectively deliver the isatin cytotoxin.
The imine linker system could also be applied to other carbonyl-containing
cytotoxins such as epipodophyllotoxin (145), camptothecin (146) and colchicine
(147). Alternatively, other acid-labile linker systems such as acetals or oximes could
be investigated since isatin-Tf based therapies display potential as new therapeutic
agents, as described by the results in this thesis.
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CHAPTER 8
Experimental
8.1 Chemical Procedures
8.1.1 General
All chemicals were purchased from Sigma-Aldrich Chemical Co. (St. Louis,
MO, USA), BDH Laboratory Supplies (Poole, England), Bachem (AusPep, Parkville,
Australia) or Accela ChemBio (San Diego, CA, USA) and used as supplied. All
solvents were AR grade expect DCM which was LR grade and distilled before use.
The term petroleum spirit (PS) refers to petroleum spirit with the boiling range of
40-60 °C. When necessary, the purification of solvents and starting materials was
carried out using standard procedures. Solvent removal was performed (in vacuo)
using a Büchi rotary evaporator at temperatures not greater than 60 °C. Sonication of
solutions was performed using a Soniclean 250HT ultrasonic bath (Soniclean,
Thebarton, Australia). Sodium hydride was supplied as a 60% dispersion in mineral
oil and masses used were calculated appropriately. Celite (Celite 545, particle size
0.02-0.1 mm, Merck) was used to remove metal catalysts from reaction mixtures.
Melting points were obtained using a Reichert melting point apparatus and are
uncorrected. Geometry optimisation (∆Hf) of tricyclic isatins was performed using
VAMP at semi-empirical level (AM1) on Materials Studio 4.4 (Accelrys Inc., San
Diego, CA, USA, 2008).
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Chromatography
Thin layer chromatography (TLC) on aluminium backed sheets of Merck Silica
Gel 60 F254 plates was employed to monitor the progress of chemical reactions.
Preparative TLC was performed on 20 x 20 cm plates of Merck Silica Gel 60 F254
plates. In general, isatins were highly coloured and were visible on the TLC plate;
colourless compounds were detected by UV light at λ 254 nm. Column
chromatography was performed on silica gel 60 (230-400 mesh) under “flash”
conditions.314 The solvent used in individual chromatographic experiments is
indicated and all solvent proportions are given as vol/vol ratios.

Nuclear Magnetic Resonance (NMR) Spectroscopy
Nuclear magnetic resonance (NMR) spectra were acquired on a Varian Unity
300 MHz spectrometer, where proton (1H) and carbon (13C) spectra were obtained at
300 MHz and 75 MHz respectively, or on a Varian Inova 500 spectrometer, where the
1

H and

13

C were obtained at 500 MHz and 126 MHz respectively. All spectra were

obtained with a probe temperature of 298 K. Spectra were recorded in the deuterated
solvent indicated in brackets and were referenced to the residual non-deuterated
solvent signal. Chemical shifts (δ) were measured in parts per million (ppm).
Hydrogen and carbon assignments were made using gradient correlation spectroscopy
(gCOSY), gradient heteronuclear single quantum correlation (gHSQC) and gradient
heteronuclear multiple bond correlation (gHMBC) spectroscopic techniques. The
superscript letter

a

denotes coincident peaks. The symbol ¶ denotes the carboxylic

acid proton signal was not observed. Multiplicities are reported as singlet (s), broad
singlet (bs), doublet (d), doublet of doublets (dd), doublet of triplets (dt), triplet (t)
and multiplet (m).
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Mass Spectrometry
Low resolution electron ionisation mass spectra (LREI-MS) were obtained
using a Shimadzu QP5050 spectrometer. Low resolution electrospray ionisation mass
spectra (LRESI-MS) were obtained using a Waters Platform LCZ spectrometer. High
resolution electron ionisation mass spectra (HREI-MS) were obtained using a
Fisons/VG Autospec spectrometer operating with an electron beam of 70 eV, with a
source temperature of 250 °C and perfluorokerosene as the internal standard. High
resolution electrospray ionisation spectra (HRESI-MS) were obtained using a Waters
Q-TOF Ultima spectrometer using leucine enkephalin as the internal standard. The
term “MS” refers to LREI-MS unless stated otherwise. Protein samples were analysed
using a Waters SYNAPTTM High Definition Mass Spectrometer (HDMS) in +ve
mode under nanospray conditions: injection volume of 3 µL, at 200 sampling and 4
extraction cone volts, with a source temperature of 50 °C and a vacuum backing of
3.86 mbar.
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8.1.2 Experimental for Chapter 2
Synthesis of 7-bromo-1H-indole-2,3-dione315 (55)
4

3a

Chloral hydrate (5.01 g, 30.2 mmol) and Na2SO4 (35.0 g,

O
O

6

246 mmol) were dissolved in H2O (70 mL) in a 300 mL beaker and

N

Br

7a H 1

55

heated to 35 °C. 2-Bromoaniline (51) (4.75 g, 3.12 mL, 27.6 mmol)
in H2O (20 mL) and conc. HCl (3 mL) were warmed and added to

the reaction mixture. Hydroxylamine HCl (6.10 g, 87.8 mmol) in H2O (27.5 mL) was
warmed and added before the mixture was heated at 85 °C for 3 h. The mixture was
cooled, filtered and washed with H2O (100 mL) to yield the intermediate 53 (5.75 g,
86%) as a fluffy light brown powder.
Conc. H2SO4 (100 mL) was heated in a 1 L beaker to 60 °C. The intermediate
53 was added in portions over 15 min so the temperature did not exceed 65 °C. The
reaction mixture was then heated at 80 °C for 15 min before being poured into ice
(500 mL). The precipitate was washed with H2O (100 mL) to yield 55 (2.94 g, 47%)
as a fine dark red powder, m.p. 192-194 °C (lit.316 191-198 °C), Rf 0.51 (silica,
DCM:MeOH, 9:1).
1

H MR (DMSO-d6, 500 MHz): δ 7.02 (t, J = 7.5 Hz, 1H, H5), 7.51 (d,

J = 7.5 Hz, 1H, H4), 7.78 (d, J = 7.5 Hz, 1H, H6), 11.31 (bs, 1H, NH). The 1H NMR
spectral data coincided with those reported in the literature.168 LREI-MS: m/z 225;
227 [M+]79Br; 81Br.
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Synthesis of 1-allyl-7-bromo-1H-indole-2,3-dione (49)
A mixture of 7-bromoisatin (55) (250 mg, 1.11 mmol) and NaH

O

4

3a

O
6

7a

Br

(62.3 mg, 1.55 mmol) was dissolved in anh. DMF (6 mL) and

N1
1'

2'
3'

49

stirred under N2 at RT for 20 min before the addition of KI
(37.2 mg,

222 µmol)

and

allyl

bromide

(295 mg,

211 µL,

2.44 mmol). The reaction mixture was heated at 60 °C and stirred at this temperature
for 18 h. After cooling, EtOAc (25 mL) was added and the resulting solution was
extracted with 0.5 M HCl (25 mL) followed by brine (25 mL). The orange organic
layer was dried over MgSO4 and the solvent was removed by rotary evaporation to
yield a sticky red residue. The resulting solid was purified by flash chromatography
on silica gel (100% DCM) to yield 49 (236 mg, 81%) as orange crystals, m.p.
112-114 °C, Rf 0.44 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.80 (m, J = 3.5 Hz, 2H, H1’), 5.23 (d,

J = 2.0 Hz, 1H, H3’), 5.26 (d, J = 2.0 Hz, 1H, H3’), 5.99 (m, 1H, H2’), 7.00 (t,
J = 8.0 Hz, 1H, H5), 7.59 (d, J = 7.5 Hz, 1H, H4), 7.69 (d, J = 7.5 Hz, 1H, H6).
13

C MR (CDCl3, 126 MHz): δ 43.4 (C1’), 104.5 (ArC), 117.7 (C3’), 120.9 (ArC),

124.9 (C4), 125.3 (C5), 132.0 (C2’), 144.2 (C6), 148.0 (C7a), 158.7 (C2), 182.6 (C3).
LREI-MS:

m/z

265;

267

[M+]79Br;

81

C11H8NO279Br [M+]: 264.9738; found 264.9736.
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Attempted synthesis of 5-methyl-4,5-dihydro-pyrrolo[3,2,1-hi]indole-1,2-dione
(50)
8

6

8a

1

5b N

5a

Method A: According to the method of Mbere,317 the isatin 49

O
O
3

(80.0 mg, 301 µmol) was dissolved in anh. PhMe (5 mL) and heated
at reflux under a N2 atmosphere. Bu3SnH (371 mg, 344 µL,

4

50

1.28 mmol) and AIBN (52.4 mg, 319 µmol) were dissolved in anh.

PhMe (7 mL) and added dropwise over 2 h, and the reaction mixture heated at reflux
for another 3 h. The solvent was then removed by rotary evaporation and Et2O (5 mL)
and sat. KF solution (5 mL) were added and the solution stirred at RT for 1 h. The
organic layer was separated, washed with H2O (2 × 5 mL) and dried over MgSO4.
The crude product contained many impurities MS.
Method B: According to the method of Rashatasakon et al.,170 the isatin 49 (195 mg,
730 µmol) was heated at reflux in anh. benzene (70 mL). AIBN (12.2 mg, 73.0 µmol)
and Bu3SnH (335 mg, 1.15 mmol) were dissolved in anh. benzene (3 mL) and added
dropwise over 1.5 h, before being heated at reflux for 14 h (total volume of benzene
was 73 mL to give a 0.1 M solution). The solvent was removed by rotary evaporation
but there were difficulties in purifying the product.

Synthesis of 7-iodo-1H-indole-2,3-dione (56)
4

This compound was prepared using the same method as that for

O
3a

O
6

7a

I
56

N1
H

7-bromoisatin (55). Chloral hydrate (6.67 g, 40.3 mmol) and
Na2SO4 (46.2 g, 325 mmol) were dissolved in H2O (115 mL) and
heated to 35 °C. 2-Iodoaniline (52) (8.00 g, 36.5 mmol) in H2O

(33 mL) and conc. HCl (4.8 mL) were warmed and added to the reaction mixture.
Hydroxylamine HCl (8.13 g, 117 mmol) in H2O (44 mL) was warmed and added
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before the mixture was heated at 80 °C for 3 h. The mixture was cooled, filtered and
washed with H2O to yield the intermediate 54 (8.77 g, 83%) as a fluffy beige/tan
coloured powder.
Conc. H2SO4 (160 mL) was heated to 60 °C. The intermediate 54 was added in
portions over 15 min so the temperature did not exceed 65 °C. The reaction mixture
was then heated at 85 °C for 15 min before being poured into ice (600 mL). The
precipitate was washed with H2O to yield 56 (5.77 g, 58%) as a dark red/brown
powder, m.p. 205-206 °C (lit.318 208 °C), Rf 0.56 (silica, DCM/MeOH 9:1).
1

H MR (DMSO-d6, 500 MHz): δ 6.89 (t, J = 7.5 Hz, 1H, H5), 7.49 (d,

J = 7.5 Hz, 1H, H4), 7.94 (d, J = 8.0 Hz, 1H, H6), 11.00 (bs, 1H, NH). The 1H NMR
spectral data coincided with those reported in the literature.204 LREI-MS: m/z
273 [M+].

Synthesis of 7-(phenylethynyl)-1H-indole-2,3-dione (65)
4

According to the methods of Layek et al.229 and Batchu et al.,196

O
3a

O
6

N1
H

7a

7.35 µmol), CuI (9.60 mg, 36.7 µmol) and Et3N (92.5 mg, 128 µL,
915 µmol) were added to anh. DMF (1 mL) and stirred at RT for

1'

5'

7-iodoisatin (56) (100 mg, 367 µmol), Pd(PPh3)4 (8.50 mg,

3'

65

1 h. Phenylacetylene (64) (56.0 mg, 60 µL, 550 µmol) was added
and the reaction mixture was heated at 80 ºC for 4 h before being

filtered through Celite, diluted with EtOAc (10 mL), then extracted with H2O
(2 × 10 mL) and brine (2 × 10 mL). The organic layer was dried over MgSO4, filtered
and the solvent removed by rotary evaporation. The resulting solid was purified by
flash chromatography on silica gel (100% CHCl3) to yield 65 (62.2 mg, 69%) as a red
powder, m.p. 137-139 °C, Rf 0.72 (silica, DCM/MeOH, 9:1).
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1

H MR (CDCl3, 500 MHz): δ 7.12 (t, J = 7.5 Hz, 1H, H5), 7.40 (m, 3H, H3’,

H4’, H5’), 7.58 (m, 3H, H4, H2’, H6’), 7.67 (d, J = 8.0 Hz, 1H, H6), 8.44 (bs, 1H,
NH).

13

C MR (CDCl3, 126 MHz): δ 81.4 (C≡C), 96.9 (C≡C), 108.5 (C7 or C3a),

118.1 (C7 or C3a), 121.9 (C1’), 124.0 (C5), 125.4 (C4), 128.9 (C3’, C5’), 129.6 (C4’),
132.0 (C2’/C6’), 140.4 (C6), 150.5 (C7a), 158.7 (C2), 182.7 (C3). LREI-MS: m/z
247 [M+]. HREI-MS: m/z calcd for C16H9NO2 [M+]: 247.0633; found 247.0634.

Attempted synthesis of 4-phenylpyrrolo[3,2,1-hi]indole-1,2-dione (66)
8

6

8a

5b

5a
5

Method A: According to the method of Ezquerra et al.,198

O
1

N3

7-phenylethynylisatin (65) (100 mg, 404 µmol) and CuI (212 mg,

O

808 µmol) were dissolved in anh. DMF (1.62 mL) and heated at

1'
3'

100 ºC for 3.5 h. The reaction mixture was filtered through Celite,

5'

66

washed with Et2O (25 mL), extracted with brine (25 mL), dried

over MgSO4, filtered and the solvent removed by rotary evaporation. Analysis by
TLC and 1H NMR spectroscopy revealed the crude product contained starting
material 65 and no desired product.
Method B: According to the method of Jury et al.,206 7-phenylethynylisatin (65)
(40.0 mg, 162 µmol), PdCl2(PPh3)2 (4.50 mg, 6.48 µmol), CuI (3.10 mg, 16.2 µmol)
and Cs2CO3 (79.2 mg, 243 µmol) were dissolved in anh. DMF (1 mL) and heated at
80 ºC for 5.5 h. H2O (10 mL) was added to the reaction mixture before it was
extracted with EtOAc (2 × 10 mL), dried over MgSO4, filtered and the solvent
removed by rotary evaporation. Analysis by TLC and 1H NMR spectroscopy revealed
the crude product contained starting material 65 and no desired product.
Method C: The preparation of this compound was attempted according to Method B
using 7-phenylethynylisatin (65) (40.0 mg, 162 µmol) and AgNO3 (5.50 mg,
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32.4 µmol) as starting materials. Analysis by TLC and 1H NMR spectroscopy
revealed the crude product contained starting material 65 and no desired product.
Method D: The preparation of this compound was attempted according to Method B
using 7-phenylethynylisatin (65) (40.0 mg, 162 µmol) and Au(PPh3)Cl (16.0 mg,
32.4 µmol) in anh. EtOH (1 mL) as starting materials. The reaction mixture was
heated at 70 ºC for 5.5 h. Analysis by TLC and 1H NMR spectroscopy revealed the
crude product contained starting material 65 and no desired product.

Synthesis of 7’-(phenylethynyl)spiro[[1,3]dioxolane-2,3’-indolin]-2’-one (67)
According to the method of Ribeiro et al.,319 7-phenylethynylisatin

5
1
4'

4

O

O3

3a'

O
6'

N1'
H

7a'

(65) (300 mg, 1.21 mmol), ethylene glycol (751 mg, 675 µL,
12.1 mmol) and PTSA (30 mg, 10% of starting material weight)
were dissolved in PhMe (25 mL) and heated at reflux under

1''

5''

Dean-Stark conditions for 48 h. No evidence of product had formed
3''

67

so more ethylene glycol was added (1.50 g, 1.35 mL, 24.2 mmol)
and the solution was heated at reflux for a further 24 h before the

solvent was removed by rotary evaporation. The resulting solid was purified by flash
chromatography on silica gel (100% CHCl3) to yield 67 (151 mg, 43%) as light
golden brown crystals, m.p. 190-192 °C, Rf 0.76 (silica, DCM/MeOH, 9:1).
1

H MR (CDCl3, 500 MHz): δ 4.31 (t, J = 7.0 Hz, 2H, H4, H5), 4.53 (t,

J = 7.0 Hz, 2H, H4, H5), 7.06 (t, J = 7.5 Hz, 1H, H5’), 7.32 (d, J = 8.0 Hz, 1H, H4’),
7.37 (m, 3H, H3’, H4’, H5’), 7.44 (d, J = 7.5 Hz, 1H, H6’), 7.53 (m, 2H, H2’, H6’),
7.72 (bs, 1H, NH). 13C MR (CDCl3, 126 MHz): δ 66.1 (C4/C5),a 83.1 (C≡C), 95.2
(C≡C), 102.7 (ArC), 106.5 (ArC), 123.4 (C5’), 124.5 (ArC), 125.3 (C4’), 128.7 (C3’,
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C5’),a 129.1 (C4’), 131.0 (ArC), 131.9 (C2’/C6’),a 134.1 (C6’), 143.7 (C3’), 174.5
(C2’). LREI-MS: m/z 291 [M+]. HREI-MS: m/z calcd for C18H13NO3 [M+]:
291.0895; found 291.0893.

Attempted synthesis of
4’-phenyl-2’H-spiro[[1,3]dioxolane-2,1’-pyrrolo[3,2,1-hi]indol]-2’-one (68)

8'

Method A: The preparation of this compound was attempted

5

1

4

O
8a'

6'
5a'
5'

according to the method for 66 using 67 (50.0 mg, 172 µmol), CuI

O3

5b' N

O

(65.5 mg, 344 µmol) and anh. DMF (700 µL) as starting

3'

1''

materials. The reaction mixture was heated at 100 ºC for 24 h,
3''

5''

68

filtered through Celite, washed with Et2O (15 mL), extracted with
brine (15 mL), dried over MgSO4, filtered and the solvent

removed by rotary evaporation to give a brown solid. 1H NMR spectroscopy revealed
no product had formed and only starting material 67 was present.
Method B: According to the method of Marchand et al.,212 67 (44.8 mg, 154 µmol)
and PdCl2 (2.73 mg, 15.4 µmol) were dissolved in anh. CH3CN (1.10 mL) and heated
at 70-75 ºC for 11.5 h. The reaction mixture was then filtered through Celite, washed
with Et2O (25 mL), extracted with brine (25 mL), dried over MgSO4, filtered and the
solvent removed by rotary evaporation. 1H NMR spectroscopy revealed no product
had formed and only starting material 67 was present.

~ 188 ~

Chapter 8 - Experimental
____________________________________________________________________
Synthesis of 2-(phenylethynyl)aniline (71)
This compound was prepared according to the method for 65

NH2

6

3'

1

using 2-iodoaniline (52) (2.00 g, 9.13 mmol), Pd(PPh3)4

1'

2
5'

4

71

(211 mg, 183 µmol), CuI (244 mg, 1.28 mmol), Et3N (2.31 g,
3.18 mL, 22.8 mmol) and phenylacetylene (64) (1.40 g,

1.51 mL, 13.7 mmol) as starting materials. The resulting solid was purified by flash
chromatography on silica gel (CHCl3/hexane gradient) to yield 71 (1.26 g, 72%) as a
beige powder, m.p. 85-86 °C (lit.214 89-91 °C), Rf 0.57 (silica, CHCl3).
1

H MR (DMSO-d6, 300 MHz): δ 4.28 (bs, 2H, NH2), 6.70-6.75 (m, 2H, H4,

H6), 7.15 (t, J = 8.7 Hz, 1H, H5), 7.34-7.38 (m, 4H, H3, H3’, H4’, H5’), 7.52-7.55 (m,
2H, H2’, H6’). The 1H NMR spectral data coincided with those reported in the
literature.213 LREI-MS: m/z 193 [M+].

Synthesis of 2-phenylindole (72)
According
4

to

the

method

of

Iritani

et

al.,211

3'
2 1'

6

N1
H
72

2-(phenylethynyl)aniline (71) (300 mg, 1.55 mmol) and PdCl2
5'

(27.5 mg, 155 µmol) were dissolved in dry CH3CN (10 mL)
and heated at 70-75 °C for 8 h. Upon cooling, the reaction

mixture was filtered through Celite, washed with Et2O (100 mL), extracted with brine
(100 mL), dried over MgSO4, filtered and the solvent removed by rotary evaporation.
The resulting solid was purified by flash chromatography on silica gel (100% CHCl3)
to yield 72 (223 mg, 74%) as a light brown powder, m.p. 190-192 °C (lit.316
188-190 °C), Rf 0.04 (silica, CHCl3).
1

H MR (DMSO-d6, 500 MHz): δ 6.84 (s, 1H, H3), 7.13 (t, J = 7.5 Hz, 1H,

ArH), 7.20 (t, J = 7.5 Hz, 1H, ArH), 7.33 (t, J = 7.5 Hz, 1H, ArH), 7.41 (d,
~ 189 ~

Chapter 8 - Experimental
____________________________________________________________________
J = 8.0 Hz, 1H, ArH), 7.45 (t, J = 7.5 Hz, 2H, H3’, H5’), 7.64 (d, J = 7.5 Hz, 1H,
ArH), 7.67 (d, J = 7.5 Hz, 2H, H2’, H6’), 8.37 (bs, 1H, NH). The 1H NMR spectral
data coincided with those reported in the literature.214 LREI-MS: m/z 193 [M+].

Synthesis of 1-vinyl-1H-indole-2,3-dione (75)

4

According to the method of Bayer and Geckeler,216 isatin (11)

O
3a

O
7

N1

7a

(500 mg, 3.40 mmol), vinyl acetate (7.90 g, 8.46 mL, 91.8 mmol)
and Na2PdCl4 (10.0 mg, 34.0 µmol) were heated at reflux for 12 h.

1'

2'

75

Charcoal (34.7 mg, 2.89 mmol) was added and the reaction mixture

was stirred at RT for 10 min, then filtered and the solvent removed by rotary
evaporation. The starting materials were added again and the procedure was repeated.
Et2O (75 mL) was added and the reaction mixture was extracted with H2O
(3 × 25 mL), the organic layer was dried over MgSO4, the suspension filtered and the
solvent removed by rotary evaporation. The resulting solid was purified by flash
chromatography on silica gel (100% DCM) to yield 75 (500 mg, 42%) as an orange
powder, m.p. 112-113 °C (lit.216 117 °C), Rf 0.43 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 5.17 (d, J = 10 Hz, 1H, H2’), 5.87 (d,

J = 11 Hz, 1H, H2’), 6.64-6.69 (m, 1H, H1’), 7.18 (t, J = 7.5 Hz, 2H, H5, H6), 7.64
(dd, J = 3.5, 8.0 Hz, 2H, H4, H7). 13C MR (CDCl3, 126 MHz): δ 106.1 (C2’), 111.2
(C5 or C6), 118.0 (C3a), 124.8 (C5 or C6), 125.2 (C1’), 125.9 (C7), 138.7 (C4), 150.0
(C7a), 157.3 (C2), 182.2 (C3). LREI-MS: m/z 173 [M+]. HREI-MS: m/z calcd for
C10H7NO2 [M+]: 173.0477; found 173.0474.
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Attempted synthesis of 7-bromo-1-vinyl-1H-indole-2,3-dione (73)
4

Method A: According to the method for 75, 7-bromoisatin (55)

O
3a

O

(500 mg, 2.21 mmol), vinyl acetate (5.14 g, 5.50 mL, 59.7 mmol),

N1

7a

Br

Na2PdCl4 (6.50 mg, 22.1 µmol) and charcoal (22.6 mg, 1.88 mmol)

1'
2'

were used as starting materials. MS analysis revealed only starting

73

material 55.
Method B: According to the method of Iddon et al.,217 7-bromoisatin (55) (1.00 g,
4.42 mmol), 1,2-dibromoethane (8.30 g, 3.81 mL, 44.2 mmol), Et3N (35.8 g, 49.3 mL,
354 mmol) and CH3CN (49.3 mL) were stirred at 70 ºC for 6 h. The solvent was
removed by rotary evaporation and DCM (20 mL) was added to the residue. The
mixture was extracted with H2O (20 mL), after which the organic layer was dried over
MgSO4, the suspension filtered and the solvent removed by rotary evaporation. The
resulting solid was partially purified by flash chromatography on silica gel using
DCM. Analysis by 1H NMR spectroscopy revealed many impurities were still present
in the product.

Synthesis of 1-allylindoline-2,3-dione (76)
4

This compound was prepared according to the method for 49 using

O
3a

O
7

isatin (11) (1.00 g, 6.80 mmol), NaH (381 mg, 9.52 mmol), KI

N1

7a

1'

2'
3'

76

(226 mg, 1.36 mmol) and allyl bromide (1.82 g, 1.30 mL, 15.0 mmol)
as starting materials. The reaction mixture was heated at 65 °C for

18 h. The resulting solid was purified by flash chromatography on silica gel (100%
DCM) to yield 76 (874 mg, 69%) as a bright red powder, m.p. 85-86 °C
(lit.219 88-89 °C), Rf 0.36 (silica, DCM).
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1

H MR (CDCl3, 500 MHz): δ 4.37 (d, J = 5.0 Hz, 2H, H1’), 5.29 (t,

J = 5.0 Hz, 2H, H3’), 5.81-5.88 (m, 1H, H2’), 6.89 (d, J = 8.0 Hz, 1H, H7), 7.12 (t,
J = 8.0 Hz, 1H, H5), 7.56 (t, J = 8.0 Hz, 1H, H6), 7.62 (d, J = 7.5 Hz, 1H, H4). The
1

H NMR spectral data coincided with those reported in the literature.219 LREI-MS:

m/z 187 [M+].

Attempted synthesis of
5-iodomethyl-4,5-dihydropyrrolo[3,2,1-hi]indole-1,2-dione (77)
8

6

8a

1

N3

5b

5a

According to the method of Albrecht et al.,218 a mixture of 76

O

4

I

O

(200 mg, 1.07 mmol), I2 (1.09 g, 4.28 mmol) and K2CO3 (592 mg,
4.28 mmol) was dissolved in anh. CH3CN (6 mL) and stirred under
N2 at RT for 20 h. A sat. solution of sodium thiosulfate (18 mL) was

77

added until the I2 was consumed. CHCl3 (20 mL) was added and the solution was
extracted with H2O (3 × 20 mL). The organic extract was dried over MgSO4, filtered
and evaporated. MS and TLC analysis revealed only starting material 76 was present.

Synthesis of -formylindoline (78)
4

Method A: According to the method of Yamada et al.,223 to a solution

3
2

of EDCI (1.61 g, 8.40 mmol) in CHCl3 (4.5 mL) was added formic

O

acid (773 mg, 634 µL, 16.8 mmol) at 0 ºC under N2. The mixture was

N
7

H
78

stirred for 5 min before a solution of indoline (40) (500 mg, 470 µL,

4.20 mmol) in pyridine (3 mL) was added dropwise over 30 min. The reaction
mixture was warmed to RT, stirred for 24 h and then the solvent was removed by
rotary evaporation. CHCl3 (50 mL) was added to the red/pink residue and the reaction
mixture was extracted with brine (4 × 20 mL), the organic layer was dried over
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MgSO4, the suspension filtered and the solvent removed by rotary evaporation. The
resulting solid was purified by flash chromatography on silica gel using a
hexane/EtOAc gradient followed by a CHCl3/MeOH gradient. NMR spectroscopy
and MS analysis on representative fractions did not reveal any expected product.
Method B: According to the method of Berry et al.,221 imidazole (5.15 g, 75.6 mmol)
and anh. DMF (2.13 g, 2.26 mL, 29.2 mmol) were stirred under N2 before the
dropwise addition of TMSCl (8.21 g, 9.59 mL, 75.6 mmol). The reaction mixture was
stirred at RT for 20 min. Indoline (40) (3.00 g, 2.82 mL, 25.2 mmol) in anh. DMF
(11.0 g, 11.7 mL, 151 mmol) was added dropwise and the reaction mixture was
stirred at RT for 12 h. A mixture of ice/H2O:0.1 M HCl (2:1) (50 mL) was added and
the reaction mixture was extracted with EtOAc (2 × 50 mL), the organic layer was
dried over MgSO4, the suspension filtered and the solvent removed by rotary
evaporation. The resulting solid was purified by flash chromatography on silica gel
using a hexane/EtOAc gradient (2:1 to 1:1) to yield 78 (364 mg, 10%) as a lilac
powder in a mixture of rotamers (83:17), m.p. 58-59 °C (lit.222 58-61 ºC), Rf 0.18
(silica, hexane/EtOAc, 2:1).
1

H MR (CDCl3, 500 MHz): Major rotamer: δ 3.15 (t, J = 8.5 Hz, 2H, H3),

4.06 (t, J = 8.5 Hz, 2H, H2), 7.15-7.27 (m, 4H, H4-H7), 8.93 (s, 1H, CHO). Minor
rotamer: δ 3.19 (t, J = 8.5 Hz, 2H, H3), 4.11 (t, J = 8.5 Hz, 2H, H2), 7.04-7.07 (m,
4H, H4-H7), 8.52 (s, 1H, CHO). The 1H NMR spectral data coincided with those
reported in the literature.223 LREI-MS: m/z 147 [M+].
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Synthesis of 4,5-dihydropyrrolo[3,2,1-hi]indole-1,2-dione (46)
8

6

8a
5b N

5a
5

46

Method A: According to the method of Welstead Jr. et al.,156

O
1

O
3

indoline (40) (1.00 g, 941 µL, 8.39 mmol) and oxalyl chloride
(2.13 g, 1.46 mL, 16.8 mmol) were dissolved in anh. THF (20 mL)
and heated at reflux for 3.5 h. The solvent was removed by rotary

evaporation to yield a blood red residue. The residue was dissolved in anh. DCM
(80 mL) and heated at reflux before the addition of AlCl3 (2.24 g, 16.8 mmol)
portionwise over 10 min. The reaction mixture was heated at reflux for a further 1 h,
the solution was evaporated, H2O (15 mL) was added and the solution was extracted
with CHCl3 (3 × 15 mL) and brine (1 × 15 mL). The organic layer was dried over
MgSO4, the suspension filtered and the solvent removed by rotary evaporation. MS
analysis revealed too many impurities.
Method B: The preparation of this compound was attempted according to Method A
for 46 with the following modifications: the solution was evaporated and the red
residue was dissolved in anh. CHCl3 (80 mL) and heated at reflux. AlCl3 was added
portionwise over 30 min and the mixture was heated at reflux for another 3 h. MS
analysis revealed too many impurities.
Method C: The preparation of this compound was attempted according to Method A
for 46 with the following modification: K2CO3 (200 mg, 1.45 mmol) was added to
oxalyl chloride (2.13 g, 1.46 mL, 16.8 mmol) in anh. THF (10 mL) to remove excess
HCl. MS analysis did not reveal the acid chloride intermediate 80 had been produced
so the experiment was abandoned.
Method D: The preparation of this compound was attempted according to Method A
for 46 with the following modification: the solution was evaporated and the red
residue was dissolved in anh. 1,2-dichloroethane (80 mL) and heated at reflux. AlCl3
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was added portionwise over 30 min and the mixture was heated at reflux for another
1.5 h. MS analysis revealed no product had been formed.
Method E: According to the method of Meth-Cohn and Goon,220 )-formylindoline
(78) (300 mg, 2.04 mmol) and oxalyl chloride (259 mg, 178 µL, 2.04 mmol) were
stirred at RT for 5 min under N2. Anh. THF (2.10 mL) was added and the reaction
mixture was stirred with ice-bath cooling while DIPEA (264 mg, 355 µL, 2.04 mmol)
was added dropwise. The mixture was heated to 35 ºC for 1 h and cooled on ice again
while Br2 (163 mg, 52.0 µL, 1.02 mmol) in CHCl3 (400 µL) was added dropwise.
H2O (10 mL) was then added and the mixture was extracted with Et2O (2 × 10 mL),
washed with 1 M HCl (3 × 5 mL) and H2O (10 mL). The organic layer was dried over
MgSO4, the suspension filtered and the solvent removed by rotary evaporation. MS
analysis revealed many products but no expected product.
Method F: According to the method of Norman et al.,225 a solution of indoline (40)
(10.0 g, 9.40 mL, 84.0 mmol) in anh. DCM (75 mL) was added to a solution of oxalyl
chloride (21.3 g, 14.7 mL, 168 mmol) in anh. DCM (75 mL) slowly over 2 h. The
reaction mixture was stirred at RT for a further 3 h, left to stand overnight and then
concentrated. Et2O (200 mL) was added to the residue, the suspension filtered and the
filtrate was concentrated to yield 80 (7.04 g, 40%) as a light brown powder.
AlCl3 (21.3 g, 160 mmol) and the acid chloride 80 (6.70 g, 32.0 mmol) were stirred
neat in a beaker for 20 min at 110 ºC until all of the gas had been released. The sticky
red residue was cooled to RT before the addition of ice-H2O (500 mL) and further
stirring at RT for 2 h. The red solution was extracted with CHCl3 (2 × 300 mL), the
organic layer was dried over MgSO4, the suspension filtered, the solvent removed by
rotary evaporation and triturated with acetone to remove grey impurities. The solution
was concentrated and the resulting sticky red residue was purified by flash
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chromatography on silica gel (hexane/EtOAc, 1:1) to yield 46 [845 mg, 15%; overall
6% based on starting indoline (40)] as a red powder, m.p. 195-197 °C (lit.225
203-207 ºC), Rf 0.26 (silica, hexane/EtOAc, 1:1).
1

H MR (DMSO-d6, 500 MHz): δ 3.38 (t, J = 7.5 Hz, 2H, H5), 4.09 (t,

J = 7.5 Hz, 2H, H4), 6.98 (t, J = 7.5 Hz, 1H, H7), 7.26 (d, J = 7.0 Hz, 1H, H6), 7.48
(d, J = 7.0 Hz, 1H, H8). The 1H NMR spectral data coincided with those reported in
the literature.225 LREI-MS: m/z 173 [M+].

Synthesis of 7-bromo-4,5-dihydropyrrolo[3,2,1-hi]indole-1,2-dione (82)
8

Br
6

8a
5b N

5a

Method A: The cyclised isatin 46 (100 mg, 577 µmol) was

O
1

O
3

5

82

dissolved in glacial AcOH (4 mL) and heated to 75 ºC. Br2
(276 mg, 88.7 µL, 1.73 mmol) was added dropwise while the
solution was still hot. The reaction mixture was then cooled on

ice, filtered and concentrated. MS analysis revealed a variety of products but no
starting material or expected product.
Method B: The cyclised isatin 46 (100 mg, 577 µmol) was dissolved in 95% EtOH
(4 mL) and heated to 75 ºC. Br2 (276 mg, 88.7 µL, 1.73 mmol) was added dropwise
while the solution was still hot. The reaction mixture was then cooled on ice, filtered
and concentrated. The resulting solid was purified by flash chromatography on silica
gel (100% DCM) to yield 82 (47.8 mg, 33%) as dark red crystals, m.p. 162-164 °C,
Rf 0.33 (silica, DCM).
1

H MR (DMSO-d6, 500 MHz): δ 3.38 (t, J = 7.5 Hz, 2H, H5), 4.07 (t,

J = 7.5 Hz, 2H, H4), 7.49 (s, 1H, H8), 7.66 (s, 1H, H6).

13

C MR (DMSO-d6,

126 MHz): δ 30.7 (C5), 46.7 (C4), 113.7 (ArC), 115.3 (ArC), 124.7 (ArC), 128.3
(C8), 136.1 (C6), 155.9 (ArC), 159.3 (C2), 183.1 (C1). LREI-MS: m/z 251; 253
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[M+]79Br;

81

Br. HRESI-MS: m/z calcd for C10H7NO279Br [M+H]+: 251.9660; found

251.9655.

Attempted synthesis of pyrrolo[3,2,1-hi]indole-1,2-dione (74)
8

6

8a
5b N

5a
5

74

The preparation of this compound was attempted according to

O
1

Method F for 46 using indole (83) (5.00 g, 42.7 mmol) and oxalyl
O

3

chloride (10.8 g, 7.42 mL, 85.4 mmol) as starting materials. The
reaction mixture was stirred at RT for a further 3 h, left to stand

overnight and then concentrated. Et2O (100 mL) was added to the residue, the
suspension filtered and the filtrate was concentrated to yield 84 (1.70 g, 19%) as a
red/brown powder.
AlCl3 (5.17 g, 38.8 mmol) and the acid chloride 84 (1.61 g, 7.75 mmol) were
stirred neat in a beaker for 20 min at 110 ºC until all of the gas had been released. The
red/black powder was cooled to RT before the addition of ice-H2O (250 mL) and
further stirring at RT for 2 h. The red solution was extracted with CHCl3
(2 × 150 mL), the organic layer was dried over MgSO4, the suspension filtered, the
solvent removed by rotary evaporation. Analysis by MS revealed the sample was a
complex mixture of products and contained none of the desired product 74.
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8.1.3 Experimental for Chapter 3
Synthesis of 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (85)
9

Method A: Chloral hydrate (1.37 g, 8.26 mmol) and Na2SO4

O
9a

1

O
7

6a

6b N 3
5

(9.49 g, 66.8 mmol) were dissolved in H2O (20 mL) and heated at
35 ºC in a 100 mL beaker. THQ (88) (1.00 g, 946 µL, 7.51 mmol)
and conc. HCl (820 mg, 707 µL, 22.5 mmol) in H2O (6 mL) were

85

warmed and added, followed by hydroxylamine HCl (1.67 g,
24.0 mmol) in H2O (8 mL). The reaction mixture was heated at 70-80 ºC for 1.5 h,
then cooled on ice and filtered. MS analysis on the solid and filtrate revealed mainly
starting material 88 so the experiment was abandoned.
Method B: According to the method of Cheng,236 oxalyl chloride (1.05 g, 720 µL,
8.26 mmol) was added dropwise to a solution of DABCO (1.69 g, 15.0 mmol) in
CHCl3 (7.5 mL) to form a pale yellow salt. A solution of THQ (88) (1.00 g, 946 µL,
7.51 mmol) in CHCl3 (40 mL) was added slowly with ice-bath cooling, before the
reaction mixture was heated at reflux for 20 h. Upon cooling, H2O (50 mL) was added
and the mixture was extracted with CHCl3 (50 mL). The organic layer was dried over
MgSO4, the suspension filtered and the solvent removed by rotary evaporation. MS
analysis on the yellow semi-solid revealed only starting material 88 was present.
Method C:237 A mixture of THQ (88) (1.00 g, 946 µL, 7.51 mmol) and oxalyl
chloride (1.91 g, 1.27 mL, 15.0 mmol) was dissolved in anh. THF (20 mL) and heated
at reflux for 3.5 h. The solution was evaporated and the red residue was dissolved in
anh. DCM (80 mL) and heated at reflux. AlCl3 was added portionwise over 30 min
and the mixture was heated at reflux for another 3 h. The solution was evaporated,
H2O (15 mL) was added and the solution was extracted with CHCl3 (3 × 15 mL) and
brine (1 × 15 mL). The organic layer was dried over MgSO4, the suspension filtered
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and the solvent removed by rotary evaporation. The resulting solid was purified using
flash chromatography on silica gel (100% DCM) to yield 85 (437 mg, 31%) as red
crystals, m.p. 195-197 °C (lit.237 198-200 °C), Rf 0.14 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 2.04 (m, J = 6.0 Hz, 2H, H5), 2.77 (t,

J = 6.0 Hz, 2H, H6), 3.75 (t, J = 6.0 Hz, 2H, H4), 6.99 (t, J = 7.5 Hz, 1H, H8), 7.32
(d, J = 7.5 Hz, 1H, H7), 7.37 (d, J = 7.5 Hz, 1H, H9). 13C MR (CDCl3, 126 MHz):
δ 20.2 (C5), 23.9 (C6), 38.4 (C4), 115.7 (C9a), 121.9 (C6a), 123.0 (C9), 123.2 (C8),
137.1 (C7), 147.6 (C6a’), 156.9 (C2), 183.9 (C1). LREI-MS: m/z 187 [M+].
HREI-MS: m/z calcd for C11H9NO2 [M+]: 187.0633; found 187.0638.

Synthesis of 8-bromo-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (92)
9

Br

According to the method of Vine et al.,81 the isatin 85 (150 mg,

O
9a

1

O
7

N3
6b

6a

801 µmol) was dissolved in 95% EtOH (5 mL) at 70-75 °C. Br2
(384 mg, 123 µL, 2.40 mmol) was added dropwise while the

5

92

solution was still hot. The reaction mixture was then cooled,

filtered and washed with H2O and cold absolute EtOH. The resulting solid was
purified by flash chromatography on silica gel (100% DCM) to yield 92 (166 mg,
78%) as dark red crystals, m.p. 201-203 °C (lit.238 185-187 °C), Rf 0.17 (silica,
DCM).
1

H MR (CDCl3, 500 MHz): δ 2.04 (quintet, J = 5.5, 6.0 Hz, 2H, H5), 2.77 (t,

J = 6.0 Hz, 2H, H6), 3.75 (t, J = 5.5 Hz, 2H, H4), 7.47 (s, 1H, H9), 7.49 (s, 1H, H7).
13

C MR (CDCl3, 126 MHz): δ 20.3 (C5), 23.9 (C6), 38.7 (C4), 116.3 (ArC), 117.1

(ArC), 124.3 (ArC), 125.9 (C7), 139.5 (C4), 146.7 (ArC), 156.4 (C2), 182.8 (C1).
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265;

m/z

LREI-MS:

267

[M+]79Br;

81

Br.

HREI-MS:

m/z

calcd

for

C11H8NO279Br [M+]: 264.9738; found 264.9738.

Synthesis of 2-phenyl-1,2-dihydroquinoline240 (98)
5

Quinoline (97) (6.00 g, 5.49 mL, 46.5 mmol) in anh. THF

4

4a

(20 mL) was added to 1 M PhMgBr in THF (46.5 mL,

2 1'
8

3'

8a N 1
H

46.5 mmol) at 0 °C before being heated at reflux for 18 h.
5'

Upon cooling, H2O (200 mL) was added and the solution was

98

extracted with Et2O (3 × 150 mL). The organic layer was dried over MgSO4, the
suspension filtered and the solvent removed by rotary evaporation to yield 98 as an
orange/brown oil (8.67 g, 90%), b.p. 155 °C.

Synthesis of 4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (99)
9

Dihydroquinoline 98 (1.04 g, 5.02 mmol) in anh. THF (6 mL)

O
9a

1

was added portionwise over 30 min to a refluxing solution of

O
7

6a

6b N 3

oxalyl chloride (1.27 g, 873 µL, 10.0 mmol) in anh. THF

1'

3'

5

(4 mL). The reaction mixture was heated at reflux for 3.5 h
5'

99

before the solvent was removed by rotary evaporation. The dark

residue was dissolved in anh. CHCl3 (30 mL) and heated at reflux. AlCl3 (2.01 g,
15.1 mmol) was added portionwise over 5 h and the solution was heated at reflux for
a further 18 h. The solvent was once again removed by rotary evaporation, the residue
was cooled on ice, conc. HCl (10 mL) was added, followed by H2O (10 mL) and
CHCl3 (50 mL). The phases were separated and the organic layer was washed with
H2O (2 × 50 mL), dried over MgSO4, filtered and the solvent removed by rotary
evaporation. The resulting solid was purified by flash chromatography on silica gel
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(100% DCM) to yield 99 (15.7 mg, 1%) as dark red crystals, m.p. 74-76 °C, Rf 0.41
(silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 5.83 (dd, J = 3.5 Hz, 9.5 Hz, 1H, H5), 5.88 (d,

J = 3.0 Hz, 1H, H4), 6.52 (d, J = 10 Hz, 1H, H6), 6.99 (t, J = 8.0 Hz, 1H, H8), 7.29
(d, J = 7.5 Hz, 1H, H7), 7.33 (d, J = 6.5 Hz, 1H, H9), 7.37 (m, 3H, H3’, H4’, H5’),
7.44 (d, J = 7.5 Hz, 2H, H2’, H6’). 13C MR (CDCl3, 126 MHz): δ 56.0 (C4), 114.8
(C9a), 118.0 (C6a), 120.1 (C6), 123.6 (C8), 124.1 (C9), 127.3 (C2’/C6’), 127.4 (C5),
128.7 (C4’), 129.0 (C3’/C5’), 133.7 (C7), 139.2 (C1’), 147.3 (C6b), 157.4 (C2), 182.4
(C1). LREI-MS: m/z 261[M+]. HREI-MS: m/z calcd for C17H12NO2 [M+H]+:
262.0868; found 262.0858.

Synthesis of 2-phenyl-1,2,3,4-tetrahydroquinoline240 (100)
5

4a

Dihydroquinoline 98 (4.52 g, 21.8 mmol) was dissolved in

4

absolute EtOH (87 mL) to give a 0.25 M solution of 98, which

2 1'

3'

8a N 1
H
8

was subsequently heated at reflux. Na (9.01 g, 392 mmol) was
5'

100

added portionwise over 1 h and the mixture was heated at

reflux for another 1 h. The product was added to H2O (300 mL) and the solution was
extracted with Et2O (3 × 100 mL). The organic extract was dried over MgSO4, the
suspension filtered and the solvent removed by rotary evaporation. The resulting oil
was purified by flash chromatography on alumina gel (100% DCM) to yield 100 as a
yellow/orange oil (3.18 g, 70%), b.p. 192 °C (lit. b.p. 176 °C,240 196 °C320), Rf 0.38
(silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 1.93-2.02 (m, 2H, H3), 2.73-2.78 (m, 2H,

H4), 3.97 (bs, 1H, NH), 4.44 (dd, J = 2.5 Hz, 9.0 Hz, 1H, H2), 6.46-6.67 (m, 2H,
ArH × 2), 6.94-7.03 (m, 2H, ArH × 2), 7.22-7.41 (m, 5H, H2’-H6’). The 1H NMR
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spectral data coincided with those reported in the literature.244 LREI-MS: m/z
209 [M+].

Synthesis of 5,6-dihydro-4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (101)
The compound was prepared according to the method for 99
9

O
9a

1

using 100 (2.00 g, 9.56 mmol) in anh. THF (8 mL) and oxalyl

O
7

N3

6a

chloride (2.42 g, 1.66 mL, 19.1 mmol) in anh. THF (12 mL) as

1'

3'

5

starting materials. The reaction mixture was heated at reflux for
5'

101

3.5 h before the solvent was removed by rotary evaporation.

The dark residue was dissolved in anh. CHCl3 (60 mL) and heated at reflux. AlCl3
(3.83 g, 28.7 mmol) was added portionwise over 5 h and the solution was heated at
reflux for a further 18 h. The solvent was once again removed by rotary evaporation,
the residue was cooled on ice, conc. HCl (20 mL) was added, followed by H2O
(20 mL) and DCM (100 mL). The phases were separated and the organic layer was
washed with H2O (2 × 50 mL), dried over MgSO4, filtered and the solvent removed
by rotary evaporation. The resulting solid was purified by flash chromatography on
silica gel (100% DCM) to yield 101 (120 mg, 5%) as dark red crystals, m.p.
139-140 °C (lit.237 129-130 °C), Rf 0.38 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 2.16-2.22 (m, 1H, H5), 2.26-2.29 (m, 1H,

H5), 2.47-2.53 (m, 1H, H6), 2.63-2.66 (m, 1H, H6), 5.47 (s, 1H, H4), 7.05 (t,
J = 7.5 Hz, 1H, H8), 7.16 (d, J = 7.5 Hz, 2H, H2’, H6’), 7.27 (t, J = 7.0 Hz, 1H, H4’),
7.32 (t, J = 7.0 Hz, 2H, H3’, H5’), 7.35 (d, J = 7.5 Hz, 1H, H7), 7.47 (d, J = 7.5 Hz,
1H, H9).

13

C MR (CDCl3, 126 MHz): δ 19.8 (C6), 27.7 (C5), 51.6 (C4), 115.6

(ArC), 122.0 (ArC), 123.2 (C4), 123.2 (C8), 125.4 (C2’, C6’), 127.8 (C4’), 128.9
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(C3’, C5’), 137.2 (C7), 139.1 (ArC), 147.8 (ArC), 156.8 (C2), 183.6 (C1). LREI-MS:
m/z 263 [M+]. HREI-MS: m/z calcd for C17H13NO2 [M+]: 263.0946; found 263.0949.

Synthesis

of

8-bromo-5,6-dihydro-4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-

dione (102)
9

Br

According to the method of Vine et al.,81 the isatin 101

O
9a

1

(65.2 mg, 248 µmol) was dissolved in 95% EtOH (2.60 mL)

O
7

6b N 3

6a

1'

3'

at 70-75 °C. Br2 (119 mg, 38.3 µL, 7.44 µmol) was added

5

dropwise while the solution was still hot. The reaction
5'

102

mixture was then cooled, filtered and washed with H2O and

cold absolute EtOH. The resulting solid was purified by flash chromatography on
silica gel (100% DCM) to yield 102 (42.3 mg, 50%) as red crystals, m.p. 60-62 °C,
Rf 0.82 (silica, DCM/MeOH, 9:1).
1

H MR (CDCl3, 500 MHz): δ 2.15-2.19 (m, 1H, H5), 2.26-2.29 (m, 1H,

H5), 2.50-2.53 (m, 1H, H6), 2.62-2.66 (m, 1H, H6), 5.46 (s, 1H, H4), 7.14 (d,
J = 7.5 Hz, 2H, H2’, H6’), 7.28 (m, 1H, H4’), 7.32 (d, J = 7.5 Hz, 2H, H3’, H5’), 7.50
(s, 1H, H7), 7.59 (s, 1H, H9). 13C MR (CDCl3, 126 MHz): δ 19.7 (C6), 27.6 (C5),
38.7 (C4), 116.2 (ArC), 116.7 (ArC), 124.2 (ArC), 125.3 (C2’/C6’), 125.9 (C9), 128.0
(ArC), 129.0 (C3’/C5’), 132.3 (C4’), 139.4 (C7), 146.7 (ArC), 156.0 (C2), 182.3 (C1).
LREI-MS:

m/z

341;

343

[M+]79Br;

81

Br.

C17H13NO279Br [M+H]+: 342.0130; found 342.0106.
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Synthesis of 6-bromo-2-phenyl-1,2-dihydroquinoline (104)
5

Br

4a

The compound was prepared according to the method for

4

98 using 6-bromoquinoline (103) (3.00 g, 1.95 mL,

2 1'
8

3'

8a N 1
H

14.4 mmol) in anh. THF (6 mL) and 1 M PhMgBr in
5'

THF (14.4 mL, 14.4 mmol) as starting materials. The

104

reaction mixture was heated at reflux for 18 h. Upon cooling, H2O (70 mL) was added
and the solution was extracted with Et2O (3 × 100 mL). The organic layer was dried
over MgSO4, the suspension filtered and the solvent removed by rotary evaporation to
yield 104 as light brown crystals (2.73 g, 66%), m.p. 80-82 °C, Rf 0.56 (silica,
CHCl3).

Synthesis of 8-bromo-4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (105)
9

Br

The compound was prepared according to the method for 99

O
9a

1

using 104 (1.50 g, 5.21 mmol) in anh. THF (6 mL) and

O
7

6a

6b N 3

oxalyl chloride (1.32 g, 907 µL, 10.4 mmol) in anh. THF

1'

3'

5

(9 mL) as starting materials. The reaction mixture was
5'

105

heated at reflux for 3.5 h before the solvent was removed by

rotary evaporation. The dark residue was dissolved in anh. CHCl3 (45 mL) and heated
at reflux. AlCl3 (2.08 g, 15.6 mmol) was added portionwise over 5 h and the solution
was heated at reflux for a further 18 h. The solvent was once again removed by rotary
evaporation, the residue was cooled on ice, conc. HCl (15 mL) was added, followed
by H2O (15 mL) and CHCl3 (75 mL). The phases were separated and the organic layer
was washed with H2O (2 × 30 mL), dried over MgSO4, filtered and the solvent
removed by rotary evaporation. The resulting solid was purified by flash
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chromatography on silica gel (100% DCM) to yield 105 (39.5 mg, 2%) as a dark red
powder, m.p. 47-49 °C, Rf 0.79 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 5.88 (s, 2H, H4, H5), 6.48 (d, J = 8.5 Hz, 1H,

H6), 7.33-7.39 (m, 3H, H3’, H4’, H5’), 7.42 (d, J = 7.0 Hz, 2H, H2’, H6’), 7.79 (d,
J = 9.0 Hz, 1H, H7), 7.90 (d, J = 8.5 Hz, H, H9).

13

C MR (CDCl3, 126 MHz):

δ 56.1 (C4), 116.4 (ArC), 119.3 (ArC), 119.8 (ArC), 126.5 (ArC), 127.3 (C2’, C6’),
127.5 (C5), 128.8 (C4’), 129.0 (C3’, C5’), 129.6 (ArC), 135.8 (ArC), 138.7 (C1’),
146.9 (C6b), 157.7 (C2), 181.1 (C1). LREI-MS: m/z 339; 341 [M+]79Br;

81

Br.

HRESI-MS: m/z calcd for C17H11NO279Br [M+H]+: 339.9973; found 339.9965.

Attempted synthesis of 5-methyl-pyrrolo[3,2,1-hi]indole-1,2-dione (109)
8

6
5a

Method

O

8a

1

5b N
4

109

O

A: According to the method of Sorensen and

Pombo-Villar,321 the isatin 49 (200 mg, 752 µmol), NaOAc

3

(247 mg, 3.01 mmol), TBAI (278 mg, 752 µmol), P(o-tol)3
(22.8 mg, 75.2 µmol) and Pd(OAc)2 (8.50 mg, 37.6 µmol) were

dissolved in anh. DMF (12 mL) and stirred at 110 °C for 18 h. Upon cooling, sat.
NaHCO3 (20 mL) was added and the solution was extracted with EtOAc (2 × 20 mL).
The organic layer was dried over MgSO4, the suspension filtered, and the solvent
removed by rotary evaporation. There were difficulties in purifying the product and
MS analysis revealed many components present.
Method B: The preparation of this compound was attempted according to Method A
for 109 with the following modifications: TBACl (209 mg, 75.2 µmol) was used and
the mixture was heated at 100 °C for 18 h. MS analysis revealed too many impurities.
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Method C: The preparation of this compound was attempted according to Method A
for 109 with the following modifications: TBACl (209 mg, 75.2 µmol) and PPh3
(19.7 mg, 75.2 µmol) were used and the mixture was heated at 120 °C for 18 h. TLC
analysis of the crude product indicated many components were present.
Method D: The preparation of this compound was attempted according to Method A
for 109 with the following modifications: TBACl (209 mg, 75.2 µmol) and TTFMPP
(35.0 mg, 75.2 µmol) were used and the mixture was heated at 120 °C for 18 h. MS
analysis revealed too many impurities.

Synthesis of 4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (86) and
6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (87)
9

O
9a

9

1

9a

1

O
7

6a

6b N 3

Method A: According to the method of

O
O

7

6a

6b N 3

5

5

86

87

Keller,215

)-allyl-7-bromoisatin

(49)

(200 mg, 885 µmol), Pd(OAc)2 (49.6 mg,
221 µmol), P(o-tol)3 (116 mg, 381 µmol) and

Et3N (1.01 g, 1.38 mL, 10.0 mmol) were dissolved in CH3CN (15.7 mL) and heated at
100 °C for 15 h. Upon cooling the solvent was removed by rotary evaporation and the
resulting solid was purified by flash chromatography on silica gel (100% CHCl3) and
subsequent preparative TLC (silica, 100% CHCl3) to yield 86 and 87 as dark red
crystals (25.5 mg, 16%) in a 5:4 ratio.
Method B: According to the method of Li,322 the isatin 49 (150 mg, 564 µmol),
TBACl (157 mg, 564 µmol), K2CO3 (234 mg, 1.69 mmol) and Pd(OAc)2 (12.7 mg,
56.4 µmol) were dissolved in anh. DMF (7 mL) and heated at 85 °C for 2 h. Upon
cooling, DCM (50 mL) was added and the solution was extracted with H2O

~ 206 ~

Chapter 8 - Experimental
____________________________________________________________________
(3 × 15 mL) and brine (1 × 15 mL). The organic layer was dried over MgSO4, the
suspension filtered and the solvent removed by rotary evaporation. The resulting solid
was purified by flash chromatography on silica gel (100% DCM) and subsequent
preparative TLC (silica, 100% DCM) to yield 86 and 87 as dark red crystals (54.7 mg,
52%) in a 3:1 ratio, m.p. 194-196 °C, Rf 0.31 (4H isomer, silica, CHCl3), 0.38
(6H isomer, silica, CHCl3).
1

H MR (CDCl3, 500 MHz): 4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (86):

δ 4.62 (d, J = 8.5 Hz, 2H, H4), 5.84 (dt, J = 3.5 Hz, 10.5 Hz, 1H, H5), 6.40 (m, 1H,
H6), 6.93 (dt, J = 2.5 Hz, 7.5 Hz, 1H, H8), 7.16 (dd, J = 2.0 Hz, 8.0 Hz ,1H, H7), 7.30
(dd, J = 2.0 Hz, 7.5 Hz, 1H, H9); 6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (87):
δ 3.60 (d, J = 2.5 Hz, 2H, H6), 5.29-5.32 (m, 1H, H5), 6.95 (m, 1H, H4), 7.19 (t,
J = 7.5 Hz, 1H, H8), 7.34 (d, J = 8.0 Hz, 1H, H7), 7.47 (d, J = 7.5 Hz, 1H, H9).
13

C MR (CDCl3, 126 MHz): 4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (86): δ 41.2

(C4), 114.7 (C9a), 118.3 (C6a), 121.7 (C6), 123.2 (C5), 123.8 (C8), 124.1 (C9), 133.7
(C7), 148.5 (C6b), 157.6 (C2), 182.6 (C1). 6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione
(87): δ 24.8 (C6), 108.5 (C5), 116.2 (C9a), 118.0 (C4), 119.1 (C6a), 123.6 (C9),
125.9 (C8), 136.7 (C7), 144.6 (C6b), 153.2 (C2), 182.8 (C1). LREI-MS: Both
isomers: m/z 185 [M+]. HREI-MS: m/z calcd for C11H7NO2 [M+]: 185.0477; found
185.0471 (4H isomer), 185.0474 (6H isomer).
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Synthesis of 1-allyl-5,7-dibromo-1H-indole-2,3-dione (110)

Br

This compound was prepared according to the method for 49

O

4

3a

O
6

N1

7a

Br

1'

2'
3'

110

using 5,7-dibromoisatin (17) (1.50 g, 4.92 mmol), NaH
(165 mg, 6.89 mmol), KI (163 mg, 984 µmol) and allyl bromide
(1.31 g, 937 µL, 10.8 mmol) as starting materials. The resulting

solid was purified by flash chromatography on silica gel (100% DCM) to yield 110
(1.48 g, 87%) as red crystals, m.p. 98-100 °C, (lit.64 103-105 °C), Rf 0.84 (silica,
DCM/MeOH, 9:1).
1

H MR (CDCl3, 300 MHz): δ 4.78 (d, J = 4.8 Hz, 2H, H1’), 5.25 (d,

J = 4.8 Hz, 1H, H3’), 5.90-6.03 (m, 1H, H2’), 7.69 (s, 1H, H4), 7.85 (s, 1H, H6). The
1

H NMR spectral data coincided with those reported in the literature.64 LREI-MS:

m/z 343; 345; 347 [M+]79Br79Br; 79Br 81Br;

81

Br 81Br.

Synthesis of 8-bromo-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (111) and
8-bromo-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (112)
9

Br

O
9a

9

Br

1

6a

6b N 3

O
7

6a

compounds

was

prepared

1

O
7

These

O
9a

according to Method B for 86 and 87

6b N 3

using the isatin 110 (150 mg, 435 µmol),
5

111

5

112

TBACl (121 mg, 435 µmol), K2CO3

(181 mg, 1.31 mmol) and Pd(OAc)2 (9.80 mg, 43.5 µmol) as starting materials. The
resulting solid was purified by flash chromatography on silica gel (CHCl3/PS, 2:1)
and subsequent preparative TLC (silica, 100% DCM) to yield 111 and 112 as dark red
crystals (55.8 mg, 49%) in a 3:2 ratio, m.p. 215-217 °C, Rf 0.56 (4H isomer, silica,
DCM), 0.67 (6H isomer, silica, DCM).
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1

H MR (CDCl3, 500 MHz): 8-bromo-4H-pyrrolo[3,2,1-ij]quinoline-1,2-

dione (111): δ 4.63 (d, J = 2.5 Hz, 2H, H4), 5.89 (dt, J = 3.0 Hz, 8.0 Hz, 1H, H5),
6.35 (d, J = 11 Hz, 1H, H6), 7.29 (s, 1H, H7), 7.42 (s, 1H, H9); 8-bromo-6Hpyrrolo[3,2,1-ij]quinoline-1,2-dione (112): δ 3.59 (m, 2H, H6), 5.30 (m, 1H, H5),
6.93 (d, J = 8.5 Hz, 1H, H4), 7.50 (s, 1H, H7), 7.59 (s, 1H, H9).

13

C MR (CDCl3,

126 MHz): 8-bromo-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (111): δ 41.2 (C4),
115.8 (ArC), 116.6 (ArC), 120.2 (ArC), 120.8 (C6), 124.7 (C5), 126.5 (C9), 135.8
(C7), 146.4 (C6b), 156.8 (C2), 181.3 (C1). 8-bromo-6H-pyrrolo[3,2,1-ij]quinoline1,2-dione (112): δ 24.8 (C6), 108.5 (C5), 118.2 (C4), 119.2 (ArC), 121.4 (ArC),
122.8 (ArC), 126.6 (C9), 139.3 (C7), 148.5 (C6b), 158.4 (C2), 182.0 (C1).
LREI-MS: Both isomers: m/z 263; 265 [M+] 79Br;

81

Br. HRESI-MS: m/z calcd for

C11H7NO279Br [M+H]+: 263.9660; found 263.9659 (4H isomer), m/z calcd for
C11H9NO281Br [M+H]+: 267.9796; found 267.9611 (6H isomer).

Synthesis of (E)-7-bromo-1-(but-2-enyl)-1H-indole-2,3-dione (113)
This compound was prepared according to the method for 49

O

4

3a

O
6

using 7-bromoisatin (55) (500 mg, 2.21 mmol), NaH (74.2 mg,

7a N 1

Br

2'

1'
3'

113

3.09 mmol), KI (73.4 mg, 442 µmol) and crotyl bromide (656 mg,
4'

500 µL, 4.86 mmol) as starting materials. The resulting solid was

purified by flash chromatography on silica gel (100% DCM) to yield 113 (363 mg,
59%) as orange crystals, m.p. 71-73 °C, Rf 0.43 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 1.69 (d, J = 6.0 Hz, 3H, H4’), 4.73 (d,

J = 4.5 Hz, 2H, H1’), 5.61-5.64 (m, 1H, H2’), 5.74-5.80 (m, 1H, H3’), 6.99 (t,
J = 8.0 Hz, 1H, H5) 7.58 (d, J = 7.0 Hz, 1H, H4), 7.69 (d, J = 8.0 Hz, 1H, H6).

~ 209 ~

Chapter 8 - Experimental
____________________________________________________________________
13

C MR (CDCl3, 126 MHz): δ 17.8 (C4’), 42.6 (C1’), 104.2 (C3a), 120.7 (C7),

124.6 (C4), 124.7 (C2’), 124.9 (C5), 129.9 (C3’), 143.9 (C6), 147.9 (C7a), 158.5 (C2),
182.7 (C3). LREI-MS: m/z 279; 281 [M+]79Br;

81

Br. HRESI-MS: m/z calcd for

C12H11NO279Br [M+H]+: 279.9973; found 279.9969.

Synthesis of 6-methyl-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (114)
9

The preparation of this compound was attempted according to the

O
9a

1

6b

N3

O
7

6a

method for 86 and 87 using the isatin 113 (161 mg, 575 µmol),
K2CO3 (239 mg, 1.73 mmol), TBACl (160 mg, 575 µmol) and

5

114

Pd(OAc)2 (12.9 mg, 57.5 µmol) as starting materials. The resulting

solid was purified by flash chromatography on silica gel (100% DCM) and
subsequent preparative TLC (silica, 100% DCM) to yield 114 a dark red powder
(9.30 mg, 8%), m.p. 96-97 °C, Rf 0.45 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 1.43 (d, J = 7.5 Hz, 3H, CH3), 3.74 (m, 1H,

H6), 5.21 (dd, J = 3.0 Hz, 8.0 Hz, 1H, H5), 6.90 (dd, J = 2.0 Hz, 7.5 Hz, 1H, H4),
7.19 (t, J = 8.0 Hz, 1H, H8), 7.43 (d, J = 8.0 Hz, 1H, H7), 7.45 (d, J = 7.0 Hz, 1H,
H9). 13C MR (CDCl3, 126 MHz): δ 23.6 (CH3), 29.8 (C6), 114.7 (C5), 116.0 (C9a),
116.3 (C4), 123.4 (C9), 124.6 (C6a), 126.0 (C8), 136.1 (C7), 143.8 (C6b), 153.2 (C1),
182.8 (C2). LREI-MS: m/z 199 [M+]. HRESI-MS: m/z calcd for C12H10NO2 [M+H]+:
200.0712; found 200.0659.
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Synthesis of (E)-7-bromo-1-(3-phenyl-allyl)-1H-indole-2,3-dione (115)
4

This compound was prepared according to the method for

O
3a

O
6

49 using 7-bromoisatin (55) (751 mg, 3.33 mmol), NaH

7a N 1
2'
Br 1'

(186 mg, 4.66 mmol), KI (111 mg, 670 µmol) and cinnamyl

1''

3'

3''

5''

115

bromide (1.45 g, 1.09 mL, 7.33 mmol) as starting materials.
The resulting solid was purified by flash chromatography on

silica gel (100% DCM) to yield 115 (551 mg, 48%) as an orange powder, m.p.
149-151 °C, Rf 0.33 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.96 (d, J = 6.0 Hz, 2H, H1’), 6.30-6.36 (m,

1H, H2’), 6.66 (d, J = 16 Hz, 1H, H3’), 7.01 (t, J = 7.0 Hz, 1H, H5), 7.24 (t,
J = 7.5 Hz, 1H, H4’) 7.30 (t, J = 7.5 Hz, 2H, H3’, H5’), 7.35 (d, J = 7.5 Hz, 2H, H2’,
H6’), 7.60 (d, J = 7.0 Hz, 1H, H4), 7.70 (d, J = 8.0 Hz, 1H, H6). 13C MR (CDCl3,
126 MHz): δ 47.8 (C1’), 104.2 (C3a), 120.8 (C7), 123.0 (C2’), 124.7 (C4), 125.1
(C5), 126.5 (C2’, C6’), 128.0 (C4’), 128.6 (C3’, C5’), 133.5 (C3’), 136.2 (C1’), 144.0
(C6), 147.7 (C7a), 158.6 (C2), 182.5 (C3). LREI-MS: m/z 341; 343 [M+]79Br;

81

Br.

HREI-MS: m/z calcd for C17H12NO279Br [M+]: 341.0051; found 341.0055.

Synthesis of 6-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (116)
9

The preparation of this compound was attempted according to

O
9a

1

O
7

6a

6b N 3

1'

5'

the method for 86 and 87 using the isatin 115 (130 mg,
380 µmol), K2CO3 (158 mg, 1.14 mmol), TBACl (106 mg,

5

380 µmol) and Pd(OAc)2 (8.50 mg, 38.0 µmol) as starting
3'

116

materials. The resulting solid was purified by flash

chromatography on silica gel (CHCl3/PS, 3:2) and subsequent preparative TLC
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(silica, 100% DCM) to yield 116 as orange/red crystals (17.2 mg, 17%), m.p.
130-132 °C, Rf 0.57 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.88 (bs, 2H, H4), 5.53 (dd, J = 4.0 Hz,

8.0 Hz, 1H, H5), 7.07 (d, J = 8.0 Hz, 1H, H4’), 7.12 (t, J = 7.5 Hz, 1H, H8), 7.25-7.29
(m, 2H, H2’/H6’), 7.36 (t, J = 7.5 Hz, 2H, H3’/H5’), 7.48 (d, J = 7.0 Hz, 1H, H9).
13

C MR (CDCl3, 126 MHz): δ 41.7 (C4), 112.8 (C5), 116.2 (ArC), 116.5 (ArC),

123.7 (C9), 126.1 (C8), 127.5 (C6a), 128.3 (C2’, C6’), 128.9 (C4’), 129.0 (C3’, C5’),
137.5 (C7), 143.4 (C6), 147.6 (ArC), 153.4 (C2), 182.5 (C1). LREI-MS: m/z
261 [M+]. HRESI-MS: m/z calcd for C17H12NO2 [M+H]+: 262.0868; found 262.0855.

Synthesis of (E)-5,7-dibromo-1-(3-phenyl-allyl)-1H-indole-2,3-dione (117)
This compound was prepared according to the method for

O

4

3a

Br
6

O

49 using 5,7-dibromoisatin (17) (600 mg, 1.97 mmol),

2'

NaH (66.2 mg, 2.76 mmol), KI (91.6 mg, 552 µmol) and

7a N 1

Br

1'
3'

117

1''

3''

cinnamyl bromide (524 mg, 393 µL, 4.33 mmol) as
5''

starting materials. The resulting solid was purified by

flash chromatography on silica gel (100% CHCl3) to yield 117 (802 mg, 97%) as red
crystals, m.p. 109-111 °C, (lit.64 115-117 °C), Rf 0.80 (silica, DCM/MeOH, 9:1).
1

H MR (CDCl3, 500 MHz): δ 4.94 (d, J = 5.5 Hz, 2H, H1’), 6.29 (dt,

J = 5.5 Hz, 16 Hz, 1H, H2’), 6.64 (d, J = 16 Hz, 1H, H3’), 7.25 (m, 1H, H4’), 7.32 (t,
J = 7.5 Hz, 2H, H3’, H5’) 7.35 (d, J = 8.0 Hz, 2H, H2’, H6’), 7.70 (d, J = 1.5 Hz, 1H,
H4), 7.86 (s, 1H, H6). The 1H NMR spectral data coincided with those reported in the
literature.64 LREI-MS: m/z 419; 421; 423 [M+] 79Br79Br; 79Br81Br; 81Br81Br.
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Attempted

synthesis

of

8-bromo-6-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-

dione (118)
The preparation of this compound was attempted according to
9

Br

O
9a

1

the method for 116 using the isatin 117 (150 mg, 356 µmol),
O

7

6a

6b N 3

K2CO3 (148 mg, 1.07 mmol), TBACl (98.9 mg, 356 µmol)

1'

5'

3'

5

and Pd(OAc)2 (8.00 mg, 35.6 µmol) as starting materials. The

118

reaction mixture was heated at 80 ºC for 2-4 h. Analysis by

TLC and MS revealed the product was predominantly starting material 117.

Synthesis of 5,6-dihydrophenanthridine (121)
Method A:260 A mixture of phenanthridine (119) (1.00 g,

9
1

5.58 mmol) and tin powder (2.52 g, 21.2 mmol, 80-200 mesh) was

10b
6a

4

4a N

6

dissolved in conc. HCl (10 mL) and heated at reflux for 4-18 h. The

H

121

solution was basified with NaOH solution and extracted with Et2O

(3 × 20 mL). MS analysis revealed only the starting material 119 was present.
Method B:261 A mixture of phenanthridine (119) (5.00 g, 27.9 mmol) and AcOH
(1.68 g, 1.60 mL, 27.9 mmol) were added to absolute EtOH (50 mL) and heated at
reflux for 30 min before the addition of NaCNBH3 (3.33 g, 53.1 mmol). The solution
was heated at reflux for a further 1.5 h, cooled and the solvent removed by rotary
evaporation. The white residue was basified with aq. NH3 (100 mL) and extracted
with Et2O (3 × 50 mL). The organic extract was evaporated and the white precipitate
was recrystallised from 95% EtOH to yield 121 (3.89 g, 77%) as yellow crystals, m.p.
64-66 °C (lit.323 102-104 °C), Rf 0.53 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 3.72 (s, 1H, NH), 4.39 (s, 2H, H6), 6.67 (m,

1H, ArH), 6.82-6.86 (m, 1H, ArH), 7.09-7.12 (m, 2H, ArH × 2), 7.21 (m, 1H, ArH),
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7.30-7.33 (m, 1H, ArH), 7.69 (m, 2H, ArH × 2). The 1H NMR spectral data coincided
with those reported in the literature.323 LREI-MS: m/z 181 [M+].

Synthesis of 7H-pyrrolo[3,2,1-de]phenanthridine-4,5-dione (126)
4

Method A: The preparation of this compound was attempted

O
O

1
11b

according to the method for 85 using 121 (785 mg, 4.33 mmol),

N6

oxalyl chloride (1.10 g, 759 µL, 8.66 mmol) and AlCl3 (1.73 g,

11

7a

13.0 mmol) as starting materials. The product was starting
9

126

material 85 as determined by MS.

Method B: A mixture of 5,6-dihydrophenanthridine (121) (500 mg, 2.76 mmol),
oxalyl chloride (701 mg, 482 µL, 5.52 mmol), DMAP (33.7 mg, 276 µmol) and
DIPEA (357 mg, 480 µL, 2.76 mmol) was dissolved in anh. THF (10 mL) and heated
at reflux for 3.5 h. The solution was evaporated and the residue was dissolved in anh.
CHCl3 (40 mL) and heated at reflux. AlCl3 (1.10 g, 8.28 mmol) was added
portionwise over 30 min and the solution was heated at reflux for a further 1.5 h.
Upon cooling, the solution was extracted with H2O (2 × 25 mL) and brine (1 ×
25 mL). The organic extract was dried over MgSO4, filtered and evaporated. The
resulting solid was purified using flash chromatography on silica gel (100% DCM) to
yield 126 (100 mg, 15%) as dark red crystals, m.p. 212-214 °C, Rf 0.24 (silica,
DCM).
1

H MR (CDCl3, 500 MHz): δ 5.06 (s, 2H, H7), 7.09 (t, J = 7.5 Hz, 1H, H2),

7.19 (d, J = 7.5 Hz, 1H, H8), 7.33 (t, J = 7.0 Hz, 1H, H9), 7.37 (t, J = 7.5 Hz, 1H,
H10), 7.42 (d, J = 7.5 Hz, 1H, H3), 7.76 (d, J = 8.0 Hz, 1H, H11), 7.87 (d, J = 8.0 Hz,
1H, H1).

13

C MR (CDCl3, 126 MHz): δ 42.6 (C7), 116.5 (C3a), 118.9 (C11b),

122.8 (C11), 124.3 (C2), 124.7 (C3), 126.9 (C11a), 128.1 (C8), 128.4 (C7a), 128.7
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(C10), 129.6 (C9), 130.7 (C1), 146.6 (C11c), 157.9 (C5), 183.2 (C4). LREI-MS:
m/z 235 [M+]. HREI-MS: m/z calcd for C15H9NO2 [M+]: 235.0633; found 235.0625.

Synthesis of 2-bromo-7H-pyrrolo[3,2,1-de]phenanthridine-4,5-dione (127)

4

Br

Method A: The preparation of this compound was attempted

O
O

1
11b

according to the method for 92 using 126 (100 mg, 426 µmol)

N6

and Br2 (205 mg, 66.0 µL, 1.28 mmol) as starting materials. The

11

7a

compound did not dissolve in 95% EtOH (12 mL).

9

127

Method B: The preparation of this compound was attempted

according to Method A for using 126 (84.0 mg, 357 µmol) and Br2 (171 mg, 55.0 µL,
1.07 mmol) as starting materials. Absolute EtOH (5 mL) did not dissolve the
compound.
Method

C:

According

to

the

7H-pyrrolo[3,2,1-de]phenanthridine-4,5-dione

method
(126)

of

Vine

(84.0 mg,

al.,81

et

357 µmol)

was

dissolved in glacial AcOH (5 mL) and heated to 75 °C. Br2 (171 mg, 55.0 µL,
1.07 mmol) was added dropwise while the solution was still hot. The reaction mixture
was then cooled, the precipitated product collected by filtration, and washed with
absolute EtOH. The resulting solid was purified by flash chromatography on silica gel
(100% CHCl3) to yield 127 (77.1 mg, 69%) as dark red powder, m.p. 239-241 °C,
Rf 0.25 (silica, CHCl3).
1

H MR (CDCl3, 300 MHz): δ 5.08 (s, 2H, H7), 7.22 (m, 1H, H11), 7.38 (m,

2H, H8, H10), 7.53 (s, 1H, H3), 7.70 (m, 1H, H9), 7.98 (s, 1H, H1).

13

C MR

(CDCl3, 75 MHz): δ 42.4 (C7), 117.1 (ArC), 117.3 (ArC), 120.7 (ArC), 122.8 (C9),
125.6 (ArC), 126.9 (C3), 128.0 (C11), 128.5 (ArC), 128.7 (C10), 130.1 (C8), 132.8
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(C1), 145.2 (C11b’), 156.8 (C5), 181.7 (C4). LREI-MS: m/z 313; 315 [M+]79Br; 81Br.
HREI-MS: m/z calcd for C15H8NO281Br [M+]: 314.9718; found 314.9731.

Synthesis of 7-iodo-1-(naphthalen-1-ylmethyl)-1H-indole-2,3-dione (128)
4

This compound was prepared according to the method for 49

O
3a

using

O
6

7a

I

7-iodoisatin

(56)

(6.00

g,

22.0

mmol)

and

N1
1'

1-(chloromethyl)naphthalene (8.11 g, 6.87 mL, 48.4 mmol) as

1''

8a''
8''

4a''
5''

128

4''

starting materials. The reaction mixture was heated at 60 °C
and stirred at this temperature for 18 h. The resulting solid was
purified by flash chromatography on silica gel (100% CHCl3)

to yield 128 (5.29 g, 58%) as a red powder, m.p. 177-178 °C, Rf 0.21 (silica, 100%
CHCl3).
1

H MR (CDCl3, 500 MHz): δ 5.89 (s, 2H, H1’), 6.90 (t, J = 8.0 Hz, 1H, H5),

7.10 (d, J = 7.0 Hz, 1H, H2’’), 7.38 (t, J = 7.5 Hz, 1H, H3’’), 7.56 (t, J = 7.5 Hz, 1H,
H6’’), 7.62 (t, J = 7.5 Hz, 1H, H7’’), 7.72 (d, J = 7.0 Hz, 1H, H4), 7.81 (d, J = 8.5 Hz,
1H, H4’’), 7.92 (dd, J = 3.5 Hz, 8.5 Hz, 2H, H5’’, H6), 7.99 (d, J = 8.0 Hz, 1H, H8’’).
13

C MR (CDCl3, 126 MHz): δ 42.1 (C1’), 74.1 (C7), 120.6 (C3a), 121.9 (C2’’),

122.3 (C8’’), 125.4 (C4, C5 or C3’’), 125.5 (C4, C5 or C3’’), 125.6 (C4, C5 or C3’’),
126.1 (C6’’), 126.6 (C7’’), 128.1 (C4’’), 129.0 (C5’’), 130.0 (C8a’’), 131.0 (C1’’),
133.9 (C4a’’), 151.0 (C7a’’), 151.1 (C6), 158.9 (C2), 182.4 (C3). LREI-MS: m/z 413
[M+]. HRESI-MS: m/z calcd for C19H12NO2I [M+H]+: 412.9913; found 412.9915.
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Synthesis

of

7’-iodo-1’-(naphthalen-1-ylmethyl)spiro[[1,3]-dioxolane-2,3’-

indolin]-2’-one (130)
According to the method of Ribeiro et al.,319 the isatin 128

5
1
4'

4

O

(4.96 g, 12.0 mmol), ethylene glycol (14.9 g, 13.4 mL,

O3

3a'

O
6'

N1'

7a'

I

1''

240 mmol) and PTSA (496 mg, 10% of starting material weight)

1'''

8a'''
8'''

were dissolved in PhMe (40 mL) and heated at reflux under
4'''
4a'''
5'''

130

Dean-Stark conditions for 24 h. No evidence of product had
formed so more ethylene glycol was added (7.45 g, 6.70 mL,

120 mmol) and the solution was heated at reflux for a further 24 h before the solvent
was removed by rotary evaporation. The resulting solid was purified by flash
chromatography on silica gel (100% DCM) to yield 130 (4.14 g, 75%) as a beige
powder, m.p. 236-238 °C, Rf 0.39 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.38 (t, J = 7.0 Hz, 2H, H4, H5), 4.63 (t,

J = 6.5 Hz, 2H, H4, H5), 5.77 (s, 2H, H1’’), 6.83 (d, J = 7.5 Hz, 1H, H5’), 7.05 (d,
J = 7.5 Hz, 1H, H2’’’), 7.37 (t, J = 7.5 Hz, 1H, H3’’’), 7.44 (d, J = 7.5 Hz, 1H, H4’),
7.53 (t, J = 7.0 Hz, 1H, H6’’’), 7.60 (t, J = 8.0 Hz, 1H, H7’’’), 7.70 (d, J = 8.0 Hz, 1H,
H6’), 7.77 (d, J = 8.0 Hz, 1H, H4’’’), 7.90 (d, J = 7.5 Hz, 1H, H5’’’), 8.00 (d,
J = 8.5 Hz, 1H, H8’’’). 13C MR (CDCl3, 126 MHz): δ 41.9 (C1’’), 66.3 (CH2CH2),a
72.8 (C7’), 101.2 (ArC), 122.3 (C2’’’), 122.7 (C8’’’), 125.2 (C4’), 125.4 (C5’), 125.9
(C3’’’), 126.0 (C6’’’), 126.5 (C7’’’), 127.5 (ArC), 127.8 (C4’’’), 129.1 (C5’’’), 130.4
(ArC), 131.9 (ArC), 134.0 (ArC), 144.7 (C6’ + ArC), 174.5 (C2’). LREI-MS:
m/z 457 [M+]. HRESI-MS: m/z calcd for C21H17NO3I [M+H]+: 458.0253; found
458.0233.
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Synthesis of spiro[benzo[i]pyrrolo[3,2,1-de]phenanthridine-4,2’-[1,3]dioxolan]5(7H)-one (131)
5
1
3'

4

O

3a'

O3

According to the method of Torres et al.,232 the ketal 130 (2.00 g,
4.37 mmol), Pd(OAc)2 (98.0 mg, 437 µmol), TBAB (1.55 g,

O

1'

N
13b' 13c'
13a'
7'
13'
7a'
7b'
8'
11a'

4.81 mmol) and NaOAc (1.79 g, 21.9 mmol) were dissolved in anh.
DMF (44 mL) and heated at 90 ºC for 5 h. Upon cooling, H2O
(200 mL) was added and the solution was extracted with EtOAc

11'

131

(3 × 100 mL). The organic extract was dried over MgSO4, filtered

and evaporated. The resulting solid was purified using flash chromatography on silica
gel (100% CHCl3) to yield 131 (1.24 g, 86%) as a light brown powder,
m.p. 222-224 °C, Rf 0.41 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.36 (t, J = 6.5 Hz, 2H, H4, H5), 4.63 (t,

J = 6.5 Hz, 2H, H4, H5), 5.27 (s, 2H, H7’), 7.08 (t, J = 7.0 Hz, 1H, H2’), 7.25 (m, 1H,
H1’ or H3’), 7.50 (t, J = 8.0 Hz, 1H, H10’), 7.56 (t, J = 8.0 Hz, 1H, H9’), 7.72 (d,
J = 8.0 Hz, 2H, H1’ or H3’ + H8’), 7.79-7.84 (m, 3H, H11’, H12’, H13’).

13

C MR

(CDCl3, 126 MHz): δ 40.7 (C7’), 65.9 (C4/C5), 103.2 (C3a’), 117.4 (C13b’), 120.0
(C11’ or C12’ or C13’), 122.3 (ArC), 122.4 (C8’), 123.4 (ArC), 123.5 (C2’), 124.3
(C1’ or C3’), 124.5 (C1’ or C3’), 125.2 (ArC), 126.4 (C10’), 127.3 (C9’), 128.7 (C11’
or C12’ or C13’), 128.8 (C11’ or C12’ or C13’), 130.3 (C7b’), 133.0 (C11a’), 139.3
(C13c’), 183.2 (C5’). LREI-MS: m/z 329 [M+]. HRESI-MS: m/z calcd for
C21H16NO3 [M+]: 330.1130; found 330.1117.
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Synthesis of 7H-benzo[i]pyrrolo[3,2,1-de]phenanthridine-4,5-dione (132)
3
1

According to the method of Torres et al.,232 the cyclised ketal 131

O
3a

O
N
13b 13c
13a

13

7a
7b

11a

(1.10 g, 3.34 mmol) was dissolved in 6 M HCl/THF (1:1, 35 mL)

7

and heated at reflux for 5 h. Upon cooling, H2O (200 mL) was

8

added, the solution filtered and washed with more H2O to yield

11

132 (641 mg, 67%) as a fine dark red powder, m.p. 251-253 °C,
132

Rf 0.29 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 5.44 (s, 2H, H7), 7.14 (t, J = 7.5 Hz, 1H, H2),

7.45 (d, J = 7.5 Hz, 1H, H1 or H3), 7.62 (t, J = 7.0 Hz, 1H, H10), 7.66 (t, J = 7.5 Hz,
1H, H9), 7.95 (d, J = 8.5 Hz, 1H, H8), 8.01 (t, J = 7.5 Hz, 2H, H11 + H12 or H13),
8.16 (d, J = 9.0 Hz, 1H, H12 or H13), 8.25 (d, J = 8.0 Hz, 1H, H1 or H3). 13C MR
(CDCl3, 126 MHz): δ 40.8 (C7), 115.7 (C3a or C13b), 118.7 (C3a or C13b), 119.6
(C11 or C12 or C13), 122.4 (C8), 123.4 (ArC), 124.4 (C2), 124.7 (C1 or C3), 127.0
(C10), 127.8 (C9), 129.2 (C11 or C12 or C13), 129.9 (ArC), 130.2 (C7b), 130.8 (C12
or C13), 133.3 (C11a), 134.2 (ArC), 146.5 (C13c), 157.8 (C4), 182.9 (C5).
LREI-MS: m/z 285 [M+]. HRESI-MS: m/z calcd for C19H12NO2 [M+H]+: 286.0868;
found 286.0829.
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Attempted synthesis of 2-bromo-7H-benzo[i]pyrrolo[3,2,1-de]phenanthridine4,5-dione (133)

Br

Method A: The preparation of this compound was attempted

O

3

3a

O

1

N
13b 13c
13a
7
13
7a
7b
8
11a

according to the method of Vine et al.81 The isatin 132 (150 mg,
526 µmol) was added to glacial AcOH (5 mL) and heated to
70-75 °C but the compound would not dissolve, even when

11

additional solvent (10 mL) was added. The isatin 132 was not
133

able to dissolve in 95% EtOH or CH3CN at 70-75 °C, so no
bromination was observed in these solvents either.
Method B: According to the method of Zysman-Colman et al.,324 the cyclised
phenanthridine 132 (100 mg, 351 µmol) was dissolved in anh. CH3CN (1 mL) at 0 ºC.
NBS (62.5 mg, 351 µmol) in anh. CH3CN (1 mL) was added and the reaction mixture
was warmed to RT and stirred for 18 h. DCM (30 mL) was then added and the
solution was extracted with H2O (3 × 20 mL). The organic extract was dried over
MgSO4, filtered and evaporated. MS analysis on the crude product revealed it only
contained the starting material 132 so the experiment was abandoned.

Synthesis of 7-iodo-1-(naphthalen-2-ylmethyl)-1H-indole-2,3-dione (129)
4

This compound was prepared according to the method for 49

O
3a

O
6

7a

I

N1

1''

1'

using
8a''

7-iodoisatin

(56)

(2.50

g,

9.16 mmol)

and

8''

2-(bromomethyl)naphthalene (3.03 g, 13.7 mmol) as starting

2''
4''

129

4a''

5''

materials. The reaction mixture was heated at 60 °C and
stirred at this temperature for 18 h. The resulting solid was

purified by flash chromatography on silica gel (100% CHCl3) to yield 129 (1.37 g,
36%) as red/brown crystals, m.p. 154-155 °C, Rf 0.41 (silica gel, DCM).
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1

H MR (CDCl3, 500 MHz): δ 5.64 (s, 2H, H1’), 6.88 (t, J = 7.5 Hz, 1H, H5),

7.38 (d, J = 7.5 Hz, 1H, H3’’), 7.46 (dd, J = 3.0 Hz 6.0 Hz, 2H, H6’’, H7’’), 7.61 (s,
1H, H1’’), 7.68 (d, J = 6.5 Hz, 1H, H4), 7.75 (dd, J = 3.0 Hz, 5.5 Hz, 1H, H8’’),
7.81-7.85 (m, 2H, H4’’, H5’’), 7.94 (d, J = 8.0 Hz, 1H, H6).

13

C MR (CDCl3,

126 MHz): δ 43.8 (C1’), 73.7 (C7), 120.8 (C3a), 124.4 (C3’’), 124.9 (C1’’), 125.5
(C4), 125.7 (C5), 126.0 (C6’’ or C7’’), 126.4 (C6’’ or C7’’), 127.7 (C4’’ or C5’’ or
C8’’), 127.8 (C4’’ or C5’’ or C8’’), 128.7 (C4’’ or C5’’), 132.7 (C4a’’), 133.3 (C8a’’ +
C2’’), 150.9 (C7a), 151.1 (C6), 159.2 (C2), 182.4 (C3). LREI-MS: m/z 413 [M+].
HRESI-MS: m/z calcd for C19H13NO2I [M+H]+: 413.9991; found 413.9950.

Synthesis

of

7’-iodo-1’-(naphthalen-2-ylmethyl)spiro[[1,3]-dioxolane-2,3’-

indolin]-2’-one (135)
According to the method of Ribeiro et al.,319 the isatin 129

5
4'

1

4

O

(1.10 g, 2.66 mmol), ethylene glycol (4.95 g, 4.45 mL,

O3

3a'

O
6'

N1'

7a'
1''
I

79.8 mmol) and PTSA (110 mg, 10% of starting material

1'''

8a'''

8'''

weight) were dissolved in PhMe (10 mL) and heated at

2'''
4'''

135

4a'''

5'''

reflux under Dean-Stark conditions for 64 h. Upon cooling,
the solvent was removed by rotary evaporation. The

resulting solid was purified by flash chromatography on silica gel (100% DCM) to
yield 135 (1.12 g, 92%) as a beige powder, m.p. 156-158 °C, Rf 0.40 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.37 (quintet, J = 1.5 Hz, 7.0 Hz, 2H, H4,

H5), 4.63 (quintet, J = 1.5 Hz, 7.5 Hz, 2H, H4, H5), 5.51 (s, 2H, H1’’), 6.82 (t,
J = 8.0 Hz, 1H, H5’), 7.35 (dd, J = 1.5 Hz, 8.5 Hz, 1H, H3’’’), 7.41 (dd, J = 1.0 Hz,
7.0 Hz, 1H, H4’), 7.43 (m, 2H, H6’’’, H7’’’), 7.57 (s, 1H, H1’’’), 7.71 (dd, J = 1.0 Hz,
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8.5 Hz, 1H, H1’’’), 7.76 (m, 1H, H8’’’), 7.81 (m, 2H, H4’’’, H5’’’). 13C MR (CDCl3,
126 MHz): δ 43.7 (C1’’), 66.3 (C4 + C5), 72.6 (C7’), 101.1 (C3a’), 124.5 (C3’’’),
124.7 (C1’’’), 124.9 (C4’), 125.2 (C5’), 125.7 (C6’’ or C7’’), 126.1 (C6’’ or C7’’),
127.4 (C3’), 127.6 (C4’’ or C5’’ or C8’’), 127.9 (C4’’ or C5’’ or C8’’), 128.5 (C4’’ or
C5’’), 132.6 (C2’’ or C4a’’ or C8a’’), 133.4 (C2’’ or C4a’’ or C8a’’), 134.1 (C2’’ or
C4a’’ or C8a’’), 144.4 (C7a’), 144.5 (C6’), 174.5 (C2’). LREI-MS: m/z 457 [M+].
HRESI-MS: m/z calcd for C21H17NO3I [M+H]+: 458.0253; found 458.0215.

Synthesis of spiro[benzo[k]pyrrolo[3,2,1-de]phenanthridine-4,2’-[1,3]dioxolan]5(7H)-one (136)
5
3'

1O
3a'

4

O3

According to the method of Torres et al.,232 the ketal 135
(1.00 g, 2.19 mmol), Pd(OAc)2 (49.2 mg, 219 µmol), TBAB

O
1'
N
13c' 13d'
13a'
7'
7a'
11'

(777 mg, 2.41 mmol) and NaOAc (902 mg, 11.0 mmol) were
dissolved in anh. DMF (22 mL) and heated at 90 ºC for 5 h.

8'

9a'

136

Upon cooling, H2O (100 mL) was added and the solution

was extracted with EtOAc (2 × 60 mL). The organic extract was dried over MgSO4,
filtered and evaporated. The resulting solid was purified using flash chromatography
on silica gel (100% CHCl3) to yield 136 (485 mg, 67%) as a beige powder, m.p.
161-163 °C, Rf 0.20 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.36 (t, J = 6.5 Hz, 2H, H4, H5), 4.61 (t,

J = 6.5 Hz, 2H, H4, H5), 5.05 (s, 2H, H7’), 7.14 (t, J = 8.0 Hz, 1H, H2’), 7.21 (d,
J = 8.5 Hz, 1H, H8’), 7.30 (d, J = 7.5 Hz, 1H, H3’), 7.50 (t, J = 7.5 Hz, 1H, H11’),
7.56 (t, J = 7.5 Hz, 1H, H12’), 7.74 (d, J = 8.0 Hz, 1H, H9’), 7.85 (d, J = 9.0 Hz, 1H,
H10’), 8.17 (d, J = 8.5 Hz, 1H, H1’), 8.63 (d, J = 9.0 Hz, 1H, H13’).
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(CDCl3, 126 MHz): δ 44.5 (C7’), 66.1 (C4, C5), 119.1 (C13c’), 121.6 (C3a’), 123.3
(C2’), 124.1 (C3’), 125.1 (C8’), 125.3 (C13’), 125.5 (C13b’), 126.1 (C11’), 127.3
(C12’), 129.2 (C9’ or C10’), 129.3 (C9’ or C10’), 129.4 (C1’), 129.8 (C7a’), 130.2
(C13a’), 134.4 (C9a’), 141.9 (C13d’, C4’), 174.3 (C5’). LREI-MS: m/z 329 [M+].
HRESI-MS: m/z calcd for C21H16NO3 [M+H]+: 330.1130; found 330.1081.

Synthesis of 7H-benzo[k]pyrrolo[3,2,1-de]phenanthridine-4,5-dione (137)
3

3a

1

N
13c 13d
13a
7
7a

11

According to the method of Torres et al.,232 the cyclised

O

8

9a

137

5

O

ketal 136 (420 mg, 1.28 mmol) was dissolved in 6 M
HCl/THF (1:1, 13.4 mL) and heated at reflux for 5 h. Upon
cooling, H2O (80 mL) was added, the solution filtered and
washed with more H2O to yield 137 (330 mg, 90%) as a fine

dark red powder, m.p. 205-207 °C, Rf 0.19 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 5.15 (s, 2H, H7), 7.18 (t, J = 8.0 Hz, 1H, H2),

7.24 (d, J = 8.0 Hz, 1H, H8), 7.48 (d, J = 7.5 Hz, 1H, H3), 7.55 (t, J = 8.5 Hz, 1H,
H11), 7.60 (td, J = 1.0 Hz, 8.5 Hz, 1H, H12), 7.80 (d, J = 8.5 Hz, 1H, H9), 7.89 (d,
J = 8.0 Hz, 1H, H10), 8.37 (d, J = 8.0 Hz, 1H, H1), 8.55 (d, J = 8.5 Hz, 1H, H13).
13

C MR (CDCl3, 126 MHz): δ 44.3 (C7), 117.2 (C13c), 120.2 (C3a), 123.6 (C2),

123.9 (C3), 124.2 (C13b), 124.6 (C13), 124.7 (C8), 126.3 (C11), 127.6 (C12), 129.2
(C10), 129.8 (C7a), 129.9 (C9), 130.8 (C13a), 134.2 (C9a), 135.6 (C1), 149.2 (C13d),
158.8 (C5), 183.1 (C4). LREI-MS: m/z 285 [M+]. HRESI-MS: m/z calcd for
C19H12NO2 [M+H]+: 286.0868; found 286.0860.
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Synthesis of 2-bromo-7H-benzo[k]pyrrolo[3,2,1-de]phenanthridine-4,5-dione
(138)
3

Br
1

N
13c 13d
13a
7
7a

11

The compound was prepared according to Method B for 133

O
3a

8

9a

138

5

O

using phenanthridine 137 (100 mg, 351 µmol) and NBS
(62.5 mg, 351 µmol) as starting materials. The resulting solid
was purified using flash chromatography on silica gel (100%
CHCl3) to yield 138 (49.2 mg, 39%) as a fine dark red

powder, m.p. 197-199 °C, Rf 0.38 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 5.09 (s, 2H, H7), 7.20 (d, J = 8.0 Hz, 1H, H8),

7.47-7.57 (m, 2H, H3, H11), 7.63 (m, 1H, H12), 7.81 (d, J = 8.0 Hz, 1H, H9), 7.87 (d,
J = 7.0 Hz, 1H, H10), 8.33 (m, 1H, H1), 8.41 (m, 1H, H13).

13

C MR (CDCl3,

126 MHz): δ 44.2 (C7), 116.6 (ArC), 118.1 (ArC), 122.0 (ArC), 122.7 (ArC), 124.0
(C13), 124.6 (C8), 126.1 (C11), 126.5 (C3), 128.1 (C12), 129.4 (C10), 129.6 (C13a),
130.7 (C9), 134.1 (C9a), 135.6 (ArC), 137.5 (C1), 147.9 (C13d), 157.9 (C5), 181.7
(C4). LREI-MS: m/z 363; 365 [M+]79Br;

81

Br. HRESI-MS: m/z calcd for

C19H11NO279Br [M+H]+: 363.9973; found 363.9991.

Synthesis of 9,10-dihydroacridine (122)
1

The compound was prepared according to the method for 121 using
9a

9

8a

8

acridine (120) (10.0 g, 55.8 mmol), AcOH (6.01 g, 5.73 mL,
4

4a N 10a

H

10

122

5

100 mmol) and NaCNBH3 (6.66 g, 106 mmol) as starting materials.
The crude white precipitate was recrystallised from 95% EtOH to

yield 122 (4.76 g, 47%) as cream coloured needles, m.p. 171-172 °C
(lit.325 166-169 °C), Rf 0.67 (silica, CHCl3).
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1

H MR (CDCl3, 500 MHz): δ 4.06 (s, 2H, CH2), 5.95 (bs, 1H, NH), 6.67 (d,

J = 8.0 Hz, 2H, ArH × 2), 6.86 (t, J = 7.5 Hz, 2H, ArH × 2), 7.06-7.11 (m, 4H,
ArH × 4). The 1H NMR spectral data coincided with those reported in the literature.274
LREI-MS: m/z 180 [M-H]+.

Synthesis of 6H-pyrrolo[3,2,1-de]acridine-1,2-dione275 (143)
The compound was prepared according to the method for 99 using

O
2a

4

1
5a

O

5b N
10a

9,10-dihydroacridine (122) (4.50 g, 24.8 mmol) in anh. THF
(27 mL) and oxalyl chloride (6.30 g, 4.33 mL, 49.6 mmol) in anh.

6a
9

7

143

THF (18 mL) as starting materials. The reaction mixture was heated
at reflux for a further 3.5 h and the solvent was removed by rotary

evaporation. The dark residue was dissolved in anh. CHCl3 (140 mL) and heated at
reflux. AlCl3 (9.92 g, 74.4 mmol) was added portionwise over 5 h and the solution
was heated at reflux for a further 16 h. The solvent was once again removed by rotary
evaporation, the residue was cooled on ice, conc. HCl (45 mL) was added, followed
by H2O (45 mL) and DCM (250 mL). The phases were separated and the organic
layer was washed with H2O (2 × 100 mL), dried over MgSO4, filtered and the solvent
removed by rotary evaporation. The resulting solid was purified by flash
chromatography on silica gel (100% CHCl3) to yield 143 (857 mg, 15%) as dark red
crystals, m.p. 204-206 °C, (lit.275 220-221 °C), Rf 0.40 (silica, CHCl3).
1

H MR (CDCl3, 500 MHz): δ 4.21 (s, 2H, H6), 7.01 (t, J = 8.0 Hz, 1H, H4),

7.14-7.22 (m, 3H, H7, H8, H9), 7.45 (t, J = 7.5 Hz, 2H, H5, H10), 7.52 (d, J = 7.5 Hz,
1H, H3). 13C MR (CDCl3, 126 MHz): δ 28.2 (C6), 119.6 (C2a), 123.3 (C10), 123.6
(C3), 126.0 (C7, C8 or C9), 127.0 (C7, C8 or C9), 127.1 (C4 + C7, C8 or C9), 132.3
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(C10a), 134.9 (C6a), 136.8 (C5), 145.6 (C5b), 155.5 (C1), 182.3 (C2). LREI-MS:
m/z 235 [M+]. HREI-MS: m/z calcd for C15H9NO2 [M+]: 235.0633; found 235.0633.

Synthesis of 4-bromo-6H-pyrrolo[3,2,1-de]acridine-1,2-dione (144)
The compound was prepared according to the method for 127

O
2a

Br

1
5a

O

5b N
10a

using 143 (100 mg, 425 µmol), which was dissolved in glacial
AcOH (5 mL) and heated to 75 °C. Br2 (205 mg, 65.9 µL,

6a
7

144

9

1.28 mmol) was added dropwise while the solution was still
hot. The reaction mixture was then cooled, the precipitated

product collected by filtration, and washed with H2O. The resulting solid was purified
by flash chromatography on silica gel (100% CHCl3) to yield 144 (54.6 mg, 41%) as
a dark red powder, m.p. 190-192 °C, Rf 0.30 (silica, CHCl3).
1

H MR (CDCl3, 500 MHz): δ 4.20 (s, 2H, H6), 7.22 (t, J = 7.5 Hz, 1H, H5),

7.41-7.47 (m, 3H, H7, H8, H9), 7.55 (t, J = 7.0 Hz, 1H, H3), 8.57 (d, J = 8.5 Hz, 1H,
H10).

13

C MR (CDCl3, 126 MHz): δ 28.1 (C6), 116.1 (ArC), 118.9 (ArC), 119.1

(C10), 123.4 (ArC), 123.9 (C3), 125.7 (C5), 131.1 (C7, C8 or C9), 131.3, (ArC),
132.5 (C7, C8 or C9), 136.8 (C7, C8 or C9), 145.1 (ArC), 155.4 (C1), 181.8 (C2).
LREI-MS: m/z 313; 315 [M+]

79

Br;

81

Br. HRESI-MS: m/z calcd for

C15H9NO279Br [M+H]+: 313.9817; found 313.9807.

~ 226 ~

Chapter 8 - Experimental
____________________________________________________________________
8.1.4 Experimental for Chapter 4
8.1.4.1 Synthesis of 3-Iminoisatins
General procedure: According to the method by Verma et al.,326 activated 3Å sieves
(1 g per 100 mg of 24), the isatin 24 (1 equiv.) and EtOH (7.5 mL per 100 mg of 24)
(MeOH was used for 153) were sonicated for 10 min. The acid (148-152, 1 equiv.)
was added and the mixture sonicated for a further 5 min before the addition of glacial
AcOH (200 µL per 100 mg of 24). The reaction mixture was heated at reflux for
1.5 h, the sieves were removed by filtration and the solution was removed by rotary
evaporation. The resulting solid was purified by column chromatography on silica gel
using a CHCl3/MeOH gradient of 100:0 to 95:5 to yield isatins 153-157.

Synthesis of (E and Z)-4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3ylideneamino]benzoic acid (153)

1'

Yield 18%. Mixture of E and Z isomers (E:Z 48:52).

1 OH

M.p. 250-252 °C (orange powder). Rf 0.26 (silica,

N 4'

4''

Br

O

DCM).

O
6''

1

N 1''
Br 1'''

H MR (DMSO-d6, 500 MHz): δ 3.71 (s, 3H, OCH3,

1''''
4''''

Z), 3.73 (s, 3H, OCH3, E), 5.12 (s, 2H, H1’’’, E), 5.30

OCH 3
153

(s, 2H, H1’’’, Z), 6.44 (s, 1H, H4’’, E) 6.86 (d,
J = 8.0 Hz, 2H, H3’’’’/H5’’’’, Z), 6.90 (d, J = 8.0 Hz,

2H, H3’’’’/H5’’’’, E), 7.13 (d, J = 7.5 Hz, 4H, H2’/H6’, E + Z), 7.18 (d, J = 8.0 Hz,
2H, H2’’’’/H6’’’’, Z), 7.25 (d, J = 8.0 Hz, 2H, H2’’’’/H6’’’’, E), 7.84 (s, 1H, H6’’, E),
7.87 (s, 1H, H4’’, Z), 7.91 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 7.93 (s, 1H, H6’’, Z), 8.08
(d, J = 8.0 Hz, 2H, H3’/H5’, E).¶ 13C MR (DMSO-d6, 126 MHz): δ 44.0 (C1’’’, E),
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44.5 (C1’’’, Z), 55.6 (OCH3, E), 55.7 (OCH3, Z), 104.2, 104.8, 113.2, 114.6
(C3’’’’/C5’’’’, E),a 114.6 (C3’’’’/C5’’’’, Z),a 114.9, 116.1, 117.6 (C2’/C6’, E),a 119.5
(C2’/C6’, Z),a 120.6, 125.5, 126.3, 127.7 (C3’/C5’, E),a 128.2 (C2’’’’/C6’’’’, Z),a 128.2
(C2’’’’/C6’’’’, E),a 129.3 (C4’’, E), 129.4 (C3’/C5’, Z),a 130.6,a 131.9, 141.1 (C4’’, Z),
141.3 (C6’’, E), 143.3 (C7a’’, E), 144.5 (C7a’’, Z), 151.1 (C3’’, Z), 152.4 (C3’’, E),
153.4 (C4’, Z), 154.0 (C4’, E), 158.1 (C2’’, E), 159.1 (C4’’’’, E + Z),a 163.5 (C2’’, Z),
167.6 (COOH, Z), 167.8 (COOH, E).
79

Br79Br;

79

Br81Br;

81

LRESI-MS: m/z 541; 543; 545 [M-H]-

Br81Br. HRESI-MS: m/z calcd for C23H15N2O479Br79Br [M-H]-:

540.9399; found 540.9496.

Synthesis of (E and Z)-2-{4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3ylideneamino]phenyl}acetic acid (154)
Yield 68%. Mixture of E and Z isomers (E:Z
1'

Br
6''

1 OH

(silica, DCM/MeOH, 9:1).

O

1

N 1''
Br 1'''

58:42). M.p. 151-153 °C (red crystals). Rf 0.40

O

N 4'

4''

2

H MR (DMSO-d6, 500 MHz): δ 3.57 (s,

1''''
4''''

OCH 3
154

2H, H2, Z), 3.65 (s, 2H, H2, E), 3.71 (s, 3H,
OCH3, Z), 3.73 (s, 3H, OCH3, E), 5.14 (s, 2H,
H1’’’, Z), 5.30 (s, 2H, H1’’’, E), 6.60 (d,

J = 1.5 Hz, 1H, H4’’, E), 6.86 (d, J = 9.0 Hz, 2H, H3’’’’/H5’’’’, Z), 6.90 (d, J = 9.0 Hz,
2H, H3’’’’/H5’’’’, E), 7.00 (d, J = 8.5 Hz, 2H, H2’/H6’, E), 7.13 (d, J = 8.5 Hz, 2H,
H2’’’’/H6’’’’, Z), 7.17 (d, J = 8.0 Hz, 2H, H2’’’’/H6’’’’, E), 7.25 (t, 4H, J = 7.5 Hz,
H2’/H6’ + H3’/H5’, Z), 7.41 (d, J = 8.5 Hz, 2H, H3’/H5’, E), 7.81 (d, J = 2.0 Hz, 2H,
H4’’, Z + H6’’, E), 7.89 (d, J = 2.0 Hz, 1H, H6’’, Z).¶

~ 228 ~

13

C MR (DMSO-d6,

Chapter 8 - Experimental
____________________________________________________________________
126 MHz): δ 30.0 (C2, E + Z),a 44.6 (C1’’’, E + Z),a 55.8 (OCH3, E + Z),a 104.1,
104.8, 112.5, 114.5 (C3’’’’/C5’’’’, Z),a 114.7 (C3’’’’/C5’’’’, E),a 115.0, 116.1, 117.8
(C2’/C6’),a 120.7,a 121.1,a 125.1, 127.0, 127.6, 128.2 (C2’’’’/C6’’’’, E),a 128.3
(C2’’’’/C6’’’’, Z),a 129.5, 130.1, 130.5,a 131.5,a 133.5, 133.7, 141.1, 142.8 (C7a’’, Z),
144.4 (C7a’’, E), 146.8, 148.0, 148.9, 158.2 (C2’’, Z), 159.1 (C4’, E + Z),a 163.8 (C2’’,
E), 173.5 (COOH, E + Z).a LRESI-MS: m/z 557; 559; 561 [M+H]+
79

Br81Br;

81

79

Br79Br;

Br81Br. HRESI-MS: m/z calcd for C24H19N2O479Br81Br [M+H]+:

558.9692; found 558.9678.

Synthesis of (E and Z)-3-{4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3ylideneamino]phenyl}propanoic acid (155)
Yield 71%. Mixture of E and Z isomers (E:Z
3
1'

1 OH

M.p. 79-81 °C

1

O
6''

55:45).

(orange/red

crystals).

Rf 0.43 (silica, DCM/MeOH, 9:1).

N 4'

4''

Br

O

H MR (DMSO-d6, 500 MHz): δ 2.55

N 1''
Br 1'''

1''''

(t, J = 7.5 Hz, 2H, H2, E), 2.56 (t, J = 8.0 Hz, 2H,
4''''

H2, Z), 2.83 (t, J = 7.5 Hz, 2H, H3, Z), 2.89 (t,

OCH 3
155

J = 7.5 Hz, 2H, H3, E), 3.71 (s, 3H, OCH3, Z),

3.73 (s, 3H, OCH3, E), 5.15 (s, 2H, H1’’’, Z), 5.29 (s, 2H, H1’’’, E), 6.54 (s, 1H, H4’’,
E), 6.86 (d, J = 8.0 Hz, 2H, H3’’’’/H5’’’’, Z), 6.90 (d, J = 7.5 Hz, 2H, H3’’’’/H5’’’’, E),
6.96 (d, J = 7.5 Hz, 2H, H2’/H6’, E), 7.13 (d, J = 8.0 Hz, 2H, H2’’’’/H6’’’’, Z), 7.18 (d,
J = 8.0 Hz, 2H, H2’’’’/H6’’’’, E), 7.22-7.24 (m, 4H, H2’/H6’ + H3’/H5’, Z), 7.38 (d,
J = 8.0 Hz, 2H, H3’/H5’, E), 7.80 (m, 2H, H4’’, Z + H6’’, E), 7.88 (s, 1H, H6’’, Z),
12.13 (br s, 2H, OH, E + Z).

13

C MR (DMSO-d6, 126 MHz): δ 30.7 (C3, Z), 30.8
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(C3, E), 36.1 (C2, Z), 36.5 (C2, E), 44.0 (C1’’’, Z), 44.5 (C1’’’, E), 55.7 (OCH3, Z),
55.8 (OCH3, E), 104.0, 104.7, 114.6 (C3’’’’/C5’’’’, E),a 114.6 (C3’’’’/C5’’’’, Z),a 114.9,
116.0, 117.8 (C2’/C6’),a 120.6,a 121.5, 124.9, 127.0, 127.5, 128.1 (C2’’’’/C6’’’’, E),a
128.3 (C2’’’’/C6’’’’, Z),a 128.8,a 129.4, 129.5, 130.2,a 139.5, 140.0, 140.4, 140.9,
142.6 (C7a’’, Z), 144.2 (C7a’’, E), 146.4, 148.4, 149.8, 152.3 (C3’’, E), 158.0 (C2’’,
Z), 159.0 (C4’’’’, Z), 159.1 (C4’’’’, E), 163.7 (C2’’, E), 174.5 (COOH, E + Z).a
LRESI-MS: m/z 569; 571; 573 [M-H]- 79Br79Br; 79Br81Br; 81Br81Br. HRESI-MS: m/z
calcd for C24H19N2O279Br81Br [M-CO2H]-: 526.9799; found 526.9722.

Synthesis of (E and Z)-3-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3ylideneamino]benzoic acid (156)
Yield 56%. Mixture of E and Z isomers (E:Z 49:51).

5'

Br

1' 1
OH

N

4''

2'

O
O
6''

N 1''
Br

1'''

M.p. 229-231 °C (orange powder). Rf 0.37 (silica,

1

1''''
4''''

OCH 3
156

DCM/MeOH, 9:1).
H MR (DMSO-d6, 500 MHz): δ 3.71 (s, 3H,

OCH3, Z), 3.73 (s, 3H, OCH3, E), 5.13 (s, 2H, H1’’’,
Z), 5.30 (s, 2H, H1’’’, E), 6.41 (s, 1H, H4’’, E), 6.86 (d,

J = 8.5 Hz, 2H, H3’’’’/H5’’’’, E), 6.90 (d, J = 9.0 Hz, 2H, H3’’’’/H5’’’’, Z), 7.17 (d,
J = 8.0 Hz, 2H, H2’’’’/H6’’’’, E), 7.25 (d, J = 8.5 Hz, 2H, H2’’’’/H6’’’’, Z), 7.29 (d,
J = 7.5 Hz, 1H, H4’, Z), 7.34 (d, J = 8.0 Hz, 1H, H4’, E), 7.47 (t, J = 8.0 Hz, 1H, H5’,
Z), 7.59 (s 1H, H2’, E), 7.65 (t, J = 8.0 Hz, 2H, H2’, E + H5’, Z), 7.74 (d, J = 7.5 Hz,
1H, H6’, E), 7.82 (s, 1H, H6’’, E), 7.85 (s, 1H, H4’’, Z), 7.88 (d, J = 7.5 Hz, 1H, H6’,
Z), 7.91 (s, 1H, H6’’, Z), 13.13 (br s, 2H, OH, E + Z).

13

C MR (DMSO-d6,

126 MHz): δ 44.0 (C1’’’, Z), 44.5 (C1’’’, E), 55.7 (OCH3, E + Z), 104.1, 104.7, 114.6
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(C3’’’’/C5’’’’, E),a 114.6 (C3’’’’/C5’’’’, Z),a 114.8, 116.0, 118.3, 120.7, 120.9, 122.0
(C2’, Z), 124.5, 125.2, 126.6, 126.8, 126.9, 127.5, 128.1 (C2’’’’/C6’’’’),a 128.2
(C2’’’’/C6’’’’),a 129.3,a 129.4, 130.8, 132.1, 140.8, 141.0, 143.1, (C7a’’, Z),a 144.5
(C7a’’, E),a 149.1, 150.4, 151.2, 153.0 (C3’’, E),a 158.1 (C2’’, Z), 159.0 (C4’’’’, E +
Z),a 163.6 (C2’’, E), 167.5 (C3’’, Z), 167.8 (COOH, E + Z).a LRESI-MS: m/z 541;
543; 545 [M-H]-

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: m/z calcd for

C23H15N2O479Br79Br [M-H]-: 540.9399; found 540.9424.

Synthesis of (E and Z)-2-{3-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3ylideneamino]phenyl}acetic acid (157)
Yield 71%. Mixture of E and Z isomers (E:Z 67:33).

5'

O
1'

N

4''

Br

2

2'

DCM/MeOH, 9:1).

O
6''

N 1''
Br

1'''

1

1''''
4''''

OCH 3
157

M.p. 182-184 °C (red powder). Rf 0.33 (silica,

1 OH

H MR (DMSO-d6, 500 MHz): δ 3.56 (s,

2H, H2, Z), 3.63 (s, 2H, H2, E), 3.71 (s, 3H, OCH3,
Z), 3.73 (s, 3H, OCH3, E), 5.14 (s, 2H, H1’’’, Z),

5.30 (s, 2H, H1’’’, E), 6.61 (s, 1H, H4’’, E), 6.86 (d, J = 8.0 Hz, 2H, H3’’’’/H5’’’’, Z),
6.90 (d, J = 8.5 Hz, 2H, H3’’’’/H5’’’’, E), 6.94 (d, J = 8.5 Hz, 1H, H4’, E), 7.04 (s, 1H,
H2’, E), 7.08 (d, J = 7.5 Hz, 1H, H4’, Z), 7.17 (d, J = 8.5 Hz, 2H, H2’’’’/H6’’’’, Z),
7.20 (d, J = 8.0 Hz, 2H, H6’, E + Z), 7.23 (d, J = 8.0 Hz, 2H, H2’’’’/H6’’’’, E), 7.28 (t,
J = 7.5 Hz, 1H, H5’, Z), 7.46 (t, J = 7.5 Hz, 1H, H5’, E), 7.78-7.80 (m, 2H, H6’’, E +
H2’, Z), 7.90 (s, 1H, H4’’, Z), 8.00 (s, 1H, H6’’, Z), 12.34 (br s, 2H, OH, E + Z).
13

C MR (DMSO-d6, 126 MHz): δ 41.2 (C2, E), 41.6 (C2, Z), 43.9 (C1’’’, Z), 44.5

(C1’’’, E), 55.7 (OCH3, E + Z),a 104.1, 104.6, 114.5 (C3’’’’/C5’’’’, Z),a 114.6
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(C3’’’’/C5’’’’, E),a 115.1, 115.4, 115.9, 116.0, 117.4, 118.6, 118.7, 120.6, 121.8 (C6’,
E), 125.0, 126.8, 126.9, 127.3, 127.5, 127.8, 128.1 (C2’’’’/C6’’’’, E),a 128.2
(C2’’’’/C6’’’’, Z),a 128.8, 129.3, 129.4, 130.3, 140.6, 141.0, 142.8 (C3’’, Z), 144.3,
148.6, 150.3, 152.3 (C3’’, E), 158.0 (C2’’, Z), 159.0 (C4’’’’, E + Z),a 163.7 (C2’’, E),
173.0 (COOH, E), 173.1 (COOH, Z).
79

Br79Br;

79

Br81Br;

81

LRESI-MS: m/z 555; 557; 559 [M-H]-

Br81Br. HRESI-MS: m/z calcd for C24H17N2O479Br81Br [M-H]-:

556.9535; found 556.9568.

8.1.4.2 Synthesis of Isatin-Lysine Conjugates
General procedure: According to the method of Nozaki,295 the 3-iminoisatin
(153-157, 1 equiv.) was dissolved in anh. DCM (1 mL per 30 mg of imine) with the
aid of sonication. On ice, HOBt (1 equiv.) was added, followed by DCC (1 equiv.),
DIPEA (1.1 equiv.) and Ac-Lys-OMe. HCl (1 equiv.). The reaction mixture was
warmed to RT and stirred for 24 h. The precipitate was then filtered off and the
solvent removed by rotary evaporation. The resulting solid was purified by column
chromatography on silica gel using a CHCl3/MeOH gradient of 100:0 to 95:5 to yield
158-162.
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Synthesis

of

methyl

(S,E

and

S,Z)-2-acetamido-6-{4-[5,7-dibromo-1-(4-

methoxybenzyl)-2-oxoindolin-3-ylideneamino]benzamido} hexanoate (158)
Yield 50%. Mixture of E and Z

O
1''

5''

O

1' N 6

1 OCH 3

H
N

4'''

Br

NH

3''

165-167 °C
Rf 0.41

N1'''
Br 1''''

(E:Z

53:47).

(orange

M.p.

crystals).

O

O
6'''

isomers

1'''''

(silica,

CHCl3/MeOH,

95:5).

4'''''

OCH 3

1

158

H

MR

(CDCl3,

500 MHz): δ 1.39-1.89 (m, 12H,

H3/H4/H5, E + Z), 2.00 (s, 6H, COCH3, E + Z), 3.42-3.53 (m, 4H, H6, E + Z), 3.73
(s, 3H, COOCH3, E), 3.75 (s, 3H, COOCH3, Z), 3.77 (s, 3H, Ar-OCH3, E), 3.79 (s,
3H, Ar-OCH3, Z), 4.59-4.64 (m, 2H, H2, E + Z), 5.24 (s, 2H, H1’’’’, E), 5.44 (s, 2H,
H1’’’’, Z), 6.23 (dd, J = 7.0 Hz, 15 Hz, 2H, NHCOCH3, E + Z), 6.33 (br s, 1H,
Ar-CONH, Z), 6.51 (br s, 1H, Ar-CONH, E), 6.77 (s, 1H, H4’’’, E), 6.82 (d,
J = 8.5 Hz, 2H, H3’’’’’/H5’’’’’, Z), 6.86 (d, J = 8.5 Hz, 2H, H3’’’’’/H5’’’’’, E), 7.03 (d,
J = 8.5 Hz, 2H, H3’’/H5’’, E), 7.06 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 7.15 (d,
J = 8.5 Hz, 2H, H2’’’’’/H6’’’’’, Z), 7.22 (d, J = 8.0 Hz, 2H, H2’’’’’/H6’’’’’, E), 7.61 (s,
1H, H6’’’, E), 7.72 (s, 1H, H4’’’, Z), 7.81 (d, J = 7.5 Hz, 2H, H2’’/H6’’, E), 7.84 (s,
1H, H6’’’, Z), 7.96 (d, J = 8.5 Hz, 2H, H2’’/H6’’, Z).

13

C MR (CDCl3, 126 MHz):

δ 22.5 (CH2, Z), 22.6 (CH2, E), 23.4 (COCH3, E + Z),a 28.7 (CH2, E), 29.1 (CH2, Z),
32.2 (CH2, E), 32.5 (CH2, Z), 39.5 (C6, E), 39.7 (C6, Z), 44.0 (C1’’’’, Z), 44.6 (C1’’’’,
E), 51.9 (C2, E), 52.1 (C2, Z), 52.7 (COOCH3, E + Z),a 55.5 (Ar-OCH3, E + Z),a
104.0, 104.8, 111.4, 114.4 (C3’’’’’/C5’’’’’, E),a 114.4 (C3’’’’’/C5’’’’’, Z),a 115.9, 116.8,
117.4 (C3’’/C5’’, E),a 119.4 (C3’’/C5’’, Z),a 119.6, 120.6, 125.8 (C6’’’, Z), 127.9
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(C2’’/C6’’, E),a 128.2 (C2’’’’’/C6’’’’’, E),a 128.3 (C2’’’’’/C6’’’’’, Z),a 128.4 (C4’’’, E),
129.1 (C2’’/C6’’, Z),a 132.1, 133.2, 141.5 (C4’’’, Z), 142.1 (C6’’’, E), 142.5 (C7a’’’,
E), 144.2 (C7a’’’, Z), 146.6, 150.4, 151.4, 151.9, 152.1, 157.6 (C2’’’, E), 159.3
(C4’’’’’, E + Z),a 163.6 (C2’’’, Z), 167.0 (Ar-CONH, E), 167.4 (Ar-CONH, Z), 170.0
(COCH3, Z), 170.5 (COCH3, E), 173.3 (COOCH3, E + Z).a LRESI-MS: m/z 727;
729; 731 [M+H]+ ; 749; 751; 753 [M+Na]+ 79Br79Br; 79Br81Br; 81Br81Br. HRESI-MS:
m/z calcd for C32H32N4NaO679Br81Br [M+Na]+: 751.0566; found 751.0531.

Synthesis of methyl (S,E and S,Z)-2-acetamido-6-(2-{4-[5,7-dibromo-1-(4methoxybenzyl)-2-oxoindolin-3-ylideneamino]phenyl}acetamido)

hexanoate

(159)

1''

5''

4'''

Br

2'

O

H
1' N 6

1 OCH 3

O

N

isomers

(E:Z

49:51).

M.p.

NH

3''

O
O
6'''

Yield 41%. Mixture of E and Z

99-101 °C

(red

crystals).

Rf 0.33 (silica, CHCl3/MeOH,

N 1'''
Br 1'''' 1'''''

95:5).

4'''''

OCH 3

1

H

MR

(CDCl3,

159

500 MHz): δ 1.21-1.82 (m,
12H, H3/H4/H5, E + Z), 1.98 (s, 3H, COCH3, E), 2.02 (s, 3H, COCH3, Z), 3.17-3.27
(m, 4H, H6, E + Z), 3.57 (s, 2H, H2’, Z), 3.62 (s, 2H, H2’, E), 3.71 (s, 3H, COOCH3,
Z), 3.73 (s, 3H, COOCH3, E), 3.76 (s, 3H, Ar-OCH3, Z), 3.78 (s, 3H, Ar-OCH3, E),
4.51-4.58 (m, 2H, H2, E + Z), 5.27 (s, 2H, H1’’’’, E), 5.43 (s, 2H, H1’’’’, Z), 5.65 (br
s, 1H, NHCOCH3, Z), 5.72 (br s, 1H, NHCOCH3, E), 6.23 (d, J = 8.0 Hz, 1H,
CH2-CONH, Z), 6.27 (d, J = 8.0 Hz, 1H, CH2-CONH, E), 6.80 (d, J = 1.5 Hz, 1H,
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H4’’’, E), 6.82 (d, J = 8.5 Hz, 2H, H3’’’’’/H5’’’’’, Z), 6.85 (d, J = 8.0 Hz, 2H,
H3’’’’’/H5’’’’’, E), 6.97 (d, J = 8.5 Hz, 2H, H2’’/H6’’ or H3’’/H5’’, Z), 7.11-7.15 (m,
4H, H2’’’’’/H6’’’’’, Z + H2’’/H6’’ or H3’’/H5’’, E), 7.22 (d, J = 9.0 Hz, 2H,
H2’’’’’/H6’’’’’, E), 7.37 (d, J = 8.0 Hz, 2H, H2’’/H6’’ or H3’’/H5’’, Z), 7.40-7.46 (m,
2H, H2’’/H6’’ or H3’’/H5’’, E), 7.59 (d, J = 1.5 Hz, 1H, H6’’’, E), 7.69 (s, 1H, H4’’’,
Z), 7.83 (d, J = 1.5 Hz, 1H, H6’’’, Z). 13C MR (CDCl3, 126 MHz): δ 22.5 (CH2, E +
Z),a 23.3 (COCH3, Z), 23.4 (COCH3, E), 29.1 (CH2, E), 30.0 (CH2, Z), 31.9 (CH2, E),
32.2 (CH2, Z), 39.2 (C6, Z), 39.3 (C6, E), 43.5 (C2’, E), 43.7 (C2’, Z), 44.0 (C1’’’’, Z),
44.6 (C1’’’’, E), 52.1 (C2, E + Z),a 52.6 (COOCH3, Z), 52.7 (COOCH3, E), 55.5
(Ar-OCH3, E + Z),a 104.0, 104.7, 114.3 (C3’’’’’/C5’’’’’, E),a 114.4 (C3’’’’’/C5’’’’’, Z),a
115.6, 116.7, 117.4, 118.2,a 120.1, 121.1,a 125.5, 126.2, 127.7, 128.2 (C2’’’’’/C6’’’’’,
E),a 128.2 (C2’’’’’/C6’’’’’, Z),a 128.5, 128.9, 129.9,a 130.9,a 132.3, 133.3, 141.0, 141.7,
142.1 (C7a’’’, Z), 144.0 (C7a’’’, E), 148.6, 149.7, 151.9, 157.9 (C2’’’, Z), 159.3
(C4’’’’’, E + Z),a 163.8 (C2’’’, E), 170.4 (COCH3 or CH2-CONH, E + Z),a 171.2
(COCH3 or CH2-CONH), 171.4 (COCH3 or CH2-CONH), 173.2 (COOCH3, E + Z).a
HRESI-MS: m/z calcd for C33H35N4O679Br81Br [M+H]+: 743.0903; found 743.0888.
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Synthesis of methyl (S,E and S,Z)-2-acetamido-6-(3-{4-[5,7-dibromo-1-(4methoxybenzyl)-2-oxoindolin-3-ylideneamino]phenyl}propanamido)

hexanoate

(160)
O
1''

5''

O

3'
1' N 6

H
N

4'''

Br

NH

3''

161-163 °C

(red

powder).

Rf 0.42 (silica, DCM/MeOH,

N 1'''
Br 1''''

Z isomers (E:Z 55:45). M.p.

O

O
6'''

1 OCH 3

Yield 70%. Mixture of E and

1'''''

9:1).

4'''''

OCH 3

1

160

H

MR

(CDCl3,

500 MHz): δ 1.29-1.82 (m,

12H, H3/H4/H5, E + Z), 1.99 (s, 3H, COCH3, Z), 2.03 (s, 3H, COCH3, E), 2.43-2.52
(m, 4H, H2’, E + Z), 2.94-3.04 (m, 4H, H3’, E + Z), 3.12-3.27 (m, 4H, H6, E + Z),
3.72 (s, 3H, COOCH3, Z), 3.73 (s, 3H, COOCH3, E), 3.76 (s, 3H, Ar-OCH3, Z), 3.78
(s, 3H, Ar-OCH3, E), 4.55 (t, J = 4.0 Hz, 2H, H2, E + Z), 5.27 (s, 2H, H1’’’’, Z), 5.43
(s, 2H, H1’’’’, E), 5.62 (br s, 1H, NHCOCH3, Z), 5.66 (br s, 1H, NHCOCH3, E), 6.32
(d, J = 6.0 Hz, 2H, CH2-CONH, E + Z), 6.81 (d, J = 4.0 Hz, 2H, H3’’/H5’’, E), 6.83
(s, 1H, H4’’’, E), 6.85 (d, J = 8.5 Hz, 2H, H3’’’’’/H5’’’’’, E), 6.90 (d, J = 7.5 Hz, 2H,
H3’’’’’/H5’’’’’, Z), 7.10 (d, J = 8.0 Hz, 2H, H3’’/H5’’, Z), 7.15 (d, J = 8.5 Hz, 2H,
H2’’/H6’’, E), 7.21 (t, J = 7.5 Hz, 4H, H2’’’’’/H6’’’’’, E + H2’’/H6’’, Z), 7.29 (d,
J = 8.0 Hz, 2H, H2’’’’’/H6’’’’’, Z), 7.58 (s, 1H, H6’’’, E), 7.68 (s, 1H, H4’’’, Z), 7.85 (s,
1H, H6’’’, Z).

13

C MR (CDCl3, 126 MHz): δ 22.5 (CH2, Z), 22.6 (CH2, E), 23.3

(COCH3, Z), 23.4 (COCH3, E), 28.9 (C3’, Z), 29.1 (C3’, E), 31.6 (CH2, E), 31.7 (CH2,
Z), 32.1 (CH2, Z), 32.3 (CH2, E), 38.6 (C2’, Z), 38.9 (C2’, E), 39.0 (C6, Z), 39.1 (C6,
E), 43.9 (C1’’’’, Z), 44.6 (C1’’’’, E), 52.0 (C2, Z), 52.1 (C2, E), 52.6 (COOCH3, E
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+ Z),a 55.5 (Ar-OCH3, E + Z),a 103.8, 104.6, 114.3 (C3’’’’’/C5’’’’’, Z),a 114.4
(C3’’’’’/C5’’’’’, E),a 115.6, 116.6, 117.9,a 119.8, 121.2 (C3’’/C5’’, Z),a 125.4 (C6’’’, Z),
126.5, 128.1, 128.2 (C2’’’’’/C6’’’’’, E),a 128.2 (C2’’’’’/C6’’’’’, Z),a 128.6,a 128.6,a
128.8, 129.9, 139.4, 140.1, 140.7, 141.5, 141.9 (C7a’’’, Z), 144.0 (C7a’’’, E), 146.2,
147.7, 149.2, 151.8, 157.9 (C2’’’, Z), 159.2 (C4’’’’’, Z), 159.3 (C4’’’’’, E), 163.9 (C2’’’,
E), 170.5 (COCH3 or CH2-CONH, E + Z),a 172.4 (COCH3 or CH2-CONH), 172.6
(COCH3 or CH2-CONH), 173.2 (COOCH3, E + Z). LRESI-MS: m/z 755; 757; 759
[M+H]+

79

Br79Br;

79

Br81Br;

81

Br81Br.

HRESI-MS:

calcd

m/z

for

C34H36N4NaO679Br81Br [M+Na]+: 779.0879; found 779.0896.

Synthesis

of

methyl

(S,E

and

S,Z)-2-acetamido-6-{3-[5,7-dibromo-1-(4-

methoxybenzyl)-2-oxoindolin-3-ylideneamino]benzamido} hexanoate (161)
O
5''
6
4'''

Br

1''1'
N

N

2''

H
O

NH
1 OCH
3

O

O
6'''

Yield 78%. Mixture of E and Z
isomers
74-76 °C
Rf 0.56

N 1'''
Br 1'''' 1'''''

(E:Z

47:53).

(orange
(silica,

M.p.

crystals).

CHCl3/MeOH,

95:5).
4'''''

OCH 3

1

161

H

MR

(CDCl3,

500 MHz): δ 1.36-1.91 (m, 12H,

H3/H4/H5, E + Z), 1.97 (t, J = 7.0 Hz, 6H, COCH3, E + Z), 3.41-3.48 (m, 4H, H6, E +
Z), 3.72 (s, 3H, COOCH3, Z), 3.73 (s, 3H, COOCH3, E), 3.76 (s, 3H, Ar-OCH3, Z),
3.79 (s, 3H, Ar-OCH3, E), 4.56-4.62 (m, 2H, H2, E + Z), 5.25 (s, 2H, H1’’’’, Z), 5.43
(s, 2H, H1’’’, E), 6.24 (d, J = 7.5 Hz, 1H, NHCOCH3, E), 6.28 (d, J = 7.5 Hz, 1H,
NHCOCH3, Z), 6.40 (t, J = 5.5 Hz, 1H, Ar-CONH, Z), 6.55 (t, J = 5.5 Hz, 1H,
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Ar-CONH, E), 6.70 (d, J = 1.5 Hz, 1H, H4’’’, E), 6.82 (d, J = 8.0 Hz, 2H,
H3’’’’’/H5’’’’’, Z), 6.86 (d, J = 8.5 Hz, 2H, H3’’’’’/H5’’’’’, E), 7.08 (d, J = 8.0 Hz, 2H,
H2’’’’’/H6’’’’’, E), 7.14 (d, J = 9.0 Hz, 2H, H2’’’’’/H6’’’’’, Z), 7.21 (d, J = 9.0 Hz, 2H,
H4’’, E + Z), 7.43 (t, J = 8.0 Hz, 1H, H5’’, E), 7.46 (s, 1H, H2’’, E), 7.53 (t,
J = 8.0 Hz, 1H, H5’’, Z), 7.54 (d, J = 1.5 Hz, 1H, H2’’, Z), 7.59 (d, J = 1.5 Hz, 1H,
H6’’’, E), 7.63 (d, J = 8.0 Hz, 1H, H6’’, Z), 7.70 (d, J = 2.0 Hz, 1H, H4’’’, Z), 7.74 (d,
J = 7.5 Hz, 1H, H6’’, E), 7.83 (d, J = 2.0 Hz, 1H, H6’’’, Z).

13

C MR (CDCl3,

126 MHz): δ 22.5 (CH2, Z), 22.6 (CH2, E), 23.3 (COCH3, Z), 23.4 (COCH3, E), 28.7
(CH2, E), 29.0 (CH2, Z), 32.1 (CH2, Z), 32.4 (CH2, E), 39.5 (C6, Z), 39.8 (C6, E), 44.0
(C1’’’’, Z), 44.6 (C1’’’’, E), 51.9 (C2, E), 52.0 (C2, Z), 52.6 (COOCH3, Z), 52.7
(COOCH3, E), 55.5 (Ar-OCH3, E + Z),a 104.0, 104.8, 114.3 (C3’’’’’/C5’’’’’, Z),a 114.4
(C3’’’’’/C5’’’’’, E),a 115.8, 116.5 (C2’’, E), 116.7, 118.9 (C5’’, Z), 120.1, 123.0 (C4’’),
124.7 (C6’’, E), 124.9 (C6’’, Z), 125.6, 126.0, 126.9, 127.8 (C2’’’’’/C6’’’’’, E),a 128.1
(C2’’’’’/C6’’’’’, Z),a 128.2 (C2’’’’’/C6’’’’’, Z),a 128.3 (C4’’), 128.4 (C6’’, E), 129.1
(C5’’, E), 130.2 (C6’’’, Z), 135.4, 141.3 (C4’’’, Z), 141.9 (C6’’’, E), 142.3 (C5’’, E),
144.1, 148.3, 149.7, 150.4, 152.3, 157.8 (C2’’’, Z), 159.2 (C4’’’’’, Z), 159.3 (C4’’’’’,
E), 163.6 (C2’’’, E), 166.9 (Ar-CONH, E), 167.5 (Ar-CONH, Z), 170.4 (COCH3, Z),
170.5 (COCH3, E), 173.2 (COOCH3, E + Z). LRESI-MS: m/z 727; 729; 731 [M+H]+
79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: m/z calcd for C32H31N4O679Br81Br [M-H]-:

727.0590; found 727.0380.

~ 238 ~

Chapter 8 - Experimental
____________________________________________________________________
Synthesis of methyl (S,E and S,Z)-2-acetamido-6-(2-{3-[5,7-dibromo-1-(4methoxybenzyl)-2-oxoindolin-3-ylideneamino]phenyl}acetamido)

hexanoate

(162)
O

5''

O

6

1''

Br

4'''

N

2''

2'

1' N

H

NH

Yield 82%. Mixture of E and Z
isomers

(E:Z

37:63).

M.p.

1 OCH 3

O

194-196 °C

(red

powder).

O
6'''

Rf 0.44 (silica, DCM/MeOH,

N 1'''
Br

1'''' 1'''''

9:1).

4'''''

OCH 3

1

H

MR

(CDCl3,

162

500 MHz): δ 1.16-1.69 (m,
12H, H3/H4/H5, E + Z), 1.98 (s, 3H, COCH3, Z), 2.01 (s, 3H, COCH3, E), 3.09-3.10
(m, 2H, H6, E), 3.14-3.24 (m, 2H, H6, Z), 3.59 (s, 4H, H2’, E + Z), 3.69 (s, 3H,
COOCH3, Z), 3.73 (s, 3H, COOCH3, E), 3.77 (s, 3H, Ar-OCH3, Z), 3.78 (s, 3H,
Ar-OCH3, E), 4.45 (d, J = 3.5 Hz, 1H, H2, Z), 4.53 (d, J = 3.5 Hz, 1H, H2, E), 5.24 (s,
2H, H1’’’’, Z), 5.43 (s, 2H, H1’’’’, E), 5.68 (br s, 1H, NHCOCH3, E), 5.91 (br s, 1H,
NHCOCH3, Z), 6.20-6.24 (m, 2H, CH2-CONH, E + Z), 6.76 (s, 1H, H4’’’, E), 6.83 (d,
J = 8.0 Hz, 4H, H3’’’’’/H5’’’’’, E + Z), 6.91 (s, 2H, H2’’, E + Z), 7.03 (d, J = 8.0 Hz,
1H, H4’’, Z), 7.10 (d, J = 8.5 Hz, 4H, H2’’’’’/H6’’’’’, E + Z), 7.21 (d, J = 7.5 Hz, 3H,
H4’’, E + H6’’, E + Z), 7.40 (t, J = 8.0 Hz, H5’’, Z), 7.45 (t, J = 7.5 Hz, 1H, H5’’, E),
7.59 (s, 1H, H6’’’, E), 7.71 (s, 1H, H4’’’, Z), 7.86 (s, 1H, H6’’’, Z). 13C MR (CDCl3,
126 MHz): δ 22.4 (CH2, Z), 22.5 (CH2, E), 23.3 (COCH3, Z), 23.4 (COCH3, E), 29.1
(CH2, Z), 29.9 (CH2, E), 31.7 (CH2, Z), 32.1 (CH2, E), 39.1 (C6, Z), 39.4 (C6, E), 43.8
(C2’, E), 44.0 (C2’, Z), 44.1 (C1’’’’, Z), 44.6 (C1’’’’, E), 52.1 (C2, E), 52.3 (C2, Z),
52.5 (COOCH3, Z), 52.6 (COOCH3, E), 55.5 (Ar-OCH3, E + Z),a 104.1, 104.7, 114.4
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(C3’’’’’/C5’’’’’, E),a 114.4 (C3’’’’’/C5’’’’’, Z),a 115.8, 116.2 (C2’’, E), 116.9, 118.3,
119.4 (C6’’, Z), 119.7, 120.4, 125.7 (C2’’, Z), 126.0, 127.1, 127.7, 128.0
(C2’’’’’/C6’’’’’, Z),a 128.2 (C2’’’’’/C6’’’’’, E),a 128.3,a 128.5, 130.0 (C5’’, Z), 130.5
(C5’’, E), 135.2, 137.3, 141.2 (C6’’, Z), 141.8 (C6’’, E), 142.1, 144.1, 148.9, 150.1,
150.3, 152.0, 158.0 (C4’’’’’, E), 159.3 (C4’’’’’, Z), 163.8 (C2’’’, E), 170.3 (CH2-CONH
or COCH3), 170.4 (CH2-CONH or COCH3), 170.7 (CH2-CONH or COCH3), 171.2
(CH2-CONH or COCH3), 173.2 (COOCH3, E + Z).a LRESI-MS: m/z 763; 765; 767
[M+Na]+

79

Br79Br;

79

Br81Br;

81

Br81Br.

HRESI-MS:

C33H33N4O679Br81Br [M-H]-: 741.0747; found 741.0779.
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8.1.5 Experimental for Chapters 5 and 6
8.1.5.1 Synthesis of Isatin-Protein Conjugates
Conjugation of (E and Z)-3-{4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin3-ylideneamino]phenyl}propanoic acid (155) to PAI-2
Preparation of the active ester (164)
O
O
N

N N
N

The propionic imine 155 (2.90 mg,
5.00 µmol) was dissolved in anh. DMF
(70 µL). On ice, HOBt (690 µg,

Br
O

5.10 µmol) in anh. DMF (17 µL) was

N
Br

added, followed by DCC (6.20 mg,
OCH 3
164

30.0 µmol) in anh. DMF (50 µL). The
orange reaction mixture was warmed to

RT, mixed for 30 min and used without purification. Rf 0.38 (silica, DCM).

Conjugation to PAI-2
A 20-fold molar excess of the active ester 164 (26.0 µL) was added to PAI-2 (474 µL
at 4.27 mg/mL) in PBS pH 8.5 and shaken at RT for 3 h. The reaction mixture was
then centrifuged at 13,000 rpm for 5 min to remove any precipitate. The conjugate
was purified by size-exclusion chromatography (PD-10 column), eluting with PBS
pH 7.4. Fractions containing the conjugate (determined by UV-Vis spectrophotometry
at λ 280 nm and 432 nm) were pooled and stored at 4 ºC for future studies. Protein
concentration was determined by the Lowry assay (see Section 8.2.7). Samples of
isatin-PAI-2 conjugate (165) (100 µL) were dialysed overnight in 10 mM NH4OAc
buffer in MilliQ H2O (2 × 2 L) prior to ESI-MS. The samples were analysed using a
Waters SynaptTM High Definition Mass Spectrometer (HDMS).
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Conjugation of (E and Z)-3-{4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin3-ylideneamino]phenyl}propanoic acid (155) to Tf
The conjugate 166 was prepared according to the method in Section 8.1.5.1 using a
20-fold molar excess of the active ester 164 (19.0 µL) and Tf (831 µL at
3.37 mg/mL). Protein concentration was determined by the Lowry assay (see Section
8.2.7).
Reducing the imine bond to an amine bond in the isatin-PAI-2 conjugate (165)
According to the method of Ding, et al.,286 NaBH4 (847 ng, 22.4 nmol) was added to
a solution of isatin-PAI-2 conjugate (165) (510 µg, 11.2 nmol at 1.46 mg/mL). The
reaction mixture was shaken at RT for 15 h before being dialysed against 0.05 M HCl
for 4 h and 10 mM NaOAc (× 2). Analysis by ESI-MS did not reveal the desired
amino product.

Reducing the imine bond to an amine bond in the isatin-Tf conjugate (166)
The method was the same as the above procedure, using NaBH4 (545 ng, 14.4 nmol)
and a solution of isatin-Tf conjugate (166) (579 µg, 7.19 nmol at 1.45 mg/mL).
Analysis by ESI-MS did not reveal the desired amino product.
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8.1.5.2 Other Molecules
Synthesis of 1-benzyl-1H-indole-2,3-dione (169)
4

This compound was prepared according to the method for 49

O
3a

using isatin (11) (200 mg, 1.36 mmol), NaH (76.0 mg,

O
7

7a

N1
1'

1''

3''

5''

169

1.90 mmol), KI (45.2 mg, 272 µmol) and benzyl bromide
(511 mg, 355 µL, 2.99 mmol) as starting materials. The reaction
mixture was heated at 75 °C for 18 h. The resulting solid was

purified by flash chromatography on silica gel (100% DCM) to yield 169 (212 mg,
66%) as orange crystals, m.p. 127-128 °C (lit.327 132-133 °C), Rf 0.32 (silica, DCM).
1

H MR (CDCl3, 500 MHz): δ 4.93 (s, 2H, H1’), 6.77 (d, J = 8.0 Hz, 1H, H4

or H7), 7.09 (t, J = 7.0 Hz, 1H, H5 or H6 ), 7.30-7.35 (m, 5H, ArH × 5), 7.48 (t,
J = 7.0 Hz, 1H, H5 or H6), 7.61 (d, J = 7.0 Hz, 1H, H4 or H7). The 1H NMR spectral
data coincided with those reported in the literature.327 LREI-MS: m/z 237 [M+].
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8.2 Biological Procedures
8.2.1 Cell Lines and Cell Culture Conditions
U937 (human, leukemic, monocyte-like, histolytic lymphoma), THP-1 (human,
acute monocytic leukemia) and MDA-MB-231 (human, metastatic breast
adenocarcinoma) cancer cells were obtained from American Type Culture Collection
(ATCC, VA, USA) distributed by Cryosite, NSW, Australia. Cells were regularly
cultured in vitro in culture medium consisting of RPMI-1640 medium, along with
2 mM L-glutamine, 5.6% (2 g/L) NaHCO3 and 5% foetal calf serum. The cells were
maintained in a Huracell incubator (Kendro Laboratory Products, Langenselbold,
Germany) at 37 °C with a humidified atmosphere containing 5% CO2. Viability of
the cells was determined by the trypan blue exclusion method and the number of
viable cells was counted with the aid of a haemocytometer. Light microscopy images
were obtained using a Leica DC500 12-megapixel high-performance FireWire
camera system (Leica Microsystems, AG, Germany) and the Leica IM50 image
manager software (Leica Microsystems AG, Heerbrugg, Germany).

8.2.2 MTS Cell Proliferation Assay
Cytotoxicity of the isatin derivatives was determined using the CellTiter 96®
AQueous One Solution Cell Proliferation Assay, utilising [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,

inner

salt]

(MTS) (Promega Co., Madison, WI, USA). Assays were performed in 96-well
microplates, consisting of: various dilutions of the test compounds dissolved in a
final concentration of 2.5% DMSO, a negative solvent control (2.5% DMSO) and
background controls (containing test compounds but no cells) (see Appendix).
Penicillin/streptomycin (1%) was added to assays containing protein samples (PAI-2
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or Tf). After incubating the test compounds and cells (1.0 x 104 cells/well) for 24 h at
37 °C in a 5% CO2 atmosphere, 20 µL of the CellTiter 96® AQueous One Solution
Reagent was added to each well and the assays were incubated at 37 °C for a further
3 h. Assays were read in a Spectromax 250 plate reader at 490 nm using Softmax Pro
software (Molecular Devices, USA). The IC50 values were determined from
sigmoidal dose-response curves (variable slope) using GraphPad Prism 5.00
(GraphPad Software, Inc., San Diego, CA, USA) and are the mean of triplicates of
at least two independent experiments.

8.2.3 Tubulin Polymerisation Assay
The in vitro tubulin polymerisation assay was obtained from Cytoskeleton Inc.
(Jomar Diagnostics, Australia) and the assay was conducted with reagents as described
by the manufacturer. Briefly, 5 µL of vehicle control, vinblastine (7), paclitaxel (8)
and compounds 26, 28, 36 and 37 at the desired concentrations were incubated with
50 µL of purified bovine neuronal tubulin reaction mix. The rate of polymerisation
was monitored kinetically for 1 h at 37 ºC using an excitation wavelength of
360±10 nm and fluorescence emission at 440±10 nm.

8.2.4 Hydrolysis Studies
Hydrolysis studies were performed on a Varian Cary 500 Scan UV-Vis-NIR
spectrophotometer with 1 cm path length disposable plastic cuvettes. Briefly, 9 µmol
of 153-157, 158-162 was dissolved in CH3CN/H2O 98.5:1.5 to yield a stock solution
of approximately 1 mM. Buffer solutions consisted of 1 M NaOAc adjusted to pH 4.5
and pH 5.3 and 1 M HEPES adjusted to pH 7.4. The pH values of the solutions were
measured using a pH Cube pH-mV-Temp Meter (TPS, Springwood, Australia). The
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final concentration within the cuvette consisted of stock solution/buffer/H2O 1:2:2.
All solutions were monitored kinetically at λ 435 nm for 4 h at either RT (23 ºC) or
37 ºC. For isatin-protein conjugates, 1 cm path length quartz microcuvettes (Starna
Pty Ltd., Baulkham Hills, Australia) were used. The pH values of these samples were
adjusted with 10 mM NaOAc buffer. The dependence of the absorption spectra
(measured at λ 435 nm) on time, expressed as A/A0 vs. t (where A = absorbance of the
sample and A0 = absorbance at time zero), was used to investigate the kinetics of
imine hydrolysis, with all measurements performed on at least two independent
occasions. The kinetic parameters k and t1/2 were derived by nonlinear regression
analysis of the ln (A/Ao) versus time plots using GraphPad Prism 5.00 (GraphPad
Software, Inc., San Diego, CA, USA), with one-way, repeated measures ANOVA
followed by a Tukey post-test to determine whether differences between data sets
were significant, with significance set at P < 0.05.

8.2.5 PKA Kinase Assays
PKA kinase inhibitory activity was determined using the Kinase Glo®
Luminescent Kinase Assay (Promega Co., Madison, WI, USA). Assays were
performed in white 96-well microtitre plates, consisting of: various dilutions of the
test compounds dissolved in 100% DMSO, a negative solvent control (containing
kinase enzyme and substrate) and a positive solvent control (containing kinase
enzyme and no substrate). ATP (25 µL) was added to all wells. After incubating the
plate at RT for 30 min, Kinase-Glo® Reagent (50 µL) was added to all wells and the
plate was incubated for a further 30 min at RT. Assays were read on a FLUOstar
Optima® Luminometer (BMG Labtech Pty. Ltd., Mornington, Australia).
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8.2.6 DNA Intercalation Studies
The DNA used was Rt1, with a length of 16 base pairs, the sequence d(CTC
GTC CGA TTC GAT C)•d(GAT CGA ATC GGA CGA G) and a mass of 9763.5 Da.
Compounds to be tested were dissolved in CH3CN to yield a 1 mM stock solution. To
prepare the samples for analysis, 5 µL of the drug from the stock solution was
aliquoted and evaporated before the addition of 79 µL of 100 mM NH4OAc. 1 µL of
1 mM double stranded DNA Rt1 in 100 mM NH4OAc was added to the sample and it
was sonicated for 5 min. A further 120 µL of 100 mM NH4OAc was added to the
sample prior to analysis. (The final solutions contained 5 µM DNA and 25 µM of
drug). The samples were analysed by ESI-MS (-ve) on a Waters Q-TOF Ultima mass
spectrometer at a speed of 20 µL/min, at 100 cone volts and a source temperature of
30 ºC.
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8.2.7 Protein Concentration Assay (Lowry Assay)
The BioRad® DC protein concentration assay kit (Bio-Rad Laboratories, Pty.
Ltd., Gladesville, Australia) was employed to determine the protein concentration of
samples. Bovine serum albumin standards (5 µL) ranging from 0-1000 µg/mL and
protein samples of unknown concentration (5 µL) were added in duplicate to wells in
a 96-well microtitre plate. Reagent A (25 µL) and Reagent B (200 µL) were added to
each well and the plate was incubated at RT for 15 min before the absorbance was
measured at 750 nm using the Spectromax® 250 UV plate reader (Molecular Devices,
Sunnyvale, CA, USA). A standard curve was generated using the Softmax Pro®
(Molecular Devices, Sunnyvale, CA, USA) software to calculate protein
concentration.
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Abstract—A range of N-phenethyl, N-phenacyl, and N-(1- and 2-naphthylmethyl) derivatives of 5,7-dibromoisatin 2 were prepared by Nalkylation reactions. Their activity against human monocyte-like histiocytic lymphoma (U937), leukemia (Jurkat), and breast carcinoma
(MDA-MB-231) cell lines was assessed. The results allowed further development of structure–activity relationships. The compound 5,7dibromo-N-(1-naphthylmethyl)-1H-indole-2,3-dione 5a was the most potent against U937 cells with an IC50 value of 0.19 lM.
 2007 Elsevier Ltd. All rights reserved.

1. Introduction
Isatin (1H-indole-2,3-dione) 1 is a synthetically versatile
molecule which has led to an array of derivatives displaying a broad spectrum of biological properties
including anti-cancer activities.1–5 Recently, it has been
reported that 5,7-dibromoisatin 2 is signiﬁcantly more
potent in vitro as a cytotoxin than the parent molecule
against U937 (human monocyte-like histiocytic lymphoma) cells.6 Other research within our laboratory
has indicated that N-benzylation of 5,7-dibromoisatin
2 further increased the cytotoxicity toward these lymphoma cells and was potent against a range of human
cancer cell lines including a metastatic breast adenocarcinoma cell line (MDA-MB-231).7 In this context, it was
of interest to further investigate the cytotoxicity of Nalkylated 5,7-dibromoisatin analogues by altering the
chain length between N-1 and the aryl group, as well
as increasing the hydrophobicity of the N-substituent
through an extra aromatic ring fusion. Together with
this, in vitro screening against various cancer cell lines
was carried out in order to establish a more comprehensive structure–activity relationship (SAR). The results
are described in this paper.

Keywords: Isatins; Cytotoxins; Cancer; Tubulin polymerization
inhibitors.
* Corresponding author. Tel.: +61 2 4221 4334; fax: +61 2 4221
4287; e-mail: lm66@uow.edu.au
0968-0896/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2007.12.026

2. Results and discussion
2.1. Chemistry
In order to determine the structural requirements necessary for cytotoxicity, a simple modiﬁcation to 2 was
envisaged with a two-atom linker bridge between the
nitrogen and a new aromatic ring, producing N-phenethyl derivatives 4a–e. The phenethyl scaﬀold was also
modiﬁed by introduction of another aromatic ring fusion which subsumed the benzylic methylene group in
the new ring, to aﬀord the 1-naphthylmethyl derivative
5a. The 2-naphthylmethyl analogue 5b was also synthesized for comparative purposes. With a view to assessing
the hydrophobicity requirements, N-phenacyl derivatives 6a–e of 5,7-dibromoisatin 2 were also investigated.
The procedure for the synthesis of the N-phenethyl
derivatives 4a–e was based on a combination of the literature methods.8–10 Brieﬂy, 2 was treated with a base
such as NaH or K2CO3 which formed an intense purple
colored anion (A) that was subsequently reacted with
the appropriate aryl alkyl halide 3a–e to give the
N-phenethyl derivatives 4a–e in moderate yields

L. Matesic et al. / Bioorg. Med. Chem. 16 (2008) 3118–3124

(Scheme 1). High temperatures are usually required in
these syntheses to drive the reactions to completion because the reaction mixtures are prone to crystallization
of the impure product at low temperatures.8 N-Benzylisatin derivatives had been obtained previously by heating at 80 C,7 however a temperature of 50 C was
used to produce 4a–e to reduce the risk of substituted
styrenes forming as side products from the base catalyzed elimination of the phenethyl bromides 3a–e. The
isatin intermediate (A) is also an ambidentate anion
which could undergo N- or O-alkylation,11 however
no evidence for O-alkylation was found through 1H
and 13C NMR spectroscopic studies.

3119

Table 1. Initial cytotoxicity screening (IC50 lM) of novel N-substituted isatin derivatives 4a–e, 5a–b, and 6a–ea
Compound
2
4a
4b
4c
4d
4e
5a
5b
6a
6b
6c
6d
6e
Vinblastine

U937b
e

10.5
0.78
0.78
0.88
1.07
2.35
0.19
0.74
9.97
6.36
9.18
4.70
5.32
6.88g

Jurkatc
e

14.3
1.52
1.21
1.15
2.00
2.66
0.91
0.41
ntf
nt
nt
nt
nt
nt

MDA-MB-231d
42.3e
4.35
2.72
2.01
5.24
4.51
2.49
2.56
nt
nt
nt
nt
nt
nt

a

The N-naphthylmethyl analogues 5a and 5b were prepared in a similar manner to the N-phenethyl series
4a–e, however, the synthesis of the N-phenacyl derivatives 6a–e proved diﬃcult. Attempts to synthesize these
compounds included various alkylation protocols and
protecting group strategies. A possible competing reaction was a Darzens condensation involving the C3 carbonyl group of the isatin 2. While the Darzens
condensation occurs when a ketone or aldehyde reacts
with a haloester to form an epoxy ester, it also proceeds
with halogenomethylsulfones and halogenoketones such
as phenacyl halides.12 It has been reported that phenacyl
halides preferentially yield a Darzens product rather
than the corresponding phenacylisatin,13 although in
the current study this was not observed in the NMR
spectra. The desired compounds 6a–e were obtained in
a pure form but in low yields, which were not optimized
as the required compounds were obtained in suﬃcient
quantity for cytotoxicity screening.

Values are means of triplicates of at least two independent
experiments.
b
Human monocyte-like histiocytic lymphoma cell line.
c
Human leukemic T-cell line.
d
Human metastatic mammary gland adenocarcinoma cell line.
e
Vine et al.6
f
Not tested.
g
Vine et al.7

2.2. Cytotoxic activity and SAR
The N-phenethyl 4a–e and N-naphthylmethyl derivatives 5a–b were initially tested for cytotoxicity using
the MTS cell proliferation assay against three human
cancer cell lines including a lymphoma (U937), leukemia
(Jurkat), and metastatic breast adenocarcinoma cell line
(MDA-MB-231). The results showed that the cytotoxicity of the parent molecule 2 signiﬁcantly increased
through N-alkylation (Table 1), as reported previously
for the 5,7-dibromo-N-benzylisatin derivatives.7 Compounds 4a–e, which contain a two-carbon linker at the
nitrogen, typically increased the anti-proliferative activity 10- to 15-fold against the three tumor cell lines compared to that of the parent brominated isatin 2. Three of
the N-phenethyl derivatives, 4a–c, displayed IC50 values
in the sub-micromolar range against U937 cells (e.g., 4a,
IC50 = 0.78 lM, Table 1). Introduction of a hydrophobic bromo substituent in the meta (4b) or para (4c) position yielded the most active compounds in this series,
while analogous compounds containing methoxy substituents 4d–e were less cytotoxic. The introduction of
a substituent in the meta position (4b and 4d) enhanced

Scheme 1. Reagents and conditions: (a) NaH or K2CO3, DMF, 4 C–rt, 20 min to 3 h; (b) KI, 50 C, 18 h (32–62%).
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Table 2. Further cytotoxicity screening (IC50 lM) of derivatives 4b–c
and 5a–b against a panel of human adherent tumor cell linesa
Compound

HCT-116b

PC-3c

MCF-7d

A375e

4b
4c
5a
5b

1.41
1.62
1.15
1.51

2.09
2.21
1.44
2.29

4.04
6.02
7.71
3.50

3.44
4.34
3.95
6.56

a

Values are means of triplicates of at least two independent
experiments.
b
Human colorectal carcinoma cell line.
c
Human prostate adenocarcinoma cell line.
d
Human non-metastatic mammary gland adenocarcinoma cell line.
e
Human malignant melanoma cell line.

cytotoxicity against the U937 and Jurkat cell lines compared to the para position (4c and 4e) although this
trend was not observed against the MDA-MB-231 cell
line. Overall, the U937 lymphoma cell line appeared to
be the most susceptible to treatment with the N-phenethylisatins 4a–e, while the metastatic MDA-MB-231 cell
line was the least susceptible.
The N-naphthylmethylisatins 5a and 5b demonstrated
enhanced cytotoxic activity against the lymphoma
(U937) and leukemia (Jurkat) cell lines compared to
the N-phenethyl derivatives 4a–e. Both 5a and 5b exhibited sub-micromolar IC50 values against these two cell
lines, and were the only compounds to do so against Jurkat cells. Compound 5a was the most cytotoxic of all
those tested, with an IC50 value of 0.19 lM against
U937 cells. This compound was four times more potent
against U937 cells than the lead N-phenethyl compounds 4a and 4b.
The most active analogue in the N-phenacyl series was
6d, which exhibited an IC50 value of 4.70 lM against
U937 cells. The parent phenacyl derivative 6a was the
least active of the series with an IC50 value of 9.97 lM
(Table 1). This suggests that the presence of the polar
carbonyl group is detrimental to activity. Since the Nphenacylisatins 6a–e were less active than the N-phenethyl 4a–e and N-naphthylmethyl 5a–b series, they were
not tested against any other cell lines.
The four most potent derivatives, 4b, 4c, 5a, and 5b,
(Table 1) were selected for further cytotoxic screening
against a panel of other adherent human tumor cell
lines: colorectal (HCT-116), prostate (PC-3), non-metastatic breast (MCF-7), and melanoma (A375). The results in Table 2 indicate that activity against the panel
of adherent cell lines varied but all compounds tested
had IC50 values in the low micromolar range. The lower
sensitivity in these adherent cell lines compared to the
non-adherent cell lines may be due to reduced cell surface areas leading to decreased drug uptake as well as
slower proliferation rates in the former.

Figure 1. Elongated U937 cell morphology after treatment with
various isatin derivatives. Cells were incubated for 24 h with (A)
DMSO vehicle control, (B) 5,7-dibromo-N-(2-naphthylmethyl)isatin
5b (0.39 lg/mL), and (C) vinblastine sulfate (0.39 lg/mL). Magniﬁcation: 1000·.

to undergo elongation. The elongated morphology was
more pronounced when the cells were treated with Nnaphthylmethyl derivatives 5a and 5b (Fig. 1B). This
morphological change was also observed in U937 cells
treated with vinblastine (Fig. 1C), a microtubule destabilizer. This suggested that these isatin analogues interfere with microtubule dynamics in a similar fashion to
previously
reported
5,7-dibromo-N-benzylisatin
derivatives.7
To further investigate the eﬀects of the aforementioned
analogues on microtubule formation, a cell-free
in vitro tubulin polymerization assay was performed
(Fig. 2). The two naphthyl derivatives 5a and 5b were
chosen due to their in vitro potency against U937 and
Jurkat cells, as well as two representative phenethyl
compounds, 4a and 4c. Vinblastine sulfate and paclitaxel were used as a known microtubule destabilizer
and stabilizer, respectively. Consistent with the literature reports,14,15 at 10 lM paclitaxel stabilized microtubules, while vinblastine sulfate was a potent microtubule
destabilizer (Fig. 2). The test compounds, in particular

2.3. Mode of action studies
While performing in vitro cytotoxicity testing, it was observed that the isatin derivatives 4a–e, 5a–b, and 6a–e
caused the U937 and, to a lesser extent, the Jurkat cells

Figure 2. Eﬀect of compounds 4a,4c, 5a, 5b, paclitaxel, and vinblastine
sulfate at 10 lM on the assembly of puriﬁed bovine neuronal tubulin.
DMSO was used as a control.
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Figure 3. Eﬀect of varying concentrations of the 2-naphthylmethyl
derivative 5b on the assembly of puriﬁed bovine neuronal tubulin.
DMSO was used as a control.
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(A375) tumor cell lines. Cytotoxicity testing showed that
5,7-dibromo-N-(1-naphthylmethyl)isatin 5a was the
most active compound against all of the cell lines tested
and exhibited an IC50 value of 0.19 lM against U937
cells. The N-phenethyl derivatives 4a–c also showed potent sub-micromolar activity against U937 cells. Additionally, the tumor cells displayed elongated cell
morphology upon treatment with these compounds,
suggesting that these analogues interfere with microtubule dynamics. The results described indicate that these
compounds could serve as the basis for the development
of a new group of cancer chemotherapeutics.
4. Experimental

Table 3. Inhibition of tubulin polymerization (IC50 lM) of compounds 4a, 5a, 5b and vinblastine at varying time pointsa

a

Compound

20 min

60 min

4a
5a
5b
Vinblastine

4.04
4.71
2.87
0.95

6.60
12.0
6.47
1.66

Values are means of duplicates in one experiment.

the 2-naphthyl derivative 5b, appeared to be potent
microtubule destabilizers at 10 lM (Fig. 2), as observed
by the shift of the curve to the right of the control, indicating a decrease in the rate of tubulin polymerization.
These results are consistent with reports that structurally similar indole16–18 and indolinone7,15,19 compounds
inhibit tubulin polymerization.
The three most potent destabilizers, 4a, 5a, and 5b, were
chosen for further studies on tubulin polymerization. All
of these compounds inhibited the rate of tubulin polymerization in a dose-dependent manner (representative
result shown in Fig. 3) and the IC50 values are reported
in Table 3. Vinblastine displayed similar inhibition in
this assay to that reported previously.20
It was of interest to note that in Figure 3, the test compound 5b displayed potent destabilizing eﬀects at higher
concentrations (as seen by the shift in the curves to the
right of the DMSO control) and stabilized microtubules
at lower concentrations (as seen by the shift in the curves
to the left of the DMSO control). This phenomenon has
also been reported in the case of vinblastine14 and suggests that these compounds may bind to more than
one binding site on tubulin with diﬀerent aﬃnities.
3. Conclusions
A number of N-phenethyl, N-phenacyl, and N-naphthylmethyl derivatives of 5,7-dibromoisatin 2 were synthesized and tested against a range of human cancer cell
lines. These compounds displayed greater cytotoxicity
against non-adherent U937 and Jurkat cells compared
to adherent human breast (MDA-MB-231 and MCF7), colon (HCT-116), prostate (PC-3), and melanoma

4.1. General
4.1.1. Chemistry. All solvents were of AR grade except
dichloromethane (DCM) which was of LR grade and
distilled before use. The term petroleum spirit (PS) refers
to petroleum spirit with a boiling range of 40–60 C.
Solvent removal was performed (in vacuo) using temperatures not greater than 60 C. Organic halides were
purchased from Sigma–Aldrich Chemical Co. and used
as supplied. Sodium hydride was supplied as a 60% dispersion in mineral oil and masses used were calculated
appropriately. Melting points were obtained using a
Reichert melting point apparatus and are uncorrected.
Thin-layer chromatography (TLC) on aluminum
backed sheets of Merck Silica Gel 60 F254 plates was employed to monitor the progress of chemical reactions.
Preparative TLC was performed on 20 · 20 cm plates.
Generally, the isatins were highly colored and visible
on the TLC plate; colorless compounds were detected
by exposure to UV light at k 254 nm. Column chromatography was performed under ‘ﬂash’ conditions21 on
silica gel 60 (230–400 mesh). The solvent used in individual chromatographic experiments is indicated and all
solvent proportions are given as vol/vol ratios. NMR
spectra were acquired on a Varian Unity 300 MHz spectrometer, where proton (1H) and carbon (13C) spectra
were obtained at 300 MHz and 75 MHz, respectively,
or on a Varian Inova 500 spectrometer, where the 1H
and 13C were obtained at 500 MHz and 126 MHz,
respectively. All spectra were obtained with a probe temperature of 298 K. Spectra were recorded in CDCl3 (unless otherwise indicated) and were referenced to the
residual non-deuterated solvent signal or TMS. Hydrogen and carbon assignments were also made using gradient correlation spectroscopy (gCOSY), gradient
heteronuclear single quantum correlation (gHSQC),
and gradient heteronuclear multiple bond correlation
(gHMBC) spectroscopic techniques. The superscript letter a denotes coincident peaks. Low resolution electron
ionization mass spectra (LREI-MS) were obtained using
a Shimadzu QP5050 spectrometer. High resolution electron ionization mass spectra (HREI-MS) were obtained
using a Fisons/VG Autospec spectrometer operating
with an electron beam of 70 eV, with a source temperature of 250 C and perﬂuorokerosene (PFK) as the internal standard. Compounds for testing were >95% pure
on the basis of TLC and 1H NMR analysis.
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4.1.2. Cell biology. All cancer cell lines were obtained
from the American Type Culture Collection (ATCC,
VA, USA). Cells were routinely maintained in RPMI1640 medium, containing 2 mM L -glutamine, 5.6%
(2 g/L) sodium bicarbonate, and 5% fetal calf serum
(FCS) (at 37 C 95% humidiﬁed atmosphere and 5%
CO2). Adherent cells were detached with sterile trypsin–EDTA, washed with culture media, and reseeded
following centrifugation for 5 min at 1600 rpm. The
number of viable cells was counted with the aid of a
hemocytometer and Trypan blue staining. Cytotoxicity
of the isatin derivatives was determined using the CellTiter 96 AQueous One Solution Cell Proliferation Assay,
utilizing [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner
salt] (MTS) (Promega Co., Madison, WI, USA) as described previously.6,7 The inhibitory concentration required to inhibit 50% of the metabolic activity of the
cell population (IC50) was calculated from sigmoidal
dose–response curves using GraphPad Prism 5.00
(GraphPad Software Inc.). Cell images were obtained
by brightﬁeld microscopy on an inverted light microscope using a Leica DC500 12-megapixel high-performance FireWire camera system. The in vitro tubulin
polymerization assay was obtained from Cytoskeleton
Inc. (Jomar Diagnostics, Australia) and the assay was
conducted with reagents as described by the manufacturer. Brieﬂy, 5 lL of vehicle control, paclitaxel, vinblastine sulfate, and compounds 4a, 4c, 5a, and 5b at the
desired concentrations were incubated with 50 lL of
puriﬁed bovine neuronal tubulin reaction mix. The rate
of polymerization was monitored kinetically for 1 h at
37 C using an excitation wavelength of 360 ± 10 nm
and ﬂuorescence emission at 440 ± 10 nm.
4.2. Chemistry
4.2.1. 5,7-Dibromoisatin (2)6. Yield: 2.90 g, (28%) as
bright red/orange needles, mp 251–253 C (lit.22 248–
250 C), Rf 0.63 (silica, DCM/MeOH, 9:1). 1H NMR
(DMSO-d6, 500 MHz): d 7.66 (d, J = 1.5 Hz, 1 H, H4),
8.02 (d, J = 1.5 Hz, 1H, H6), 11.43 (br s, 1H, NH). 13C
NMR (DMSO-d6, 126 MHz): d 105.7, 114.5, 121.3,
125.9, 141.1, 148.6, 159.4, 182.5. LREI-MS: m/z 303;
305; 307 [M+]79Br79Br; 79Br81Br; 81Br81Br.
4.2.2. 5,7-Dibromo-1-phenethyl-1H-indole-2,3-dione (4a).
A mixture of 5,7-dibromoisatin 2 (200 mg, 0.66 mmol)
and K2CO3 (128 mg, 0.92 mmol) or NaH (36.8 mg,
0.92 mmol) was dissolved in anhydrous DMF (4 mL)
and stirred under nitrogen at 4 C for 3 h (or 20 min
at rt for NaH) before the addition of KI (22.0 mg,
0.13 mmol) and (2-bromoethyl)benzene 3a (270 mg,
0.2 mL, 1.46 mmol). The reaction mixture was heated
at 50 C and stirred at this temperature for 18 h. To
the resulting solution were added water (80 mL) and
1 M HCl (2 mL) to acidify to pH 1. The suspension
was ﬁltered and the precipitate washed with water.
The resulting solid was puriﬁed by ﬂash chromatography on silica gel (CHCl3) to yield 4a (86.3 mg, 32%) as
bright red crystals, mp 165–168 C, Rf 0.71 (silica,
DCM). 1H NMR (500 MHz): d 3.03 (t, J = 8 Hz, 2H,
H2 0 ), 4.39 (t, J = 8 Hz, 2H, H1 0 ), 7.30 (m, 5H, H200 –

H600 ), 7.69 (d, J = 1.5 Hz, 1H, H4), 7.89 (d, J = 1.5 Hz,
1H, H6). 13C NMR (126 MHz): d 35.0, 42.4, 104.5,
116.6, 121.1, 126.7, 127.2, 128.4a, 128.6a, 136.7, 144.8,
146.4, 157.5, 181.1. HREI-MS: m/z calcd for
C16H11NO279Br79Br [M+]: 406.9157; found: 406.9166.
4.2.3. 5,7-Dibromo-1-[2-(3-bromophenyl)ethyl]-1H-indole2,3-dione (4b). The compound was prepared according to
the method for 4a using 5,7-dibromoisatin 2 (100 mg,
0.33 mmol) and 3-bromophenethyl bromide 3b (193 mg,
0.11 mL, 0.73 mmol) as starting materials. The resulting
solid was puriﬁed by ﬂash chromatography on silica gel
(DCM) to yield 4b (67.1 mg, 42%) as bright red/orange
crystals, mp 188–190 C, Rf 0.54 (silica, DCM). 1H NMR
(acetone-d6, 500 MHz): d 3.09 (t, J = 8 Hz, 2H, H2 0 ),
4.38 (t, J = 8 Hz, 2H, H1 0 ), 7.27 (t, J = 8 Hz, 1H, H500 ),
7.34 (d, J = 8 Hz, 1H, H600 ), 7.42 (d, J = 8 Hz, 1H, H400 ),
7.51 (s, 1H, H200 ), 7.72 (d, J = 1.5 Hz, 1H, H4), 8.06 (d,
J = 1.5 Hz, 1H, H6). 13C NMR (acetone-d6, 126 MHz): d
34.9, 42.4, 104.7, 110.0, 116.0, 122.3, 126.8, 128.2, 130.0,
130.8, 132.0, 140.9, 144.4, 147.5, 158.4, 181.6. HREI-MS:
m/z calcd for C16H10NO279Br81Br81Br [M+]: 488.8221;
found: 488.8207.
4.2.4. 5,7-Dibromo-1-[2-(4-bromophenyl)ethyl]-1H-indole2,3-dione (4c). The compound was prepared according to
the method for 4a using 5,7-dibromoisatin 2 (100 mg,
0.33 mmol) and 4-bromophenethyl bromide 3c (193 mg,
0.11 mL, 0.73 mmol) as starting materials. The resulting
solid was puriﬁed by ﬂash chromatography on silica gel
(CHCl3) to yield 4c (81.1 mg, 50%) as bright red crystals,
mp 189–190 C, Rf 0.48 (silica, DCM). 1H NMR
(300 MHz): d 2.99 (t, J = 8.4 Hz, 2H, H2 0 ), 4.35 (t,
J = 8.4 Hz, 2H, H1 0 ), 7.13 (d, J = 8.7 Hz, 2H, H200 , H600 ),
7.42 (d, J = 8.7 Hz, 2H, H300 , H500 ), 7.69 (d, J = 1.8 Hz,
1H, H4), 7.89 (d, J = 1.8 Hz, 1H, H6). 13C NMR
(126 MHz): d 35.1, 42.6, 104.9, 117.3, 121.2, 121.6, 127.9,
130.8a, 132.1a, 136.2, 145.4, 146.8, 158.0, 181.4. HREIMS: m/z calcd for C16H10NO279Br81Br81Br [M+]:
488.8221; found: 488.8214.
4.2.5. 5,7-Dibromo-1-[2-(3-methoxyphenyl)ethyl]-1H-indole2,3-dione (4d). The compound was prepared according to
the method for 4a using 5,7-dibromoisatin 2 (100 mg,
0.33 mmol) and 3-methoxyphenethyl bromide 3d
(157 mg, 0.11 mL, 0.73 mmol) as starting materials. The
resulting solid was puriﬁed by ﬂash chromatography on
silica gel (DCM) to yield 4d (65.0 mg, 45%) as bright
red/orange crystals, mp 179–180 C, Rf 0.56 (silica,
DCM). 1H NMR (500 MHz): d 3.00 (t, J = 8 Hz, 2H,
H2 0 ), 3.79 (s, 3H, OCH3), 4.38 (t, J = 8 Hz, 2H, H1 0 ),
6.76 (d, J = 7.5 Hz, 1H, H400 ), 6.80 (s, 1H, H200 ), 6.84 (d,
J = 7.5 Hz, 1H, H600 ), 7.22 (t, J = 7.5 Hz, 1H, H500 ), 7.69
(d, J = 2 Hz, 1H, H4), 7.89 (d, J = 2 Hz, 1H, H6). 13C
NMR (126 MHz): d 35.3, 42.6, 55.2, 104.8, 112.2, 114.8,
116.9, 121.2, 121.4, 127.5, 129.8, 138.5, 145.1, 146.7,
157.8, 159.8, 181.3. HREI-MS: m/z calcd for
C17H13NO3 79Br81Br [M+]: 438.9242; found: 438.9244.
4.2.6. 5,7-Dibromo-1-[2-(4-methoxyphenyl)ethyl]-1H-indole2,3-dione (4e). The compound was prepared according to
the method for 4a using 5,7-dibromoisatin 2 (100 mg,
0.33 mmol) and 4-methoxyphenethyl bromide 3e
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(157 mg, 0.11 mL, 0.73 mmol) as starting materials. The
resulting solid was puriﬁed by ﬂash chromatography on
silica gel (CHCl3) to yield 4e (89.5 mg, 62%) as bright
red/orange crystals, mp 176–178 C, Rf 0.53 (silica,
DCM). 1H NMR (500 MHz): d 2.96 (t, J = 8 Hz, 2H,
H2 0 ), 3.78 (s, 3H, OCH3), 4.34 (t, J = 8 Hz, 2H, H1 0 ),
6.83 (d, J = 8.5 Hz, 2H, H300 , H500 ), 7.16 (d, J = 8.5 Hz,
2H, H200 , H600 ), 7.68 (d, J = 2 Hz, 1H, H4), 7.89 (d,
J = 2 Hz, 1H, H6). 13C NMR (126 MHz): d 34.7, 43.1,
55.5, 105.0, 114.4a, 117.1, 121.6, 127.8, 129.2, 130.1a,
145.3, 147.0, 158.1, 158.8, 181.6. HREI-MS: m/z calcd
for C17H13NO3 79Br81Br [M+]: 438.9242; found:
438.9241.
4.2.7. 5,7-Dibromo-1-(1-naphthylmethyl)-1H-indole-2,3dione (5a). A mixture of 5,7-dibromoisatin 2 (101 mg,
0.33 mmol) and NaH (18.0 mg, 0.46 mmol) was dissolved in anhydrous DMF (2.5 mL) and stirred under
nitrogen at rt for 20 min before the addition of KI
(11.0 mg, 0.066 mmol) and 1-chloromethylnaphthalene
(128 mg, 0.11 mL, 0.73 mmol). The reaction mixture
was heated at 60 C and stirred at this temperature for
19 h. After cooling, ethyl acetate (50 mL) was added
and the resulting solution was extracted with 0.5 M
HCl (50 mL) followed by brine (50 mL). The orange organic layer was dried over MgSO4 and the solvent was
removed to yield a sticky red/orange residue. The resulting solid was puriﬁed by ﬂash chromatography on silica
gel [DCM/PS (3:2)] to yield 5a (90.8 mg, 62%) as dark
red crystals, mp 218–219 C, Rf 0.35 (silica, DCM). 1H
NMR (500 MHz): d 5.81 (s, 2H, H1 0 ), 7.06 (d, J = 7 Hz,
1H, H200 ), 7.34 (t, J = 7.5 Hz, 1H, H300 ), 7.53 (t, J = 7 Hz,
1H, H600 ), 7.58 (t, J = 7 Hz, 1H, H700 ), 7.76 (m, 3H, H4,
H6, H400 ) 7.88 (d, J = 8.5 Hz, 1H, H500 ), 7.93 (d,
J = 8.5 Hz, 1H, H800 ). 13C NMR (126 MHz): d 42.8,
105.5, 117.1, 121.3, 121.4, 122.1, 125.3, 126.0, 126.6,
127.5, 128.0, 129.0, 129.8, 130.7, 133.8, 145.3, 146.8,
158.1, 181.2. HREI-MS: m/z calcd for C19H11NO279Br81Br
[M+]: 444.9136; found: 444.9131.
4.2.8. 5,7-Dibromo-1-(2-naphthylmethyl)-1H-indole-2,3dione (5b). The compound was prepared according to
the method for 5a using 5,7-dibromoisatin 2 (50.5 mg,
0.16 mmol) and 2-bromomethylnaphthalene (80.1 mg,
0.36 mmol) as starting materials. The resulting red solid
was puriﬁed by ﬂash chromatography on silica gel
[DCM/PS (3:2)] to yield 5b (46.6 mg, 64%) as dark red
crystals, mp 140–142 C, Rf 0.58 (silica, DCM). 1H
NMR (500 MHz): d 5.56 (s, 2H, H1 0 ), 7.36 (dd,
J = 2 Hz, 8 Hz, 1H, H300 ), 7.47 (m, 2H, ArH · 2), 7.63
(s, 1H, H100 ), 7.74 (d, J = 2 Hz, 1H, H4), 7.76 (m, 1H,
ArH), 7.79 (d, J = 2 Hz, 1H, H6), 7.81 (m, 2H,
ArH · 2). 13C NMR (126 MHz): d 45.1, 105.5, 117.5,
121.7, 124.6, 125.3, 126.4, 126.7, 127.8, 128.0, 128.0,
129.1, 133.0, 133.3, 133.5, 145.6, 147.0, 158.6, 181.5.
HRMS: m/z calcd for C19H11NO279Br81Br [M+]:
444.9136; found: 444.9135.
4.2.9. 5,7-Dibromo-1-(2-oxo-2-phenylethyl)-1H-indole2,3-dione (6a). A mixture of KI (113 mg, 0.68 mmol)
and phenacyl bromide (68.0 mg, 0.34 mmol) was dissolved in anhydrous DMF (0.5 mL) and stirred at
5 C under nitrogen for 5 h, followed by cooling in a
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freezer at 18 C for 20 h.23 A mixture of the 5,7-dibromoisatin 2 (103 mg, 0.34 mmol) and K2CO3 (47.0 mg,
0.34 mmol) or NaH (13.7 mg, 0.34 mmol) was dissolved
in anhydrous DMF (5 mL) and stirred under nitrogen at
4 C for 3 h. This anion solution was added in portions
(0.5 mL) to the phenacyl iodide maintained at 2 C
such that each portion had reacted before the addition
of the next portion (monitored by TLC). The yellow/
brown reaction mixture was stirred at rt for 25 h but
no change in color intensity was observed after 2 h. To
the resulting solution were added water (60 mL) and
1 M HCl (2 mL) to acidify to pH 1. The suspension
was ﬁltered and the precipitate washed with water.
The resulting solid was puriﬁed by ﬂash chromatography on silica gel (DCM) to yield 6a (13.5 mg, 9%) as
bright red/orange crystals, mp 173–175 C, Rf 0.58 (silica, DCM). 1H NMR (500 MHz): d 5.64 (s, 2H, H1 0 ),
7.54 (t, J = 7.5 Hz, 2H, H300 , H500 ), 7.67 (t, J = 7.5 Hz,
1H, H400 ), 7.75 (d, J = 2 Hz, 1H, H4), 7.80 (d,
J = 2 Hz, 1H, H6), 8.00 (d, J = 7.5 Hz, 2H, H200 , H600 ).
13
C NMR (126 MHz): d 48.2, 105.4, 117.1, 121.3,
126.5, 127.6, 128.3a, 129.1a, 134.4, 144.8, 146.9, 158.2,
180.8, 191.3. HREI-MS: m/z calcd for C16H9NO3
79
Br81Br [M+]: 422.8929; found: 422.8928.
4.2.10. 5,7-Dibromo-1-[2-(3-bromophenyl)-2-oxo-ethyl]1H-indole-2,3-dione (6b). This compound was prepared
according to the method for 6a using 5,7-dibromoisatin
2 (305 mg, 1.00 mmol) and 3-bromophenacyl bromide
(278 mg, 1.00 mmol) as starting materials. The reaction
mixture was stirred at 100 C for 16 h.24 The resulting
solid was puriﬁed by ﬂash chromatography on silica
gel (DCM) and subsequent preparative TLC (silica,
DCM) to yield 6b (10.6 mg, 2%) as bright red/orange
crystals, mp 160–162 C, Rf 0.54 (silica, DCM). 1H
NMR (500 MHz): d 5.60 (s, 2H, H1 0 ), 7.44 (t, J = 8 Hz,
1H, H500 ), 7.77 (d, J = 2 Hz, 1H, H4), 7.80 (d, J = 8.5 Hz,
1H, H400 ), 7.81 (d, J = 2 Hz, 1H, H6), 7.93 (d, J = 8.5 Hz,
1H, H600 ), 8.13 (s, 1H, H200 ). 13C NMR (126 MHz): d
48.0, 105.3, 117.3, 121.3, 123.5, 126.6, 127.7, 130.7, 131.2,
135.4, 137.3, 144.8, 146.6, 158.0, 180.6, 190.2. HREI-MS:
m/z calcd for C16H8NO3 79Br79Br81Br [M+]: 500.8034;
found: 500.8037.
4.2.11. 5,7-Dibromo-1-[2-(4-bromophenyl)-2-oxo-ethyl]1H-indole-2,3-dione (6c). 5,7-Dibromoisatin 2(153 mg,
0.5 mmol) and NaH (20.0 mg, 0.5 mmol) were dissolved
in anhydrous DMF (1.25 mL) and stirred at rt under
nitrogen for 20 min before the addition of freshly distilled
trimethylsilyl chloride (81.0 mg, 0.095 mL, 1.5 mmol).25
The reaction mixture was heated at 50 C and stirred at
this temperature for 1 h before the addition of 4-bromophenacyl bromide (139 mg, 0.5 mmol) and further heating at 100 C for 1.5 h. Upon cooling, water (15 mL) was
added, the suspension was ﬁltered, and the precipitate
washed with hot water (90 C) to yield a rust colored compound. The product was recrystallized from glacial
AcOH, ﬁltered, and washed with ice cold water to yield
6c (11.2 mg, 5%) as a light yellow powder, mp 184–
186 C, Rf 0.65 (silica, DCM). 1H NMR (500 MHz): d
5.60 (s, 2H, H1 0 ), 7.70 (d, J = 8.5 Hz, 2H, H300 , H500 ),
7.76 (d, J = 2 Hz, 1H, H4), 7.80 (d, J = 2 Hz, 1H, H6),
7.87 (d, J = 8.5 Hz, 2H, H200 , H600 ). 13C NMR
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(126 MHz): d 47.9, 105.3, 117.2, 121.3, 127.6, 129.6a,
129.8, 132.5a, 132.5, 144.7, 146.7, 158.1, 180.7, 190.4.
HREI-MS: m/z calcd for C16H8NO3 79Br81Br81Br [M+]:
502.8013; found: 502.8007.
4.2.12. 5,7-Dibromo-1-[2-(3-methoxyphenyl)-2-oxo-ethyl]1H-indole 2,3-dione (6d). This compound was prepared
according to the method for 6a using 5,7-dibromoisatin 2
(306 mg, 1.00 mmol) and 3-methoxyphenacyl bromide
(230 mg, 1.00 mmol) as starting materials.26 The resulting
solid was puriﬁed by ﬂash chromatography on silica gel
(DCM) to yield 6d (43.5 mg, 10%) as bright orange crystals,
m.p. 155–157 C, Rf 0.50 (silica, DCM). 1H NMR
(500 MHz): d 3.88 (s, 3H, OCH3), 5.62 (s, 2H, H1 0 ), 7.20
(d, J = 8 Hz, 1H, H400 ), 7.45 (t, J = 8 Hz, 1H, H500 ), 7.51
(s, 1H, H200 ), 7.58 (d, J = 8 Hz, 1H, H600 ), 7.75 (d,
J = 2 Hz, 1H, H4), 7.81 (d, J = 2 Hz, 1H, H6). 13C NMR
(75 MHz): d 48.1, 55.5, 105.4, 112.5, 117.1, 120.5, 120.7,
121.3, 127.5, 130.1, 135.0, 144.7, 146.9, 158.1, 160.1,
180.8, 191.2. HREI-MS: m/z calcd for C17H11NO4
79
Br79Br [M+]: 450.9055; found: 450.9048.
4.2.13. 5,7-Dibromo-1-[2-(4-methoxyphenyl)-2-oxo-ethyl]1H-indole-2,3-dione (6e). This compound was prepared
according to the method for 6d using 5,7-dibromoisatin
2 (111 mg, 0.36 mmol) and 4-methoxyphenacyl bromide
(82 mg, 0.36 mmol) as starting materials. The reaction
mixture was then stirred at rt for 51 h. The suspension
was ﬁltered and the precipitate washed with water. The
resulting solid was puriﬁed by ﬂash chromatography on
silica gel (DCM) to yield 6e (18.2 mg, 11%) as bright orange crystals, mp 205–207 C, Rf 0.50 (silica, DCM). 1H
NMR (500 MHz): d 3.91 (s, 3H, OCH3), 5.59 (s, 2H,
H1 0 ), 7.00 (d, J = 8 Hz, 2H, H300 , H500 ), 7.74 (d,
J = 2 Hz, 1H, H4), 7.80 (d, J = 2 Hz, 1H, H6), 7.98 (d,
J = 8 Hz, 2H, H200 , H600 ). 13C NMR (126 MHz): d 47.9,
55.9, 105.7, 114.6a, 117.2, 121.6, 126.9, 127.7, 130.7a,
145.0, 147.3, 158.5, 164.7, 181.2, 186.9. HREI-MS: m/z
calcd for C17H11NO4 79Br81Br [M+]: 452.9034; found:
452.9048.
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Abstract: Isatin (1H-indole-2,3-dione) and its derivatives demonstrate a diverse array of biological and pharmacological activities including anticonvulsant, antibacterial, antifungal, antiviral and anticancer properties. This broad spectrum of biochemical targets has been
facilitated by the synthetic versatility of isatin, which has allowed the generation of a large number of structurally diverse derivatives including analogues derived from substitution of the aryl ring, and/or derivatisation of the isatin nitrogen and C2/C3 carbonyl moieties. The
recent FDA approval of the oxindole sunitinib malate, as a kinase inhibitor for the treatment of advanced renal carcinoma and gastrointestinal stromal tumours, underscores the increasing interest in isatins as a new class of antineoplastic agents. In addition to potent kinase
inhibition, the mechanism of action of other isatin derivatives includes the inhibition and/or modulation of proteases, translation initiation, neo-vascularisation and tubulin polymerisation. It was therefore the objective of this review to systematically evaluate the cytotoxic
and anticancer properties of various substituted isatins and collate these findings to be used as a guide for future structure-activity relationship and mode of action studies. This is the first review to comprehensively discuss the in vitro and in vivo anticancer activities of
isatin and its substituted derivatives.

Key Words: Isatin, 2,3-dioxindole, indolinone, cytotoxicity, anticancer, enzyme inhibitor, kinase, tubulin.
1. INTRODUCTION
Isatin (1H-indole-2,3-dione) (1) was first discovered by Erdmann and Laurent in 1840 as a product arising from the oxidation
of indigo (2) using nitric and chromic acids [1, 2] (Fig. (1)). The
compound was considered synthetic for almost 140 years until it
was found to be present in plants from the Isatis genus [3], in fruits
of the cannon ball tree, Couroupita guianensis Aubl. [4] and in
secretions from the parotid gland of the Bufo frog [5]. Various substituted isatins have also been identified in plants [6-8], fungi [9]
and marine molluscs [10-13].
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mono-, di-, and tri-substitution of the aryl ring A, and/or those obtained by derivatisation of the isatin nitrogen and C2/C3 carbonyl
moieties (Fig. (2)).
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Fig. (1). The chemical structures of isatin (1) and indigo (2).

In humans and other mammals, isatin is found as an endogenous molecule. The metabolic pathways of isatin (1) have not yet
been fully elucidated; however it has been proposed that it may be
synthesised in vivo from tryptophan-rich foods such as meat, dairy
and whole grains. In this pathway, it is proposed that tryptophan is
converted to indole by bacteria from the gastrointestinal tract and
then transported to the liver where it is oxidized [14, 15]. Isatin (1)
also plays a role in many physiological pathways, which are beyond
the scope of this review (for further information see refs. [16-18]).
Herein we review the most recent literature describing the cytotoxic
and anticancer activities of isatin analogues derived from either
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Fig. (2). The various substitution types and patterns possible for the isatin
scaffold.

2. REVIEWS
Human exploitation of isatin-based chemistry has its genesis in
the ancient dye industry which pre-dates Roman times [19, 20].
Isatin (1) and 6-bromoisatin (3b) were intermediates in the production of indigo (2) and Tyrian purple and were most likely also minor pigments in these dyes [21]. It is essentially through the development of synthetic dyes that the modern chemistry of isatin was
initiated. The synthetic versatility of isatin has now led to its widespread use as a substrate for organic synthesis. A number of reviews regarding the synthesis and chemistry of isatin [22, 23] and
the related oxindoles [24] as well as the utility of isatin as a precursor for the synthesis of other heterocyclic compounds have been
published [25-27]. The most recent review to discuss the advances
in the use of isatins for organic synthesis was a comprehensive
survey by da Silva et al. in 2001 [28]. A number of recent reviews
have focused on the biological role of isatin [17, 18] and the range
of biological activities displayed by assorted isatins and isatin derivatives [16, 29, 30] including oxindoles and their copper complexes[31, 32]. This review is primarily focused on the cytotoxic
and anticancer properties of this chemical class over the period of
2000-2008.
© 2009 Bentham Science Publishers Ltd.
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3. CYTOTOXIC AND ANTICANCER ACTIVITIES OF
ISATIN DERIVATIVES
3.1. General Modes of Action
The isatin molecule is a versatile moiety and its analogues display diverse types of biological activities [16, 32], including anticancer [33-35]. Many indole-based compounds appear to act as
inhibitors of various protein kinase families, particularly receptor
tyrosine kinases (RTKs) and serine/threonine-specific protein
kinases such as the cyclin-dependent kinases (CDKs). Kinases
regulate many intra- and extracellular pathways that control cell
growth, differentiation and death, and dysregulation of these enzymes contributes to the development of a range of cancers [36].
Selective small molecule kinase inhibitors are therefore appealing
new therapeutics for the treatment of cancer [37]. Isatins that slow
or stop the proliferation of cancer cells via inhibition of various
protein kinases are discussed in sections 3.4 and 3.5.
The indolic heterocyclic nucleus is also central to a number of
tubulin polymerisation inhibitors [38-42]. As isatins are oxidized
derivatives of an indolic moiety, many are also found to disrupt
microtubule dynamics (see sections 3.3 and 3.5). In addition to
these biochemical targets, isatins are also found to intercalate
between DNA base pairs (see sections 3.4 and 3.5.2), and inhibit
the ribonucleoprotein telomerase [43], which is responsible for
maintaining the telomeres of eukaryotic chromosomes. Overexpression of this enzyme is often responsible for the unlimited replicative
potential of malignant cells [36].
Finally, the ability to kill cancer cells, or cytotoxicity, of a particular compound is typically defined as the concentration required
to inhibit the growth (and ultimately kill) 50% of a cell population
in vitro, and is reported as an IC50 value. It is important to note,
however, that while this standard nomenclature allows for greater
comparison of compounds across different structural classes, the
use of diverse cell lines, assays (e.g. MTS, MTT, lactate dehydrogenase, sulforhodamine B/Kiton Red, WST-1 and clonogenic) and
incubation times always need to be taken into consideration when
comparing the potency of the compounds discussed in this review.
3.2. Mono-, Di- and Tri-Substituted Aromatic Isatin Derivatives
The isatin scaffold is a versatile moiety and its success as a new
class of antineoplastic agents is supported by the recent FDA approval of the oxindole, sunitinib maleate (Sutent), for the treatment
of advanced renal carcinoma [44] and gastrointestinal stromal tumours [45] (see section 3.5.1). Of importance to its activity is the
fluorine atom at C5, which is not surprising, as substitution at the 5position has previously been associated with increased biological
activity for a range of isatin-based compounds. For example, in
2007 Vine et al. reported the in vitro cytotoxicity of a range of
mono-substituted isatins (3a-g, Fig. (3)) on a human monocyte-like,
histiocytic lymphoma (U937) cell line [34]. Structure activity relationship (SAR) studies revealed that substitution at position 5 was
favoured over positions 4, 6 or 7, leading to greater cancer cell
killing ability. Nitration at C5 (3f) improved the anticancer activity
by a factor of 4, while the addition of a methoxy group (3g) only
mildly improved cytotoxicity (i.e. decreasing the IC50 by 145 μM)
over a 24 h period. Furthermore, halogenation yielded the most
active compounds, with 5-bromo-, 5-iodo-, and 5-fluoroisatin (3a,
3e and 3d respectively) 5-10 times more active than the unsubstituted parent compound [34]. Increasing the number of electron
withdrawing groups on the ring to make combinations of dibromo-,
tribromo-, iodo- and nitroisatin derivatives (3h-n) also enhanced the
overall activity, against a panel of human cancer cell lines, by up to
100-fold from that of the parent molecule (1). Despite this trend,
6,7-dimethylisatin was deemed inactive in a brine shrimp lethality
assay (LD50 96 ppm) compared to other substituted heterocyclic
isatins [46], suggesting that together with substitution on the aromatic ring A, substitution at N1, C2 and/or C3, may also signifi-

Vine et al.

cantly enhance the molecule’s cytotoxic effect (see sections 3.3 3.5).
In terms of its mode of action, isatin itself is proposed to inhibit
cancer cell proliferation via interaction with extracellular signalrelated protein kinases (ERKs), thereby promoting apoptosis. In
2000, Cane et al. [33] reported that isatin inhibited the proliferation
of a human promyelocytic leukemia (HL60) cancer cell line by
80% at a concentration of 0.1 mM, and consequently induced DNA
fragmentation and chromatin condensation. Moreover, treatment of
N1E-115 neuroblastoma cells with isatin at the same concentration
inhibited the phosphorylation of ERK-2, but not ERK-1, by 35%
compared to control untreated cells. A subsequent study using human neuroblastoma SH-SY5Y cells confirmed that the effect of
isatin on cell proliferation was dose and time dependent [47]. For
example, after 24 h of exposure isatin caused 35% detachment (or
cell death) of SH-SY5Y cells treated with high concentrations (400
μM) of the compound. Following a 48 h exposure, the percentage
of detached cells significantly increased to 82%. Apoptosis was
observed in cells exposed to lower concentrations of isatin (50 μM),
as indicated by morphological change (including cell shrinkage and
nuclear condensation), internucleosomal DNA fragmentation and
externalisation of plasma membrane phosphatidylserine. At higher
concentrations, (greater than 200 μM) cell death increased even
further, however evaluation of membrane permeability by FACS
analysis revealed that isatin had significantly damaged the plasma
membrane, consistent with necrotic cell death [47]. Such a time and
dose dependant switch from apoptosis to necrosis was also observed by Vine et al. whereby 5,6,7-tribromoisatin (3n) was found
to be anti-proliferative (and induced apoptosis) at low concentrations (4 μM), but cytotoxic (and induced necrosis) at high concentrations (130 μM) in U937 cells [34]. ERK activation was not tested
in this study.
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Fig. (3). Selected isatin derivatives with mono-, di- and tri- substitution on
ring A.

3.3. N-Alkyl Substituted Isatin Derivatives
N-Alkylated indoles are well known to exhibit anticancer activity [48-50]. However, until recently, little had been reported on the
antineoplastic activity of N-alkyl and N-aryl isatins. In 2003, compound 4 (Fig. (4)), was the first N-alkylisatin described to induce
apoptosis in a panel of human cancer cell lines, but not normal
cells, at micromolar concentrations [48]. Generally it was found
that normal cell lines such as peripheral blood lymphocytes and
human mammary epithelial cells were resistant to N-(3,4dichlorobenzyl)-1H-indole-2,3-dione (4) induced apoptosis, while
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Furthermore, electron-withdrawing groups substituted at the meta
or para position of the substituent phenyl ring were favoured over
the ortho orientation. Of the 24 compounds screened, nine displayed sub-micromolar IC50 values and in general demonstrated
greater selectivity toward leukemia and lymphoma cell lines over
any of the carcinoma cell lines tested. 5,7-Dibromo-N-(p-methylbenzyl)isatin (7f) was the most active compound, inhibiting the

cancer cell lines of lymphoid origin were the most sensitive. Further
screening by the National Cancer Institute (NCI) found that the
dichlorinated compound exerted a cytostatic effect (inhibiting cell
growth by 50-100%) on 40 out of the 48 cell lines tested, at a concentration of 10 μM. At 10 times this concentration however, the
compound exhibited 100% cytotoxicity on virtually all cell lines,
suggesting that this effect may be due to non-specific toxicity [48].
Later in 2003, Liu et al. [51], identified a class of isatin O-acyl
oximes (e.g. compound 5) that selectively inhibited neuronal ubiquitin C-terminal hydrolase (UCH-L1) at sub-micromolar concentrations in the H1299 lung cancer cell line (Fig. (4)). Despite being
linked to Parkinson’s disease, UCH-L1 is also expressed in many
primary lung tumours and lung cancer cell lines, but not normal
lung tissue [52, 53], where it is proposed to be linked to tumour
progression upon upregulation [49]. Expression of UCH-L1 also
correlates with tumour progression in colorectal cancer [54]. Hence
its inhibition by small molecules like compound 5 may be of great
therapeutic benefit to lung and colorectal cancer patients in the
future.
The increased potency of the halogenated isatins (see section
3.2) and the fact that N-methylation significantly enhanced the cytotoxicity of the parent compound (1) [34] led Vine et al. [35] to
synthesise a series of brominated N-substituted isatins (e.g. 6a-d
and 7a-n, Fig. (5A)) and evaluate their cytotoxicity against a panel
of cancer cell lines in vitro [35]. SAR studies indicated that the
introduction of an aromatic ring with a one or three carbon atom
linker at N1 increased the activity relative to that of the allyl (6a),
2-methoxyethyl (6b) and 3-methylbutyl (6c) N-substituted isatins.
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Fig. (4). Examples of the first synthetic cytotoxic N-substituted isatin-based
molecules.

metabolic activity of two haematopoietic cancer cell lines by 50%
at 0.49 μM. This effect was further enhanced by at least a factor of
2 when the incubation time was increased from 24 h to 72 h, making this class of compounds >10 times more active than the conventional chemotherapeutic agents 5-fluorouracil, paclitaxel and vinblastine against U937 cells (Fig. (5B)).
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Fig. (5). A Examples of cytotoxic N-substituted 5,7-dibromoisatins; B Viability of U937 cells after treatment with increasing concentrations of the commercial
anticancer agents () 5-Fluorouracil, () Vinblastine and (•) Paclitaxel or the N-alkylisatin (), 5,7-dibromo-N-(p-trifluoromethylbenzyl)isatin (7e). Briefly,
cells were incubated for 24 h at 37 °C with different concentrations of test compound, then analysed for cell viability using the MTS assay. Each data point is a
mean of triplicates (± SE) and is expressed as a percent of the DMSO control.
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Following on from this work, and in order to establish a more
comprehensive SAR for the di-brominated N-alkylisatins, Matesic
et al. synthesised a family of N-phenethyl and N-phenacyl isatin
derivatives (8a-e and 9a-e, Fig. (6)) [55]. All five N-phenethyl derivatives (8a-e) exhibited low to sub-micromolar cytotoxic activity
against a panel of human leukemic, lymphoma and carcinoma cell
lines where introduction of a hydrophobic bromo substituent in the
meta (8b) or para (8c) position yielded the most active compounds
[55]. Interestingly, the corresponding phenacyl (9a-e) derivatives
were at least 3-5 times less active against the U937 cells and as a
result were not tested against other cell lines.
O

O

Br

Br
O

O

N

O

Br

8a R = H

9a R = H

8b R = m-Br

9b R = m-Br
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dramatically alter lymphocyte morphology [35, 55]. As these morphological alterations were also seen in vinblastine and paclitaxeltreated cells, Vine et al. suggested that N-alkylisatins may either
disrupt or stabilise microtubules in a similar fashion [35]. Various
N-alkylbenzylisatins including representative phenethyl and naphthyl derivatives were therefore screened for their ability to interfere
with microtubule dynamics and were found to strongly inhibit the
rate of microtubule polymerisation. This effect was shown to be
dose-dependent, and appeared to be independent of the nature of the
p-substituent and size of the benzene carbon linker, as compounds
6d, 7e, 7f, and 7j all inhibited microtubule polymerisation at a similar rate [35]. All N-alkylbenzylisatins tested, including the phenethyl and naphthyl compounds, were found to be potent microtubule destabilisers, which is consistent with reports that structurally
similar indole [38, 42] and indolinone [56, 57] compounds inhibit
tubulin polymerisation.
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Fig. (6). A range of N-phenethyl and N-phenacyl-5,7-dibromoisatins.

Further examples of N-substituted isatins that display cytotoxic
activity include the dibrominated 1- and 2-naphthyl derivatives 10
and 11 (Fig. (7)). The N-naphthyl isatins were found to display submicromolar cytotoxicity against U937 and human leukemic T–cell
(Jurkat) cell lines (e.g. IC50 for the 1-naphthyl derivative (10) of
0.19 and 0.91 M, respectively), along with low micromolar cytotoxicity towards a panel of human carcinoma cell lines, including
those derived from breast (MDA-MB-231 and MCF-7), colon
(HCT-116) and prostate (PC-3) [55]. Interestingly, compound 10
represents the most cytotoxic dibrominated N-alkylisatin reported to
date, when compared with other N-alkylisatins tested over a 24 hour
time period. This suggests that increasing the hydrophobicity of the
N-substituent through site specific placement of an additional aromatic ring is important for activity.
In addition to their potent cell killing ability, various Nalkylisatins were also found to induce G2/M cell cycle arrest and
Table 1.

10

11

Fig. (7). Cytotoxic N-naphthyl isatin derivatives.

Considering the role that various kinases play in the regulation
of the cell cycle, together with the fact that a structural commonality exists between N-alkylisatins and a variety of other known
kinase inhibitors that induce G2/M arrest, the effect of six representative N-alkylisatins on the inhibitory activity of a range of serine/threonine-specific and tyrosine-specific protein kinases was also
investigated (Table 1). None of the isatins inhibited enzyme activity
even at the maximum concentration tested. This is interesting considering a range of small molecules based on the indole scaffold are
known to inhibit the serine/threonine kinases glycogen synthase
kinase-3 (GSK3) [58, 59] as well as CDK5 [60-62] in the nanomolar range. Furthermore GSK3 is a core component of two pathways
involved in cell fate determination and morphology, namely the

Enzyme and Cell Based Inhibitory Activity of the Representative N-Alkylisatins 6d, 7e, 7f, 7j, 7k and 7l on Serine/Threonine (CDK5 and
GSK3) and Tyrosine (DYRK1A, JAK1, JAK2 and c-FMS) Kinases
IC50 (M)

Compound

a

Cella

Enzyme
DYRK1Ab or CDK5c or GSK3d*

JAK1e or JAK2f c-FMSg†

Ba/F3-TJ2

Ba/F3-TJ3

6d

> 10

>5

0.17

<0.16

7e

>10

>5

0.29

<0.16

7f

> 10

>5

0.29

3.78

7j

> 10

>5

1.07

0.79

7k

> 10

>5

<0.16

<0.16

7l

> 10

>5

0.39

0.24

For cell based assays, the growth factor dependent myelomonocytic cell line BaF3 was transfected with either pTELJAK2 or pTELJAK3 and the cells selected for factor independent growth. Assays were conducted in the presence 15 μM ATP and performed essentially as described in Ref. [68]; b DYRK1A: Dual-specificity tyrosine-phosphorylation regulated
kinase 1A; c CDK5: Cyclin dependent kinase 5; d GSK3: Glycogen synthase kinase 3; e JAK1: Janus protein tyrosine kinase 1; f JAK2: Janus protein tyrosine kinase 2; g c-FMS:
Colony-stimulating factor-1 receptor.
*
Assays were performed as described by Leclerc et al. [69].
†
Assays were performed as described in Ref. [68].
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Wnt and hedgehog pathways which, when deregulated, are both
involved in several forms of human cancer [63]. In these pathways,
GSK3 is known to play a role in the dynamics of the mitotic spindle [64], whereby GSK3 directly phosphorylates several microtubule-associated proteins (MAPs) such as Tau, MAP1 and MAP2,
involved in microtubule stabilisation [65]. CDK5 and DYRK1A
have also been implicated in the abnormal hyperphosphorylation of
the microtubule-binding protein Tau, leading to cytoskeletal disruption [66, 67].
Additionally, the enzymatic activities of the tyrosine kinases
JAK1, JAK2 and c-FMS were not altered by the N-alkylisatins 6d,
7e, 7f, 7j, 7k, and 7l, even at the highest concentration tested (Table
1). This was further confirmed by cell based screening in the IL-3independent, TEL-JAK2 and TEL-JAK3 mouse myeloid (Ba/F3)
transfected cell lines, whereby all compounds were equipotent on
both cell lines, with the exception of the p-tolyl derivative 7f (Table
1). This indicates that the cytotoxic effect is not likely to be occurring through the JAK signaling pathway. Together, these results
suggest that despite the structural similarities that the representative
N-alkylisatins share with known kinase inhibitors, tubulin may in
fact be the primary target [68]. Inability of this class of compounds
to inhibit the mitotic and spindle assembly checkpoint kinases, for
example CDK1, the aurora kinases, and the polo-like kinases would
further support the theory that N-alkylisatin-induced microtubule
disassembly is not a secondary phenomenon.
3.4. C2 Substituted Isatin Derivatives
The best known cytotoxic C2-substituted isatin derivative is
indirubin (12a), the red component of indigo pigments used since
ancient times for dyeing textiles. This compound was obtained from
plants belonging to the genii Indigofera, Isastis and Polygonum, as
well as from marine molluscs of the Murex genus [70]. Indirubin is
the active constituent of a traditional Chinese antileukemia medicine and the lead structure of a class of compounds that display
strong antiproliferative activity via ATP-competitive inhibition of
both CDK1 and CDK2 (Fig. (8)) [71-73]. A number of modes of
action have been ascribed to the indirubins [74]. These include
induction of apoptosis through cell cycle arrest at G2/M, as a result
of inhibition of GSK3 [69], c-Src kinase and NF-B activation and
expression [75, 76], as well as activation of the aryl hydrocarbon
receptor [77, 78]. Based on a range of mechanistic and crystallographic studies of indirubins with GSK3 and CDK2, a vast number
of soluble indirubin derivatives have been synthesised and their
biological activity and specificity have been evaluated [72, 79]. The
indirubin derivatives 12a-k displayed strong inhibitory activity
towards CDK2 with IC50 values ranging from 2-0.01 M, with
derivatives 12i and 12k also showing potent activity in suppressing
the in vitro growth of MCF-7 cells [71, 72]. Some of the early indirubin derivatives were plagued by poor water solubility. However,
the addition of basic diamine side chains, as in derivatives 12i and
12k, markedly improved their water solubility. The incorporation of
a quaternary centre into the 3’-position of these polar indirubin
derivatives further improved water solubility, while retaining potency towards CDK2.
In addition to indirubin derivatives, the marine environment has
yielded an array of other novel C2-substituted indolinones including the alkaloid matemone (13, Fig. (9)). Isolated from the Indian
Ocean sponge Iotrochota purpurea, matemone was found to intercalate DNA, to inhibit the division of sea-urchin eggs and to exhibit
mild cytotoxicity towards a range of human carcinoma cell lines.
Further examples of marine-based isatins have been provided by the
sea cucumber-associated fungus Aspergillus fumigatus, which was
found to produce several novel prenylated indole diketopiperazine
alkaloids, including compound 14 and the three spirotryprostatins
C-E (15a-c, Fig. (9)). The prenylated indoles were evaluated for
their cytotoxicity with derivative 15c exhibiting the most potent
activity with IC50 values of 2-3 μM against the human non-small
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cell lung carcinoma (A549), the human acute lymphoblastic leukemic (MOLT-4) and HL60 cell lines [80].
R
O

NH

N
H

R=H
R = Cl
R = Br
R = SO3H
R = SO2NMe2
R = SO2NH(CH)2OH
R = SO2NH(CH)2CO2H
R = SO2NMe(CH)2CO2H
R = SO2NMe(CH)2NMe2
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Fig. (8). A range of C2- substituted indirubin-based CDK2 inhibitors.
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Fig. (9). Cytotoxic, marine-derived C2-substituted isatin derivatives.

A range of 2-arylidenedihydroindole-3-ones (16a-f), or azaaurones, were recently evaluated for their antiproliferative and apoptotic abilities against bladder tumours (Fig. (10)). Azaaurone (16c)
was the most active compound, which inhibited the proliferation
and induced apoptosis apparently via a fibroblast growth factor
receptor (FGFR) 3 dependent pathway in DAG-1 and RT112 bladder tumour cell lines [81].
Other pharmacologically important examples of C2-substituted
isatin derivatives are indigo carmine (5,5'-indigodisulfonic acid
sodium salt), which is widely used as a non-toxic, inexpensive stain
for colonoscopic diagnosis and management of early colorectal
cancer [82, 83], and the duocarmycins C1 (17) and C2 (18) (Fig.
(11)). The duocarmycins are C2-substituted indoles that are amongst
the most potent antitumour antibiotics discovered to date and have
been reviewed in detail elsewhere [84-86]. A review of the patent
literature on small molecule CDK inhibitors covering the period
2001-2004,includes a diverse range of C2-substituted isatin-derived
compounds [87], once again highlighting the clinical significance of
this important class of molecules.
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3.5. C3 Substituted Isatin Derivatives
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Fig. (10). Some examples of C2-substituted azaaurone isatin derivatives.
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Fig. (11). Duocarmycins C1 (17) and C2 (18), potent antitumour antibiotics.

SO2NH2

The susceptibility of isatin to attack by nucleophiles at C3 has
resulted in the generation of a large number of 3-substituted isatins,
which is reflected by the vast proportion of biologically active 3substituted indolin-2-ones reported in the literature relative to the
other substitution patterns. For example, a variety of 3phenylhydrazones (e.g. 19) and thiazoles (e.g. 20) have been shown
to slow cancer cell cycle progression via inhibition of CDK2 (Fig.
(12)) [61]. Similarly, an array of imidazole containing (e.g. 21 and
22) and pyrrole containing (e.g. 23 and 24) 3-substituted isatins
inhibit tubulin polymerisation in a range of cancer cell lines, leading to cell cycle arrest at G2/M and eventual cell death (Fig. (12))
[88, 89]. Furthermore, 3-substituted indolin-2-ones have been designed and synthesised as a novel class of tyrosine kinase inhibitors
which exhibit selectivity toward different RTKs. Sun et al. found
the pyrrole 24 to be highly specific against the vascular endothelial
growth factor (VEGF) (Flk-1) RTK and 3-(substituted benzylidenyl)indolin-2-ones (25 and 26) containing bulky groups in the
phenyl ring at the C3 position showed high selectivity towards epidermal growth factor (EGF) and Her-2 RTKs [37].
3.5.1. 3-Arylidene Derivatives
Indolinones were first reported in 1987 to possess kinase inhibitory activity [90]. Many indolinones such as SU5416 (semaxanib,
27) were discontinued in clinical trials due to dangerous side effects
[91], although SU11248, (sunitinib, 28), now marketed as Sutent®
by Pfizer, was approved by the FDA in January 2006 for the treatment of gastrointestinal stromal cancers and renal cell carcinoma
[92]. The drug is a multiple RTK inhibitor, targeting VEGF receptor-2 (VEGFR-2), platelet-derived growth receptor- (PDGFR-),
stem cell factor receptor (c-KIT), fetal liver tyrosine kinase receptor-3 [91], colony-stimulating factor type 1 and the glial cell-line
derived neurotrophic factor receptor [93]. The indolinone scaffold
is a well-known c-KIT RTK inhibitor [94]. Substituents at C4/C5
on the indolinone nucleus and substituents on the 3’- and 4’positions of the pyrrole ring are regarded as favourable for CDK2
inhibition, while substituents in the 5’-position are beneficial for
VEGFR-2 and PDGFR- inhibition [95]. 3-Substituted indolinones
possessing the Z configuration are potent inhibitors of the FGFR,
while compounds adopting the E configuration inhibit epidermal
growth factor receptor (EGFR) [42].
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Fig. (12). Examples of some 3-substituted indolin-2-ones with reported anticancer activity.
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The indolinone SU5402 (29), encompasses a Z configuration
about the alkenyl bond (Fig. (13)). Li et al. synthesised 20 new
analogues of 29 bearing the E configuration and assessed them for
cytotoxicity [96]. The lead compound, containing a methyl ester on
the pyrrole group displayed IC50 values of 98 nM and 65 nM against
human lung (A549) and breast (MDA-MB-468) carcinoma cell
lines after 72 h.
Mitochondrial damage, caspase activation and apoptosis can be
induced in a dose- and time-dependent manner by SU9516 (22) in
U937 cells [97]. Apoptosis may also be induced in Jurkat and HL60
leukemic cells treated with 10 M of 22 for 6 h, or with 5 M for
24-72 h in RKO and SW480 human colon carcinoma cell lines [62].
Pyrrolyllactone and pyrrolyllactam derivatives of 22 have been
synthesised and described as potent CDK2 inhibitors, in particular
compounds exhibiting a polar substituent in the 4-position [31, 95].
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Fig. (13). Examples of isatin-based kinase inhibitors including the clinically
employed sunitinib (28).

Imidazole derivatives of 27 have been demonstrated to possess
greater inhibition of EGF at 10 M than 27 itself (40-55% cf. 30%
respectively) [98]. A range of 3-(E)-benzylidene-2-indolinones
derived from 27 have been synthesised and their SAR has been
evaluated. Compounds incorporating a methoxy group at C6 on the
isatin moiety resulted in greater potency against PC-3, MCF-7 and
MDA-MB-231 cell lines after 72 h compared to derivatives with a
hydrogen or hydroxyl group at C6 [99]. Furthermore, the most active compounds displayed inhibition of tubulin polymerisation at
the micromolar level. By combining the most potent derivative with
the tubulin binding natural product Combretastatin A-4, the novel
compound was able to inhibit tubulin polymerisation at a greater
rate, and the cytotoxicity was also enhanced (IC50 = 0.7 nM and 0.9
nM against the MCF-7 and MDA-MB-231 cell lines, respectively).
Further investigations into the cytotoxic activity of this compound
revealed it to be extremely potent with GI50 values of < 10 nM
against 46 out of 53 NCI cell lines [100].
SU6668 (30) is efficacious when administered in athymic mice
with tumour xenografts, demonstrating over 75% growth inhibition
against a spectrum of tumour types [101]. It also significantly suppresses tumour angiogenesis [102], and is capable of inducing substantial tumour regression, regardless of initial tumour size. The
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drug was in four separate Phase I trials, but was discontinued due to
the superior activity of sunitinib.
Sunitinib (28) displays excellent activity against PDGFR- and
VEGFR-2 (IC50 = 2 nM and 80 nM respectively) and is over 30
times more potent against these kinases than the pyrrolo-containing
compounds 30 and 33 [103]. It is now the standard first-line treatment of renal cell carcinoma and is generally well tolerated, although side effects such as hypertension and asthenia still occur and
are attributed to the inhibition of VEGF receptors [93]. SU14813
(31) has also emerged as a multiple RTK inhibitor with strong
antiangiogenic and antitumour activity. It expresses dose-dependent
antitumour efficacy and aids in the regression of human acute myelogenous leukemia (MV4;11), as well as human renal carcinoma
(786-O), human colon carcinoma (Colo205 and MV522) and rat
glioma (C6) [104]. The compound also displays moderate systemic
clearance, a short plasma half-life in mice (t1/2 = 1.8 h) and inhibition of tumour growth can be improved when the morpholino derivative 31 is combined with the anti-mitotic chemotherapeutic,
docetaxel.
Islam et al. found that indolinones possessing a pyrrole ring,
similar in structure to the SU series of compounds (Fig. (13)), are
inhibitors of the cAkt2 protein kinase, which is activated by phosphoinositide-dependent kinase-1 through the support of phosphoinositide 3-kinase activity in cells [105]. Activity towards the cAkt2
kinase could be increased almost 400-fold through the addition of a
urea group at C5 on the isatin nucleus and a methyl group on the
alkene bond at C3. The novel compound named BX-517, was optimised by exploring the C4’ position on the pyrrole ring and lead to
potent phosphoinositide-dependent kinase-1 inhibitors with superior
pharmacokinetic properties compared to BX-517 [106].
A plethora of other indolinones including 4-cyclicamino and 4alkynyl-oxindoles have exhibited CDK2 inhibitory activity and
potent cytotoxicity, as reviewed by Harris [31]. Indolin-2-ones and
azo-indolinones containing a variety of ring systems have been
reported to be potent nanomolar inhibitors of the TrkA RTK and
low micromolar inhibitors of CDK2 [107], while indolinonepyridine derivatives have been found to be powerful B/Akt protein
kinase inhibitors [108].
The novel indolinones BIBF1000 (32) and BIBF1120 (33) induce apoptosis and are excellent compounds for inhibiting colony
formation of human myeloid leukemic cell lines in a dosedependent manner (Fig. (14)). Both compounds have an IC50 value
of 8 nM against the leukemic Kasumi-1 cell line and comparable
activity against the leukemic Mono-Mac-1 cell line [109].
BIBF1120 (33), inhibits VEGF, FGF and PDGF receptors, displays
efficacy in vivo amongst multiple animal models and is currently in
Phase III trials for the treatment of non-small cell lung cancer and
other cancers [110].
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Fig. (14). Examples of the BIBF series of isatin-based kinase inhibitors.

Another 3-benzylidene-indolinone, RPI-1 (34, Fig. (15)), has
been shown to inhibit the RET RTK (IC50 value = 0.17 M) and
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display antiproliferative activity, particularly towards a modified
mouse embryonic fibroblast cell line NIH3T3 (NIH3T3MEN2A) (IC50
value = 3.6 M after 72 h) [111]. Derivatives containing a diphenyl
urea functionality were introduced to the 5,6-dimethoxyindolinone
core of RPI-1 as diphenyl urea moieties are known to be potent
inhibitors of other kinases including CDKs. The lead compound
discovered, N-methyl-3-arylureidobenzylidene-indolin-2-one (35),
displayed greater activity against 3 modified NIH3T3 cell lines but
was inactive against the RET RTK, suggesting a separate mode of
action [111] (Fig. (15)).
HO
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MeO
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Vine et al.

revealed that lipophilic substituents at C4 or oxazolyl substituents at
C5 increased CDK2 inhibitory activity to the low nanomolar range.
Equally potent analogues were discovered by fusing the C4/C5
positions with a heterocycle containing a hydrophobic substituent at
C4 and a hydrogen bond acceptor at C5. These fused derivatives,
together with a 5-(2,6-dimethoxyphenyl)amide analogue displayed
notable potency against an array of human cancer cell lines, with
most of the IC50 values in the sub-micromolar region after 72 h.
A range of 5-substituted isatins with a hydrazone functionality
at C3 linked to a substituted quinazolinone (38a-d) have been synthesised and assessed for their cytotoxic activity (Fig. (17)) [113].
Three compounds (38a, 38c and 38d) exhibited comparable cytotoxicity to clinically proven thioguanine and 5-fluorouracil. A dihalosubstituted derivative (38c) displayed the most noticeable effects on renal (UO-31 and RXF 393) and neural (U251) cell lines,
with the potency attributed to the electronic nature of the molecule.
The two mono-halosubstituted compounds (38a and 38d) were
slightly less active than the di-halosubstituted derivative (38c),
while the analogue containing no halogens (38b) was the least active of the compounds tested.
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Fig. (15). The 3-benzylidene indolinone RP1-1 (34) and a potent derivative
(35).
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An indolinone substituted at C3 with an aminomethylene-lysine
derivative (36, Fig. (16)) displayed cytotoxicity after 48 h towards
human colon (DLD-1) and ovarian (PA-1) carcinoma cell lines, as
well as towards murine fibroblast cell lines (IC50 values ranged
from 10-17 M) [112]. Compounds containing more rigid side
chains derived from D-phenylalanine and L-phenylglycine were
found to be inactive. The antitumour activity of 3-imidazothiazole2-indolinones was investigated by Andreani et al. [88]. The most
active compound (37) possessed a chlorine atom at C5 and was the
most potent derivative against all cancer cell lines tested (Fig. (16)).
It displayed selectivity towards leukemic cell lines and was more
active than the commercially available anti-mitotic agent, vincristine.
H
N

N
H

O

38b Me

H

38c

F
Br

Fig. (17). Cytotoxic isatin-quinazolinone derivatives.

Recently, isatin-based hydrazones (39a-c) have been identified
as inhibitors of the protein tyrosine phosphatase Shp2, which plays
an important role in cell signalling, cell proliferation, differentiation
and migration (Fig. (18)) [114]. Compounds containing a carboxylic acid group on the hydrazone aromatic ring and a p-halosulfonamide at the C5 position (39a and 39b) selectively inhibit Shp2
in the low micromolar region. The most active analogue (39c) exhibited an IC50 value of 0.8 M against Shp2.
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Fig. (16). Examples of the 3-aminomethylene-lysine (36) and 3-imidazothiazole (37) derivatives.

3.5.2. Hydrazones and Imines
Isatin hydrazones have been explored in detail and evaluated
for their CDK2 inhibitory activity. A brominated isatin hydrazone
containing a p-sulfonamide functionality exhibited an IC50 value of
60 nM against the CDK2 enzyme and was initially the lead compound in an SAR study by Bramson et al. [61]. Their investigation
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39a SO2NHCH2(4-ClC6H4)
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3-CO2H

39c CO2H

2-CO2H

Fig. (18). Isatin-based inhibitors of Shp2.

Isatin aminoacetylhydrazones, such as compound 40 (Fig. (19))
and their benzoisatin analogues (for example, 41) have been synthesised and are speculated to be DNA intercalating agents [30].
However, none of the isatin aminoacetylhydrazones tested were
active against porcine testicular cells after 24 h at 250 g/mL.
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Among the analogous benzoisatin compounds, three exhibited cytotoxic activity and a p-methylpiperazinyl derivative (41) resulted in
100% cell death at concentrations between 120-250 g/mL.
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Further investigations into biologically active thiosemicarbazones have led to the synthesis of a range of 5-bromo-3-thiosemicarbazone isatins (e.g. 42l and 42m, Fig. (20)), including heterocyclic thiazolidinone and imidazolidinedione moieties [120]. The introduction of a bromine atom at the C5 position of the isatin ring is
known to increase the anticancer activity of the parent molecule
[121]. Four model compounds were selected after preliminary
screening to be further evaluated against the NCI’s full panel of
tumour cell lines. All of the compounds reported here were found to
possess at least comparable cytotoxicity to thioguanine and
5-fluorouracil, with the 4-fluorophenyl and 4-nitrophenyl thiosemicarbazone derivatives 42l and 42m showing even greater levels of
cytotoxicity.
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41
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Fig. (19). Isatin aminoacetylhydrazone (40) and benzoisatin (41) derivatives.

Juranic et al. [115] have reported the cytotoxic effects of isatin-thiocarbohydrazone (42a) and N-ethylisatin--thiocarbohydrazone (42b) on B16 (murine melanoma), HeLa (human cervical
carcinoma) and human peripheral blood mononuclear cell lines
after 72 h using the MTT assay. N-ethylisatin--thiocarbohydrazone
(42b) was three times more potent against the two neoplastic cell
lines than 42a (IC50 = 10.4 M cf. 34.2 M for B16 and IC50 = 21.9
M cf. 61.7 M for HeLa, respectively). Interestingly, 42a displayed greater cytotoxicity against non-stimulated human blood
mononuclear cells than 42b (IC50 = 17.6 M cf. > 47.0 M, respectively).
Thiosemicarbazones, a hydrazone derivative containing a sulfur
atom, are active against several pox viruses. The -thiosemicarbazone of N-methylisatin is a prophylactic agent for smallpox [116]
and was one of the first antiviral agents used clinically. The
thiosemicarbazones of isatin and its derivatives have been reported
in recent years to also display cytotoxic activity. Fifteen previously
reported N4-substituted isatin-3-thiosemicarbazones have been
screened for cytotoxicity against brine shrimp (Artemia salina) by
Pervez et al., including compounds 42a-e, (Fig. (20)) [117]. Only
the 2-methylphenyl (42c), 2-methoxyphenyl (42d) and 3-nitrophenyl (42e) derivatives displayed significant cytotoxic activity.
The most active analogue was 42d with a LD50 value of 11 M
against Artemia salina. Further studies into N4-substituted isatin-3thiosemicarbazones involving one, two or three phenyl substituents
have been performed by the above authors [118]. Eleven of the
twelve derivatives contained at least one fluorine atom although,
intriguingly, the most active compound was the chloro-substituted
analogue (42f) with a LD50 value of 11 M against Artemia salina
(Fig. (20)). The remaining compounds exhibited LD50 values of 16136 M.
A variety of 5-nitroisatin and 1-morpholino/piperidinomethyl5-nitroisatin derivatives containing a thiosemicarbazone group (e.g.
42g-k, Fig. (20)) have been synthesised and reported by Karali
[119]. Eight analogues were selected as prototypes and evaluated
against the NCI’s full panel of tumour cell lines. All of the compounds tested had comparable cytotoxicities to thioguanine and
5-fluorouracil. Amongst the 5-nitroisatin derivatives, phenyl (42g)
and 4-nitrophenyl (42h) substituted thiosemicarbazones were more
potent than their alkyl (42i-j) counterparts. In addition, the
1-morpholinomethyl compounds generally exhibited greater cytotoxicity than the unsubstituted compounds. The lead compound
contained a 4-chlorophenyl substituted thiosemicarbazone (42k)
and was significantly more active than thioguanine and 5-fluorouracil against non-small cell lung cancer and leukemia cell lines
[119].
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Fig. (20). Examples of cytotoxic isatin-3-thiosemicarbazones.

C3 carbonyl substitution with an imine functionality of the Nalkylated fluoroquinolone anti-bacterial isatin derivative, gatifloxacin (which is now banned), gave rise to one compound, containing
a sulfonamide attached to pyrimidine (43a) (Fig. (21)) with a GI50
value of 0.269 M against the human colon carcinoma cell line
Colo205 [122]. Additionally, 43a was >20 times more active than
the chemotherapeutic drug etoposide against this and the human
renal carcinoma cell line A498. A similar derivative, incorporating
a 4,5-dimethoxy pyrimidine (43b) displayed a GI50 value of 0.176
M after 48 h, and was 85 times more potent than etoposide against
the non-small lung carcinoma cell line HOP-92.
3-Imino-substituted indolinones bearing amino acids have been
investigated as kinase inhibitors and cytotoxins. Imino groups incorporating valine (44a and 44b) (Fig. (22)) and threonine (45a and
45b) residues proved to be inactive against the CDK1/cyclin B,
CDK5/p25 and GSK-3/ protein kinases [123]. Conversely, histidine imino groups (46a and 46b) increased kinase activity and
subsequent halogenation at C5 on the isatin core yielded extremely
potent kinase inhibitors, with the lead compound, a 5-bromo derivative (46b), displaying an IC50 value of 0.37 M against the
CDK5/p25 kinase. Interestingly, none of the analogues synthesised
displayed cytotoxicity towards human breast or lung carcinoma or
towards a human glioblastoma cell line (SF-268 cells), although
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this may be attributed to the presence of the carboxylic acid functionality which may inhibit the entry of the compound into tumour
cells.
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Fig. (21). Gatifloxacin-isatin derivatives.
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Fig. (22). Imino-isatins incorporating the amino acids valine (44), threonine
(45) and histidine (46).

Additionally, novel bis-Schiff bases of 5-fluoroisatin (3d) such
as 3,3’-[oxybis(4,1-phenylenenitrilo)]bis(1,3-dihydro)-5-fluoro-2Hindol-2-one have been found to be cytotoxic towards the human
embryonic cell line (HEL) while a dichlorinated derivative, 3,3’[methylenebis(2 - chloro - 3,5 - diethyl - 4,1 - phenylenenitrilo)]bis(1,3 dihydro)-2H-indol-2-one, displayed cytotoxicity at 16 g/mL
against African green monkey kidney (Vero) and HeLa cell lines
[124].
3.5.3. Metal Complexes
Due to cisplatin and other platinum drugs being used clinically
for the treatment of several different tumour types, other metalbased compounds have been investigated in order to find drugs with
fewer side effects and greater efficacy. Copper-based anti-cancer
drugs have been researched thoroughly with the premise that drugs
containing endogenous metals may be less toxic to the human body

Vine et al.

[125]. Copper-induced apoptosis and necrosis has been reported in
the gills of fish and the effects can be enhanced when administered
in conjunction with other agents. These complexes have the ability
to trigger oxidative stress by generating reactive oxygen species,
which attack other biomolecules during the oxidation of endogenous substances [32, 126]. Numerous oxindole-copper complexes
were reviewed by Cerchiaro and Ferreira in 2006 [32].
Two isatin–diimine copper complexes, Cu(isapn) (47) (Fig.
(23)) and Cu(isaepy)2 (48), have been evaluated against SH-SY5Y
neuroblastoma, M14 melanoma and U937 cell lines and were found
to induce pro-apoptotic activity involving the mitochondrial pathway and/or copper-dependent oxidative stress [127]. The compounds induce cell cycle arrest by strongly activating the proteins
p53 and p21, suggesting this pathway is activated in response to
cell damage. Apoptosis of these copper complexes is also caspasedependent and this seems to be the principal mechanism of cell
death [127].
Bis-isatin thiocarbohydrazones have recently been prepared and
coordinated to Cu(II) (49a) , Ni(II) (49b), Co(II) (49c) and Zn(II)
(49d) ions [128]. All compounds tested displayed cytotoxic activity
after 24 h in the brine shrimp lethality bioassay and produced 50%
cell death at or below a concentration of 19.1 g/mL against Ehrlich ascitic carcinoma (EAC) cells. In vivo studies involving female
Swiss Albino mice inoculated with EAC cells revealed that all the
compounds reduced weight gain, prolonged the mean survival times
and reversed the tumour-induced increase in white blood cell counts
compared to the control [128].
Isatins containing sulfonamides through an imine or hydrazone
linkage have been complexed with Co(II) (for example compound
50a) (Fig. (24)), Ni(II) (example 50b), Zn(II) (example 50c) and
Cu(II) (example 50d) ions [129]. By evaluating the complexes using the brine shrimp bioassay, only three complexes [one Ni(II) and
two Cu(II)] displayed potent cytotoxicity. The maximum activity
observed was a LD50 value of 156 nM.
Ruthenium compounds are known to be stable and have predictable structures in solution and solid state, and for this reason are
considered to be potential alternatives to platinum-based anti-cancer
drugs [130]. The ligands isatin-3-(4-chlorophenyl)thiosemicarbazone (icpl, 51) (Fig. (25)) and N-methylisatin-3-thiosemicarbazone
(nmit, 52) were prepared and complexed to ruthenium-1,10-phenathroline and 2,2’-bipyridine derivatives through the sulfur atom and
imine nitrogen atom [131]. The complexes were tested in vivo
against EAC bearing mice and found to increase the life span of the
mice by 57-66%. Further investigations by these researchers included the synthesis of the ligand isatin thiosemicarbazone (itsz,
53) and subsequent chelation to ruthenium-1,10-phenathroline and
2,2’-bipyridine derivatives [130]. The compounds were tested in
vitro against leukemic human (MOLT 4/C8 and CEM) and murine
(L1210) cell lines. The ruthenium complexes displayed greater
activity than their ligands and the 1,10-phenathroline derivative was
the more active of the two with an IC50 value of 3.9 M against the
CEM cell line. Once again, these compounds were evaluated in vivo
against EAC bearing mice and found to increase life span and mean
survival time compared to the control.
3.5.4. Isoindigo and Derivatives
The isomer of indirubin (12a) bearing two indolinone moieties
is known as isoindigo (54). Glycosyl-isoindigo derivatives (55)
have been prepared containing benzyl or acetyl protecting groups
on the sugar residue (Fig. (26)) [132]. Protected analogues are speculated to improve cellular penetration and thus, display enhanced
biological activity compared to the corresponding non-protected
compounds. According to Sassatelli et al., acetylated glycosylisoindigo derivatives were more cytotoxic against a panel of human
solid tumour cell lines than the analogous benzylated compounds
[132]. Further investigations revealed isoindigo (54) was almost
inactive towards 10 kinases tested, although benzylated glycosyl-
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Fig. (23). Isatin-diimine copper complexes (47 and 48) and bis-isatin thiocarbohydrazone metal complexes (49a-d).

isoindigos were active especially towards CDK2 (IC50 values typically between 0.1-0.2 M) which suggests the protected sugar functionality positively interacts with the ATP-binding sites of the enzymes [133]. Recently, compounds integrating a 7’-azaisoindigo
scaffold (56) were synthesised for the first time (Fig. (26)) [134].
These compounds displayed antiproliferative properties against the
human buccal carcinoma cell line KB, and exhibit micromolar IC50
values against this cell line after 72 h, indicating that the presence
of an additional nitrogen atom to the isoindigo nucleus improves
cytotoxicity.

cacy compared to indirubin (12a) [138]. These properties may be
attributed to meisoindigo’s increased bioavailability and water
solubility [136]. In vitro, 57 induces apoptosis in the transformed
human vein endothelial cell line, ECV304 [139], and inhibits the
growth of NB4, U937, KG1a, K562 and Jurkat leukemic cell lines
in a dose- and time-dependent fashion. In animal models meisoindigo (57) is capable of significantly inhibiting Lewis lung carcinoma and Walker carcinosarcoma 256, inhibiting DNA and RNA
synthesis in W256 cells and hindering microtubule assembly [138].
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Fig. (24). Isatin sulfonamide metal complexes.

Another isoindigo, N-methyl-isoindigotin, more commonly
known as meisoindigo (57) was first synthesised in 1982 [135] and
was approved by the Chinese government in 2001 for the treatment
of chronic mylogenous leukemia (CML) (Fig. (26)) [136]. When
combined with hydroxyurea, 57 substantially prolonged median
duration of chronic phase and median survival in CML patients
compared to meisoindigo and hydroxyurea alone [137]. Meisoindigo (57) displays a superior side effect profile and increased effi-

3.5.5. Miscellaneous
Compounds incorporating a spirocycle at C3 on the isatin moiety (often called spiro-oxindoles) are well known for their biological activities and the scaffold is common in alkaloids such as (-)horsfiline (58), (+)-elacomine (59) [140] and the Gelsemium alkaloids such as 14-acetoxygelsenicine (60) which has an EC50 value
of 0.25 M against the A431 human epidermoid carcinoma after 48
h (Fig. (27)) [141]. Recently, spiro-oxindoles integrating silyl functionalities have been synthesised [142]. Two of these compounds,
one including a tricyclic isatin core 61 and the other a Nbenzylisatin derivative 62, were evaluated against human non-small
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cell lung adenocarcinoma (A579) and human hepatocellular carcinoma (HepG2) cell lines (Fig. (27)). Both compounds displayed
comparable cytotoxicity towards the A579 cells after 24 h (EC50 =
42.8 M and 42.6 M respectively). However, when assessed
against the HepG2 cell line, 62 exhibited twice the activity of the
compound 61 (EC50 = 16.8 M and 32.5 M, respectively).
H
N

groups on 67c are pertinent for activity, and cytotoxicity can be
increased (to less than 10 nM) by replacing small and lipophilic
substituents in the 6- and/or 7-position of the isatin moiety. The
lead analogue was the 6,7-difluorooxyphenisatin which displayed
an IC50 of 3 nM against MDA-MB-468 cells [147].
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Of twenty spiro-oxindoles containing an isoxazolidine ring
system, three compounds, 63-65 (Fig. (27)), inhibited MCF-7 cell
invasion at 10 M, although no activity was apparent at 1 M
[143]. Yong et al. tested a comparable compound (66) and reported
it to be cytostatic with a GI50 value of 2.6 M against MCF-7 cells
[144].
Another class of oxindoles which have been evaluated for their
anti-proliferative activity are the 3,3-diaryloxindoles (Fig. (28)).
Natarajan et al. found that this group of compounds deplete intracellular Ca2+ stores leading to inhibition of translation initiation
[145]. The parent compound, 3,3-diaryloxindole (67a) displayed a
GI50 of 13 M against a human lung cancer cell line. By substituting the 5-position on isatin with iodine and sulfonic acid, the activity increased to 8 M and 9 M, respectively. The greatest activity
was noticed with o-hydroxy and m-t-butyl substituents on the same
phenyl ring (67b) resulting in a GI50 value of 3 M. N-Substitution
of the parent compound (67a) with alkyl, aryl and electronwithdrawing groups eliminated Ca2+ depletion activity and hence no
growth inhibitory activity was observed.
A derivative of 3,3-diaryloxindole is oxyphenisatin (67c). Oxyphenisatin acetate was used as a laxative for 40 years before its
withdrawal from the Australian and American markets in the 1970s
due to hepatotoxicity [146]. No research had been conducted into
oxyphenisatin for almost 20 years, until 2007 when Uddin et al.
published data showing that the compound and its derivatives were
potent antiproliferatives, particularly against the human breast carcinoma MDA-MB-468 cell line [147], a cell line which expresses a
high number of EGF receptors. Oxyphenisatin (67c) itself has an
IC50 of 112 nM against MDA-MB-468 cells. The two hydroxyl
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Fig. (27). Examples of biologically active spiro-oxindoles.

4. CONCLUSIONS
Isatin is the core nucleus of an array of cytotoxic and antineoplastic compounds. A SAR summary for the isatin derivatives
discussed in this review is shown in Fig. (29). The mono- di- and
tri-aryl ring substituted isatin series formed from derivatisation at X
(see section 3.2) is generally found to induce cancer cell death via
apoptosis in the mid-low micromolar range and necrosis in the high
micromolar range. This is proposed to be linked to a reduction in
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ERK activity. Small electron withdrawing groups at positions 5, 6
and/or 7 enhance, but are not essential for, anti-tubulin or antikinase activity when found as part of a larger substituted compound
(i.e. substitution at X with concomitant substitution at W, Y and Z).
This is most likely due to increased cell permeability and hydrophobicity.
R3

R2
R1

R4
O

67a R1, R2, R3, R4 = H
67b R1 = H, R2 = t-butyl,
R3 = H, R4 = OH
67c R1 = OH, R2 = H,
R3 = OH, R4 = H

N
H
Fig. (28). Examples of 3,3-diaryloxindoles.

Fig. (29). A cytotoxicity structure-activity summary for isatin derivatives
discussed in this review.

N-Alkylation at Y however, with no further substitution at W or
Z, often results in cytotoxic compounds with sub-micromolar activity; inducing morphological change, G2/M cell cycle arrest and
ultimately cell death via apoptosis (see section 3.3). The compounds discussed in this review appear to be tubulin specific and do
not inhibit serine/threonine or tyrosine kinases (see Table 1). A 1-3
carbon chain linker extending to an aromatic ring is optimal for
potent microtubule disruption and small electron withdrawing substituents on the ring in the para or meta position are favoured over
the ortho position. Most importantly, and together with its specificity, this series of novel molecules are >10 times more active than
the conventional cancer chemotherapeutics; 5-fluorouracil, vinblastine and paclitaxel on human monocytic lymphoma cells. Together with the possibility that these compounds may bind to a
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novel site on tubulin, it suggests that the development of anticancer
agents based on the N-alkylisatin scaffold may be beneficial in
combination with clinically used anticancer agents for the treatment
of multi-drug resistant tumours in the future. Further development
and preclinical assessment of this particular series of isatins is
therefore warranted.
Substitution at W has resulted in the generation of by far the
most structurally and biochemically diverse isatin-based compounds to date (see section 3.5). Yet despite over 1500 cytotoxic C3
substituted compounds reported in the literature, only one has made
it to market as an anti-cancer drug. This is primarily due to their
non-specific toxicity, as these molecules often target the ATP binding site of multiple kinases, therefore affecting a magnitude of cellular targets. For example, substitution at W on the 3’- and 4’positions of the pyrrole ring of some arylidene derivatives is regarded as favourable for CDK2 inhibition, while substituents in the
5’-position are beneficial for VEGFR-2 and PDGFR- inhibition.
3-Substituted indolinones possessing the Z configuration are potent
FGFR inhibitors, while compounds adopting the E configuration
inhibit EGFR. Despite this, toxic related side effects of C3 substituted isatins may be overcome in the future through the use of a
targeted or ligand directed prodrug approach. This promising new
strategy would specifically deliver a potent class of isatin-based
molecules to cancer cells via receptor mediated endocytosis and
concentrate it within these cells only after site specific cleavage,
ultimately reducing toxicity. Alternatively, further SAR studies may
identify sites and substituents necessary to confer target specificity.
Finally, dimerisation at Z often results in ATP-competitive
inhibition of CDK1, CDK2 and GSK3, as well as reduction in the
activation and expression of c-Src kinase and NF-B (the most
renowned modulators being the indirubins, see section 3.4). Although the early indirubin derivatives were plagued by poor water
solubility, the addition of basic diamine side chains and the incorporation of a quaternary centre into the 3’-position markedly improved their water solubility, while retaining potency towards
CDK2. Such small modifications have led to large advances in the
development of this class of molecules as potential new anticancer
agents. In general the C2 substituted class of isatins is active in the
micro to nanomolar range and extend from kinase inhibitors to
potent anticancer antibiotics.
In summary, isatin has already proven to be an excellent scaffold for both the natural and synthetic construction of molecules
with interesting biological activities. With the possibility of derivatising the N1, C2 and C3 positions, along with substitution on the
aromatic ring, the synthetic permutations for isatin are almost endless. Despite the fact that the isatins are well studied compounds,
new derivatives are continually being discovered and known isatinbased compounds are constantly being rediscovered in terms of
their biological activity. Isatins, in general, are therefore still worthy of further exploration for the purpose of discovering new and
exciting molecules with anticancer activity.
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ABBREVIATIONS
Only abbreviations that appear more than twice in the text are
listed here
A549
CDK
c-KIT
CML
EAC
EGF/R
ERK
FGF/R
GI50

=
=
=
=
=
=
=
=
=

GSK3
HeLa
HL60
IC50

=
=
=
=

Jurkat
LD50
MAP
MCF-7

=
=
=
=

MDAMB-231
MTS

=
=

MTT

=

NCI
PC-3
PDGF/R
RTK
SAR
SF-268
SH-SY5Y
U937
VEGF/R
WST-1

=
=
=
=
=
=
=
=
=
=

Human non-small cell lung adenocarcinoma
Cyclin dependent kinase
Stem cell factor receptor
Chronic mylogenous leukemia
Ehrlich ascitic carcinoma
Epidermal growth factor/receptor
Extracellular signal-related protein kinase
Fibroblast growth factor/receptor
Concentration required to inhibit the growth a cellular population by 50%
Glycogen synthase kinase 3
Human cervical carcinoma
Human promyleocytic leukemic cell line
Concentration required for 50% inhibition of a
biological or biochemical process in vitro
Human leukemic T-cell
Median lethal dose
Microtubule-associated protein
Human non-metastatic mammary gland adenocarcinoma
Human metastatic mammary gland adenocarcinoma
[3-(4,5-Dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt]
[3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide]
National Cancer Institute
Human prostate adenocarcinoma
Platelet-derived growth/receptor
Receptor tyrosine kinase
Structure activity relationship
Human glioblastoma
Human neuroblastoma
Human monocyte-like histiocytic lymphoma
Vascular endothelial growth factor/receptor
[2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4disulfophenyl)-2H-tetrazolium, monosodium salt]
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Silibinin might impede proliferation and invasion of MDA-MB-231 cells through
enhancing the mRNA expression of Lipocalin 2 and thus, impinging on phosphorylation
and activation of ERK 1/2. Furthermore, silibinin may cramp cathepsin B-dependent
invasion through induction of mRNA levels of cystatin M. Activation of procaspase 3 by
silibinin may trigger caspase3-mediated cleavage of NHE1 and subsequently, induction
of apoptosis in MDA-MB-231 cells.

C09 GENERATION OF FUSION PROTEIN WITH EGFRVIII EPITOPE
FUSED TO HBCAG AND ANTI-TUMOR EFFECT IN VIVO
X.Y. Duan1, J.S. Wang1, M.X. Zhang1, Y.M. Guo2
First affiliant hospital of Xi`an jiaotong university, Xi`an City, China. 2Second
affiliated Hospital of Xi`an Jiaotong University, Xi`an,710049, China

1

Background: The epidermal growth factor receptor (EGFR) play an important role in
tumor cell proliferation, differentiation and survival. The type variant III (EGFRvIII) is
the most common variation of EGFR and is correlated with tumor progression and poor
survival. Because EGFRvIII is present with high frequency in several different tumor
type and has not been detected in normal tissues, it is an ideal target for tumor specific
therapy.
Methods: Using genetic engineering technology, we developed the recombinant
fusion protein by inserting foreign epitope, encoding mutant region of EGFRvIII
(LEEKKGNYVVTDH) into the immunodominant e1 loop of the HBcAg. Next,
we immunized BALB/c mice with fusion protein, then detect antibody titer in sera.
ELISPOT was used to evaluate tumor-specific IFN-g-secreting cells after vaccination.
Using Renca-vIII(+) cells as specific stimulator, cytotoxic activity of splenocytes was
examined. BALB/c mice were challenged with Renca-vIII(+) cells after immunization
and the protective immune responses against the tumor cells were evaluated.
Results: Pep3-HBcAg/pET-28a(+) recombinant plasmids was construced successfully
as expected. EGFRvIII-HBcAg fusion proteins were adequately expressed in Escherichia
coli BL21 (DE3). Western blot analysis demonstrated that the fusion protein could
selectively combinate with EGFRvIII-specific antibody. Using ELISA, we found that the
titers of anti-fusion protein antibody in mice immunized with fusion protein were much
higher than those immunized with HBcAg or PBS. Further observation showed fusion
protein induced a high frequency of IFN-g-secreting lymphocytes. CD4+T cells rather
than CD8+T cells were associated with the production of IFN-g. Using Renca-vIII(+)
cell as specific stimulator, we observed remarkable cytotoxic activity in splenocytes from
mice immunized with fusion protein, which further indicate that anti-tumor effect of
fusion protein is EGFRvIII-specific. In vivo study, fusion protein showed resistance to
tumor development. These findings demonstrate that EGFRvIII-HBcAg fusion protein
triggered a protective response against tumor expressing EGFRvIII.
Conclusion: In this study, we successfully prepared the EGFRvIII-HBcAg fusion protein.
Immunization of animals with fusion protein stimulates a Ag-specific humoral response,
and confers protective immunity to tumor challenge of EGFRvIII(+) tumor cells. We
hope our approach will be helpful to the further research into a viable practical tumor
vaccine.

C10 PROMISING IN VITRO ANTITUMOR PROPERTIES OF NEWLY
SYNTHESIZED CAMPTOTHECIN GLUCURONIDE PRODRUG FOR
TARGETED TUMOR THERAPY BY ENZYME/PRODRUG STRATEGY
Z.M. Prijovich1, P.T. Huang1, Y.L. Leu2, S.R. Roffler1
IBMS, Academia Sinica, Taipei, Taiwan; 2Chia-Nan College of Pharmacy and
Sciences, Tainan Hsien, Taiwan

1

Systemic toxicity caused by non-selective mode of action, poor water solubility and
interaction with human serum albumin are major serious problems with existing
camptothecin drugs. We previously successfully solved most of the problems
conjugating camptothecin derivative 9AC with glucuronic acid via a self-immolative
linker to obtain a prodrug suitable for enzyme/prodrug tumor targeting therapy.
Despite excellent results on animal models, interaction with HSA remained an
obstacle for its use in humans. To overcome this problems an experimental anticancer
camptothecin derivative C70 is conjugated with glucuronic acid by the same approach
as 9AC producing C70-glucuronide (C70G). C70G is ~200 times more water soluble
than C70. It is stabile in human plasma, but can be completely re-activated to C70 by
enzymatic hydrolysis with variety of bacterial and mammalian b-glucuronidases. In
vitro anticancer properties of C70 and C70G toward a panel of cancer cell lines are
compared with the properties of other camptothecin derivatives, some of them already
in human use. C70 was most active among the drugs investigated with IC50 ~2 - 4
nM. C70G is about 30 times less toxic with IC50 ~100 nM. However, in presence
of b-glucuronidase C70G expressed the same activity as C70. Most important, C70
retained high activity with IC50 ~ 10 - 20 nM even when generated from C70G by
enzymatic hydrolysis in presence of 40 mg/ml of human serum albumin, a common
obstacle to many other camptothecin (pro)drugs. Overall, C70G may be promising
experimental anticancer (pro)drug suitable for monotherapy as well as for targeted
tumor therapies based on enzyme-prodrug concept.
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C11 PH-TRIGGERED RELEASE OF POTENT ISATIN-DERIVED
CYTOTOXINS CONJUGATED TO THE TUMOUR TARGETING
PROTEIN PAI-2
L. Matesic, K.L. Vine, J.M. Locke, M. Ranson, D. Skropeta
University of Wollongong, Wollongong, Australia
Introduction: N-Alkylated derivatives of 5,7-dibromoisatin, in particular those
containing N-benzyl, N-phenethyl and N-naphthylmethyl moieties (e.g. 1), have
been shown to possess sub-micromolar cytotoxicity in vitro against a diverse panel of
human cancer cell lines. To increase both the availability of these drugs at their target
site and to reduce unwanted side effects, the isatin derivatives were conjugated to free
lysines on the cancer targeting protein PAI-2 through an acid-labile imine linker. In
order to model the pH-triggered release mechanism of the cytotoxins the isatin derivatives were first conjugated to a single lysine amino acid residue and the hydrolysis
of these model conjugates were assessed.

Methods: Five structurally different isatin-lysine conjugates were synthesised using
standard peptide coupling techniques. The model conjugates were monitored for hydrolysis by UV-Vis spectrophotometry over a 4 hour period at 37°C at both lysosomal
and endosomal pH (4-5), while retaining stability at physiological pH. The isatin
conjugates with favourable kinetic profiles were then linked to PAI-2 via its free lysine
residues and their hydrolysis monitored by UV-Vis spectrophotometry at various pH
conditions. The isatin-PAI-2 conjugates were also examined in vitro against U937 and
THP-1 leukemic cell lines for evidence of internalisation and hydrolysis.
Results: All five model isatin-lysine conjugates were capable of cleaving and releasing
the free drug under mildly acidic conditions (e.g. pH 4 and pH 5), with varying degrees of stability at physiological pH. Extension of the imine chain length, such as with
a C3-propionic acid linker increased stability at pH 7 and was therefore chosen as the
linker for the isatin-PAI-2 conjugate. The C3-linked isatin-PAI-2 conjugate displayed
the most promising cell assay results, hydrolysis characteristics, and kinetic profile of
all the complexes examined.
Conclusions: The results demonstrate that potent isatin-based cytotoxins can be
successfully conjugated to free lysine residues on the tumour targeting agent PAI-2
through acid-labile imine linkers. These isatin-PAI-2 conjugates, while displaying
stability at physiological pH, are subsequently cleaved under mildly acidic conditions
such as endosomal and lysosomal pH. These results strongly suggest that isatin-PAI-2
conjugates warrant further development as a potential new and effective targeted
anticancer treatment.

C12 EVALUATION OF ANTITUMOR ACTIVITY AND MOLECULAR
MECHANISM OF PENTACYCLIC TRITERPENOID
LANTADENE A
M. Sharma1, P.D. Sharma2, M.P. Bansal3
1
Rayat Institute of Pharmacy, Railmajra, India; 2University Institute of
Pharmaceutical Sciences, Panjab University, Chandigarh, India;
3
Department of Biophysics, Panjab University, Chandigarh, India
Lantadene A (LA, 22b-angeloyloxy-3-oxoolean-12-en-28-oic acid) a pentacyclic
triterpenoid isolated from leaves of obnoxious weed Lantana camara L. was evaluated
for its antitumor activity. LA showed apoptosis in human leukemia HL-60 cell line.
Typical morphological changes including cell shrinkage, chromatin condensation and
characteristic DNA ladder formation in agarose gel electrophoresis were observed.
LA induced marked concentration and time dependant inhibition of cancer cell
proliferation with IC50 value of 19.8±0.10 µg/ml following 48h incubation. Flow
cytometric analysis showed suppressed cell proliferation associated with cell cycle
arrest in the G0/G1 phase. LA significantly inhibited cell proliferation of HL-60 cells
and induced cell apoptosis through down regulating Bcl-2 and up regulating Bax
expression. The peptidic caspase-3 inhibitors DEVD-CHO (NH2-Asp-Glu-Val-AspCHO, 2 µM), increased the viability of HL-60 cells, previously treated with LA. The
LA was further evaluated for its tumor suppression potential in DMBA/TPA induced
squamous cell carcinogenesis in Swiss albino mice. A significant decrease in the
incidence of number of lesions in mice was observed in LA treated groups as compared
to DMBA/TPA alone. The RNA of tumors were isolated, after 20 weeks study and
evaluated for various signaling factors like p53, p65 and c-jun. Significant increase
in the protein levels of c-jun, p65, and p53 by ELISA were observed in DMBA/TPA
treated mice tumors whereas less expression was observed in LA treated tumors.
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a b s t r a c t
In this study a series of isatin-based, pH-sensitive aryl imine derivatives with differing aromatic substituents and substitution patterns were synthesised and their acid-catalysed hydrolysis evaluated. These
derivatives were functionalised at the C3 carbonyl group of a potent N-substituted isatin cytotoxin and
were stable at physiological pH but readily cleaved at pH 4.5. Observed rates of hydrolysis for the
embedded imine-acid moiety were in the order para-phenylpropionic acid > phenylacetic acid
(para > meta) > benzoic acid (meta > para). The ability to ﬁne-tune hydrolysis rates in this way has potential implications for optimising imine linked, tumour targeting cytotoxin–protein conjugates.
Ó 2011 Elsevier Ltd. All rights reserved.

1. Introduction
A promising strategy for anti-cancer drug delivery involves conjugating a cytotoxin with a tumour targeting protein through an
acid-labile linker that is stable at physiological pH.1,2 Internalisation at the target tumour site via processes such as receptor mediated endocytosis3 exposes the conjugate to the acidic environment
of the endosomes or lysosomes (pH 4.5–6.0), resulting in selective
release of the original cytotoxin inside the tumour cell.4,5
Over the years, a wide variety of functional groups have been employed in the development of linkers that are stable at physiological
pH (7.4), but cleave at endosomal/lysosomal pH including acidsensitive hydrazones,6–9 cis-aconityl groups,10 trityl groups,4,11
orthoesters12 and N-ethoxybenzylimidazoles.13 In particular, the
antineoplastic anthracyclines doxorubicin and daunorubicin have
been conjugated through hydrazone and cis-aconityl linkers.4,6,10,14,15 The hydrazone linker has, however, been reported to
cleave at non-target sites16 and at pH 7.4,17 which suggests that this
linker may be unstable in the circulatory system. Other less commonly employed acid-labile linkers include acetals,18,19 ketals,19
oximes20 and imines.21,22
The imine group as part of a selective acid-sensitive linker to tumour targeting proteins was of potential interest in our work on

⇑ Corresponding author. Tel.: +61 2 42214360; fax: +61 2 4221 4287.
E-mail addresses: skropeta@uowmail.edu.au, skropeta@uow.edu.au (D. Skropeta).
0968-0896/$ - see front matter Ó 2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2011.01.015

potent isatin-based cytotoxins.23–25 The cytotoxicities against
U937 lymphoma cells of these compounds, together with that of
isatin itself for comparison purposes, is shown in Figure 1.
The most potent isatin-based cytotoxins we have developed are
derivatised on both the aromatic ring and via N-substitution.23–25
Therefore the aim of this study was to generate a pH-sensitive linker that did not interfere with these areas of the molecule, but instead capitalised on the available carbonyl group at C-3, which is
present in all of our isatin-derived cytotoxins. This could be
achieved using an imine linker. Although imine linkers are not
widely employed in drug delivery,26 they have gained attention
in recent years with several studies showing that aromatic imines
with extended p–p conjugation are stable at physiological pH,
while readily hydrolysing in mildly acidic solutions (e.g., pH
4.5–6.8).27–31
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Figure 1. Cytotoxic activity of isatin and its derivatives against the human
monocyte-like histiocytic lymphoma U937 cell line.23–25
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Scheme 1. Reagents and conditions: (a) EtOH, AcOH (cat.), reﬂux, 1.5 h, 18–71%; (b) DCC, HOBt, DIPEA, Ac-Lys-OMeHCl, CH2Cl2, rt, 24 h, 41–82% (PMB = paramethoxybenzyl).

Thus, reaction of our isatin-derived cytotoxins (e.g., 1) with a
bifunctional linker such as the anilino carboxylic acids 2a–e,
would give the aryl imine linked cytotoxins 3a–e shown in
Scheme 1. These compounds, with a free carboxylic acid available for potential coupling via amide formation to the exposed
lysine residues on a suitable tumour targeting protein, would
be expected to be stabilised by extended resonance delocalisation. Furthermore, acid-catalysed hydrolysis of the imine-linked
cytotoxins should result in selective release of the original isatin
cytotoxin (1). This would be an improvement over some of the
existing pH-sensitive bioconjugation strategies, where hydrolysis
of the linker generates a modiﬁed derivative of lower potency
than the original cytotoxin.13
The benchmark chemical studies required to establish the
imine group as a feasible cytotoxin linking option for isatins, together with related model work, are now presented in this paper. In particular, we have prepared the aryl imine derivatives
(3a–e) of the cytotoxic isatin (1) via reaction with the bifunctional, acid–amine linkers (2a–e) (Scheme 1). The carboxylic
moieties in 3a–e were then used to react with the e-amino
group of an a-N,C-protected lysine derivative to afford the
amides (4a–e), as a preliminary model of such reactions with
protein based lysine residues. The hydrolytic efﬁciencies of the
imines (3a–e) and amides (4a–e) were evaluated using UV–vis
spectrophotometry. Herein, we report the ﬁrst instance of the
pH-dependent selective release of a potent N-alkylisatin derived
cytotoxin through the acid-catalysed hydrolysis of an aryl imine
linker.

2. Results
2.1. Synthesis
The ﬁve novel aryl imine derivatives 3a–e were readily prepared by the acid-catalysed reaction of the brominated cytotoxin,
N-para-methoxybenzylisatin cytotoxin (1), with a range of commercially available anilino carboxylic acids (2a–e), differing in
terms of their aromatic substitution patterns and by the length
of the linker between the aromatic ring and the carboxylic acid
moiety (Scheme 1). For this study, para- and meta-benzoic (2a,
2d), para- and meta-phenylacetic (2b, 2e) and para-phenylpropionic (2c) anilino carboxylic acids were selected. The isatin 1 and
the appropriate acids 2a–e were then heated at reﬂux in MeOH
or EtOH together with a catalytic amount of AcOH for 1.5 h to yield
the imines 3a–e. Reactions in this study proceeded in moderate to
high yield, with the phenylacetic and phenylpropionic acids (e.g.,
3b, 3c, 3e) affording higher yields. Imines 3b–e were produced
in higher yields with the higher boiling EtOH rather than MeOH,
while 3a was the only imine to favour MeOH over EtOH. Lack of
the AcOH catalyst led to a decrease in chemical yield. There was
also no evidence, as seen by 1H NMR spectroscopy, (DMSO-d6) of
self-cleavage of the imines 3a–e to the free isatin 1.
Imines 3a–e were obtained as mixtures of E and Z isomers about
the imine bond and could not be separated by either thin-layer
chromatography or HPLC, as has been reported for other 3-arylimino-2-indolinones.32 The 1H NMR spectra of the imines 3a–e in
DMSO-d6, revealed that most compounds (3a–d) were synthesised
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as approximately 1:1 mixtures of E/Z isomers, apart from the metaphenylacetic imine (3e) where the E isomer was favoured over the
Z isomer in an approximate 2:1 ratio. The E stereochemistry was
assigned to a particular isomer based on the following: the signal
from H4 (on the isatin core) of the E isomer in the 1H NMR spectrum was shifted upﬁeld 1.2–1.4 ppm relative to the H4 signals
of the Z isomer and the parent compound 1, presumably due to
shielding by the ring current on the iminophenyl ring. The isomeric
ratios of each compound were therefore determined by comparing
the size of the integrals from the H4 signals of the E and Z isomers,
as has been described previously by our group for a related series
of compounds.23 Although some 2-indolinones containing a substituent at C-3 have been described as predominantly E isomers,33
elsewhere it has been reported that the E and Z isomers of 3-imino-2-indolinones interconvert rapidly in solution at room temperature and that the ratio of isomers is solvent dependent.32 The
imines 3b–e were formed in good yields (56–71%), whereas 3a
was obtained in only 18% yield. This presumably results from the
reduced nucleophilicity of the amino moiety in 3a, relative to that
in 3b–e, due to the strong electron withdrawing effect of the parasubstituted carboxyl group.
The imino acids (3a–e) were then selectively coupled to the
protected lysine derivative Ac-Lys-OMe under standard carbodiimide coupling procedures,34,35 to give the desired novel imine–lysine
model conjugates 4a–e in good to excellent yields (Scheme 1).
Once again, the 1H NMR spectra (CDCl3) of the isatin–lysine series
(4a–e) revealed that most compounds (4a–d) were synthesised as
approximately 1:1 mixtures of E/Z isomers, apart from the metaphenylacetic analogue (4e) where the Z isomer was favoured over
the E isomer in an approximate 2:1 ratio, the reverse ratio to that
observed for the precursor imine 3e. This may, however, be due to
the change in NMR solvent from DMSO-d6 with 3e to CDCl3 with
4e, as has been observed for other imines.32 All of the imines
(3a–e, 4a–e) were fully characterised by 1H and 13C NMR spectroscopy and mass spectrometry.
2.2. Hydrolysis studies
The rate of acid-catalysed hydrolysis in the imino acids 3a–e as
a function of imine absorbance at k = 435 nm over time is shown in
Figure 2A (middle panel). Analysis of the hydrolysis kinetics conducted at pH 4.5 (37 °C) indicated an exponential ﬁrst order decay
process as evidenced by the ln (A/A0) versus time plots (Fig. 2A,
bottom panel), which showed a linear relationship at the initial
reaction times. The ﬁrst order rate constants, k, determined
by non-linear regression, ranged from 0.95 to 3.99  102 min1
(Table 1), which is comparable to those reported in an earlier study
by Kalavska et al. of acid-catalysed hydrolysis of some substituted
derivatives of 3-phenyliminoxindole at pH 2.0–5.0.36 It should be
noted, however, that these derivatives differ from those herein in
that they are neither N-alkylated nor halogenated on the isatin aromatic ring, and bear different imino aryl substituents at the C3 position. The fastest hydrolysis rate, as indicated by the largest k
value, was observed for the para-phenylpropionic acid derivative
3c, with a half-life of 17.4 min. Conversely, the smallest k value
was found for the para-benzoic acid derivative 3a, which displayed
a fourfold greater half-life of 72.6 min. As discussed earlier, this
compound had the lowest yield of imine formation (18%). In contrast, imines which demonstrated efﬁcient hydrolytic release (3b,
3d, and 3e) were formed in good yields (>68%). These three imino
acid derivatives did not show any signiﬁcant differences to one another in their hydrolysis rates, as judged by one-way ANOVA, and
displayed half-lives ranging from 24.3 to 29.7 min. Although compounds 3a–e were monitored kinetically over a 240 min period, results are only displayed over a 60 min period as all derivatives
reached a plateau in terms of hydrolysis in less than 240 min. No
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hydrolysis was detected for the derivatives 3a–e when maintained
at physiological pH (7.4) in 1 M HEPES buffer at 37 °C over a
240 min period (the ﬁrst 60 min shown in Fig. 2A, top panel).
A similar trend in the rate of hydrolysis was obtained for the
imino lysine conjugates 4a–e (Fig. 2B) with ﬁrst order rate constants, k, ranging from 0.81 to 4.07  102 min1 (Table 1). Again,
the fastest hydrolysis rate was observed for the para-phenylpropionic acid derivative 4c with a half-life of 17.0 min, and the lowest
hydrolysis rate was found for the para-benzoic acid derivative 4a,
which had a ﬁvefold greater half-life of 85.2 min. In this case, the
hydrolysis rates of all but 4d versus 4e were found to be signiﬁcantly different from one another, as judged by one-way ANOVA,
with the para-phenylacetic acid derivative 4b signiﬁcantly faster
than both 4d and 4e, with half-lives of 34.1 and 33.0 min, respectively, compared to 23.0 min for 4b. As for the imino acids 3a–e, no
hydrolysis was detected for the imino lysine derivatives 4a–e
when maintained at physiological pH (7.4) in 1 M HEPES buffer
at 37 °C over a 240 min period (Figure 2B, top panel).
Hydrolysis of the various derivatives was found to depend on
the aromatic substitution pattern and linker length and was not
inﬂuenced by whether the derivatives were in the imino acid or
imino lysine form. This can be seen by comparing the hydrolysis
rates of each pair of derivatives (e.g., 3a: k = 0.95  102 min1 vs
4a: k = 0.81  102 min1), which showed no signiﬁcant difference
as judged by one-way ANOVA (see Supplementary data).
In addition to the hydrolysis experiments conducted at physiological temperatures (37 °C), selected hydrolyses for 3a, 3b and 3d
were also conducted at ambient temperature. As expected, the rates
of hydrolysis at pH 4.5 were signiﬁcantly lower at 23 °C compared to
those conducted at 37 °C, while no hydrolysis was detected at physiological pH at either 23 °C or 37 °C (see Supplementary data).
3. Discussion and conclusion
We have reacted various anilino carboxylic acids (2a–e) with
the potent cytotoxin para-methoxybenzylisatin (1) to generate a
series of aryl imine derivatives (3a–e, Scheme 1) with differing aromatic substitution patterns and linker length. Alkyl imine derivatives are known to hydrolyse at physiological pH, however, aryl
imines are signiﬁcantly more stable and have found recent potential application as pH-sensitive linkers in drug delivery.27–31
Accordingly, the aryl imines we prepared were all found to be stable at physiological pH but readily cleaved at reduced pH. Furthermore, in order to model the conjugation of these acid-labile
derivatives to the lysine residues of a tumour-targeting protein,
the aryl imines 3a–e were coupled via their free carboxylic acids
to a protected lysine amino acid residue to produce a novel series
of aryl imine-lysine conjugates 4a–e. These were all found to be
stable for an extended period at pH 7.4 but readily cleaved in aqueous acidic solutions at physiological temperature, with half-lives
ranging from 17.0 to 85.2 min, consistent with those reported recently for the acid-catalysed hydrolysis of other aryl imines.31
The rates of acid-catalysed hydrolysis of both the imino acids
3a–e and imino lysines 4a–e, followed the expected trend, with
the para-phenyl propionic acid derivatives (3c and 4c) displaying
the fastest hydrolysis rates, and the para-benzoic acid derivatives
(3a and 4a) displaying the lowest rates.
Acid-catalysed hydrolysis of imines involves the protonation of
the imine to give an iminum species, which undergoes nucleophilic
attack by water. This gives an unstable hemiaminal intermediate,
which upon protonation of the amine nitrogen, readily collapses
to the protonated ketone and free amine, with subsequent proton
loss furnishing the ketone.37 The crucial ﬁrst step in the mechanism, imine protonation, is largely dependent on the basicity of
the imine. In derivatives 3a and 4a, the electron-withdrawing carbonyl group directly attached to the para-position on the phenyl
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Figure 2. Rates of hydrolysis expressed as a function of absorbance (A/Ao) over time (pH 7.4 top panel and pH 4.5 middle panel) and the natural log of absorbance (A/Ao) over
time (bottom panel, pH 4.5), measured at 435 nm in 1 M sodium acetate buffer at 37 °C for (A, middle panel): the imino acid derivatives 3a–e (⁄P <0.05 for 3a vs 3b–e; 3c vs
3b, 3d and 3e); and (B, middle panel): the imino lysine derivatives 4a–e (⁄P <0.05 for 4a vs 4b–e; 4b vs 4c–e; 4c vs 4d and 4e).

Table 1
Rate constants (k) and half-lives (t1/2) for the hydrolysis of the imino acids 3a–e and
the imino lysines 4a–e at pH 4.5a

O
O

O
N
Br
O
Br
Imine

OH
R

n

H +/37°C

O

N
PMB
n

O
Br

Substitution pattern

R = OH
3a
0
para3b
1
para3c
2
para3d
0
meta3e
1
metaR = (CH2)4CH(NHAc)CO2Me
4a
0
para4b
1
para4c
2
para4d
0
meta4e
1
meta-

N
PMB

n

H 2N

OH

N

O

Br

N

Br

t1/2 (min)

0.95 ± 0.0  102
2.85 ± 0.2  102
3.99 ± 0.3  102
2.33 ± 0.2  102
2.55 ± 0.2  102

72.6
24.3
17.4
29.7
27.2

0.81 ± 0.0  102
3.02 ± 0.2  102
4.07 ± 0.2  102
2.03 ± 0.1  102
2.10 ± 0.1  102

85.2
23.0
17.0
34.1
33.0

a
Rates of hydrolysis were measured at 37 °C in 1 M sodium acetate buffer at pH
4.5 using UV spectrophotometry (k = 435 nm). See Section 4 for further details.

ring, will reduce the relative basicity of the imine nitrogen through
extended conjugation (Fig. 3), leading to lower rates of hydrolysis
as observed. Conversely, for the homologous 3b and 4b derivatives,
conjugation with the acid or amide carbonyl is disrupted leading to
greater availability of the imine nitrogen lone pair of electrons for
protonation. Furthermore, hyperconjugation38 in these neutral
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Figure 3. Resonance contributors of the imine 3a showing extended p
delocalisation.

derivatives could be involved in increasing electron density on
the carbon adjacent to the imine nitrogen and thereby its relative
basicity. This hyperconjugative interaction could be more signiﬁcant with the para-propionic derivatives 3c and 4c, with the counter delocalising effect of the carbonyl group adjacent to the
negative charge on the Ar–CH carbon being removed. The hyperconjugative effects associated with these groups in the meta-position would not be expected to have a marked effect on the imine
basicity.
Our results are consistent with those from complementary
studies on 3-phenyliminoxindole derivatives, where it was found
that electron-donating groups at the para-position of the aryl ring
enhanced the rates of acid-catalysed hydrolysis.36 Conversely, the
incorporation of electron-withdrawing groups on a series of related aryl imines were found to have a stabilising effect at physiological pH.31 Thus, it is expected that the incorporation of other
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electron donating or withdrawing groups would allow for more
tunable hydrolysis rates of imine-based compounds.
Adjusting the linker length was more important in determining
hydrolysis rates in the para-series compared to the meta-series. For
both the para-substituted carboxylic acid derivatives 3a–c and the
lysine derivatives 4a–c, lengthening the linker resulted in a significant increase in the hydrolysis rate. However, the two metasubstituted derivatives in each series (3b,d and 4b,d), showed no
signiﬁcant difference in their hydrolysis rates. Overall, it appears
that electronic effects such as the presence or absence of a conjugated electron-withdrawing group may play a larger role in determining the hydrolysis rate than extending the linker.
In this study we chose the para-methoxybenzylisatin (1), which
has an IC50 value of 1.83 lM24 against the human monocyte-like
histiocytic lymphoma U937 cell line, as our starting cytotoxin
due to its ready synthetic availability and structural simplicity,
which facilitates product characterisation via NMR spectroscopy.
While 1 is less active than our most promising cytotoxins
(IC50 = 1.83 lM vs <1 lM, respectively),24 the bioconjugation strategy presented here should apply equally well to any of the Nsubstituted isatin derived cytotoxins we have developed, all of
which contain an available carbonyl at C-3. This strategy is also
potentially applicable to the bioconjugation of well known anticancer agents such as epipodophyllotoxin, camptothecin and colchicine to enhance their effectiveness even further.39,40 In
conclusion, a series of novel aryl imine linked isatins (3a–e), which
could potentially be coupled to the lysine residues of a tumour targeting protein via standard peptide coupling techniques, were synthesised from the N-substituted isatin-derived cytotoxin (1).
Compounds (3a–e) and the model lysine coupled derivatives
(4a–e) are stable at physiological pH but readily undergo acid-catalysed imine hydrolysis at pH 4.5. Furthermore, the rate of hydrolysis can be ﬁne-tuned through the use of different aromatic
substitution patterns on the anilino carboxylic acids (2a–e) and
by adjusting the linker length. Based on the strategy described
here, work is currently underway on the development of potential
imine-linked N-alkylisatin based tumour targeting cytotoxin-protein conjugates.

4. Experimental
4.1. Synthesis
All chemicals were purchased from Sigma–Aldrich Chemical Co.
(St. Louis, MO, USA), BDH Laboratory Supplies (Poole, England) or
Bachem (AusPep, Parkville, Australia) and used as supplied. Flash
column chromatography41 was performed on Silica Gel 60
(230–400 mesh). Thin layer chromatography (TLC) on aluminium
backed sheets of Merck Silica Gel 60 F254 plates were employed
to monitor the progress of chemical reactions. Preparative TLC
was performed on 20  20 cm plates. Solvent ratios are v/v and solvents were removed by rotary evaporation in vacuo. IR spectra
were obtained on a Nicolet Avatar 360 FT-IR spectrometer. NMR
spectra were acquired on a Varian Inova 500 spectrometer, where
the proton (1H) and carbon (13C) were obtained at 500 and
126 MHz, respectively. All spectra were obtained with a probe
temperature of 298 K. Hydrogen and carbon assignments were also
made using gradient correlation spectroscopy (gCOSY), gradient
heteronuclear single quantum correlation (gHSQC) and gradient
heteronuclear multiple bond correlation (gHMBC) spectroscopic
techniques. Low resolution electrospray ionisation mass spectra
(ESI) were obtained using a Waters Platform LCZ spectrometer
and high resolution ESI spectra (HRMS) on a Waters Q-TOF Ultima
spectrometer. Melting points were obtained using a Reichert melting point apparatus and are uncorrected.
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4.1.1. General procedure for the synthesis of the imines (3a–e)
Activated 3 Å sieves (1 g per 100 mg of 1), the isatin 1 (1 equiv)
and EtOH (7.5 mL per 100 mg of 1) (MeOH was used for 3a) were
sonicated for 10 min. The acid (2a–e, 1 equiv) was added and the
mixture sonicated for a further 5 min before the addition of glacial
AcOH (0.2 mL per 100 mg of 1). The reaction mixture was heated at
reﬂux for 1.5 h, the sieves were ﬁltered and the solution was evaporated. The resulting solid was puriﬁed by column chromatography on silica gel using a CHCl3/MeOH gradient of 100:0 to 95:5
to yield isatins 3a–e.
4.1.1.1. (E and Z)-4-[5,7-Dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3-ylideneamino]benzoic acid (3a).
Orange powder
(46.5 mg, 18%); mixture of E and Z isomers (E/Z 48:52); mp 250–
252 °C; Rf 0.26 (silica, DCM); IR mmax 2955 (COOH), 1696 (CO),
1598, 1515, 1446, 1248, 1143, 863, 810 cm1. dH (500 MHz;
DMSO-d6): 3.71 (s, 3H), 3.73 (s, 3H), 5.12 (s, 2H), 5.30 (s, 2H),
6.44 (s, 1H), 6.86 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 8.0 Hz, 2H), 7.13
(d, J = 7.5 Hz, 4H), 7.18 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H),
7.84 (s, 1H), 7.87 (s, 1H), 7.91 (d, J = 8.5 Hz, 2H), 7.93 (s, 1H), 8.08
(d, J = 8.0 Hz, 2H); dC (126 MHz; DMSO-d6): 44.0, 44.5, 55.6, 55.7,
104.2, 104.8, 113.2, 114.6,à 114.6, 114.9, 116.1, 117.6, . 119.5, .
120.6, 125.5, 126.3, 127.7, . 128.2, . 128.2, . 129.3, 129.4, . 130.6, .
131.9, 141.1, 141.3, 143.3, 144.5, 151.1, 152.4, 153.4, 154.0, 158.1,
159.1, . 163.5, 167.6, 167.8. MS (ESI-) m/z: 541; 543; 545 [MH];
79
Br79Br; 79Br81Br; 81Br81Br; HRMS (ESI-) m/z: calcd for
C23H15N2O479Br79Br: 540.9399 [MH]; found: 540.9496 [MH].
4.1.1.2. (E and Z)-2-{4-[5,7-Dibromo-1-(4-methoxybenzyl)-2oxoindolin-3-ylideneamino]phenyl}acetic acid (3b).
Red
crystals (356 mg, 68%); mixture of E and Z isomers (E/Z 58:42);
mp 151153 °C. Rf 0.40 (silica, DCM/MeOH 9:1); IR mmax 2935
(COOH), 1708 (CO), 1516, 1445, 1309, 1247, 1142, 802, 753 cm1.
dH (500 MHz; DMSO-d6): 3.57 (s, 2H), 3.65 (s, 2H), 3.71 (s, 3H),
3.73 (s, 3H), 5.14 (s, 2H), 5.30 (s, 2H), 6.60 (d, J = 1.5 Hz, 1H), 6.87
(d, J = 9.0 Hz, 2H), 6.90 (d, J = 9.0 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H),
7.13 (d, J = 8.5 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.24 (t, J = 7.5 Hz,
4H), 7.41 (d, J = 8.5 Hz, 2H), 7.81 (d, J = 2.0 Hz, 2H), 7.89 (d,
J = 2.0 Hz, 1H).à dC (126 MHz; DMSO-d6): d 44.0, 44.6, 55.8, .
104.1, 104.8, 112.5, 114.5, 114.7, . 115.0, 116.1, 117.8, . 120.7, .
121.1, . 125.1, 127.0, 127.6, 128.2, . 128.3, . 129.5, 130.1, 130.5, .
131.5, . 133.5, 133.7, 141.1, 142.8, 144.4, 146.8, 148.0, 148.9,
158.2, 159.1, . 163.8, 173.5. . MS (ESI+) m/z: 557; 559; 561
[MH]+; 79Br79Br; 79Br81Br; 81Br81Br; HRMS (ESI+) m/z: calcd for
C24H19N2O479Br81Br: 558.9692 [MH]+; found 558.9678 [MH]+.
4.1.1.3. (E and Z)-3-{4-[5,7-Dibromo-1-(4-methoxybenzyl)-2oxoindolin-3-ylideneamino]phenyl}propanoic acid (3c).
Orange/red crystals (384 mg, 71%); mixture of E and Z isomers
(E/Z 55:45); mp 79–81 °C; Rf 0.43 (silica, DCM/MeOH 9:1); IR mmax
2986 (COOH), 1718 (CO), 1514, 1445, 1320, 1247, 1140, 848 cm1.
dH (500 MHz; DMSO-d6): 2.55 (t, J = 7.5 Hz, 2H), 2.56 (t, J = 8.0 Hz,
2H), 2.83 (t, J = 7.5 Hz, 2H), 2.89 (t, J = 7.5 Hz, 2H), 3.71 (s, 3H),
3.73 (s, 3H), 5.15 (s, 2H), 5.29 (s, 2H), 6.54 (s, 1H), 6.86 (d,
J = 8.0 Hz, 2H), 6.90 (d, J = 7.5 Hz, 2H), 6.96 (d, J = 7.5 Hz, 2H),
7.13 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 7.22–7.24 (m, 4H),
7.38 (d, J = 8.0 Hz, 2H), 7.80 (m, 2H), 7.88 (s, 1H).à dC (126 MHz;
DMSO-d6): 30.7, 30.8, 36.1, 36.5, 44.0, 44.5, 55.7, 55.8, 104.0,
104.7, 114.6, . 114.6, . 114.9, 116.0, 117.8, . 120.6, . 121.5, 124.9,
127.0, 127.5, 128.1, . 128.3, . 128.8, . 129.4, 129.5, 130.2, . 139.5,
140.0, 140.4, 140.9, 142.6, 144.2, 146.4, 148.4, 149.8, 152.3,
158.0, 159.0, 159.1, 163.7, 174.5. . MS (ESI-) m/z: 569; 571; 573

à

Coincident peaks.
Carboxylic acid proton not detected.
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[MH]; 79Br79Br; 79Br81Br; 81Br81Br; HRMS (ESI-) m/z: calcd for
C24H19N2O279Br81Br: 526.9799 [MCO2H]; found 526.9722
[MCO2H].
4.1.1.4. (E and Z)-3-[5,7-Dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3-ylideneamino]benzoic acid (3d).
Orange powder
(144 mg, 56%); mixture of E and Z isomers (E/Z 49:51); mp 229–
231 °C; Rf 0.37 (silica, DCM/MeOH 9:1); IR mmax 2950 (COOH),
1719 (CO), 1698, 1515, 1449, 1297, 1250, 1141, 812, 768 cm1.
dH (500 MHz; DMSO-d6): 3.71 (s, 3H), 3.73 (s, 3H), 5.13 (s, 2H),
5.30 (s, 2H), 6.41 (s, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.90 (d,
J = 9.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H),
7.29 (d, J = 7.5 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz,
1H), 7.59 (s, 1H), 7.65 (t, J = 8.0 Hz, 2H), 7.74 (d, J = 7.5 Hz, 1H),
7.82 (s, 1H), 7.85 (s, 1H), 7.88 (d, J = 7.5 Hz, 1H), 7.91 (s, 1H),
13.13 (br s, 2H). dC (126 MHz; DMSO-d6): d 44.0, 44.5, 55.7, .
104.1, 104.7, 114.6, . 114.6, . 114.8, 116.0, 118.3, 120.7, 120.9,
122.0, 124.5, 125.2, 126.6, 126.8, 126.9, 127.5, 128.1, . 128.2, .
129.3, . 129.4, 130.8, 132.1, 140.8, 141.0, 143.1, 144.5, 149.1,
150.4, 151.2, 153.0, 158.1, 159.0, . 163.6, 167.5, 167.8. . MS (ESI-)
m/z: 541; 543; 545 [MH]; 79Br79Br; 79Br81Br; 81Br81Br; HRMS
(ESI-) m/z: calcd for C23H15N2O479Br79Br: 540.9399 [MH]; found
540.9424 [MH].
4.1.1.5. (E and Z)-2-{3-[5,7-Dibromo-1-(4-methoxybenzyl)-2oxoindolin-3-ylideneamino]phenyl}acetic acid (3e).
Red
powder (187 mg, 71%); mixture of E and Z isomers (E/Z 67:33);
mp 182–184 °C; Rf 0.33 (silica, DCM/MeOH 9:1); IR mmax 2944
(COOH), 1719 (CO), 1698, 1515, 1449, 1297, 1250, 1141, 812,
768 cm1. dH (500 MHz; DMSO-d6): d 3.56 (s, 2H), 3.63 (s, 2H),
3.71 (s, 3H), 3.73 (s, 3H), 5.14 (s, 2H), 5.30 (s, 2H), 6.61 (s, 1H),
6.86 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.94 (d, J = 8.5 Hz,
1H), 7.04 (s, 1H), 7.08 (d, J = 7.5 Hz, 1H), 7.17 (d, J = 8.5 Hz, 2H),
7.20 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.28 (t, J = 7.5 Hz,
1H), 7.46 (t, J = 7.5 Hz, 1H), 7.78–7.80 (m, 2H), 7.90 (s, 1H), 8.00
(s, 1H).à dC (126 MHz; DMSO-d6): 41.2, 41.6, 43.9, 44.5, 55.7, .
104.1, 104.6, 114.5, . 114.6, . 115.1, 115.4, 115.9, 116.0, 117.4,
118.6, 118.7, 120.6, 121.8, 125.0, 126.8, 126.9, 127.3, 127.5,
127.8, 128.1, . 128.2, . 128.8, 129.3, 129.4, 130.3, 140.6, 141.0,
142.8, 144.3, 148.6, 150.3, 152.3, 158.0, 159.0, . 163.7, 173.0,
173.1. MS (ESI-) m/z: 555; 557; 559 [MH]; 79Br79Br; 79Br81Br;
81
Br81Br; HRMS (ESI-) m/z: calcd for C24H17N2O479Br81Br:
556.9535 [MH]; found 556.9568 [MH].
4.1.2. General procedure for the synthesis of the imine–lysine
conjugates (4a–e)
The isatin imine (3a–e, 1 equiv) was dissolved in dry DCM (1 mL
per 30 mg of imine) with the aid of sonication. On ice, 1-hydroxybenzotriazole hydrate (HOBt) (1 equiv) was added, followed by
N,N0 -dicyclohexylcarbodiimide (DCC) (1 equiv), N,N-diisopropylethylamine (DIPEA) (1.1 equiv) and (S)-Na-acetyl-lysine methyl ester hydrochloride (Ac-Lys-OMeHCl) (1 equiv). The reaction
mixture was warmed to rt and stirred for 24 h. The precipitate
was removed by ﬁltration and the ﬁltrate evaporated. The resulting
solid was puriﬁed by column chromatography on silica gel using a
CHCl3/MeOH gradient of 100:0 to 95:5 to yield the imine-lysine
conjugate 4a–e.
4.1.2.1. Methyl (S,E and S,Z)-2-acetamido-6-{4-[5,7-dibromo-1(4-methoxybenzyl)-2-oxoindolin-3-ylideneamino]benzamido}
hexanoate (4a).
Orange crystals (18.7 mg, 50%); mixture of E
and Z isomers (E/Z 53:47); mp 165–167 °C; Rf 0.41 (silica, CHCl3/
MeOH 95:5). dH (500 MHz; CDCl3): 1.39–1.89 (m, 12H), 2.00 (s,
6H), 3.42–3.53 (m, 4H), 3.73 (s, 3H), 3.75 (s, 3H), 3.77 (s, 3H),
3.79 (s, 3H), 4.59–4.64 (m, 2H), 5.24 (s, 2H), 5.44 (s, 2H), 6.23
(dd, J = 7.0, 15 Hz, 2H), 6.33 (br s, 1H), 6.51 (br s, 1H), 6.77

(s, 1H), 6.82 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 7.03 (d,
J = 8.5 Hz, 2H), 7.06 (d, J = 8.5 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H),
7.22 (d, J = 8.0 Hz, 2H), 7.61 (s, 1H), 7.72 (s, 1H), 7.81 (d,
J = 7.5 Hz, 2H), 7.84 (s, 1H), 7.96 (d, J = 8.5 Hz, 2H). dC (126 MHz;
CDCl3): 22.5, 22.6, 23.4, . 28.7, 29.1, 32.2, 32.5, 39.5, 39.7, 44.0,
44.6, 51.9, 52.1, 52.7, . 55.5, . 104.0, 104.8, 111.4, 114.4, . 114.4, .
115.9, 116.8, 117.4, . 119.4, . 119.6, 120.6, 125.8, 127.9, . 128.2, .
128.3, . 128.4, 129.1, . 132.1, 133.2, 141.5, 142.1, 142.5, 144.2,
146.6, 150.4, 151.4, 151.9, 152.1, 157.6, 159.3, . 163.6, 167.0,
167.4, 170.0, 170.5, 173.3. . MS (ESI+) m/z: 727; 729; 731 [MH]+;
749; 751; 753 [M+Na]+; 79Br79Br; 79Br81Br; 81Br81Br; HRMS (ESI+)
m/z: calcd for C32H32N4NaO679Br81Br: 751.0566 [M+Na]+; found
751.0531 [M+Na]+.
4.1.2.2. Methyl (S,E and S,Z)-2-acetamido-6-(2-{4-[5,7-dibromo1-(4-methoxybenzyl)-2-oxoindolin-3-ylideneamino]phenyl}acetamido)hexanoate
(4b).
Red
crystals
(33.3 mg, 41%); mixture of E and Z isomers (E/Z 49:51); mp 99–
101 °C; Rf 0.33 (silica, CHCl3/MeOH 95:5). dH (500 MHz; CDCl3):
1.21–1.82 (m, 12H), 1.98 (s, 3H), 2.02 (s, 3H), 3.17–3.27 (m, 4H),
3.57 (s, 2H), 3.62 (s, 2H), 3.71 (s, 3H), 3.73 (s, 3H), 3.76 (s, 3H),
3.78 (s, 3H), 4.51–4.58 (m, 2H), 5.27 (s, 2H), 5.43 (s, 2H), 5.65 (br
s, 1H), 5.72 (br s, 1H), 6.23 (d, J = 8.0 Hz, 1H), 6.27 (d, J = 8.0 Hz,
1H), 6.80 (d, J = 1.5 Hz, 1H), 6.82 (d, J = 8.5 Hz, 2H), 6.85 (d,
J = 8.0 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 7.11–7.15 (m, 4H), 7.22 (d,
J = 9.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.40–7.46 (m, 2H), 7.59 (d,
J = 1.5 Hz, 1H), 7.69 (s, 1H), 7.83 (d, J = 1.5 Hz, 1H). dC (126 MHz;
CDCl3): d 22.5, . 23.3, 23.4, 29.1, 30.0, 31.9, 32.2, 39.2, 39.3, 43.5,
43.7, 44.0, 44.6, 52.1, . 52.6, 52.7, 55.5, . 104.0, 104.7, 114.3, .
114.4, . 115.6, 116.7, 117.4, 118.2, . 120.1, 121.1, . 125.5, 126.2,
127.7, 128.2, . 128.2, . 128.5, 128.9, 129.9, . 130.9, . 132.3, 133.3,
141.0, 141.7, 142.1, 144.0, 148.6, 149.7, 151.9, 157.9, 159.3, .
163.8, 170.4, . 171.2, 171.4, 173.2. . HRMS (ESI+) m/z: calcd for
C33H35N4O679Br81Br: 743.0903 [MH]+; found 743.0888 [MH]+.
4.1.2.3. Methyl (S,E and S,Z)-2-acetamido-6-(3-{4-[5,7-dibromo1-(4-methoxybenzyl)-2-oxoindolin-3-ylideneamino]phenyl}propanamido)hexanoate
(4c).
Red
powder
(111 mg, 70%); mixture of E and Z isomers (E/Z 55:45); mp 161–
163 °C; Rf 0.42 (silica, DCM/MeOH 9:1); IR mmax 3288 (NH), 1734
(CO), 1638, 1558, 1446, 1296, 1251, 1180, 1137, 804, 721 cm1.
dH (500 MHz; CDCl3): 1.29–1.82 (m, 12H), 1.99 (s, 3H), 2.03 (s,
3H), 2.43–2.52 (m, 4H), 2.94–3.04 (m, 4H), 3.12–3.27 (m, 4H),
3.72 (s, 3H), 3.73 (s, 3H), 3.76 (s, 3H), 3.78 (s, 3H), 4.55 (t,
J = 4.0 Hz, 2H), 5.27 (s, 2H), 5.43 (s, 2H), 5.62 (br s, 1H), 5.66 (br
s, 1H), 6.32 (d, J = 6.0 Hz, 2H), 6.81 (d, J = 4.0 Hz, 2H), 6.83 (s, 1H),
6.85 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 7.5 Hz, 2H), 7.10 (d, J = 8.0 Hz,
2H), 7.15 (d, J = 8.5 Hz, 2H), 7.21 (t, J = 7.5 Hz, 4H), 7.29 (d,
J = 8.0 Hz, 2H), 7.58 (s, 1H), 7.68 (s, 1H), 7.85 (s, 1H). dC
(126 MHz; CDCl3): 22.5, 22.6, 23.3, 23.4, 28.9, 29.1, 31.6, 31.7,
32.1, 32.3, 38.6, 38.9, 39.0, 39.1, 43.9, 44.6, 52.0, 52.1, 52.6, .
55.5, . 103.8, 104.6, 114.3, . 114.4, . 115.6, 116.6, 117.9, . 119.8,
121.2, . 125.4, 126.5, 128.1, 128.2, . 128.2, . 128.6, . 128.6, . 128.8,
129.9, 139.4, 140.1, 140.7, 141.5, 141.9, 144.0, 146.2, 147.7,
149.2, 151.8, 157.9, 159.2, 159.3, 163.9, 170.5, . 172.4, 172.6,
173.2. . MS (ESI+) m/z: 755; 757; 759 [MH]+; 79Br79Br; 79Br81Br;
81
Br81Br; HRMS (ESI+) m/z: calcd for C34H36N4NaO679Br81Br:
779.0879 [M+Na]+; found 779.0896 [M+Na]+.
4.1.2.4. Methyl (S,E and S,Z)-2-acetamido-6-{3-[5,7-dibromo-1(4-methoxybenzyl)-2-oxoindolin-3-ylideneamino]benzamido}
hexanoate (4d).
Orange crystals (83.4 mg, 78%); mixture of E
and Z isomers (E/Z 47:53); mp 74–76 °C; Rf 0.56 (silica, CHCl3/
MeOH 95:5). IR mmax 3293 (NH), 1734 (CO), 1645, 1547, 1446,
1318, 1249, 1142, 801, 721 cm1. dH (500 MHz; CDCl3): 1.36–
1.91 (m, 12H), 1.97 (t, J = 7.0 Hz, 6H), 3.41–3.48 (m, 4H), 3.72
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(s, 3H), 3.73 (s, 3H), 3.76 (s, 3H), 3.79 (s, 3H), 4.56–4.62 (m, 2H),
5.25 (s, 2H), 5.43 (s, 2H), 6.24 (d, J = 7.5 Hz, 1H), 6.28 (d,
J = 7.5 Hz, 1H), 6.40 (t, J = 5.5 Hz, 1H), 6.55 (t, J = 5.5 Hz, 1H), 6.70
(d, J = 1.5 Hz, 1H), 6.82 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H),
7.08 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 9.0 Hz, 2H), 7.21 (d, J = 9.0 Hz,
2H), 7.43 (t, J = 8.0 Hz, 1H), 7.46 (s, 1H), 7.53 (t, J = 8.0 Hz, 1H),
7.54 (d, J = 1.5 Hz, 1H), 7.59 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 8.0 Hz,
1H), 7.70 (d, J = 2.0 Hz, 1H), 7.74 (d, J = 7.5 Hz, 1H), 7.83 (d,
J = 2.0 Hz, 1H). dC (126 MHz; CDCl3): 22.5, 22.6, 23.3, 23.4, 28.7,
29.0, 32.1, 32.4, 39.5, 39.8, 44.0, 44.6, 51.9, 52.0, 52.6, 52.7, 55.5, .
104.0, 104.8, 114.3, . 114.4, . 115.8, 116.5, 116.7, 118.9, 120.1,
123.0, 124.7, 124.9, 125.6, 126.0, 126.9, 127.8, . 128.1, . 128.2, .
128.3, 128.4, 129.1, 130.2, 135.4, 141.3, 141.9, 142.3, 144.1,
148.3, 149.7, 150.4, 152.3, 157.8, 159.2, 159.3, 163.6, 166.9,
167.5, 170.4, 170.5, 173.2. . MS (ESI+) m/z: 727; 729; 731 [MH]+;
79
Br79Br; 79Br81Br; 81Br81Br. HRMS (ESI-) m/z: calcd for
C32H31N4O679Br81Br: 727.0590 [MH]; found 727.0380 [MH].
4.1.2.5. Methyl (S,E and S,Z)-2-acetamido-6-(2-{3-[5,7-dibromo1-(4-methoxybenzyl)-2-oxoindolin-3-ylideneamino]phenyl}
acetamido)hexanoate (4e).
Red powder (98.5 mg, 82%); mixture of E and Z isomers (E/Z 37:63); mp 194–196 °C; Rf 0.44 (silica,
DCM/MeOH 9:1). IR mmax 3288 (NH), 1721 (CO), 1647, 1558, 1516,
1447, 1316, 1252, 1140, 720 cm1. dH (500 MHz; CDCl3): d 1.16–
1.69 (m, 12H), 1.98 (s, 3H), 2.01 (s, 3H), 3.09 (m, 2H), 3.14–3.24
(m, 2H), 3.59 (s, 4H), 3.69 (s, 3H), 3.73 (s, 3H), 3.77 (s, 3H), 3.78
(s, 3H), 4.45 (d, J = 3.5 Hz, 1H), 4.53 (d, J = 3.5 Hz, 1H), 5.24 (s,
2H), 5.43 (s, 2H), 5.68 (br s, 1H), 5.91 (br s, 1H), 6.20-6.24 (m,
2H), 6.76 (s, 1H), 6.83 (d, J = 8.0 Hz, 4H), 6.91 (s, 2H), 7.03 (d,
J = 8.0 Hz, 1H), 7.10 (d, J = 8.5 Hz, 4H), 7.21 (d, J = 7.5 Hz, 3H),
7.40 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 7.5 Hz, 1H), 7.59 (s, 1H), 7.71 (s,
1H), 7.86 (s, 1H). dC (126 MHz; CDCl3): 22.4, 22.5, 23.3, 23.4,
29.1, 29.9, 31.7, 32.1, 39.1, 39.4, 43.8, 44.0, 44.1, 44.6, 52.1, 52.3,
52.5, 52.6, 55.5, . 104.1, 104.7, 114.4, . 114.4, . 115.8, 116.2,
116.9, 118.3, 119.4, 119.7, 120.4, 125.7, 126.0, 127.1, 127.7,
128.0, . 128.2, . 128.3, . 128.5, 130.0, 130.5, 135.2, 137.3, 141.2,
141.8, 142.1, 144.1, 148.9, 150.1, 150.3, 152.0, 158.0, 159.3,
163.8, 170.3, 170.4, 170.7, 171.2, 173.2. . MS (ESI+) m/z: 763;
765; 767 [M+Na]+; 79Br79Br; 79Br81Br; 81Br81Br. HRMS (ESI-) m/z:
calcd for C33H33N4O679Br81Br: 741.0747 [MH]; found 741.0779
[MH].
4.2. Hydrolysis studies
Hydrolysis studies were performed using a Varian Cary 500
Scan UV–vis-NIR spectrophotometer with 1 cm path length and
disposable plastic cuvettes. Brieﬂy, 9 lmol of either 3a–e or 4a–e
were dissolved in acetonitrile/water 98.5:1.5 (10 mL) to yield a
stock solution of approximately 1 mM. Buffer solutions consisted
of 1 M sodium acetate adjusted to pH 4.5 and pH 5.3 and 1 M
HEPES adjusted to pH 7.4. The pH values of the solutions were
measured using a pH Cube pH–mV–temp Meter (TPS, Springwood,
Australia). The ﬁnal reaction mixture in the cuvette consisted of
stock solution/buffer/water in the ratio 1:2:2. All solutions were
monitored kinetically at 435 nm for 4 h at either rt (23 °C) or
37 °C. The dependence of the absorption spectra (measured at
k = 435 nm) on time, expressed as A/A0 versus t (where A = absorbance of the sample and A0 = absorbance at time zero), was used
to investigate the kinetics of imine hydrolysis, with all measurements performed on at least two independent occasions. The kinetic parameters k and t1/2 were derived by nonlinear regression
analysis of the ln (A/Ao) versus time plots using GraphPad Prism
5.00 (GraphPad Software, Inc., San Diego, CA, USA), with oneway, repeated measures ANOVA followed by a Tukey post-test to
determine whether differences between data sets were signiﬁcant,
with signiﬁcance set at P <0.05.
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